{"e6d830f9b2738258f51538d147c8833a9b3617ff": [["The ongoing COVID-19 pandemic has forced us to re-negotiate life with this new normal situation, which includes following guidelines related to social distancing, travel restrictions, wearing personal protective equipment and increasing virtual contact with others.", [["The ongoing COVID", "TEST", 0, 17]]], ["The world is gradually realizing the scale of collateral damage which has been caused by COVID-19 pandemic and our response towards it which has led to closure of schools, offices, cancellation of public events, workstudy from home restrictions, restricted socialization and limitations on national and international level (Tandon, 2020) .", [["collateral", "ANATOMY", 46, 56], ["collateral damage", "DISEASE", 46, 63], ["collateral", "TISSUE", 46, 56], ["collateral damage", "PROBLEM", 46, 63], ["collateral damage", "OBSERVATION", 46, 63]]], ["In this scenario of changed social and occupational environment, the mental health experts are now foreseeing a manifold increase in mental health illnesses.", [["a manifold increase in mental health illnesses", "PROBLEM", 110, 156]]], ["However, there has been a substantial increase in reported rates from across the world of self-harm behaviors, domestic violence, substance use, technology addiction, loneliness, depressive and anxiety disorders (Tandon, 2020) .", [["self-harm behaviors", "DISEASE", 90, 109], ["domestic violence", "DISEASE", 111, 128], ["loneliness", "DISEASE", 167, 177], ["depressive and anxiety disorders", "DISEASE", 179, 211], ["depressive and anxiety disorders", "PROBLEM", 179, 211], ["substantial", "OBSERVATION_MODIFIER", 26, 37], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["rates", "OBSERVATION_MODIFIER", 59, 64]]], ["Addressing mental health needs may become a challenge if information technology is not used to deliver mental health services, including psychotherapy services.", [["psychotherapy services", "TREATMENT", 137, 159]]]], "14a86f296914eeefb4232f547ffafdd538700291": [["IntroductionLeishmaniasis is a longstanding infectious disease that represents a major public health problem in various tropical and subtropical regions of the world (Trouiller et al., 2002) .", [["IntroductionLeishmaniasis", "DISEASE", 0, 25], ["infectious disease", "DISEASE", 44, 62], ["a longstanding infectious disease", "PROBLEM", 29, 62], ["longstanding", "OBSERVATION_MODIFIER", 31, 43], ["infectious", "OBSERVATION", 44, 54], ["major", "OBSERVATION_MODIFIER", 81, 86], ["tropical", "OBSERVATION_MODIFIER", 120, 128], ["subtropical", "ANATOMY_MODIFIER", 133, 144]]], ["It is estimated that around one billion individuals suffer from one or more parasitic infections, with the greatest causes of morbidity being attributed to the trypanosomatid parasites.", [["parasitic infections", "DISEASE", 76, 96], ["trypanosomatid parasites", "DISEASE", 160, 184], ["more parasitic infections", "PROBLEM", 71, 96], ["morbidity", "PROBLEM", 126, 135], ["the trypanosomatid parasites", "PROBLEM", 156, 184], ["parasitic", "OBSERVATION_MODIFIER", 76, 85], ["infections", "OBSERVATION", 86, 96], ["morbidity", "OBSERVATION", 126, 135], ["trypanosomatid parasites", "OBSERVATION", 160, 184]]], ["A variety of Leishmania organisms (approximately 20 species) are reported to cause disease which has afflicted about 12 million people in 98 countries of which Indian subcontinent, Sudan and Brazil are the major regions with more incidence of leishmaniasis (Balana-Fouce et al., 1998; Dorlo et al., 2012) .", [["leishmaniasis", "DISEASE", 243, 256], ["Leishmania organisms", "ORGANISM", 13, 33], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["Leishmania organisms", "PROBLEM", 13, 33], ["disease", "PROBLEM", 83, 90], ["leishmaniasis", "PROBLEM", 243, 256], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["Leishmania organisms", "OBSERVATION", 13, 33], ["leishmaniasis", "OBSERVATION", 243, 256]]], ["The estimated annual number of new cases of leishmaniasis is 2 million, which is usually fatal.", [["leishmaniasis", "DISEASE", 44, 57], ["leishmaniasis", "PROBLEM", 44, 57], ["annual", "OBSERVATION_MODIFIER", 14, 20], ["number", "OBSERVATION_MODIFIER", 21, 27], ["new", "OBSERVATION_MODIFIER", 31, 34], ["leishmaniasis", "OBSERVATION", 44, 57], ["fatal", "OBSERVATION_MODIFIER", 89, 94]]], ["Currently, no vaccines are available against this disease, which necessitates the development of alternate strategies to limit its transmission and infection (Modabber, 2010) .IntroductionThe current treatment regimens for this disease include amphotericin B, miltefosine and paromomycin.", [["infection", "DISEASE", 148, 157], ["amphotericin B", "CHEMICAL", 244, 258], ["miltefosine", "CHEMICAL", 260, 271], ["paromomycin", "CHEMICAL", 276, 287], ["amphotericin B", "CHEMICAL", 244, 258], ["miltefosine", "CHEMICAL", 260, 271], ["paromomycin", "CHEMICAL", 276, 287], ["amphotericin B", "SIMPLE_CHEMICAL", 244, 258], ["miltefosine", "SIMPLE_CHEMICAL", 260, 271], ["paromomycin", "SIMPLE_CHEMICAL", 276, 287], ["vaccines", "TREATMENT", 14, 22], ["this disease", "PROBLEM", 45, 57], ["alternate strategies", "TREATMENT", 97, 117], ["infection", "PROBLEM", 148, 157], ["The current treatment regimens", "TREATMENT", 188, 218], ["this disease", "PROBLEM", 223, 235], ["amphotericin B", "TREATMENT", 244, 258], ["miltefosine", "TREATMENT", 260, 271], ["paromomycin", "TREATMENT", 276, 287]]], ["However, they are not ideal because they are often associated with severe side effects (Murray, 2001) .", [["severe side effects", "PROBLEM", 67, 86]]], ["The emergence of resistance to currently used drugs exacerbates the need to identify novel drug targets and develop new drugs (Berman, 1988) .", [["drugs", "TREATMENT", 46, 51]]], ["Drugs like amphotericin B cause hepatotoxicity and nephrotoxicity whereas miltefosine causes severe teratogenicity (Pandey et al., 2009) .IntroductionPlant extracts or plant-derived compounds have proven to be a valuable source of new medicinal agents (De Carvalho and Ferreira, 2001; Kayser and Kiderlen, 2001) .", [["extracts", "ANATOMY", 156, 164], ["amphotericin B", "CHEMICAL", 11, 25], ["hepatotoxicity", "DISEASE", 32, 46], ["nephrotoxicity", "DISEASE", 51, 65], ["miltefosine", "CHEMICAL", 74, 85], ["amphotericin B", "CHEMICAL", 11, 25], ["miltefosine", "CHEMICAL", 74, 85], ["amphotericin B", "SIMPLE_CHEMICAL", 11, 25], ["miltefosine", "SIMPLE_CHEMICAL", 74, 85], ["Plant extracts", "ORGANISM_SUBSTANCE", 150, 164], ["Drugs", "TREATMENT", 0, 5], ["amphotericin", "TREATMENT", 11, 23], ["hepatotoxicity", "PROBLEM", 32, 46], ["nephrotoxicity", "PROBLEM", 51, 65], ["miltefosine", "TREATMENT", 74, 85], ["severe teratogenicity", "PROBLEM", 93, 114], ["severe", "OBSERVATION_MODIFIER", 93, 99]]], ["WHO advocated the use of traditional medicine where appropriate health services are inaccessible (Ei Tahir et al., 1998; Weniger et al., 2001; Bhadra, 1993) .", [["traditional medicine", "TREATMENT", 25, 45]]], ["Furthermore, the leads obtained from the search for natural products with antileishmanial activity give new impetus for obtaining valuable synthetic compounds (Carvalho et al., 2000) .IntroductionRecently attention is being focused on the sterol metabolism of Leishmania as a potential molecular drug target for therapy.", [["sterol", "CHEMICAL", 239, 245], ["sterol", "SIMPLE_CHEMICAL", 239, 245], ["Leishmania", "ORGANISM", 260, 270], ["natural products", "TREATMENT", 52, 68], ["antileishmanial activity", "TREATMENT", 74, 98], ["Leishmania", "PROBLEM", 260, 270], ["therapy", "TREATMENT", 312, 319]]], ["Parasites synthesize sterols and isoprenoids via mevalonate pathway.", [["sterols", "CHEMICAL", 21, 28], ["isoprenoids", "CHEMICAL", 33, 44], ["mevalonate", "CHEMICAL", 49, 59], ["sterols", "CHEMICAL", 21, 28], ["isoprenoids", "CHEMICAL", 33, 44], ["mevalonate", "CHEMICAL", 49, 59], ["Parasites", "CELL", 0, 9], ["sterols", "SIMPLE_CHEMICAL", 21, 28], ["isoprenoids", "SIMPLE_CHEMICAL", 33, 44], ["mevalonate", "SIMPLE_CHEMICAL", 49, 59], ["Parasites synthesize sterols", "TREATMENT", 0, 28], ["isoprenoids", "TREATMENT", 33, 44], ["mevalonate pathway", "TREATMENT", 49, 67]]], ["Ergosterol is the primary component of the Leishmania membrane and is functionally linked to maintenance of structural integrity and protection from biotic stress (Galea and Brown, 2009 ).Introduction3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) is a key enzyme in this pathway.", [["membrane", "ANATOMY", 54, 62], ["Ergosterol", "CHEMICAL", 0, 10], ["Ergosterol", "CHEMICAL", 0, 10], ["Introduction3-hydroxy-3-methylglutaryl coenzyme A", "CHEMICAL", 188, 237], ["Ergosterol", "SIMPLE_CHEMICAL", 0, 10], ["Leishmania membrane", "CELLULAR_COMPONENT", 43, 62], ["Introduction3-hydroxy-3-methylglutaryl coenzyme A reductase", "GENE_OR_GENE_PRODUCT", 188, 247], ["HMGR", "GENE_OR_GENE_PRODUCT", 249, 253], ["methylglutaryl coenzyme A reductase", "PROTEIN", 212, 247], ["HMGR", "PROTEIN", 249, 253], ["Ergosterol", "TREATMENT", 0, 10], ["the Leishmania membrane", "PROBLEM", 39, 62], ["Introduction3", "TEST", 188, 201], ["hydroxy", "TEST", 202, 209], ["methylglutaryl coenzyme", "TREATMENT", 212, 235], ["primary", "OBSERVATION_MODIFIER", 18, 25], ["component", "OBSERVATION_MODIFIER", 26, 35], ["Leishmania membrane", "OBSERVATION", 43, 62], ["structural integrity", "OBSERVATION", 108, 128], ["biotic stress", "OBSERVATION", 149, 162]]], ["The mevalonate pathway is directly relevant to human health and inhibition of HMGR by statins controls sterol production and lowers blood pressure, and helps in the treatment of cardiovascular disease and inflammatory processes (Liao and Laufs, 2005) .", [["blood", "ANATOMY", 132, 137], ["cardiovascular", "ANATOMY", 178, 192], ["mevalonate", "CHEMICAL", 4, 14], ["statins", "CHEMICAL", 86, 93], ["cardiovascular disease", "DISEASE", 178, 200], ["mevalonate", "CHEMICAL", 4, 14], ["statins", "CHEMICAL", 86, 93], ["sterol", "CHEMICAL", 103, 109], ["mevalonate", "SIMPLE_CHEMICAL", 4, 14], ["human", "ORGANISM", 47, 52], ["HMGR", "GENE_OR_GENE_PRODUCT", 78, 82], ["statins", "SIMPLE_CHEMICAL", 86, 93], ["sterol", "SIMPLE_CHEMICAL", 103, 109], ["blood", "ORGANISM_SUBSTANCE", 132, 137], ["cardiovascular", "ANATOMICAL_SYSTEM", 178, 192], ["HMGR", "PROTEIN", 78, 82], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["The mevalonate pathway", "TREATMENT", 0, 22], ["HMGR", "TREATMENT", 78, 82], ["statins controls sterol production", "TREATMENT", 86, 120], ["blood pressure", "TEST", 132, 146], ["cardiovascular disease", "PROBLEM", 178, 200], ["inflammatory processes", "PROBLEM", 205, 227], ["cardiovascular", "ANATOMY", 178, 192], ["disease", "OBSERVATION", 193, 200], ["inflammatory", "OBSERVATION_MODIFIER", 205, 217]]], ["In L. donovani this pathway is currently being explored as a potential drug target.IntroductionGlycyrrhiza glabra, popularly known as liquorice, is one of the most important medicinal plants used for treatment of pulmonary diseases and inflammatory processes (Davis and Morris, 1991) .", [["pulmonary", "ANATOMY", 213, 222], ["Glycyrrhiza glabra", "CHEMICAL", 95, 113], ["pulmonary diseases", "DISEASE", 213, 231], ["L. donovani", "ORGANISM", 3, 14], ["Glycyrrhiza glabra", "ORGANISM", 95, 113], ["pulmonary", "ORGAN", 213, 222], ["L. donovani", "SPECIES", 3, 14], ["Glycyrrhiza glabra", "SPECIES", 95, 113], ["L. donovani", "SPECIES", 3, 14], ["Glycyrrhiza glabra", "SPECIES", 95, 113], ["IntroductionGlycyrrhiza glabra", "TREATMENT", 83, 113], ["pulmonary diseases", "PROBLEM", 213, 231], ["inflammatory processes", "PROBLEM", 236, 258], ["donovani", "OBSERVATION", 6, 14], ["Glycyrrhiza glabra", "OBSERVATION", 95, 113], ["pulmonary", "ANATOMY", 213, 222], ["diseases", "OBSERVATION", 223, 231], ["inflammatory", "OBSERVATION_MODIFIER", 236, 248]]], ["The major bioactive components in liquorice root include glycyrrhizic acid (GA), licochalone A and Glycyrrhetinic acid that were reported to exert antileishmanial properties (Bhattacharjee et al., 2012; Fu et al., 2004; Ukil et al., 2005) .", [["liquorice root", "ANATOMY", 34, 48], ["glycyrrhizic acid", "CHEMICAL", 57, 74], ["GA", "CHEMICAL", 76, 78], ["licochalone A", "CHEMICAL", 81, 94], ["Glycyrrhetinic acid", "CHEMICAL", 99, 118], ["glycyrrhizic acid", "CHEMICAL", 57, 74], ["licochalone A", "CHEMICAL", 81, 94], ["Glycyrrhetinic acid", "CHEMICAL", 99, 118], ["liquorice root", "MULTI-TISSUE_STRUCTURE", 34, 48], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 57, 74], ["GA", "SIMPLE_CHEMICAL", 76, 78], ["licochalone A", "SIMPLE_CHEMICAL", 81, 94], ["Glycyrrhetinic acid", "SIMPLE_CHEMICAL", 99, 118], ["glycyrrhizic acid (GA)", "TREATMENT", 57, 79], ["licochalone A and Glycyrrhetinic acid", "TREATMENT", 81, 118], ["major", "OBSERVATION_MODIFIER", 4, 9], ["bioactive components", "OBSERVATION", 10, 30], ["liquorice root", "OBSERVATION", 34, 48]]], ["GA was reported to exhibit potent antileishmanial immunomodulatory property with enhanced parasite clearance (Bhattacharjee et al., 2012) .", [["GA", "CHEMICAL", 0, 2], ["GA", "SIMPLE_CHEMICAL", 0, 2], ["enhanced parasite clearance", "PROBLEM", 81, 108], ["potent", "OBSERVATION_MODIFIER", 27, 33], ["antileishmanial immunomodulatory", "OBSERVATION", 34, 66]]], ["Besides, GA has shown broad spectrum of antimicrobial, antiprotozoal, antiallergic, antiviral, anti-cancer, antioxidant and anti-inflammatory activities with various pharmacological effects and multiple sites of action (Kumagai et al., 1967; Lin, 2003; Hibasami et al., 2005; Fujisawa et al., 2000) .", [["GA", "CHEMICAL", 9, 11], ["GA", "SIMPLE_CHEMICAL", 9, 11], ["antimicrobial", "TREATMENT", 40, 53], ["antiprotozoal", "TREATMENT", 55, 68], ["antiallergic", "TREATMENT", 70, 82], ["antiviral", "TREATMENT", 84, 93], ["anti-cancer", "TREATMENT", 95, 106], ["antioxidant", "TREATMENT", 108, 119], ["anti-inflammatory activities", "TREATMENT", 124, 152], ["various pharmacological effects", "TREATMENT", 158, 189], ["antimicrobial", "OBSERVATION_MODIFIER", 40, 53]]], ["GA was reported to suppress the rise in fasting blood glucose and insulin levels and improve glucose tolerance (Takii et al., 2001) .IntroductionGA inhibits the replication of the severe acute respiratory syndrome virus (SARS) (Hoever et al., 2005) .", [["blood", "ANATOMY", 48, 53], ["GA", "CHEMICAL", 0, 2], ["glucose", "CHEMICAL", 54, 61], ["glucose", "CHEMICAL", 93, 100], ["IntroductionGA", "CHEMICAL", 133, 147], ["acute respiratory syndrome virus", "DISEASE", 187, 219], ["SARS", "DISEASE", 221, 225], ["glucose", "CHEMICAL", 54, 61], ["glucose", "CHEMICAL", 93, 100], ["GA", "SIMPLE_CHEMICAL", 0, 2], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["glucose", "SIMPLE_CHEMICAL", 54, 61], ["insulin", "GENE_OR_GENE_PRODUCT", 66, 73], ["glucose", "SIMPLE_CHEMICAL", 93, 100], ["severe acute respiratory syndrome virus", "ORGANISM", 180, 219], ["severe acute respiratory syndrome virus", "SPECIES", 180, 219], ["fasting blood glucose", "TEST", 40, 61], ["insulin levels", "TEST", 66, 80], ["IntroductionGA", "TREATMENT", 133, 147], ["the severe acute respiratory syndrome virus", "PROBLEM", 176, 219], ["severe", "OBSERVATION_MODIFIER", 180, 186], ["acute", "OBSERVATION_MODIFIER", 187, 192], ["respiratory syndrome", "OBSERVATION", 193, 213]]], ["GA is involved in the treatment of hepatitis C virus (HCV) infection where it inhibits HCV viral particles and its gene expression in a dose-dependent manner and has shown synergistic effect with interferon.", [["GA", "CHEMICAL", 0, 2], ["hepatitis C virus (HCV) infection", "DISEASE", 35, 68], ["GA", "SIMPLE_CHEMICAL", 0, 2], ["hepatitis C virus", "ORGANISM", 35, 52], ["HCV", "ORGANISM", 54, 57], ["HCV", "ORGANISM", 87, 90], ["interferon", "GENE_OR_GENE_PRODUCT", 196, 206], ["interferon", "PROTEIN", 196, 206], ["hepatitis C virus", "SPECIES", 35, 52], ["hepatitis C virus", "SPECIES", 35, 52], ["HCV", "SPECIES", 54, 57], ["HCV", "SPECIES", 87, 90], ["hepatitis C virus (HCV) infection", "PROBLEM", 35, 68], ["HCV viral particles", "PROBLEM", 87, 106], ["interferon", "TREATMENT", 196, 206], ["hepatitis", "OBSERVATION", 35, 44], ["infection", "OBSERVATION", 59, 68], ["HCV", "OBSERVATION_MODIFIER", 87, 90], ["viral particles", "OBSERVATION", 91, 106]]], ["GA affects various cellular signalling pathways such as casein kinase II, protein kinase C and transcription factors.", [["cellular", "ANATOMY", 19, 27], ["GA", "CHEMICAL", 0, 2], ["GA", "SIMPLE_CHEMICAL", 0, 2], ["cellular", "CELL", 19, 27], ["casein kinase II", "GENE_OR_GENE_PRODUCT", 56, 72], ["protein kinase C", "GENE_OR_GENE_PRODUCT", 74, 90], ["casein kinase II", "PROTEIN", 56, 72], ["protein kinase C", "PROTEIN", 74, 90], ["transcription factors", "PROTEIN", 95, 116], ["casein kinase II", "TEST", 56, 72], ["protein kinase C", "TEST", 74, 90], ["transcription factors", "PROBLEM", 95, 116]]], ["The powerful anti-inflammatory capabilities of GA make it effective in the treatment of various types of viral hepatitis also (Ashfaq et al., 2011) .IntroductionSeveral mechanisms were proposed for the mode of action of GA in L. donovani.", [["GA", "CHEMICAL", 47, 49], ["viral hepatitis", "DISEASE", 105, 120], ["GA", "CHEMICAL", 220, 222], ["GA", "SIMPLE_CHEMICAL", 47, 49], ["GA", "SIMPLE_CHEMICAL", 220, 222], ["L. donovani", "ORGANISM", 226, 237], ["L. donovani", "SPECIES", 226, 237], ["L. donovani", "SPECIES", 226, 237], ["The powerful anti-inflammatory capabilities of GA", "TREATMENT", 0, 49], ["viral hepatitis", "PROBLEM", 105, 120], ["viral hepatitis", "OBSERVATION", 105, 120]]], ["Bhattacharjee et al., have reported prostaglandin E2 (PGE2) , inhibition and NO generation as mechanism of action of GA, thus suggesting potential immunomodulatory role of GA against VL (Bhattacharjee et al., 2012) .", [["prostaglandin E2", "CHEMICAL", 36, 52], ["PGE2", "CHEMICAL", 54, 58], ["NO", "CHEMICAL", 77, 79], ["GA", "CHEMICAL", 117, 119], ["GA", "CHEMICAL", 172, 174], ["VL", "DISEASE", 183, 185], ["prostaglandin E2", "CHEMICAL", 36, 52], ["PGE2", "CHEMICAL", 54, 58], ["NO", "CHEMICAL", 77, 79], ["prostaglandin E2", "SIMPLE_CHEMICAL", 36, 52], ["PGE2", "SIMPLE_CHEMICAL", 54, 58], ["NO", "SIMPLE_CHEMICAL", 77, 79], ["GA", "SIMPLE_CHEMICAL", 117, 119], ["GA", "SIMPLE_CHEMICAL", 172, 174], ["prostaglandin E2 (PGE2", "TREATMENT", 36, 58], ["action of GA", "PROBLEM", 107, 119]]], ["Recently, GA was reported to reduce the parasite load in sodium antimony gluconate (SAG) resistant L. donovani infected macrophages.", [["macrophages", "ANATOMY", 120, 131], ["GA", "CHEMICAL", 10, 12], ["sodium antimony gluconate", "CHEMICAL", 57, 82], ["SAG", "CHEMICAL", 84, 87], ["sodium antimony gluconate", "CHEMICAL", 57, 82], ["SAG", "CHEMICAL", 84, 87], ["GA", "SIMPLE_CHEMICAL", 10, 12], ["sodium antimony gluconate", "SIMPLE_CHEMICAL", 57, 82], ["SAG", "SIMPLE_CHEMICAL", 84, 87], ["L. donovani", "ORGANISM", 99, 110], ["macrophages", "CELL", 120, 131], ["sodium antimony gluconate (SAG) resistant L. donovani infected macrophages", "CELL_LINE", 57, 131], ["L. donovani", "SPECIES", 99, 110], ["L. donovani", "SPECIES", 99, 110], ["the parasite load", "PROBLEM", 36, 53], ["sodium antimony gluconate", "TREATMENT", 57, 82], ["resistant L. donovani infected macrophages", "PROBLEM", 89, 131], ["donovani infected macrophages", "OBSERVATION", 102, 131]]], ["When, GA was used in combination with SAG, intracellular antimony levels were greatly reduced by suppressing the cell surface expression of multidrug resistanceassociated protein1 (MRP1) gene and ABC transporter MRPA (PGPA) transporters which are responsible for antimony efflux during SAG treatment (Bhattacharjee et al., 2015) .IntroductionEarlier reports suggested GA to be very effective as a lipidlowering agent in hamsters with diet induced hyperlipidemia and the effect was demonstrated to be via decreased HMGR activity and HMGR mRNA expression (Maurya and Srivastava, 2011) .", [["intracellular", "ANATOMY", 43, 56], ["cell surface", "ANATOMY", 113, 125], ["GA", "CHEMICAL", 6, 8], ["SAG", "CHEMICAL", 38, 41], ["antimony", "CHEMICAL", 57, 65], ["antimony", "CHEMICAL", 263, 271], ["SAG", "CHEMICAL", 286, 289], ["GA", "CHEMICAL", 368, 370], ["hyperlipidemia", "DISEASE", 447, 461], ["SAG", "CHEMICAL", 38, 41], ["SAG", "CHEMICAL", 286, 289], ["GA", "SIMPLE_CHEMICAL", 6, 8], ["SAG", "SIMPLE_CHEMICAL", 38, 41], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 56], ["antimony", "SIMPLE_CHEMICAL", 57, 65], ["cell", "CELL", 113, 117], ["multidrug resistanceassociated protein1", "GENE_OR_GENE_PRODUCT", 140, 179], ["MRP1", "GENE_OR_GENE_PRODUCT", 181, 185], ["ABC transporter MRPA (PGPA) transporters", "GENE_OR_GENE_PRODUCT", 196, 236], ["antimony", "SIMPLE_CHEMICAL", 263, 271], ["SAG", "SIMPLE_CHEMICAL", 286, 289], ["GA", "SIMPLE_CHEMICAL", 368, 370], ["hamsters", "ORGANISM", 420, 428], ["HMGR", "GENE_OR_GENE_PRODUCT", 514, 518], ["HMGR", "GENE_OR_GENE_PRODUCT", 532, 536], ["multidrug resistanceassociated protein1 (MRP1) gene", "PROTEIN", 140, 191], ["ABC transporter MRPA (PGPA) transporters", "PROTEIN", 196, 236], ["HMGR", "PROTEIN", 514, 518], ["HMGR mRNA", "RNA", 532, 541], ["hamsters", "SPECIES", 420, 428], ["SAG", "TREATMENT", 38, 41], ["intracellular antimony levels", "TEST", 43, 72], ["multidrug resistanceassociated protein1 (MRP1", "TREATMENT", 140, 185], ["ABC transporter MRPA", "TREATMENT", 196, 216], ["antimony efflux", "PROBLEM", 263, 278], ["SAG treatment", "TREATMENT", 286, 299], ["a lipidlowering agent", "TREATMENT", 395, 416], ["diet induced hyperlipidemia", "PROBLEM", 434, 461], ["decreased HMGR activity", "PROBLEM", 504, 527], ["HMGR mRNA expression", "PROBLEM", 532, 552], ["hyperlipidemia", "OBSERVATION", 447, 461], ["HMGR activity", "OBSERVATION", 514, 527]]], ["This led us to investigate its effect on L. donovani parasite HMGR activity and ergosterol levels.", [["ergosterol", "CHEMICAL", 80, 90], ["ergosterol", "CHEMICAL", 80, 90], ["L. donovani", "ORGANISM", 41, 52], ["parasite", "ORGANISM", 53, 61], ["HMGR", "GENE_OR_GENE_PRODUCT", 62, 66], ["ergosterol", "SIMPLE_CHEMICAL", 80, 90], ["HMGR", "PROTEIN", 62, 66], ["L. donovani", "SPECIES", 41, 52], ["L. donovani", "SPECIES", 41, 52], ["L. donovani parasite HMGR activity", "TEST", 41, 75], ["ergosterol levels", "TEST", 80, 97], ["donovani parasite", "OBSERVATION", 44, 61], ["ergosterol levels", "OBSERVATION", 80, 97]]], ["In view of the potential use of GA for the specific treatment of parasitic diseases like leishmaniasis, we have tried to elucidate its effect on sterol metabolism of the parasite.", [["GA", "CHEMICAL", 32, 34], ["parasitic diseases", "DISEASE", 65, 83], ["leishmaniasis", "DISEASE", 89, 102], ["sterol", "CHEMICAL", 145, 151], ["GA", "SIMPLE_CHEMICAL", 32, 34], ["sterol", "SIMPLE_CHEMICAL", 145, 151], ["GA", "TREATMENT", 32, 34], ["parasitic diseases", "PROBLEM", 65, 83], ["leishmaniasis", "PROBLEM", 89, 102], ["parasitic", "OBSERVATION_MODIFIER", 65, 74], ["leishmaniasis", "OBSERVATION", 89, 102]]], ["Our study reveals that it interferes with parasite sterol metabolism by inhibiting HMGR activity and lowering ergosterol levels.ChemicalsGlycyrrhizic acid, ergosterol and methanol solvent were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [["ergosterol", "CHEMICAL", 110, 120], ["Glycyrrhizic acid", "CHEMICAL", 137, 154], ["ergosterol", "CHEMICAL", 156, 166], ["sterol", "CHEMICAL", 51, 57], ["ergosterol", "CHEMICAL", 110, 120], ["Glycyrrhizic acid", "CHEMICAL", 137, 154], ["ergosterol", "CHEMICAL", 156, 166], ["methanol", "CHEMICAL", 171, 179], ["sterol", "SIMPLE_CHEMICAL", 51, 57], ["HMGR", "GENE_OR_GENE_PRODUCT", 83, 87], ["ergosterol", "SIMPLE_CHEMICAL", 110, 120], ["Glycyrrhizic acid", "SIMPLE_CHEMICAL", 137, 154], ["ergosterol", "SIMPLE_CHEMICAL", 156, 166], ["methanol solvent", "SIMPLE_CHEMICAL", 171, 187], ["Sigma-Aldrich", "ORGANISM", 208, 221], ["St. Louis", "ORGANISM", 223, 232], ["HMGR", "PROTEIN", 83, 87], ["Our study", "TEST", 0, 9], ["parasite sterol metabolism", "TREATMENT", 42, 68], ["lowering ergosterol levels", "TEST", 101, 127], ["ChemicalsGlycyrrhizic acid", "TREATMENT", 128, 154], ["ergosterol and methanol solvent", "TREATMENT", 156, 187], ["ergosterol levels", "OBSERVATION", 110, 127]]], ["Atorvastatin was a kind gift from Dr. S. Suresh, NIPER, S.A.S. Nagar, India.", [["Atorvastatin", "CHEMICAL", 0, 12], ["Atorvastatin", "CHEMICAL", 0, 12], ["Atorvastatin", "SIMPLE_CHEMICAL", 0, 12], ["Atorvastatin", "TREATMENT", 0, 12]]], ["Polyclonal anti-rat HMGR antibody was kindly gifted by Dr. Peter Edwards, UCLA Laboratory (Los Angeles, CA) (Garc\u00eda-Pelayo et al., 2004) .", [["anti-rat HMGR antibody", "GENE_OR_GENE_PRODUCT", 11, 33], ["Polyclonal anti-rat HMGR antibody", "PROTEIN", 0, 33], ["anti-rat", "SPECIES", 11, 19], ["Polyclonal anti-rat HMGR antibody", "TEST", 0, 33], ["CA", "TEST", 104, 106], ["Garc\u00eda", "TEST", 109, 115]]], ["The anti-LdAceCS antibody was customized from Imgenex, Bhubaneshwar, India (Soumya et al., 2015) .Parasite and cell line maintenanceWild type L. donovani (WT, MHOM/80/IN/Dd8) promastigotes were maintained at 24 C in RPMI-1640 HEPES modified medium (Gibco/BRL, Life Technologies, Scotland, UK) containing 10% heatinactivated foetal bovine serum (HI-FBS) supplemented with 0.2% sodium bicarbonate, 100 mg/mL penicillin, 100 mg/mL streptomycin and 100 mg/mL gentamycin.", [["cell line", "ANATOMY", 111, 120], ["serum", "ANATOMY", 338, 343], ["FBS", "ANATOMY", 348, 351], ["sodium bicarbonate", "CHEMICAL", 376, 394], ["penicillin", "CHEMICAL", 406, 416], ["streptomycin", "CHEMICAL", 428, 440], ["gentamycin", "CHEMICAL", 455, 465], ["sodium bicarbonate", "CHEMICAL", 376, 394], ["penicillin", "CHEMICAL", 406, 416], ["streptomycin", "CHEMICAL", 428, 440], ["gentamycin", "CHEMICAL", 455, 465], ["Parasite", "CELL", 98, 106], ["cell line maintenanceWild type L. donovani", "ORGANISM", 111, 153], ["WT, MHOM/80/IN", "ORGANISM", 155, 169], ["Dd8", "GENE_OR_GENE_PRODUCT", 170, 173], ["promastigotes", "CELL", 175, 188], ["bovine", "ORGANISM", 331, 337], ["serum", "ORGANISM_SUBSTANCE", 338, 343], ["FBS", "ORGANISM_SUBSTANCE", 348, 351], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 376, 394], ["penicillin", "SIMPLE_CHEMICAL", 406, 416], ["streptomycin", "SIMPLE_CHEMICAL", 428, 440], ["gentamycin", "SIMPLE_CHEMICAL", 455, 465], ["anti-LdAceCS antibody", "PROTEIN", 4, 25], ["L. donovani", "SPECIES", 142, 153], ["bovine", "SPECIES", 331, 337], ["L. donovani", "SPECIES", 142, 153], ["bovine", "SPECIES", 331, 337], ["The anti-LdAceCS antibody", "TEST", 0, 25], ["Parasite", "TREATMENT", 98, 106], ["cell line", "TREATMENT", 111, 120], ["WT", "TEST", 155, 157], ["MHOM", "TEST", 159, 163], ["10% heatinactivated foetal bovine serum (HI-FBS", "TREATMENT", 304, 351], ["0.2% sodium bicarbonate", "TREATMENT", 371, 394], ["penicillin", "TREATMENT", 406, 416], ["streptomycin", "TREATMENT", 428, 440], ["gentamycin", "TREATMENT", 455, 465], ["cell line", "OBSERVATION", 111, 120], ["donovani", "OBSERVATION_MODIFIER", 145, 153]]], ["The pH of the media was maintained at 7.2.", [["The pH", "TEST", 0, 6], ["the media", "TEST", 10, 19]]], ["LdHMGR overexpressing transgenic promastigotes were maintained in the same medium with 60 mg/mL of hygromycin B.Parasite and cell line maintenanceTHP-1 monocyte cell line was maintained in RPMI-1640 medium containing 10% HI-FBS in a humidified atmosphere with 5% CO 2 at 37 C.In vitro antipromastigote assayPromastigotes of L. donovani strain were grown in RPMI-1640 medium as mentioned earlier .", [["cell line", "ANATOMY", 125, 134], ["THP-1 monocyte cell line", "ANATOMY", 146, 170], ["hygromycin B.Parasite", "CHEMICAL", 99, 120], ["RPMI-1640", "CHEMICAL", 189, 198], ["RPMI-1640", "CHEMICAL", 357, 366], ["hygromycin", "CHEMICAL", 99, 109], ["CO 2", "CHEMICAL", 263, 267], ["LdHMGR", "GENE_OR_GENE_PRODUCT", 0, 6], ["hygromycin B.Parasite", "SIMPLE_CHEMICAL", 99, 120], ["cell line", "CELL", 125, 134], ["THP-1 monocyte cell line", "CELL", 146, 170], ["RPMI-1640", "CELL", 189, 198], ["FBS", "ORGANISM_SUBSTANCE", 224, 227], ["L. donovani", "ORGANISM", 324, 335], ["strain", "ORGANISM", 336, 342], ["LdHMGR", "PROTEIN", 0, 6], ["THP-1 monocyte cell line", "CELL_LINE", 146, 170], ["L. donovani", "SPECIES", 324, 335], ["L. donovani", "SPECIES", 324, 335], ["LdHMGR overexpressing transgenic promastigotes", "PROBLEM", 0, 46], ["hygromycin B.Parasite", "TREATMENT", 99, 120], ["cell line maintenance", "TREATMENT", 125, 146], ["THP", "TEST", 146, 149], ["1 monocyte cell line", "TREATMENT", 150, 170], ["a humidified atmosphere", "TREATMENT", 231, 254], ["5% CO", "TREATMENT", 260, 265], ["vitro antipromastigote assayPromastigotes", "TREATMENT", 279, 320], ["L. donovani strain", "PROBLEM", 324, 342], ["transgenic", "OBSERVATION_MODIFIER", 22, 32], ["promastigotes", "OBSERVATION_MODIFIER", 33, 46], ["cell line", "OBSERVATION", 125, 134], ["monocyte cell line", "OBSERVATION", 152, 170], ["donovani strain", "OBSERVATION", 327, 342]]], ["Two hundred microliters of culture with a cell density of 2 \u00c2 10 5 promastigotes with or without various GA concentrations (10 mMe100 mM) was seeded in 96-well microtiter plate.", [["cell", "ANATOMY", 42, 46], ["GA", "CHEMICAL", 105, 107], ["cell", "CELL", 42, 46], ["GA", "SIMPLE_CHEMICAL", 105, 107], ["culture", "TEST", 27, 34], ["a cell density", "TEST", 40, 54], ["various GA concentrations", "PROBLEM", 97, 122], ["cell density", "OBSERVATION", 42, 54]]], ["After 48 h of incubation at 24 C, 20 ml of 5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) dye was added to each well.", [["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 54, 115], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 54, 115], ["MTT", "CHEMICAL", 117, 120], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "SIMPLE_CHEMICAL", 54, 115], ["MTT", "SIMPLE_CHEMICAL", 117, 120], ["incubation", "TREATMENT", 14, 24], ["dimethylthiazol", "TREATMENT", 61, 76], ["diphenyl tetrazolium bromide (MTT) dye", "TREATMENT", 87, 125]]], ["The plates were incubated for another 4 h at 37 C and read with a BIOTEK microplate reader at 540 nm.", [["a BIOTEK microplate", "TREATMENT", 64, 83]]], ["The decrease of absorbance (which indicated inhibition) was expressed as the percentage of the absorbance of the control cultures and plotted against the drug concentrations.", [["control cultures", "CELL_LINE", 113, 129], ["The decrease of absorbance", "PROBLEM", 0, 26], ["the control cultures", "TEST", 109, 129], ["the drug concentrations", "PROBLEM", 150, 173], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["absorbance", "OBSERVATION_MODIFIER", 16, 26]]], ["The 50% inhibitory concentrations (IC 50 ) was calculated from the sigmoidal inhibition curves.", [["The 50% inhibitory concentrations (IC", "TREATMENT", 0, 37], ["the sigmoidal inhibition curves", "TEST", 63, 94]]], ["Data were expressed as mean \u00b1 standard deviations from three independent experiments.In vitro anti-amastigote assayAntileishmanial screening against L. donovani amastigotes residing in differentiated THP-1 monocytes was adapted from that of Jain and co-workers (Jain et al., 2012) .", [["THP-1 monocytes", "ANATOMY", 200, 215], ["Antileishmanial", "CHEMICAL", 115, 130], ["L. donovani", "ORGANISM", 149, 160], ["amastigotes", "ORGANISM", 161, 172], ["THP-1 monocytes", "CELL", 200, 215], ["THP-1 monocytes", "CELL_LINE", 200, 215], ["L. donovani", "SPECIES", 149, 160], ["L. donovani", "SPECIES", 149, 160], ["Antileishmanial screening", "TEST", 115, 140], ["L. donovani amastigotes", "PROBLEM", 149, 172]]], ["THP-1 monocytes were seeded at density of 2 \u00c2 10 5 /well in 96-well plate and differentiated into macrophages by inducing with phorbol 12-myristate 13acetate (PMA, 20 ng/mL).", [["THP-1 monocytes", "ANATOMY", 0, 15], ["macrophages", "ANATOMY", 98, 109], ["phorbol 12-myristate 13acetate", "CHEMICAL", 127, 157], ["PMA", "CHEMICAL", 159, 162], ["phorbol 12-myristate 13acetate", "CHEMICAL", 127, 157], ["PMA", "CHEMICAL", 159, 162], ["THP-1 monocytes", "CELL", 0, 15], ["macrophages", "CELL", 98, 109], ["phorbol 12-myristate 13acetate", "SIMPLE_CHEMICAL", 127, 157], ["PMA", "SIMPLE_CHEMICAL", 159, 162], ["THP-1 monocytes", "CELL_LINE", 0, 15], ["macrophages", "CELL_TYPE", 98, 109], ["THP", "TEST", 0, 3], ["monocytes", "TEST", 6, 15], ["phorbol", "TREATMENT", 127, 134], ["myristate 13acetate (PMA", "TREATMENT", 138, 162], ["1 monocytes", "OBSERVATION_MODIFIER", 4, 15], ["macrophages", "OBSERVATION", 98, 109]]], ["Macrophages were infected with 2 \u00c2 10 6 of L. donovani promastigotes at 37 C in 5% CO 2 for 24 h.", [["Macrophages", "ANATOMY", 0, 11], ["2 \u00c2 10 6 of L. donovani", "CHEMICAL", 31, 54], ["CO 2", "CHEMICAL", 83, 87], ["Macrophages", "CELL", 0, 11], ["L. donovani", "ORGANISM", 43, 54], ["promastigotes", "ORGANISM", 55, 68], ["Macrophages", "CELL_TYPE", 0, 11], ["L. donovani", "SPECIES", 43, 54], ["L. donovani", "SPECIES", 43, 54], ["Macrophages", "PROBLEM", 0, 11], ["L. donovani promastigotes", "TREATMENT", 43, 68]]], ["Unadhered promastigotes were removed by washing with RPMI-1640 medium and the amastigote-infected macrophages were treated with GA at different concentrations (5, 10, 20, 50 and 100 mM) for 48 h.", [["macrophages", "ANATOMY", 98, 109], ["RPMI-1640", "CHEMICAL", 53, 62], ["GA", "CHEMICAL", 128, 130], ["promastigotes", "CELL", 10, 23], ["macrophages", "CELL", 98, 109], ["GA", "SIMPLE_CHEMICAL", 128, 130], ["amastigote-infected macrophages", "CELL_TYPE", 78, 109], ["Unadhered promastigotes", "TREATMENT", 0, 23], ["RPMI", "TEST", 53, 57], ["infected macrophages", "PROBLEM", 89, 109], ["infected", "OBSERVATION_MODIFIER", 89, 97], ["macrophages", "OBSERVATION", 98, 109]]], ["Infected macrophages were lysed by treating the cells with 20 mL of 0.05% sodium dodecyl sulfate (SDS) and amastigotes were reverted back into the promastigotes under suitable conditions.", [["macrophages", "ANATOMY", 9, 20], ["cells", "ANATOMY", 48, 53], ["sodium dodecyl sulfate", "CHEMICAL", 74, 96], ["sodium dodecyl sulfate", "CHEMICAL", 74, 96], ["SDS", "CHEMICAL", 98, 101], ["macrophages", "CELL", 9, 20], ["cells", "CELL", 48, 53], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 74, 96], ["macrophages", "CELL_TYPE", 9, 20], ["Infected macrophages", "PROBLEM", 0, 20], ["0.05% sodium dodecyl sulfate", "TREATMENT", 68, 96], ["amastigotes", "TREATMENT", 107, 118], ["macrophages", "OBSERVATION", 9, 20]]], ["After 48 h, MTT assay was performed as described earlier.", [["MTT", "CHEMICAL", 12, 15], ["MTT assay", "TEST", 12, 21]]], ["Miltefosine was used as the standard anti-leishmanial drug.Cytotoxicity evaluation of glycyrrhizic acidTo estimate 50% inhibitory concentrations of GA on the viability of THP cell lines, MTT assay was performed as previously described (Mosmann, 1983) .", [["THP cell lines", "ANATOMY", 171, 185], ["Miltefosine", "CHEMICAL", 0, 11], ["glycyrrhizic acidTo", "CHEMICAL", 86, 105], ["GA", "CHEMICAL", 148, 150], ["Miltefosine", "CHEMICAL", 0, 11], ["glycyrrhizic acidTo", "CHEMICAL", 86, 105], ["MTT", "CHEMICAL", 187, 190], ["Miltefosine", "SIMPLE_CHEMICAL", 0, 11], ["glycyrrhizic acidTo", "SIMPLE_CHEMICAL", 86, 105], ["GA", "SIMPLE_CHEMICAL", 148, 150], ["THP cell lines", "CELL", 171, 185], ["THP cell lines", "CELL_LINE", 171, 185], ["Miltefosine", "TREATMENT", 0, 11], ["the standard anti-leishmanial drug", "TREATMENT", 24, 58], ["Cytotoxicity evaluation", "TEST", 59, 82], ["glycyrrhizic acidTo", "TREATMENT", 86, 105], ["THP cell lines", "TREATMENT", 171, 185], ["MTT assay", "TEST", 187, 196], ["cell lines", "OBSERVATION", 175, 185]]], ["Briefly, THP cells (1 \u00c2 10 5 cells/100 mL) was seeded in 96-well microliter plates at 37 C, 5% CO 2 .", [["THP cells", "ANATOMY", 9, 18], ["cells", "ANATOMY", 29, 34], ["THP", "CHEMICAL", 9, 12], ["CO", "CHEMICAL", 95, 97], ["THP cells", "CELL", 9, 18], ["cells", "CELL", 29, 34], ["THP cells", "CELL_LINE", 9, 18]]], ["After 48 h of incubation varying concentrations (10e100 mM) of GA was added in fresh medium.", [["GA", "CHEMICAL", 63, 65], ["GA", "SIMPLE_CHEMICAL", 63, 65], ["incubation varying concentrations (10e100 mM) of GA", "TREATMENT", 14, 65]]], ["MTT was added after 48 h of incubation followed by 4 h incubation at 37 C. The cells were harvested, the violet crystals were dissolved by DMSO and finally the OD was measured at 540 nm using micro plate reader.Growth curve of promastigotes in the presence and absence of GAThe effect of GA on growth of wild type promastigotes was determined in 25 cm 2 flasks.", [["cells", "ANATOMY", 79, 84], ["MTT", "CHEMICAL", 0, 3], ["DMSO", "CHEMICAL", 139, 143], ["GA", "CHEMICAL", 288, 290], ["MTT", "CHEMICAL", 0, 3], ["DMSO", "CHEMICAL", 139, 143], ["MTT", "SIMPLE_CHEMICAL", 0, 3], ["cells", "CELL", 79, 84], ["violet crystals", "SIMPLE_CHEMICAL", 105, 120], ["DMSO", "SIMPLE_CHEMICAL", 139, 143], ["promastigotes", "CELL", 227, 240], ["GA", "SIMPLE_CHEMICAL", 288, 290], ["promastigotes", "CELL", 314, 327], ["incubation", "TREATMENT", 28, 38], ["the violet crystals", "TREATMENT", 101, 120], ["DMSO", "TREATMENT", 139, 143], ["micro plate reader", "TREATMENT", 192, 210], ["wild type promastigotes", "PROBLEM", 304, 327], ["25 cm", "OBSERVATION_MODIFIER", 346, 351]]], ["Initially, 1 \u00c2 10 6 cells/mL were seeded at 24 C in RPMI-1640 medium supplemented with 10% heat inactivated fetal bovine serum.", [["cells", "ANATOMY", 20, 25], ["fetal bovine serum", "ANATOMY", 108, 126], ["RPMI-1640", "CHEMICAL", 52, 61], ["cells", "CELL", 20, 25], ["bovine", "ORGANISM", 114, 120], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["bovine", "SPECIES", 114, 120], ["bovine", "SPECIES", 114, 120], ["RPMI", "TEST", 52, 56], ["10% heat inactivated fetal bovine serum", "TREATMENT", 87, 126]]], ["Cell density was determined by Neubauer hemocytometer at every 24 h intervals for five days (120 h).", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell density", "TEST", 0, 12], ["density", "OBSERVATION", 5, 12]]], ["Inhibitory concentration of GLA (34 mM) was added to cells at 48 h and the growth of GA treated promastigotes was compared with the untreated promastigotes.Inhibition of recombinant L. donovani HMG-CoA reductase by glycyrrhizic acidIn order to express the recombinant L. donovani HMGR protein, E. coli BL21(DE3) cells were transformed with the construct pET30a-LdHMGR and then recombinant LdHMGR enzyme was purified by using affinity chromatography as reported earlier .", [["cells", "ANATOMY", 53, 58], ["cells", "ANATOMY", 312, 317], ["GLA", "CHEMICAL", 28, 31], ["GA", "CHEMICAL", 85, 87], ["GLA", "CHEMICAL", 28, 31], ["HMG-CoA", "CHEMICAL", 194, 201], ["glycyrrhizic acidIn", "CHEMICAL", 215, 234], ["GLA", "SIMPLE_CHEMICAL", 28, 31], ["cells", "CELL", 53, 58], ["GA", "SIMPLE_CHEMICAL", 85, 87], ["promastigotes", "CELL", 142, 155], ["L. donovani", "ORGANISM", 182, 193], ["HMG-CoA reductase", "GENE_OR_GENE_PRODUCT", 194, 211], ["glycyrrhizic acidIn", "SIMPLE_CHEMICAL", 215, 234], ["L. donovani", "ORGANISM", 268, 279], ["HMGR", "GENE_OR_GENE_PRODUCT", 280, 284], ["E. coli", "ORGANISM", 294, 301], ["BL21", "ORGANISM", 302, 306], ["DE3) cells", "CELL", 307, 317], ["pET30a-LdHMGR", "GENE_OR_GENE_PRODUCT", 354, 367], ["LdHMGR", "GENE_OR_GENE_PRODUCT", 389, 395], ["recombinant L. donovani HMG-CoA reductase", "PROTEIN", 170, 211], ["recombinant L. donovani HMGR protein", "PROTEIN", 256, 292], ["E. coli BL21(DE3) cells", "CELL_LINE", 294, 317], ["pET30a", "PROTEIN", 354, 360], ["LdHMGR", "PROTEIN", 361, 367], ["recombinant LdHMGR enzyme", "PROTEIN", 377, 402], ["L. donovani", "SPECIES", 182, 193], ["L. donovani", "SPECIES", 268, 279], ["E. coli BL21", "SPECIES", 294, 306], ["L. donovani", "SPECIES", 182, 193], ["L. donovani", "SPECIES", 268, 279], ["E. coli BL21", "SPECIES", 294, 306], ["Inhibitory concentration of GLA (34 mM)", "TREATMENT", 0, 39], ["GA treated promastigotes", "TREATMENT", 85, 109], ["recombinant L. donovani HMG", "TREATMENT", 170, 197], ["CoA reductase", "TREATMENT", 198, 211], ["glycyrrhizic acidIn order", "TREATMENT", 215, 240], ["the recombinant L. donovani HMGR protein", "TEST", 252, 292], ["E. coli BL21(DE3) cells", "PROBLEM", 294, 317], ["the construct pET30a", "TEST", 340, 360], ["LdHMGR", "TEST", 361, 367], ["recombinant LdHMGR enzyme", "TEST", 377, 402], ["affinity chromatography", "TEST", 425, 448], ["donovani HMG", "OBSERVATION", 185, 197], ["CoA", "ANATOMY", 198, 201]]], ["LdHMGR enzyme activity measurements were carried out to determine the effect of GA on the activity of recombinant L. donovani HMGR enzyme in the presence of different concentrations of GA after 5 min incubation.", [["GA", "CHEMICAL", 80, 82], ["GA", "CHEMICAL", 185, 187], ["LdHMGR", "GENE_OR_GENE_PRODUCT", 0, 6], ["GA", "SIMPLE_CHEMICAL", 80, 82], ["L. donovani", "ORGANISM", 114, 125], ["HMGR enzyme", "GENE_OR_GENE_PRODUCT", 126, 137], ["GA", "SIMPLE_CHEMICAL", 185, 187], ["LdHMGR", "PROTEIN", 0, 6], ["recombinant L. donovani HMGR enzyme", "PROTEIN", 102, 137], ["L. donovani", "SPECIES", 114, 125], ["L. donovani", "SPECIES", 114, 125], ["LdHMGR enzyme activity measurements", "TEST", 0, 35], ["recombinant L. donovani HMGR enzyme", "TREATMENT", 102, 137], ["different concentrations of GA", "PROBLEM", 157, 187], ["donovani HMGR", "OBSERVATION", 117, 130]]], ["The oxidation of NADPH was monitored at 340 nm.", [["NADPH", "CHEMICAL", 17, 22], ["NADPH", "CHEMICAL", 17, 22], ["NADPH", "SIMPLE_CHEMICAL", 17, 22], ["NADPH", "TEST", 17, 22]]], ["One unit (U) of HMGR was defined as the amount of enzyme required to catalyze the oxidation of 1 mmol of NADPH per min.", [["NADPH", "CHEMICAL", 105, 110], ["NADPH", "CHEMICAL", 105, 110], ["HMGR", "GENE_OR_GENE_PRODUCT", 16, 20], ["NADPH", "SIMPLE_CHEMICAL", 105, 110], ["HMGR", "PROTEIN", 16, 20], ["HMGR", "TREATMENT", 16, 20]]], ["Atorvastatin, the chemical inhibitor of HMGR was taken as the positive control.", [["Atorvastatin", "CHEMICAL", 0, 12], ["Atorvastatin", "CHEMICAL", 0, 12], ["Atorvastatin", "SIMPLE_CHEMICAL", 0, 12], ["HMGR", "GENE_OR_GENE_PRODUCT", 40, 44], ["HMGR", "PROTEIN", 40, 44], ["Atorvastatin", "TREATMENT", 0, 12], ["the chemical inhibitor of HMGR", "TREATMENT", 14, 44]]], ["Various concentrations of atorvastatin ranging from 1 to 1000 nM were used in the assay.Preparation of total cell lysates and HMGR activity in L. donovani promastigotesApproximately, 1 \u00c2 10 8 cells were grown for 48 h and treated with IC 50 concentration of GA (34 mM) and atorvastatin (19 mM) for 48 h at 24 C. Atorvastatin was taken as the positive control for HMGR inhibition.", [["cell lysates", "ANATOMY", 109, 121], ["cells", "ANATOMY", 192, 197], ["atorvastatin", "CHEMICAL", 26, 38], ["GA", "CHEMICAL", 258, 260], ["atorvastatin", "CHEMICAL", 273, 285], ["Atorvastatin", "CHEMICAL", 312, 324], ["atorvastatin", "CHEMICAL", 26, 38], ["atorvastatin", "CHEMICAL", 273, 285], ["Atorvastatin", "CHEMICAL", 312, 324], ["atorvastatin", "SIMPLE_CHEMICAL", 26, 38], ["cell lysates", "ORGANISM_SUBSTANCE", 109, 121], ["HMGR", "GENE_OR_GENE_PRODUCT", 126, 130], ["L. donovani", "ORGANISM", 143, 154], ["promastigotes", "ORGANISM", 155, 168], ["cells", "CELL", 192, 197], ["GA", "SIMPLE_CHEMICAL", 258, 260], ["atorvastatin", "SIMPLE_CHEMICAL", 273, 285], ["Atorvastatin", "SIMPLE_CHEMICAL", 312, 324], ["HMGR", "GENE_OR_GENE_PRODUCT", 363, 367], ["HMGR", "PROTEIN", 126, 130], ["HMGR", "PROTEIN", 363, 367], ["L. donovani", "SPECIES", 143, 154], ["L. donovani", "SPECIES", 143, 154], ["atorvastatin", "TREATMENT", 26, 38], ["total cell lysates", "TREATMENT", 103, 121], ["HMGR activity in L. donovani promastigotes", "TREATMENT", 126, 168], ["IC 50 concentration of GA", "TREATMENT", 235, 260], ["atorvastatin", "TREATMENT", 273, 285], ["Atorvastatin", "TREATMENT", 312, 324], ["HMGR inhibition", "TREATMENT", 363, 378], ["total cell lysates", "OBSERVATION", 103, 121], ["donovani promastigotes", "OBSERVATION", 146, 168]]], ["The cells were harvested at 6000g for 10 min and washed with PBS.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["PBS", "TREATMENT", 61, 64]]], ["The cell pellet was resuspended in lysis buffer [50 mM KH 2 PO 4 (pH 7.2), 1 mM DTT, 2 mM PMSF and 0.5 mg/mL leupeptin] and lysed by repeated freeze thaw cycles in liquid nitrogen and at 37 C. The cell lysate was extracted after centrifugation at 13000g for 30 min at 4 C. Cell lysate from untreated parasites was taken as control.", [["cell pellet", "ANATOMY", 4, 15], ["cell lysate", "ANATOMY", 197, 208], ["Cell lysate", "ANATOMY", 273, 284], ["KH 2 PO 4", "CHEMICAL", 55, 64], ["DTT", "CHEMICAL", 80, 83], ["PMSF", "CHEMICAL", 90, 94], ["leupeptin", "CHEMICAL", 109, 118], ["nitrogen", "CHEMICAL", 171, 179], ["cell", "CELL", 4, 8], ["DTT", "SIMPLE_CHEMICAL", 80, 83], ["PMSF", "SIMPLE_CHEMICAL", 90, 94], ["leupeptin", "SIMPLE_CHEMICAL", 109, 118], ["cell lysate", "CELL", 197, 208], ["Cell lysate", "CELL", 273, 284], ["The cell pellet", "TREATMENT", 0, 15], ["lysis buffer", "TREATMENT", 35, 47], ["pH", "TEST", 66, 68], ["DTT", "TEST", 80, 83], ["leupeptin", "TREATMENT", 109, 118], ["repeated freeze thaw cycles in liquid nitrogen", "TREATMENT", 133, 179], ["The cell lysate", "TREATMENT", 193, 208], ["centrifugation", "TREATMENT", 229, 243], ["Cell lysate", "TREATMENT", 273, 284], ["untreated parasites", "PROBLEM", 290, 309], ["cell pellet", "OBSERVATION", 4, 15]]], ["HMGR activity was carried out as described earlier using an equal amount of untreated, GA treated and atorvastatin treated total cell lysate.Preparation of total cell lysates and HMGR activity in L. donovani promastigotes2.9.", [["cell lysate", "ANATOMY", 129, 140], ["cell lysates", "ANATOMY", 162, 174], ["GA", "CHEMICAL", 87, 89], ["atorvastatin", "CHEMICAL", 102, 114], ["atorvastatin", "CHEMICAL", 102, 114], ["HMGR", "GENE_OR_GENE_PRODUCT", 0, 4], ["GA", "SIMPLE_CHEMICAL", 87, 89], ["atorvastatin", "SIMPLE_CHEMICAL", 102, 114], ["cell", "CELL", 129, 133], ["cell lysates", "ORGANISM_SUBSTANCE", 162, 174], ["HMGR", "GENE_OR_GENE_PRODUCT", 179, 183], ["L. donovani promastigotes2.9", "ORGANISM", 196, 224], ["HMGR", "PROTEIN", 0, 4], ["HMGR", "PROTEIN", 179, 183], ["L. donovani", "SPECIES", 196, 207], ["L. donovani", "SPECIES", 196, 207], ["HMGR activity", "TEST", 0, 13], ["GA", "TREATMENT", 87, 89], ["atorvastatin", "TREATMENT", 102, 114], ["total cell lysate", "TREATMENT", 123, 140], ["total cell lysates", "TREATMENT", 156, 174], ["HMGR activity", "TREATMENT", 179, 192], ["total cell lysates", "OBSERVATION", 156, 174], ["activity", "OBSERVATION_MODIFIER", 184, 192]]], ["Protein immunoblotting 1 \u00c2 10 8 promastigotes were inoculated in 25 cm 2 tissue culture flasks and treated with IC 50 concentrations of GA for 48 h.", [["GA", "CHEMICAL", 136, 138], ["GA", "SIMPLE_CHEMICAL", 136, 138], ["Protein immunoblotting", "TREATMENT", 0, 22], ["tissue culture flasks", "TEST", 73, 94], ["IC 50 concentrations of GA", "TREATMENT", 112, 138], ["25 cm", "OBSERVATION_MODIFIER", 65, 70]]], ["The cells were lysed as described in section 2.7 and approximately 100 mg of protein samples were subjected to 10% SDS-PAGE and transferred onto nitrocellulose membrane by electroblotting (Bio-Rad) at 50 V, 350 mA for 3 h.", [["cells", "ANATOMY", 4, 9], ["samples", "ANATOMY", 85, 92], ["membrane", "ANATOMY", 160, 168], ["SDS", "CHEMICAL", 115, 118], ["nitrocellulose", "CHEMICAL", 145, 159], ["cells", "CELL", 4, 9], ["membrane", "CELLULAR_COMPONENT", 160, 168], ["protein samples", "TEST", 77, 92], ["nitrocellulose membrane", "TREATMENT", 145, 168]]], ["The membrane was incubated with polyclonal antirat HMGR antibody (1:500) for overnight at 4 C temperature followed by anti-rabbit IgG alkaline phosphatase conjugate as secondary antibody (Sigma,1:10,000) for 1 h.", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["HMGR antibody", "GENE_OR_GENE_PRODUCT", 51, 64], ["polyclonal antirat HMGR antibody", "PROTEIN", 32, 64], ["anti-rabbit IgG alkaline phosphatase conjugate", "PROTEIN", 118, 164], ["secondary antibody", "PROTEIN", 168, 186], ["anti-rabbit", "SPECIES", 118, 129], ["anti-rabbit", "SPECIES", 118, 129], ["polyclonal antirat HMGR antibody", "TEST", 32, 64], ["temperature", "TEST", 94, 105], ["anti-rabbit IgG alkaline phosphatase conjugate", "TEST", 118, 164]]], ["The specific protein bands were visualized by incubating with nitro blue tetrazolium (NBT) and 5-bromo-4-chloro3-indolyl phosphate disodium salt (BCIP) as substrates .", [["nitro blue tetrazolium", "CHEMICAL", 62, 84], ["NBT", "CHEMICAL", 86, 89], ["5-bromo-4-chloro3-indolyl phosphate disodium salt", "CHEMICAL", 95, 144], ["BCIP", "CHEMICAL", 146, 150], ["nitro blue tetrazolium", "CHEMICAL", 62, 84], ["NBT", "CHEMICAL", 86, 89], ["5-bromo-4-chloro3-indolyl phosphate disodium salt", "CHEMICAL", 95, 144], ["BCIP", "CHEMICAL", 146, 150], ["nitro blue tetrazolium", "SIMPLE_CHEMICAL", 62, 84], ["NBT", "SIMPLE_CHEMICAL", 86, 89], ["5-bromo-4-chloro3-indolyl phosphate disodium salt", "SIMPLE_CHEMICAL", 95, 144], ["BCIP", "SIMPLE_CHEMICAL", 146, 150], ["The specific protein bands", "TEST", 0, 26], ["nitro blue tetrazolium", "TREATMENT", 62, 84], ["NBT", "TEST", 86, 89], ["bromo", "TREATMENT", 97, 102], ["chloro3-indolyl phosphate disodium salt (BCIP)", "TREATMENT", 105, 151], ["protein bands", "OBSERVATION", 13, 26]]], ["Densitometric analysis of the blot was performed using Image J software.", [["Densitometric analysis", "TEST", 0, 22], ["the blot", "TEST", 26, 34], ["Image J software", "TEST", 55, 71]]], ["Acetyl CoA synthetase earlier reported from our lab was used as a negative control to show the specific effect of GA on HMGR (Soumya et al., 2015) .HPLC analysis of ergosterol levels in L. donovani promastigotesA solution of 1 mg/mL of ergosterol served as the control.", [["Acetyl CoA", "CHEMICAL", 0, 10], ["GA", "CHEMICAL", 114, 116], ["ergosterol", "CHEMICAL", 165, 175], ["ergosterol", "CHEMICAL", 236, 246], ["Acetyl CoA", "CHEMICAL", 0, 10], ["ergosterol", "CHEMICAL", 165, 175], ["ergosterol", "CHEMICAL", 236, 246], ["Acetyl CoA synthetase", "GENE_OR_GENE_PRODUCT", 0, 21], ["GA", "SIMPLE_CHEMICAL", 114, 116], ["HMGR", "GENE_OR_GENE_PRODUCT", 120, 124], ["ergosterol", "SIMPLE_CHEMICAL", 165, 175], ["L. donovani", "ORGANISM", 186, 197], ["promastigotesA", "ORGANISM", 198, 212], ["ergosterol", "SIMPLE_CHEMICAL", 236, 246], ["Acetyl CoA synthetase", "PROTEIN", 0, 21], ["HMGR", "PROTEIN", 120, 124], ["L. donovani", "SPECIES", 186, 197], ["L. donovani", "SPECIES", 186, 197], ["Acetyl CoA synthetase", "TREATMENT", 0, 21], ["HPLC analysis", "TEST", 148, 161], ["ergosterol levels", "TEST", 165, 182], ["L. donovani promastigotesA solution", "TREATMENT", 186, 221], ["ergosterol", "TREATMENT", 236, 246], ["ergosterol levels", "OBSERVATION", 165, 182]]], ["The injection volume was 50 mL.", [["The injection volume", "TREATMENT", 0, 20]]], ["An Agilent technologies C 18 column, 100 mm \u00c2 4.6 mm, 3.5 mm particles was used for RP-HPLC.", [["An Agilent technologies C 18 column", "TREATMENT", 0, 35], ["3.5 mm particles", "TREATMENT", 54, 70], ["RP-HPLC", "TEST", 84, 91]]], ["To evaluate the effect of GA on ergosterol biosynthesis, promastigotes approximately 1 \u00c2 10 6 cells/mL were seeded in culture flask.", [["cells", "ANATOMY", 94, 99], ["GA", "CHEMICAL", 26, 28], ["ergosterol", "CHEMICAL", 32, 42], ["ergosterol", "CHEMICAL", 32, 42], ["GA", "SIMPLE_CHEMICAL", 26, 28], ["ergosterol", "SIMPLE_CHEMICAL", 32, 42], ["cells", "CELL", 94, 99], ["ergosterol biosynthesis", "TREATMENT", 32, 55], ["promastigotes", "TREATMENT", 57, 70], ["culture flask", "TEST", 118, 131]]], ["After 48 h of incubation, the cells were treated with GA (at IC 50 concentration) and further incubated for 48 h.", [["cells", "ANATOMY", 30, 35], ["GA", "CHEMICAL", 54, 56], ["cells", "CELL", 30, 35], ["GA", "SIMPLE_CHEMICAL", 54, 56], ["incubation", "TREATMENT", 14, 24], ["GA (at IC 50 concentration", "TREATMENT", 54, 80]]], ["The cells were harvested and the sample was prepared for HPLC as reported earlier (Ng et al., 2008) .", [["cells", "ANATOMY", 4, 9], ["sample", "ANATOMY", 33, 39], ["cells", "CELL", 4, 9], ["HPLC", "TEST", 57, 61]]], ["Appropriate controls without GA treatment was also taken.Ergosterol reversion assayThis study was performed to examine the rescue of GA treated L. donovani promastigotes upon ergosterol supplementation.", [["GA", "CHEMICAL", 29, 31], ["Ergosterol", "CHEMICAL", 57, 67], ["GA", "CHEMICAL", 133, 135], ["ergosterol", "CHEMICAL", 175, 185], ["Ergosterol", "CHEMICAL", 57, 67], ["ergosterol", "CHEMICAL", 175, 185], ["GA", "SIMPLE_CHEMICAL", 29, 31], ["Ergosterol", "SIMPLE_CHEMICAL", 57, 67], ["GA", "SIMPLE_CHEMICAL", 133, 135], ["L. donovani", "ORGANISM", 144, 155], ["promastigotes", "ORGANISM", 156, 169], ["ergosterol", "SIMPLE_CHEMICAL", 175, 185], ["L. donovani", "SPECIES", 144, 155], ["L. donovani", "SPECIES", 144, 155], ["GA treatment", "TREATMENT", 29, 41], ["Ergosterol reversion assay", "TEST", 57, 83], ["This study", "TEST", 83, 93], ["L. donovani promastigotes", "TREATMENT", 144, 169], ["ergosterol supplementation", "TREATMENT", 175, 201]]], ["Briefly, promastigotes were seeded in 96-well plate for 48 h, treated with GA at its IC 50 concentration.", [["promastigotes", "ANATOMY", 9, 22], ["GA", "CHEMICAL", 75, 77], ["promastigotes", "CELL", 9, 22], ["GA", "SIMPLE_CHEMICAL", 75, 77], ["GA at its IC", "TREATMENT", 75, 87]]], ["The cells were simultaneously supplemented with exogenous ergosterol in varying concentrations 50e200 mmol/L dissolved in methanol.", [["cells", "ANATOMY", 4, 9], ["ergosterol", "CHEMICAL", 58, 68], ["methanol", "CHEMICAL", 122, 130], ["ergosterol", "CHEMICAL", 58, 68], ["methanol", "CHEMICAL", 122, 130], ["cells", "CELL", 4, 9], ["ergosterol", "SIMPLE_CHEMICAL", 58, 68], ["methanol", "SIMPLE_CHEMICAL", 122, 130], ["exogenous ergosterol in varying concentrations", "TREATMENT", 48, 94], ["methanol", "TREATMENT", 122, 130]]], ["The cells were supplemented with 200 mmol/L ergosterol as control.", [["cells", "ANATOMY", 4, 9], ["ergosterol", "CHEMICAL", 44, 54], ["ergosterol", "CHEMICAL", 44, 54], ["cells", "CELL", 4, 9], ["ergosterol", "SIMPLE_CHEMICAL", 44, 54], ["L ergosterol", "TREATMENT", 42, 54]]], ["The percentage of promastigotes that were live upon rescue was analyzed by MTT assay.", [["MTT", "CHEMICAL", 75, 78], ["promastigotes", "CELL", 18, 31], ["MTT assay", "TEST", 75, 84]]], ["All assays were performed in triplicates and growth controls with the solvent and the solvent plus ergosterol were included to verify the lack of promastigote growth inhibitory effects.Effect of glycyrrhizic acid on HMGR overexpressing L. donovani promastigotesTo confirm the specificity of GA towards L. donovani HMGR we used previously generated HMGR overexpressor promastigotes as described earlier .", [["ergosterol", "CHEMICAL", 99, 109], ["glycyrrhizic acid", "CHEMICAL", 195, 212], ["GA", "CHEMICAL", 291, 293], ["ergosterol", "CHEMICAL", 99, 109], ["glycyrrhizic acid", "CHEMICAL", 195, 212], ["ergosterol", "SIMPLE_CHEMICAL", 99, 109], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 195, 212], ["HMGR", "GENE_OR_GENE_PRODUCT", 216, 220], ["L. donovani", "ORGANISM", 236, 247], ["promastigotes", "ORGANISM", 248, 261], ["GA", "SIMPLE_CHEMICAL", 291, 293], ["L. donovani", "ORGANISM", 302, 313], ["HMGR", "GENE_OR_GENE_PRODUCT", 314, 318], ["HMGR", "GENE_OR_GENE_PRODUCT", 348, 352], ["HMGR", "PROTEIN", 216, 220], ["L. donovani HMGR", "PROTEIN", 302, 318], ["HMGR", "PROTEIN", 348, 352], ["L. donovani", "SPECIES", 236, 247], ["L. donovani", "SPECIES", 302, 313], ["L. donovani", "SPECIES", 236, 247], ["L. donovani", "SPECIES", 302, 313], ["All assays", "TEST", 0, 10], ["the solvent", "TREATMENT", 66, 77], ["the solvent plus ergosterol", "TREATMENT", 82, 109], ["promastigote growth inhibitory effects", "PROBLEM", 146, 184], ["glycyrrhizic acid", "TREATMENT", 195, 212], ["HMGR overexpressing L. donovani promastigotes", "TREATMENT", 216, 261], ["L. donovani HMGR", "TREATMENT", 302, 318], ["previously generated HMGR overexpressor promastigotes", "TREATMENT", 327, 380], ["donovani promastigotes", "OBSERVATION", 239, 261]]], ["Briefly, late log phase wild type and overexpressing promastigotes were seeded in a 96-well flat bottom plate and incubated for 48 h at 24 C. To examine the effect of GA, the parasites were incubated with range of concentrations of GA from 10 to 100 mM for 48 h.", [["promastigotes", "ANATOMY", 53, 66], ["GA", "CHEMICAL", 167, 169], ["GA", "CHEMICAL", 232, 234], ["promastigotes", "CELL", 53, 66], ["GA", "SIMPLE_CHEMICAL", 167, 169], ["GA", "SIMPLE_CHEMICAL", 232, 234], ["overexpressing promastigotes", "PROBLEM", 38, 66], ["flat bottom plate", "TREATMENT", 92, 109], ["the parasites", "PROBLEM", 171, 184], ["GA", "TEST", 232, 234], ["log phase", "OBSERVATION_MODIFIER", 14, 23]]], ["After 72 h of incubation, MTT (5 mg/mL, 20 mL per well) was added to each well and the plates were incubated for an additional 4 h at 37 C. Then the cells were harvested and resultant pellet dissolved in DMSO.", [["cells", "ANATOMY", 149, 154], ["MTT", "CHEMICAL", 26, 29], ["DMSO", "CHEMICAL", 204, 208], ["MTT", "CHEMICAL", 26, 29], ["DMSO", "CHEMICAL", 204, 208], ["MTT", "SIMPLE_CHEMICAL", 26, 29], ["cells", "CELL", 149, 154], ["DMSO", "SIMPLE_CHEMICAL", 204, 208], ["incubation", "TREATMENT", 14, 24], ["MTT", "TREATMENT", 26, 29], ["pellet dissolved", "OBSERVATION", 184, 200]]], ["The final absorbance was measured at 540 nm.Statistical analysisOne-way analysis of variance (ANOVA) was performed for comparison between groups.", [["The final absorbance", "TEST", 0, 20], ["Statistical analysis", "TEST", 44, 64], ["variance (ANOVA)", "TEST", 84, 100], ["absorbance", "OBSERVATION_MODIFIER", 10, 20]]], ["Statistical analysis of the data was done using Graph Pad Prism software version 5.0.", [["Statistical analysis", "TEST", 0, 20], ["the data", "TEST", 24, 32], ["Graph Pad Prism software version", "TEST", 48, 80]]], ["Only values of p 0.05 were considered significant.Effect of glycyrrhizic acid on promastigotes, intracellular amastigotes and macrophagesThe chemical structure of GA is shown in Fig. 1 .", [["intracellular amastigotes", "ANATOMY", 96, 121], ["macrophages", "ANATOMY", 126, 137], ["glycyrrhizic acid", "CHEMICAL", 60, 77], ["GA", "CHEMICAL", 163, 165], ["glycyrrhizic acid", "CHEMICAL", 60, 77], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 60, 77], ["promastigotes", "CELL", 81, 94], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 96, 109], ["amastigotes", "CELL", 110, 121], ["macrophages", "CELL", 126, 137], ["GA", "SIMPLE_CHEMICAL", 163, 165], ["macrophages", "CELL_TYPE", 126, 137], ["glycyrrhizic acid on promastigotes", "TREATMENT", 60, 94], ["intracellular amastigotes", "TREATMENT", 96, 121], ["macrophages", "TREATMENT", 126, 137], ["glycyrrhizic acid", "OBSERVATION", 60, 77], ["macrophages", "OBSERVATION", 126, 137], ["chemical structure", "OBSERVATION", 141, 159], ["GA", "OBSERVATION", 163, 165]]], ["To determine the dose-dependent effect of GA on L. donovani promastigotes, the cells were plated with various concentrations of investigating compound.", [["cells", "ANATOMY", 79, 84], ["GA", "CHEMICAL", 42, 44], ["GA", "SIMPLE_CHEMICAL", 42, 44], ["L. donovani", "ORGANISM", 48, 59], ["promastigotes", "ORGANISM", 60, 73], ["cells", "CELL", 79, 84], ["L. donovani", "SPECIES", 48, 59], ["L. donovani", "SPECIES", 48, 59], ["L. donovani promastigotes", "TREATMENT", 48, 73], ["the cells", "TREATMENT", 75, 84]]], ["The viability was assessed after 48 h exposure to the drug using MTT assay.", [["MTT", "CHEMICAL", 65, 68], ["MTT assay", "TEST", 65, 74], ["viability", "OBSERVATION_MODIFIER", 4, 13]]], ["In the presence of GA, a dose-dependent inhibition of the viability of L. donovani promastigotes was observed.", [["GA", "CHEMICAL", 19, 21], ["GA", "SIMPLE_CHEMICAL", 19, 21], ["L. donovani", "ORGANISM", 71, 82], ["promastigotes", "ORGANISM", 83, 96], ["L. donovani", "SPECIES", 71, 82], ["L. donovani", "SPECIES", 71, 82], ["L. donovani promastigotes", "TREATMENT", 71, 96], ["donovani promastigotes", "OBSERVATION", 74, 96]]], ["The concentration of GA required to inhibit parasite viability by 50% was determined from the plot of drug concentrations against % of viability of promastigotes, assuming control (without drug) as 100% viable.", [["GA", "CHEMICAL", 21, 23], ["GA", "SIMPLE_CHEMICAL", 21, 23], ["parasite", "CELL", 44, 52], ["promastigotes", "CELL", 148, 161], ["The concentration of GA", "TREATMENT", 0, 23], ["parasite viability", "TREATMENT", 44, 62], ["drug concentrations", "TREATMENT", 102, 121]]], ["The IC 50 determined from the graph was 34 \u00b1 3 mM.", [["the graph", "TEST", 26, 35]]], ["The cytotoxic property of the GA against macrophages was determined in 96-well microliter plate by MTT assay and the results were expressed as the concentration of GA that inhibited cell viability by 50% of the control.", [["macrophages", "ANATOMY", 41, 52], ["cell", "ANATOMY", 182, 186], ["GA", "CHEMICAL", 30, 32], ["GA", "CHEMICAL", 164, 166], ["MTT", "CHEMICAL", 99, 102], ["GA", "SIMPLE_CHEMICAL", 30, 32], ["macrophages", "CELL", 41, 52], ["GA", "SIMPLE_CHEMICAL", 164, 166], ["cell", "CELL", 182, 186], ["macrophages", "CELL_TYPE", 41, 52], ["MTT assay", "TEST", 99, 108], ["cell viability", "TEST", 182, 196], ["cytotoxic", "OBSERVATION_MODIFIER", 4, 13], ["property", "OBSERVATION_MODIFIER", 14, 22]]], ["Macrophage cells were treated with varying concentrations of GA for 48 h, using standard drug miltefosine as the positive control.", [["Macrophage cells", "ANATOMY", 0, 16], ["GA", "CHEMICAL", 61, 63], ["miltefosine", "CHEMICAL", 94, 105], ["miltefosine", "CHEMICAL", 94, 105], ["Macrophage cells", "CELL", 0, 16], ["GA", "SIMPLE_CHEMICAL", 61, 63], ["miltefosine", "SIMPLE_CHEMICAL", 94, 105], ["Macrophage cells", "CELL_TYPE", 0, 16], ["Macrophage cells", "PROBLEM", 0, 16], ["varying concentrations of GA", "TREATMENT", 35, 63], ["standard drug miltefosine", "TREATMENT", 80, 105], ["the positive control", "TREATMENT", 109, 129]]], ["GA did not cause macrophage killing upto 100 mM concentrations.", [["macrophage", "ANATOMY", 17, 27], ["GA", "CHEMICAL", 0, 2], ["GA", "SIMPLE_CHEMICAL", 0, 2], ["macrophage", "CELL", 17, 27], ["macrophage killing", "PROBLEM", 17, 35]]], ["The reference drug miltefosine however, decreased the viability of macrophages up to 90% at 100 mM concentration (data not shown).", [["macrophages", "ANATOMY", 67, 78], ["miltefosine", "CHEMICAL", 19, 30], ["miltefosine", "CHEMICAL", 19, 30], ["miltefosine", "SIMPLE_CHEMICAL", 19, 30], ["macrophages", "CELL", 67, 78], ["macrophages", "CELL_TYPE", 67, 78], ["The reference drug miltefosine", "TREATMENT", 0, 30], ["drug miltefosine", "OBSERVATION", 14, 30], ["macrophages", "OBSERVATION_MODIFIER", 67, 78]]], ["GA was found to inhibit intracellular amastigotes in a dose dependent manner with an IC 50 value of 20 \u00b1 4.2 mM.", [["intracellular", "ANATOMY", 24, 37], ["GA", "CHEMICAL", 0, 2], ["GA", "SIMPLE_CHEMICAL", 0, 2], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 37], ["intracellular amastigotes", "PROBLEM", 24, 49], ["amastigotes", "OBSERVATION", 38, 49]]], ["A comparison of the IC 50 and 50% cytotoxic concentration (CC 50 ) values obtained for GA and miltefosine were represented in Table 1 .", [["CC", "CHEMICAL", 59, 61], ["GA", "CHEMICAL", 87, 89], ["miltefosine", "CHEMICAL", 94, 105], ["miltefosine", "CHEMICAL", 94, 105], ["GA", "SIMPLE_CHEMICAL", 87, 89], ["miltefosine", "SIMPLE_CHEMICAL", 94, 105], ["the IC", "TREATMENT", 16, 22], ["50% cytotoxic concentration (CC", "TREATMENT", 30, 61], ["GA", "TREATMENT", 87, 89], ["miltefosine", "TREATMENT", 94, 105]]], ["Selectivity index (SI) was calculated by dividing the CC 50 value of THP cell line with IC 50 value of amastigotes.", [["THP cell line", "ANATOMY", 69, 82], ["CC", "CHEMICAL", 54, 56], ["THP cell line", "CELL", 69, 82], ["THP cell line", "CELL_LINE", 69, 82], ["Selectivity index", "TEST", 0, 17], ["THP cell line", "TREATMENT", 69, 82], ["cell line", "OBSERVATION", 73, 82]]], ["The SI was calculated for GA and was found to be >5 whereas for miltefosine it was 11.5 (Table 1) .Effect of GA on growth of L. donovani promastigotesTo determine the inhibitory effect of GA on growth of wild type promastigote parasite, the growth of L. donovani promastigote was monitored over a period of 120 h.", [["miltefosine", "CHEMICAL", 64, 75], ["GA", "CHEMICAL", 109, 111], ["GA", "CHEMICAL", 188, 190], ["miltefosine", "CHEMICAL", 64, 75], ["miltefosine", "SIMPLE_CHEMICAL", 64, 75], ["GA", "SIMPLE_CHEMICAL", 109, 111], ["L. donovani", "ORGANISM", 125, 136], ["promastigotes", "ORGANISM", 137, 150], ["GA", "SIMPLE_CHEMICAL", 188, 190], ["L. donovani", "ORGANISM", 251, 262], ["promastigote", "ORGANISM", 263, 275], ["L. donovani", "SPECIES", 125, 136], ["L. donovani", "SPECIES", 251, 262], ["L. donovani", "SPECIES", 125, 136], ["L. donovani", "SPECIES", 251, 262], ["The SI", "TEST", 0, 6], ["GA", "TEST", 26, 28], ["miltefosine", "TREATMENT", 64, 75], ["L. donovani promastigotes", "TREATMENT", 125, 150], ["wild type promastigote parasite", "PROBLEM", 204, 235], ["L. donovani promastigote", "TREATMENT", 251, 275], ["donovani promastigotes", "OBSERVATION", 128, 150], ["growth", "OBSERVATION_MODIFIER", 241, 247]]], ["Parasites were enumerated every 24 h by counting using hemocytometer.", [["Parasites", "CELL", 0, 9], ["Parasites", "PROBLEM", 0, 9], ["hemocytometer", "TEST", 55, 68]]], ["IC 50 concentration of GA (34 mM) was added after 48 h.", [["GA", "CHEMICAL", 23, 25], ["GA", "SIMPLE_CHEMICAL", 23, 25], ["IC 50 concentration of GA (34 mM)", "TREATMENT", 0, 33]]], ["The result showed that GA affected the growth of L. donovani promastigotes.", [["GA", "CHEMICAL", 23, 25], ["GA", "SIMPLE_CHEMICAL", 23, 25], ["L. donovani promastigotes", "ORGANISM", 49, 74], ["L. donovani", "SPECIES", 49, 60], ["L. donovani", "SPECIES", 49, 60], ["GA", "PROBLEM", 23, 25], ["L. donovani promastigotes", "TREATMENT", 49, 74], ["growth", "OBSERVATION_MODIFIER", 39, 45], ["donovani promastigotes", "OBSERVATION", 52, 74]]], ["A decrease in growth rate of~1.4 fold after 24 h and~2.1 fold after 48 h of GA treated promastigotes compared to untreated wild type promastigotes was observed ( Fig. 2A) .", [["GA", "CHEMICAL", 76, 78], ["GA", "SIMPLE_CHEMICAL", 76, 78], ["promastigotes", "CELL", 133, 146], ["A decrease", "PROBLEM", 0, 10], ["growth rate", "TEST", 14, 25], ["GA treated promastigotes", "TREATMENT", 76, 100], ["untreated wild type promastigotes", "PROBLEM", 113, 146], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["growth", "OBSERVATION_MODIFIER", 14, 20], ["rate", "OBSERVATION_MODIFIER", 21, 25]]], ["This data revealed that GA affected the proliferation of L. donovani promastigotes.Inhibition of L. donovani HMG-CoA reductase enzyme by glycyrrhizic acidTo investigate the effect of GA on the catalytic efficiency of recombinant HMGR, the enzyme used for the assay was expressed and purified as reported earlier .", [["GA", "CHEMICAL", 24, 26], ["glycyrrhizic acid", "CHEMICAL", 137, 154], ["GA", "CHEMICAL", 183, 185], ["HMG-CoA", "CHEMICAL", 109, 116], ["glycyrrhizic acid", "CHEMICAL", 137, 154], ["GA", "SIMPLE_CHEMICAL", 24, 26], ["L. donovani promastigotes", "ORGANISM", 57, 82], ["L. donovani", "ORGANISM", 97, 108], ["HMG-CoA reductase", "GENE_OR_GENE_PRODUCT", 109, 126], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 137, 154], ["GA", "SIMPLE_CHEMICAL", 183, 185], ["HMGR", "GENE_OR_GENE_PRODUCT", 229, 233], ["L. donovani HMG-CoA reductase enzyme", "PROTEIN", 97, 133], ["recombinant HMGR", "PROTEIN", 217, 233], ["enzyme", "PROTEIN", 239, 245], ["L. donovani", "SPECIES", 57, 68], ["L. donovani", "SPECIES", 97, 108], ["L. donovani", "SPECIES", 57, 68], ["L. donovani", "SPECIES", 97, 108], ["This data", "TEST", 0, 9], ["GA", "PROBLEM", 24, 26], ["L. donovani promastigotes", "TREATMENT", 57, 82], ["L. donovani HMG", "TREATMENT", 97, 112], ["CoA reductase enzyme", "TEST", 113, 133], ["glycyrrhizic acid", "TREATMENT", 137, 154], ["recombinant HMGR", "TREATMENT", 217, 233], ["the enzyme", "TEST", 235, 245], ["the assay", "TEST", 255, 264], ["proliferation", "OBSERVATION_MODIFIER", 40, 53], ["L.", "OBSERVATION_MODIFIER", 57, 59], ["donovani promastigotes", "OBSERVATION", 60, 82], ["donovani HMG", "OBSERVATION", 100, 112]]], ["GA was tested at the range of 10e100 mM concentration.", [["GA", "CHEMICAL", 0, 2], ["GA", "SIMPLE_CHEMICAL", 0, 2]]], ["At higher concentrations 50 and 100 mM of GA only 15% residual HMGR activity was observed indicating that GA binds to HMGR causing its inhibition (Fig. 2B left panel) .", [["GA", "CHEMICAL", 42, 44], ["GA", "CHEMICAL", 106, 108], ["GA", "SIMPLE_CHEMICAL", 42, 44], ["HMGR", "GENE_OR_GENE_PRODUCT", 63, 67], ["GA", "SIMPLE_CHEMICAL", 106, 108], ["HMGR", "GENE_OR_GENE_PRODUCT", 118, 122], ["HMGR", "PROTEIN", 63, 67], ["HMGR", "PROTEIN", 118, 122], ["GA", "TEST", 42, 44], ["residual HMGR activity", "PROBLEM", 54, 76], ["GA binds", "PROBLEM", 106, 114], ["HMGR activity", "OBSERVATION", 63, 76]]], ["Atorvastatin was used a positive control for comparative analysis of GA as LdHMGR inhibitor (Fig. 2B right panel).", [["Atorvastatin", "CHEMICAL", 0, 12], ["GA", "CHEMICAL", 69, 71], ["Atorvastatin", "CHEMICAL", 0, 12], ["Atorvastatin", "SIMPLE_CHEMICAL", 0, 12], ["GA", "SIMPLE_CHEMICAL", 69, 71], ["LdHMGR", "SIMPLE_CHEMICAL", 75, 81], ["Atorvastatin", "TREATMENT", 0, 12], ["a positive control", "TREATMENT", 22, 40], ["comparative analysis", "TEST", 45, 65], ["GA", "TEST", 69, 71], ["LdHMGR inhibitor", "TREATMENT", 75, 91]]], ["At 1 mM approximately 86% inhibition was observed.Inhibition of L. donovani HMG-CoA reductase enzyme by glycyrrhizic acidThe IC 50 value was calculated to be 300 nM, which correlates with previously reported data .", [["glycyrrhizic acid", "CHEMICAL", 104, 121], ["HMG-CoA", "CHEMICAL", 76, 83], ["glycyrrhizic acid", "CHEMICAL", 104, 121], ["L. donovani", "ORGANISM", 64, 75], ["HMG-CoA reductase", "GENE_OR_GENE_PRODUCT", 76, 93], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 104, 121], ["L. donovani HMG-CoA reductase enzyme", "PROTEIN", 64, 100], ["L. donovani", "SPECIES", 64, 75], ["L. donovani", "SPECIES", 64, 75], ["L. donovani HMG", "TEST", 64, 79], ["CoA reductase enzyme", "TEST", 80, 100], ["glycyrrhizic acid", "TEST", 104, 121], ["L.", "OBSERVATION_MODIFIER", 64, 66], ["donovani HMG", "OBSERVATION", 67, 79]]], ["Atorvastatin is a more sensitive inhibitor of HMGR than GA as it inhibits the enzyme in lower micromolar range.", [["Atorvastatin", "CHEMICAL", 0, 12], ["GA", "CHEMICAL", 56, 58], ["Atorvastatin", "CHEMICAL", 0, 12], ["Atorvastatin", "SIMPLE_CHEMICAL", 0, 12], ["HMGR", "GENE_OR_GENE_PRODUCT", 46, 50], ["GA", "SIMPLE_CHEMICAL", 56, 58], ["HMGR", "PROTEIN", 46, 50], ["Atorvastatin", "TREATMENT", 0, 12], ["the enzyme", "TEST", 74, 84], ["lower", "ANATOMY_MODIFIER", 88, 93], ["micromolar range", "OBSERVATION", 94, 110]]], ["HMGR activity was also measured in the promastigotes in the absence and presence of GA.", [["GA", "CHEMICAL", 84, 86], ["HMGR", "GENE_OR_GENE_PRODUCT", 0, 4], ["GA", "SIMPLE_CHEMICAL", 84, 86], ["HMGR", "PROTEIN", 0, 4], ["HMGR activity", "PROBLEM", 0, 13]]], ["The GA treated promastigotes exhibited~30% reduction in HMGR activity in comparison to untreated parasites.", [["GA", "CHEMICAL", 4, 6], ["GA", "SIMPLE_CHEMICAL", 4, 6], ["HMGR", "GENE_OR_GENE_PRODUCT", 56, 60], ["HMGR", "PROTEIN", 56, 60], ["The GA treated promastigotes", "PROBLEM", 0, 28], ["HMGR activity", "PROBLEM", 56, 69], ["untreated parasites", "PROBLEM", 87, 106], ["HMGR activity", "OBSERVATION", 56, 69]]], ["Promastigotes treated with 19 mM of atorvastatin exhibited 51% inhibition thus serving as a positive control and inhibitor of HMGR (Fig. 2C) .Effect of GA on HMGR protein expression by western blot analysisEffect of GA on HMGR protein expression was evaluated by western blotting of L. donovani cell extracts obtained from promastigotes treated with IC 50 concentration of GA.", [["cell extracts", "ANATOMY", 295, 308], ["promastigotes", "ANATOMY", 323, 336], ["Promastigotes", "DISEASE", 0, 13], ["atorvastatin", "CHEMICAL", 36, 48], ["GA", "CHEMICAL", 152, 154], ["GA", "CHEMICAL", 216, 218], ["GA", "CHEMICAL", 373, 375], ["atorvastatin", "CHEMICAL", 36, 48], ["atorvastatin", "SIMPLE_CHEMICAL", 36, 48], ["HMGR", "GENE_OR_GENE_PRODUCT", 126, 130], ["GA", "SIMPLE_CHEMICAL", 152, 154], ["HMGR", "GENE_OR_GENE_PRODUCT", 158, 162], ["GA", "SIMPLE_CHEMICAL", 216, 218], ["HMGR", "GENE_OR_GENE_PRODUCT", 222, 226], ["L. donovani", "ORGANISM", 283, 294], ["cell extracts", "ORGANISM_SUBSTANCE", 295, 308], ["promastigotes", "CELL", 323, 336], ["GA", "SIMPLE_CHEMICAL", 373, 375], ["HMGR", "PROTEIN", 126, 130], ["HMGR", "PROTEIN", 158, 162], ["HMGR", "PROTEIN", 222, 226], ["L. donovani", "SPECIES", 283, 294], ["L. donovani", "SPECIES", 283, 294], ["Promastigotes", "TREATMENT", 0, 13], ["atorvastatin", "TREATMENT", 36, 48], ["a positive control", "TREATMENT", 90, 108], ["HMGR (Fig", "TREATMENT", 126, 135], ["HMGR protein expression", "TEST", 158, 181], ["blot analysisEffect", "TEST", 193, 212], ["HMGR protein expression", "TEST", 222, 245], ["L. donovani cell extracts", "TREATMENT", 283, 308], ["IC 50 concentration of GA", "TREATMENT", 350, 375], ["donovani cell", "OBSERVATION", 286, 299]]], ["The blot was stained with Ponceau S which served as loading control.", [["Ponceau S", "CHEMICAL", 26, 35], ["Ponceau S", "CHEMICAL", 26, 35], ["Ponceau S", "SPECIES", 26, 35], ["Ponceau S", "TREATMENT", 26, 35], ["loading control", "TREATMENT", 52, 67]]], ["Densitometric analysis of the blot revealed fivefold reduction in HMGR expression in GA treated promastigotes further confirming the effect of GA on HMGR (Fig. 3A) .", [["GA", "CHEMICAL", 85, 87], ["GA", "CHEMICAL", 143, 145], ["HMGR", "GENE_OR_GENE_PRODUCT", 66, 70], ["GA", "SIMPLE_CHEMICAL", 85, 87], ["GA", "SIMPLE_CHEMICAL", 143, 145], ["HMGR", "GENE_OR_GENE_PRODUCT", 149, 153], ["HMGR", "PROTEIN", 66, 70], ["HMGR", "PROTEIN", 149, 153], ["Densitometric analysis", "TEST", 0, 22], ["the blot", "TEST", 26, 34], ["fivefold reduction in HMGR expression", "PROBLEM", 44, 81], ["GA treated promastigotes", "TREATMENT", 85, 109], ["fivefold", "OBSERVATION_MODIFIER", 44, 52], ["reduction", "OBSERVATION_MODIFIER", 53, 62], ["HMGR expression", "OBSERVATION", 66, 81]]], ["To further prove the specificity of GA for HMGR, we randomly selected acetylCoA synthetase (AceCS) as control protein.", [["GA", "CHEMICAL", 36, 38], ["acetylCoA", "CHEMICAL", 70, 79], ["acetylCoA", "CHEMICAL", 70, 79], ["GA", "SIMPLE_CHEMICAL", 36, 38], ["HMGR", "GENE_OR_GENE_PRODUCT", 43, 47], ["acetylCoA synthetase", "GENE_OR_GENE_PRODUCT", 70, 90], ["AceCS", "SIMPLE_CHEMICAL", 92, 97], ["HMGR", "PROTEIN", 43, 47], ["acetylCoA synthetase", "PROTEIN", 70, 90], ["AceCS", "PROTEIN", 92, 97], ["control protein", "PROTEIN", 102, 117], ["HMGR", "TEST", 43, 47], ["selected acetylCoA synthetase (AceCS)", "TREATMENT", 61, 98]]], ["There are no reports of AceCS being targeted by GA.", [["GA", "CHEMICAL", 48, 50], ["AceCS", "GENE_OR_GENE_PRODUCT", 24, 29], ["GA", "SIMPLE_CHEMICAL", 48, 50], ["AceCS", "TREATMENT", 24, 29], ["no", "UNCERTAINTY", 10, 12]]], ["Densitometric analysis revealed no change in expression of AceCS when promastigotes were treated with GA (Fig. 3B) .Lowering of ergosterol levels in L. donovani promastigotes by glycyrrhizic acidStandardized HPLC method was used for the isolation of neutral lipids of L. donovani promastigotes.", [["GA", "CHEMICAL", 102, 104], ["ergosterol", "CHEMICAL", 128, 138], ["ergosterol", "CHEMICAL", 128, 138], ["AceCS", "GENE_OR_GENE_PRODUCT", 59, 64], ["GA", "SIMPLE_CHEMICAL", 102, 104], ["ergosterol", "SIMPLE_CHEMICAL", 128, 138], ["L. donovani promastigotes", "ORGANISM", 149, 174], ["glycyrrhizic", "SIMPLE_CHEMICAL", 178, 190], ["L. donovani promastigotes", "ORGANISM", 268, 293], ["AceCS", "PROTEIN", 59, 64], ["L. donovani", "SPECIES", 149, 160], ["L. donovani", "SPECIES", 268, 279], ["L. donovani", "SPECIES", 149, 160], ["L. donovani", "SPECIES", 268, 279], ["Densitometric analysis", "TEST", 0, 22], ["ergosterol levels", "TEST", 128, 145], ["L. donovani promastigotes", "TREATMENT", 149, 174], ["glycyrrhizic acidStandardized HPLC method", "TREATMENT", 178, 219], ["neutral lipids", "TREATMENT", 250, 264], ["L. donovani promastigotes", "TREATMENT", 268, 293], ["no", "UNCERTAINTY", 32, 34], ["change", "OBSERVATION_MODIFIER", 35, 41], ["ergosterol levels", "OBSERVATION", 128, 145], ["donovani promastigotes", "OBSERVATION", 271, 293]]], ["The retention time of ergosterol extracted from promastigotes was found at 11.18 min which correlated with standard ergosterol peak retention time (Fig. 4A) .", [["ergosterol", "CHEMICAL", 22, 32], ["ergosterol", "CHEMICAL", 116, 126], ["ergosterol", "CHEMICAL", 22, 32], ["ergosterol", "CHEMICAL", 116, 126], ["ergosterol", "SIMPLE_CHEMICAL", 22, 32], ["ergosterol", "SIMPLE_CHEMICAL", 116, 126], ["ergosterol", "TREATMENT", 22, 32], ["promastigotes", "PROBLEM", 48, 61], ["standard ergosterol peak retention", "TREATMENT", 107, 141], ["retention", "OBSERVATION_MODIFIER", 4, 13], ["peak retention", "OBSERVATION", 127, 141]]], ["HPLC chromatograms of wild type control parasites and GA treated parasites (34 mM) are shown in Fig. 4B left and right panel respectively which revealed almost 43% reduction in ergosterol levels in GA treated wild type promastigotes.", [["left", "ANATOMY", 104, 108], ["right panel", "ANATOMY", 113, 124], ["GA", "CHEMICAL", 54, 56], ["ergosterol", "CHEMICAL", 177, 187], ["GA", "CHEMICAL", 198, 200], ["ergosterol", "CHEMICAL", 177, 187], ["ergosterol", "SIMPLE_CHEMICAL", 177, 187], ["GA", "SIMPLE_CHEMICAL", 198, 200], ["promastigotes", "CELL", 219, 232], ["HPLC chromatograms", "TEST", 0, 18], ["wild type control parasites", "PROBLEM", 22, 49], ["4B left and right panel", "TEST", 101, 124], ["almost 43% reduction in ergosterol levels", "PROBLEM", 153, 194], ["left", "ANATOMY_MODIFIER", 104, 108], ["right", "ANATOMY_MODIFIER", 113, 118], ["almost", "OBSERVATION_MODIFIER", 153, 159], ["43%", "OBSERVATION_MODIFIER", 160, 163], ["reduction", "OBSERVATION_MODIFIER", 164, 173], ["ergosterol levels", "OBSERVATION", 177, 194]]], ["The % peak area for wild type control and GA treated promastigotes was 100% and 57% respectively.", [["GA", "CHEMICAL", 42, 44], ["The % peak area", "TREATMENT", 0, 15], ["wild type control", "TREATMENT", 20, 37], ["GA treated promastigotes", "TREATMENT", 42, 66]]], ["We had also estimated ergosterol levels in HMGR overexpressing untreated and GA treated L. donovani promastigotes (34 mM) as seen in Fig. 4C left and right panel respectively.", [["left", "ANATOMY", 141, 145], ["right panel", "ANATOMY", 150, 161], ["ergosterol", "CHEMICAL", 22, 32], ["GA", "CHEMICAL", 77, 79], ["ergosterol", "CHEMICAL", 22, 32], ["ergosterol", "SIMPLE_CHEMICAL", 22, 32], ["HMGR", "GENE_OR_GENE_PRODUCT", 43, 47], ["L. donovani", "ORGANISM", 88, 99], ["promastigotes", "ORGANISM", 100, 113], ["HMGR", "PROTEIN", 43, 47], ["L. donovani", "SPECIES", 88, 99], ["L. donovani", "SPECIES", 88, 99], ["estimated ergosterol levels", "TEST", 12, 39], ["L. donovani promastigotes", "TREATMENT", 88, 113], ["ergosterol levels", "OBSERVATION", 22, 39], ["donovani promastigotes", "OBSERVATION", 91, 113], ["left", "ANATOMY_MODIFIER", 141, 145], ["right", "ANATOMY_MODIFIER", 150, 155]]], ["The results showed that there was only~20% reduction in ergosterol levels in HMGR overexpressors upon treatment with GA in comparison to wild type where 43% reduction was observed.", [["ergosterol", "CHEMICAL", 56, 66], ["GA", "CHEMICAL", 117, 119], ["ergosterol", "CHEMICAL", 56, 66], ["ergosterol", "SIMPLE_CHEMICAL", 56, 66], ["HMGR", "GENE_OR_GENE_PRODUCT", 77, 81], ["GA", "SIMPLE_CHEMICAL", 117, 119], ["HMGR", "PROTEIN", 77, 81], ["ergosterol levels", "TEST", 56, 73], ["HMGR overexpressors", "TREATMENT", 77, 96], ["treatment", "TREATMENT", 102, 111], ["GA", "TREATMENT", 117, 119], ["reduction", "OBSERVATION_MODIFIER", 43, 52], ["ergosterol levels", "OBSERVATION", 56, 73]]], ["The % peak area for HMGR overexpressing control and GA treated promastigotes was found to be 330% and 274% respectively, calculated relatively from % peak area of wild type control which was considered 100%.", [["GA", "CHEMICAL", 52, 54], ["HMGR", "GENE_OR_GENE_PRODUCT", 20, 24], ["HMGR", "PROTEIN", 20, 24], ["The % peak area", "TREATMENT", 0, 15], ["HMGR overexpressing control", "TREATMENT", 20, 47], ["GA treated promastigotes", "TREATMENT", 52, 76], ["wild type control", "TREATMENT", 163, 180]]], ["It was observed that the ergosterol levels in HMGR overexpressors was~3 fold higher compared to wild type promastigotes.", [["ergosterol", "CHEMICAL", 25, 35], ["ergosterol", "CHEMICAL", 25, 35], ["ergosterol", "SIMPLE_CHEMICAL", 25, 35], ["HMGR", "GENE_OR_GENE_PRODUCT", 46, 50], ["promastigotes", "CELL", 106, 119], ["HMGR", "PROTEIN", 46, 50], ["the ergosterol levels", "TEST", 21, 42], ["HMGR overexpressors", "TEST", 46, 65]]], ["When the wild type and HMGR overexpressors were treated with the IC 50 concentration of GA, wild type parasites exhibited~2 fold reduction in ergosterol levels as compared to the HMGR overexpressors (Fig. 4D) .Reversal of glycyrrhizic acid mediated parasite inhibition by ergosterol supplementation in vitroGA treated Leishmania promastigote cultures were exogenously supplemented with different concentrations of ergosterol to study the role of exogenous sterol to overcome GA mediated inhibition.", [["cultures", "ANATOMY", 342, 350], ["GA", "CHEMICAL", 88, 90], ["ergosterol", "CHEMICAL", 142, 152], ["glycyrrhizic acid", "CHEMICAL", 222, 239], ["ergosterol", "CHEMICAL", 272, 282], ["vitroGA", "CHEMICAL", 302, 309], ["ergosterol", "CHEMICAL", 414, 424], ["GA", "CHEMICAL", 475, 477], ["ergosterol", "CHEMICAL", 142, 152], ["glycyrrhizic acid", "CHEMICAL", 222, 239], ["ergosterol", "CHEMICAL", 272, 282], ["ergosterol", "CHEMICAL", 414, 424], ["sterol", "CHEMICAL", 456, 462], ["HMGR", "GENE_OR_GENE_PRODUCT", 23, 27], ["GA", "SIMPLE_CHEMICAL", 88, 90], ["ergosterol", "SIMPLE_CHEMICAL", 142, 152], ["HMGR", "GENE_OR_GENE_PRODUCT", 179, 183], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 222, 239], ["ergosterol", "SIMPLE_CHEMICAL", 272, 282], ["vitroGA", "SIMPLE_CHEMICAL", 302, 309], ["ergosterol", "SIMPLE_CHEMICAL", 414, 424], ["sterol", "SIMPLE_CHEMICAL", 456, 462], ["GA", "SIMPLE_CHEMICAL", 475, 477], ["HMGR overexpressors", "PROTEIN", 23, 42], ["HMGR overexpressors", "PROTEIN", 179, 198], ["vitroGA treated Leishmania promastigote cultures", "CELL_LINE", 302, 350], ["HMGR overexpressors", "TREATMENT", 23, 42], ["the IC 50 concentration of GA", "TREATMENT", 61, 90], ["wild type parasites", "PROBLEM", 92, 111], ["ergosterol levels", "TEST", 142, 159], ["glycyrrhizic acid mediated parasite inhibition", "TREATMENT", 222, 268], ["ergosterol supplementation", "TREATMENT", 272, 298], ["vitroGA", "TREATMENT", 302, 309], ["Leishmania promastigote cultures", "TEST", 318, 350], ["ergosterol", "TREATMENT", 414, 424], ["exogenous sterol", "TREATMENT", 446, 462], ["GA mediated inhibition", "TREATMENT", 475, 497], ["reduction", "OBSERVATION_MODIFIER", 129, 138], ["ergosterol levels", "OBSERVATION", 142, 159], ["glycyrrhizic acid", "OBSERVATION", 222, 239], ["ergosterol supplementation", "OBSERVATION", 272, 298]]], ["Ergosterol rescued GA treated promastigotes at concentrations ranging from 50 to 200 mmol/L causing the reversal of GA mediated growth inhibition (Fig. 5 ).", [["Ergosterol", "CHEMICAL", 0, 10], ["GA", "CHEMICAL", 19, 21], ["GA", "CHEMICAL", 116, 118], ["Ergosterol", "CHEMICAL", 0, 10], ["Ergosterol", "SIMPLE_CHEMICAL", 0, 10], ["GA", "SIMPLE_CHEMICAL", 19, 21], ["GA", "SIMPLE_CHEMICAL", 116, 118], ["Ergosterol", "TREATMENT", 0, 10], ["GA mediated growth inhibition", "PROBLEM", 116, 145]]], ["Promastigotes treated with IC 50 value of GA showed 60% inhibition whereas in case of GA treated promastigotes supplemented with 200 mmol/L ergosterol showed only 20% inhibition i. e.", [["GA", "CHEMICAL", 42, 44], ["GA", "CHEMICAL", 86, 88], ["ergosterol", "CHEMICAL", 140, 150], ["ergosterol", "CHEMICAL", 140, 150], ["GA", "SIMPLE_CHEMICAL", 42, 44], ["GA", "SIMPLE_CHEMICAL", 86, 88], ["ergosterol", "SIMPLE_CHEMICAL", 140, 150], ["GA", "TEST", 42, 44], ["GA treated promastigotes", "TREATMENT", 86, 110], ["L ergosterol", "TREATMENT", 138, 150]]], ["40% reversal of inhibition.", [["40% reversal of inhibition", "TREATMENT", 0, 26]]], ["These results indicate that GA inhibition occurred by interfering with ergosterol biosynthesis which is a key sterol component for the survival of the parasite.", [["GA", "CHEMICAL", 28, 30], ["ergosterol", "CHEMICAL", 71, 81], ["ergosterol", "CHEMICAL", 71, 81], ["sterol", "CHEMICAL", 110, 116], ["GA", "SIMPLE_CHEMICAL", 28, 30], ["ergosterol", "SIMPLE_CHEMICAL", 71, 81], ["GA inhibition", "PROBLEM", 28, 41], ["ergosterol biosynthesis", "TREATMENT", 71, 94], ["a key sterol component", "TREATMENT", 104, 126]]], ["Solvent and solvent plus ergosterol were taken as controls and no background inhibition was observed.Reversal of glycyrrhizic acid mediated parasite inhibition by ergosterol supplementation in vitro3.7.", [["ergosterol", "CHEMICAL", 25, 35], ["glycyrrhizic acid", "CHEMICAL", 113, 130], ["ergosterol", "CHEMICAL", 163, 173], ["ergosterol", "CHEMICAL", 25, 35], ["glycyrrhizic acid", "CHEMICAL", 113, 130], ["ergosterol", "CHEMICAL", 163, 173], ["ergosterol", "SIMPLE_CHEMICAL", 25, 35], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 113, 130], ["ergosterol", "SIMPLE_CHEMICAL", 163, 173], ["Solvent and solvent plus ergosterol", "TREATMENT", 0, 35], ["background inhibition", "PROBLEM", 66, 87], ["glycyrrhizic acid mediated parasite inhibition", "TREATMENT", 113, 159], ["ergosterol supplementation", "TREATMENT", 163, 189], ["vitro3.7", "TREATMENT", 193, 201], ["glycyrrhizic acid", "OBSERVATION", 113, 130], ["ergosterol supplementation", "OBSERVATION", 163, 189]]], ["Effect of glycyrrhizic acid on L. donovani transfectants overexpressing HMGR L. donovani promastigotes overexpressing HMGR was maintained in the RPMI-1640 medium with constant selection pressure of hygromycin B. The half-maximum inhibitory concentration (IC 50 ) was 34 \u00b1 3 mM and 74 \u00b1 3.8 mM for wild type and LdHMGR overexpressing cells respectively.", [["cells", "ANATOMY", 333, 338], ["glycyrrhizic acid", "CHEMICAL", 10, 27], ["RPMI-1640", "CHEMICAL", 145, 154], ["hygromycin", "CHEMICAL", 198, 208], ["glycyrrhizic acid", "CHEMICAL", 10, 27], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 10, 27], ["L. donovani transfectants", "ORGANISM", 31, 56], ["HMGR L. donovani promastigotes", "ORGANISM", 72, 102], ["HMGR", "GENE_OR_GENE_PRODUCT", 118, 122], ["LdHMGR", "GENE_OR_GENE_PRODUCT", 311, 317], ["cells", "CELL", 333, 338], ["HMGR", "PROTEIN", 72, 76], ["HMGR", "PROTEIN", 118, 122], ["LdHMGR overexpressing cells", "CELL_LINE", 311, 338], ["L. donovani", "SPECIES", 31, 42], ["L. donovani", "SPECIES", 77, 88], ["L. donovani", "SPECIES", 31, 42], ["L. donovani", "SPECIES", 77, 88], ["glycyrrhizic acid", "TREATMENT", 10, 27], ["L. donovani transfectants", "TREATMENT", 31, 56], ["HMGR L. donovani promastigotes overexpressing HMGR", "TREATMENT", 72, 122], ["constant selection pressure of hygromycin", "TREATMENT", 167, 208], ["wild type and LdHMGR overexpressing cells", "PROBLEM", 297, 338], ["glycyrrhizic acid", "OBSERVATION", 10, 27], ["overexpressing cells", "OBSERVATION", 318, 338]]], ["LdHMGR overexpressors exhibited~2 fold increase in IC 50 of GA as compared to the wild-type promastigotes (Fig. 6) .", [["GA", "CHEMICAL", 60, 62], ["LdHMGR", "GENE_OR_GENE_PRODUCT", 0, 6], ["GA", "SIMPLE_CHEMICAL", 60, 62], ["promastigotes", "CELL", 92, 105], ["LdHMGR", "PROTEIN", 0, 6], ["LdHMGR overexpressors", "PROBLEM", 0, 21], ["~", "OBSERVATION_MODIFIER", 31, 32], ["2 fold", "OBSERVATION_MODIFIER", 32, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47]]], ["The result indicates that a higher concentration of drug is needed in case of LdHMGR overexpressing cells when compared to the wild type for obtaining similar therapeutic results.", [["cells", "ANATOMY", 100, 105], ["LdHMGR", "GENE_OR_GENE_PRODUCT", 78, 84], ["cells", "CELL", 100, 105], ["LdHMGR overexpressing cells", "CELL_LINE", 78, 105], ["a higher concentration of drug", "TREATMENT", 26, 56], ["LdHMGR overexpressing cells", "PROBLEM", 78, 105], ["overexpressing cells", "OBSERVATION", 85, 105]]], ["These results supports that HMGR overexpressing promastigotes showed resistance to GA, which depicts its prime role in inhibiting the sterol biosynthetic pathway.Discussion3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is an enzyme that catalyzes the conversion of HMG-CoA to mevalonate, a precursor of cholesterol in humans, and ergosterol in plants, fungi and protozoa (Henriksen et al., 2006; Macreadie et al., 2006) .", [["GA", "CHEMICAL", 83, 85], ["Discussion3-Hydroxy-3-methylglutaryl-coenzyme A", "CHEMICAL", 162, 209], ["mevalonate", "CHEMICAL", 287, 297], ["cholesterol", "CHEMICAL", 314, 325], ["ergosterol", "CHEMICAL", 341, 351], ["sterol", "CHEMICAL", 134, 140], ["Discussion3-Hydroxy-3-methylglutaryl-coenzyme A", "CHEMICAL", 162, 209], ["HMG-CoA", "CHEMICAL", 211, 218], ["HMG-CoA", "CHEMICAL", 276, 283], ["mevalonate", "CHEMICAL", 287, 297], ["cholesterol", "CHEMICAL", 314, 325], ["ergosterol", "CHEMICAL", 341, 351], ["HMGR", "GENE_OR_GENE_PRODUCT", 28, 32], ["GA", "SIMPLE_CHEMICAL", 83, 85], ["sterol", "SIMPLE_CHEMICAL", 134, 140], ["Discussion3-Hydroxy-3-methylglutaryl-coenzyme A", "SIMPLE_CHEMICAL", 162, 209], ["HMG-CoA) reductase", "GENE_OR_GENE_PRODUCT", 211, 229], ["HMG-CoA", "SIMPLE_CHEMICAL", 276, 283], ["mevalonate", "SIMPLE_CHEMICAL", 287, 297], ["cholesterol", "SIMPLE_CHEMICAL", 314, 325], ["humans", "ORGANISM", 329, 335], ["ergosterol", "SIMPLE_CHEMICAL", 341, 351], ["HMGR", "PROTEIN", 28, 32], ["Discussion3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase", "PROTEIN", 162, 229], ["humans", "SPECIES", 329, 335], ["humans", "SPECIES", 329, 335], ["HMGR overexpressing promastigotes", "PROBLEM", 28, 61], ["resistance to GA", "PROBLEM", 69, 85], ["Discussion3", "TEST", 162, 173], ["Hydroxy", "TEST", 174, 181], ["methylglutaryl", "TREATMENT", 184, 198], ["coenzyme A (HMG-CoA) reductase", "TREATMENT", 199, 229], ["an enzyme", "TEST", 233, 242], ["mevalonate", "TREATMENT", 287, 297], ["a precursor of cholesterol in humans", "TREATMENT", 299, 335], ["ergosterol in plants", "TREATMENT", 341, 361], ["CoA", "ANATOMY", 215, 218]]], ["Ergosterol is reported to be essential for growth and replication of Leishmania and fungi (Kulkarni et al., 2013) .", [["Ergosterol", "CHEMICAL", 0, 10], ["Ergosterol", "CHEMICAL", 0, 10], ["Ergosterol", "SIMPLE_CHEMICAL", 0, 10], ["Leishmania", "ORGANISM", 69, 79], ["Ergosterol", "TREATMENT", 0, 10], ["Leishmania", "PROBLEM", 69, 79], ["Leishmania", "OBSERVATION", 69, 79]]], ["Efficacy of ergosterol biosynthesis inhibitors as antiproliferative agents against Trypanosoma cruzi has been already reported (Urbina et al., 1995) .", [["ergosterol", "CHEMICAL", 12, 22], ["Trypanosoma cruzi", "DISEASE", 83, 100], ["ergosterol", "CHEMICAL", 12, 22], ["ergosterol", "SIMPLE_CHEMICAL", 12, 22], ["Trypanosoma cruzi", "ORGANISM", 83, 100], ["Trypanosoma cruzi", "SPECIES", 83, 100], ["Trypanosoma cruzi", "SPECIES", 83, 100], ["ergosterol biosynthesis inhibitors", "TREATMENT", 12, 46], ["antiproliferative agents", "TREATMENT", 50, 74], ["Trypanosoma cruzi", "PROBLEM", 83, 100], ["ergosterol biosynthesis", "OBSERVATION", 12, 35]]], ["HMGR is proposed as a potential drug target in L. donovani.", [["HMGR", "GENE_OR_GENE_PRODUCT", 0, 4], ["L. donovani", "ORGANISM", 47, 58], ["HMGR", "PROTEIN", 0, 4], ["L. donovani", "SPECIES", 47, 58], ["L. donovani", "SPECIES", 47, 58], ["donovani", "OBSERVATION", 50, 58]]], ["Several natural and synthetic statins are reported to interfere with the growth of L. donovani by inhibiting HMGR .", [["statins", "CHEMICAL", 30, 37], ["statins", "CHEMICAL", 30, 37], ["statins", "SIMPLE_CHEMICAL", 30, 37], ["L. donovani", "ORGANISM", 83, 94], ["HMGR", "GENE_OR_GENE_PRODUCT", 109, 113], ["HMGR", "PROTEIN", 109, 113], ["L. donovani", "SPECIES", 83, 94], ["L. donovani", "SPECIES", 83, 94], ["Several natural and synthetic statins", "TREATMENT", 0, 37]]], ["Besides several compounds from natural sources like cholestin, diosgenin and GA were reported to inhibit HMGR (Arguelles et al., 2010; Maurya and Srivastava, 2011) .DiscussionOver the past few years it has been well documented that the plant source is being used for treating inflammation, asthma, bronchitis, tumor, fungal diseases and recently GA and its analogs were also reported as anti-filarial agents (Pandey et al., 2009; Kim et al., 2013; Kalani et al., 2013) .", [["tumor", "ANATOMY", 310, 315], ["cholestin", "CHEMICAL", 52, 61], ["diosgenin", "CHEMICAL", 63, 72], ["GA", "CHEMICAL", 77, 79], ["inflammation", "DISEASE", 276, 288], ["asthma", "DISEASE", 290, 296], ["bronchitis", "DISEASE", 298, 308], ["tumor", "DISEASE", 310, 315], ["fungal diseases", "DISEASE", 317, 332], ["GA", "CHEMICAL", 346, 348], ["cholestin", "CHEMICAL", 52, 61], ["diosgenin", "CHEMICAL", 63, 72], ["cholestin", "SIMPLE_CHEMICAL", 52, 61], ["diosgenin", "SIMPLE_CHEMICAL", 63, 72], ["GA", "SIMPLE_CHEMICAL", 77, 79], ["HMGR", "GENE_OR_GENE_PRODUCT", 105, 109], ["tumor", "CANCER", 310, 315], ["HMGR", "PROTEIN", 105, 109], ["inflammation", "PROBLEM", 276, 288], ["asthma", "PROBLEM", 290, 296], ["bronchitis", "PROBLEM", 298, 308], ["tumor", "PROBLEM", 310, 315], ["fungal diseases", "PROBLEM", 317, 332], ["recently GA", "PROBLEM", 337, 348], ["inflammation", "OBSERVATION", 276, 288], ["asthma", "OBSERVATION", 290, 296], ["bronchitis", "OBSERVATION", 298, 308], ["tumor", "OBSERVATION", 310, 315], ["fungal diseases", "OBSERVATION", 317, 332]]], ["Several mechanisms were proposed for GA mediated inhibition, which includes the anti-inflammatory property of GA by suppressing the TNF-a and anti-apoptotic effect via suppression of caspase-3, which have explained the hepatoprotective properties (Nasyrov et al., 1995; Wan et al., 2009 ).DiscussionAs part of our drug discovery research, we were interested in natural product entities which could target sterol biosynthetic pathway and serve as antileishmanial agents and we came across GA.", [["GA", "CHEMICAL", 37, 39], ["GA", "CHEMICAL", 110, 112], ["GA", "CHEMICAL", 488, 490], ["sterol", "CHEMICAL", 405, 411], ["GA", "SIMPLE_CHEMICAL", 37, 39], ["GA", "SIMPLE_CHEMICAL", 110, 112], ["TNF", "GENE_OR_GENE_PRODUCT", 132, 135], ["caspase-3", "GENE_OR_GENE_PRODUCT", 183, 192], ["sterol", "SIMPLE_CHEMICAL", 405, 411], ["TNF", "PROTEIN", 132, 135], ["caspase-3", "PROTEIN", 183, 192], ["GA mediated inhibition", "TREATMENT", 37, 59], ["suppression of caspase", "TREATMENT", 168, 190], ["sterol biosynthetic pathway", "TREATMENT", 405, 432], ["antileishmanial agents", "TREATMENT", 446, 468]]], ["Literature search revealed antileishmanial activity of GA which proved to be efficacious causing enhanced release of cytokines (IL-12 and TNF-a) in Leishmania infected macrophages thus, indicating its immunomodulatory property (Bhattacharjee et al., 2012) .", [["macrophages", "ANATOMY", 168, 179], ["GA", "CHEMICAL", 55, 57], ["GA", "SIMPLE_CHEMICAL", 55, 57], ["IL-12", "GENE_OR_GENE_PRODUCT", 128, 133], ["TNF-a", "GENE_OR_GENE_PRODUCT", 138, 143], ["Leishmania", "ORGANISM", 148, 158], ["macrophages", "CELL", 168, 179], ["cytokines", "PROTEIN", 117, 126], ["IL-12", "PROTEIN", 128, 133], ["TNF", "PROTEIN", 138, 141], ["Leishmania infected macrophages", "CELL_TYPE", 148, 179], ["Literature search", "TEST", 0, 17], ["antileishmanial activity of GA", "PROBLEM", 27, 57], ["cytokines", "TEST", 117, 126], ["IL", "TEST", 128, 130], ["TNF", "TEST", 138, 141], ["Leishmania infected macrophages", "PROBLEM", 148, 179], ["antileishmanial activity", "OBSERVATION", 27, 51], ["Leishmania", "ANATOMY", 148, 158], ["infected macrophages", "OBSERVATION", 159, 179]]], ["These cytokines play an important role in controlling disease progression in visceral leishmaniasis (Descoteaux and Matlashewski, 1989; McSorley et al., 1996; Taylor and Murray, 1997) .", [["visceral leishmaniasis", "ANATOMY", 77, 99], ["visceral leishmaniasis", "DISEASE", 77, 99], ["cytokines", "PROTEIN", 6, 15], ["controlling disease progression in visceral leishmaniasis", "PROBLEM", 42, 99], ["visceral", "ANATOMY", 77, 85], ["leishmaniasis", "OBSERVATION", 86, 99]]], ["These findings prompted us to investigate the mechanism of antileishmanial action of GA in Leishmania promastigotes.", [["GA", "CHEMICAL", 85, 87], ["GA", "SIMPLE_CHEMICAL", 85, 87], ["Leishmania promastigotes", "ORGANISM", 91, 115], ["Leishmania promastigotes", "SPECIES", 91, 115], ["GA in Leishmania promastigotes", "PROBLEM", 85, 115], ["Leishmania promastigotes", "OBSERVATION", 91, 115]]], ["In this work, we have investigated for the first time the effect of GA on sterol metabolism of the parasite.", [["GA", "CHEMICAL", 68, 70], ["sterol", "CHEMICAL", 74, 80], ["GA", "SIMPLE_CHEMICAL", 68, 70], ["sterol", "SIMPLE_CHEMICAL", 74, 80], ["GA on sterol metabolism", "TREATMENT", 68, 91]]], ["The results of the present study showed in vitro growth suppression of L. donovani promastigotes and intracellular amastigotes by GA.", [["intracellular", "ANATOMY", 101, 114], ["GA", "CHEMICAL", 130, 132], ["L. donovani promastigotes", "ORGANISM", 71, 96], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 101, 114], ["amastigotes", "CELL", 115, 126], ["GA", "SIMPLE_CHEMICAL", 130, 132], ["L. donovani", "SPECIES", 71, 82], ["L. donovani", "SPECIES", 71, 82], ["the present study", "TEST", 15, 32], ["L. donovani promastigotes", "TREATMENT", 71, 96], ["intracellular amastigotes", "TREATMENT", 101, 126], ["donovani promastigotes", "OBSERVATION", 74, 96]]], ["Our results indicate that the GA exerts its antileishmanial action by significant reduction in the parasite viability at concentrations far below the cytotoxic concentration.", [["GA", "CHEMICAL", 30, 32], ["GA", "SIMPLE_CHEMICAL", 30, 32], ["the GA", "PROBLEM", 26, 32], ["the parasite viability", "PROBLEM", 95, 117], ["the cytotoxic concentration", "TREATMENT", 146, 173], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["reduction", "OBSERVATION_MODIFIER", 82, 91], ["parasite viability", "OBSERVATION", 99, 117], ["cytotoxic concentration", "OBSERVATION", 150, 173]]], ["It was earlier reported that 50 mg/mL of GA reduced the parasite burden up to 90% in L. donovani infected murine peritoneal macrophages and~10 mg/mL resulted in 50%Discussioninhibition (Bhattacharjee et al., 2012) .", [["peritoneal macrophages", "ANATOMY", 113, 135], ["GA", "CHEMICAL", 41, 43], ["GA", "SIMPLE_CHEMICAL", 41, 43], ["L. donovani", "ORGANISM", 85, 96], ["murine", "ORGANISM", 106, 112], ["peritoneal macrophages", "CELL", 113, 135], ["murine peritoneal macrophages", "CELL_TYPE", 106, 135], ["L. donovani", "SPECIES", 85, 96], ["murine", "SPECIES", 106, 112], ["L. donovani", "SPECIES", 85, 96], ["GA", "TREATMENT", 41, 43], ["the parasite burden", "PROBLEM", 52, 71], ["parasite", "OBSERVATION_MODIFIER", 56, 64], ["burden", "OBSERVATION_MODIFIER", 65, 71], ["donovani", "OBSERVATION_MODIFIER", 88, 96], ["infected", "OBSERVATION_MODIFIER", 97, 105], ["murine", "OBSERVATION_MODIFIER", 106, 112], ["peritoneal macrophages", "OBSERVATION", 113, 135]]], ["The results showed that GA displayed antileishmanial activity at non-cytotoxic concentrations.", [["GA", "CHEMICAL", 24, 26], ["GA", "SIMPLE_CHEMICAL", 24, 26], ["antileishmanial activity at non-cytotoxic concentrations", "PROBLEM", 37, 93], ["antileishmanial activity", "OBSERVATION", 37, 61]]], ["The standard drug miltefosine exhibited~2 fold higher sensitivity against promastigotes and~5 fold higher sensitivity against amastigotes when compared to GA.", [["miltefosine", "CHEMICAL", 18, 29], ["GA", "CHEMICAL", 155, 157], ["miltefosine", "CHEMICAL", 18, 29], ["miltefosine", "SIMPLE_CHEMICAL", 18, 29], ["The standard drug miltefosine", "TREATMENT", 0, 29], ["promastigotes", "PROBLEM", 74, 87], ["amastigotes", "PROBLEM", 126, 137]]], ["However, the selectivity index was >5 for GA and almost comparable to miltefosine.", [["GA", "CHEMICAL", 42, 44], ["miltefosine", "CHEMICAL", 70, 81], ["miltefosine", "CHEMICAL", 70, 81], ["GA", "SIMPLE_CHEMICAL", 42, 44], ["miltefosine", "SIMPLE_CHEMICAL", 70, 81], ["the selectivity index", "TEST", 9, 30], ["GA", "TEST", 42, 44], ["miltefosine", "TREATMENT", 70, 81]]], ["The sensitivity of promastigotes, amastigotes and macrophages towards miltefosine was in agreement with the previously published data (Corral et al., 2014; Calogeropoulou et al., 2008; Dube et al., 2007) .", [["amastigotes", "ANATOMY", 34, 45], ["macrophages", "ANATOMY", 50, 61], ["miltefosine", "CHEMICAL", 70, 81], ["miltefosine", "CHEMICAL", 70, 81], ["promastigotes", "CELL", 19, 32], ["amastigotes", "CELL", 34, 45], ["macrophages", "CELL", 50, 61], ["miltefosine", "SIMPLE_CHEMICAL", 70, 81], ["macrophages", "CELL_TYPE", 50, 61], ["amastigotes", "TEST", 34, 45], ["miltefosine", "TREATMENT", 70, 81]]], ["Earlier studies showed that HMGR mRNA expression was markedly decreased in GA treated dyslipidemic hamsters (Maurya and Srivastava, 2011) .", [["GA", "CHEMICAL", 75, 77], ["dyslipidemic", "DISEASE", 86, 98], ["HMGR", "GENE_OR_GENE_PRODUCT", 28, 32], ["GA", "SIMPLE_CHEMICAL", 75, 77], ["hamsters", "ORGANISM", 99, 107], ["HMGR mRNA", "RNA", 28, 37], ["Earlier studies", "TEST", 0, 15], ["HMGR mRNA expression", "PROBLEM", 28, 48], ["markedly", "OBSERVATION_MODIFIER", 53, 61], ["decreased", "OBSERVATION_MODIFIER", 62, 71]]], ["Keeping this in view, effect of GA was studied on recombinant HMGR and native enzyme in promastigotes.", [["GA", "CHEMICAL", 32, 34], ["GA", "SIMPLE_CHEMICAL", 32, 34], ["HMGR", "GENE_OR_GENE_PRODUCT", 62, 66], ["promastigotes", "CELL", 88, 101], ["recombinant HMGR", "PROTEIN", 50, 66], ["native enzyme", "PROTEIN", 71, 84], ["recombinant HMGR", "TEST", 50, 66]]], ["At 100 mM concentration of GA, the recombinant LdHMGR activity was reduced by 90%.", [["GA", "CHEMICAL", 27, 29], ["GA", "SIMPLE_CHEMICAL", 27, 29], ["LdHMGR", "GENE_OR_GENE_PRODUCT", 47, 53], ["LdHMGR", "PROTEIN", 47, 53], ["GA", "TEST", 27, 29], ["the recombinant LdHMGR activity", "TEST", 31, 62], ["reduced", "OBSERVATION_MODIFIER", 67, 74]]], ["Interestingly, it was found that GA inhibits the recombinant enzyme at an IC 50 value, which is close to the IC 50 value obtained from cell based inhibition studies.", [["cell", "ANATOMY", 135, 139], ["GA", "CHEMICAL", 33, 35], ["GA", "SIMPLE_CHEMICAL", 33, 35], ["cell", "CELL", 135, 139], ["recombinant enzyme", "PROTEIN", 49, 67], ["the recombinant enzyme", "TEST", 45, 67], ["cell based inhibition studies", "TEST", 135, 164]]], ["This suggested that GA might specifically bind to LdHMGR enzyme.", [["GA", "CHEMICAL", 20, 22], ["GA", "SIMPLE_CHEMICAL", 20, 22], ["LdHMGR enzyme", "GENE_OR_GENE_PRODUCT", 50, 63], ["LdHMGR enzyme", "PROTEIN", 50, 63], ["GA", "PROBLEM", 20, 22], ["LdHMGR enzyme", "TEST", 50, 63]]], ["HMGR activity was also measured in GA treated L. donovani promastigotes wher\u1ebd 30% reduction was observed.", [["GA", "CHEMICAL", 35, 37], ["HMGR", "GENE_OR_GENE_PRODUCT", 0, 4], ["GA", "SIMPLE_CHEMICAL", 35, 37], ["L. donovani", "ORGANISM", 46, 57], ["promastigotes", "ORGANISM", 58, 71], ["HMGR", "PROTEIN", 0, 4], ["L. donovani", "SPECIES", 46, 57], ["L. donovani", "SPECIES", 46, 57], ["HMGR activity", "PROBLEM", 0, 13], ["L. donovani promastigotes", "TREATMENT", 46, 71], ["30% reduction", "TREATMENT", 78, 91]]], ["It was observed that the recombinant enzyme inhibition by GA was more compared to inhibition of native enzyme in L. donovani promastigotes (50% inhibition of recombinant HMGR at 24 mM of GA whereas only 30% inhibition of native HMGR in L. donovani promastigotes was observed at 34 mM of GA concentration).", [["GA", "CHEMICAL", 58, 60], ["GA", "CHEMICAL", 187, 189], ["GA", "CHEMICAL", 287, 289], ["GA", "SIMPLE_CHEMICAL", 58, 60], ["L. donovani promastigotes", "ORGANISM", 113, 138], ["HMGR", "GENE_OR_GENE_PRODUCT", 170, 174], ["HMGR", "GENE_OR_GENE_PRODUCT", 228, 232], ["L. donovani promastigotes", "ORGANISM", 236, 261], ["GA", "SIMPLE_CHEMICAL", 287, 289], ["recombinant enzyme", "PROTEIN", 25, 43], ["native enzyme", "PROTEIN", 96, 109], ["recombinant HMGR", "PROTEIN", 158, 174], ["native HMGR", "PROTEIN", 221, 232], ["L. donovani", "SPECIES", 113, 124], ["L. donovani", "SPECIES", 236, 247], ["L. donovani", "SPECIES", 113, 124], ["L. donovani", "SPECIES", 236, 247], ["the recombinant enzyme inhibition", "TEST", 21, 54], ["L. donovani promastigotes", "TREATMENT", 113, 138], ["recombinant HMGR", "TREATMENT", 158, 174], ["GA", "TEST", 187, 189], ["native HMGR in L. donovani promastigotes", "TREATMENT", 221, 261], ["donovani promastigotes", "OBSERVATION", 116, 138]]], ["The differences in effect of GA on the recombinant enzyme activity and that of parasite enzyme activity may be due to the multi-targeted effect of GA (Bhattacharjee et al., 2012) .", [["GA", "CHEMICAL", 29, 31], ["GA", "CHEMICAL", 147, 149], ["GA", "SIMPLE_CHEMICAL", 29, 31], ["parasite enzyme", "GENE_OR_GENE_PRODUCT", 79, 94], ["GA", "SIMPLE_CHEMICAL", 147, 149], ["recombinant enzyme", "PROTEIN", 39, 57], ["parasite enzyme", "PROTEIN", 79, 94], ["GA", "TREATMENT", 29, 31], ["the recombinant enzyme activity", "TEST", 35, 66], ["parasite enzyme activity", "PROBLEM", 79, 103]]], ["Moreover, the effect of GA in promastigotes was measured on the whole cell lysate of parasite and not purified native HMGR enzyme.", [["cell lysate", "ANATOMY", 70, 81], ["GA", "CHEMICAL", 24, 26], ["GA", "SIMPLE_CHEMICAL", 24, 26], ["promastigotes", "CELL", 30, 43], ["cell lysate", "ORGANISM_SUBSTANCE", 70, 81], ["parasite", "CELL", 85, 93], ["HMGR enzyme", "GENE_OR_GENE_PRODUCT", 118, 129], ["HMGR enzyme", "PROTEIN", 118, 129], ["GA in promastigotes", "PROBLEM", 24, 43], ["the whole cell lysate", "TREATMENT", 60, 81]]], ["In both the native and recombinant HMGR inhibition studies, atorvastatin was used as chemical inhibitor of HMGR enzyme and acted as positive control.", [["atorvastatin", "CHEMICAL", 60, 72], ["atorvastatin", "CHEMICAL", 60, 72], ["HMGR", "GENE_OR_GENE_PRODUCT", 35, 39], ["atorvastatin", "SIMPLE_CHEMICAL", 60, 72], ["HMGR enzyme", "GENE_OR_GENE_PRODUCT", 107, 118], ["HMGR", "PROTEIN", 35, 39], ["HMGR enzyme", "PROTEIN", 107, 118], ["atorvastatin", "TREATMENT", 60, 72], ["chemical inhibitor of HMGR enzyme", "TREATMENT", 85, 118]]], ["Fivefold lower HMGR expression was observed in immunoblot, which further indicated the specificity of GA for HMGR.", [["GA", "CHEMICAL", 102, 104], ["HMGR", "GENE_OR_GENE_PRODUCT", 15, 19], ["GA", "SIMPLE_CHEMICAL", 102, 104], ["HMGR", "GENE_OR_GENE_PRODUCT", 109, 113], ["HMGR", "PROTEIN", 15, 19], ["HMGR", "PROTEIN", 109, 113], ["Fivefold lower HMGR expression", "PROBLEM", 0, 30], ["immunoblot", "TEST", 47, 57], ["HMGR", "PROBLEM", 109, 113], ["lower", "ANATOMY_MODIFIER", 9, 14], ["HMGR expression", "OBSERVATION", 15, 30]]], ["Thus, the reduction of HMGR enzyme activity is associated with the reduction of HMGR protein levels.", [["HMGR enzyme", "GENE_OR_GENE_PRODUCT", 23, 34], ["HMGR", "GENE_OR_GENE_PRODUCT", 80, 84], ["HMGR enzyme", "PROTEIN", 23, 34], ["HMGR", "PROTEIN", 80, 84], ["HMGR enzyme activity", "PROBLEM", 23, 43], ["the reduction of HMGR protein levels", "PROBLEM", 63, 99], ["reduction", "OBSERVATION_MODIFIER", 10, 19], ["HMGR enzyme activity", "OBSERVATION", 23, 43], ["HMGR protein levels", "OBSERVATION", 80, 99]]], ["AceCS was selected as control protein however if GA has multitargeted effect, proteomics can provide more information regarding other targets.", [["GA", "CHEMICAL", 49, 51], ["AceCS", "GENE_OR_GENE_PRODUCT", 0, 5], ["GA", "SIMPLE_CHEMICAL", 49, 51], ["AceCS", "PROTEIN", 0, 5], ["AceCS", "TREATMENT", 0, 5], ["GA", "PROBLEM", 49, 51]]], ["We also confirmed that GA treatment reduces the biosynthesis of ergosterol by inhibiting HMGR enzyme.", [["GA", "CHEMICAL", 23, 25], ["ergosterol", "CHEMICAL", 64, 74], ["ergosterol", "CHEMICAL", 64, 74], ["GA", "SIMPLE_CHEMICAL", 23, 25], ["ergosterol", "SIMPLE_CHEMICAL", 64, 74], ["HMGR enzyme", "GENE_OR_GENE_PRODUCT", 89, 100], ["HMGR enzyme", "PROTEIN", 89, 100], ["GA treatment", "TREATMENT", 23, 35], ["the biosynthesis of ergosterol", "TREATMENT", 44, 74], ["HMGR enzyme", "TEST", 89, 100]]], ["Ergosterol levels in GA treated wild type promastigotes significantly decreased up to 40% whereas only 20% reduction was observed in GA treated HMGR overexpressors.", [["Ergosterol", "CHEMICAL", 0, 10], ["GA", "CHEMICAL", 21, 23], ["GA", "CHEMICAL", 133, 135], ["Ergosterol", "CHEMICAL", 0, 10], ["Ergosterol", "SIMPLE_CHEMICAL", 0, 10], ["GA", "SIMPLE_CHEMICAL", 21, 23], ["GA", "SIMPLE_CHEMICAL", 133, 135], ["HMGR", "GENE_OR_GENE_PRODUCT", 144, 148], ["HMGR overexpressors", "PROTEIN", 144, 163], ["Ergosterol levels", "TEST", 0, 17], ["wild type promastigotes", "PROBLEM", 32, 55], ["HMGR overexpressors", "TREATMENT", 144, 163]]], ["This explains that it affects the sterol biosynthesis in the parasite and is one of the reasons for parasite killing.", [["sterol", "CHEMICAL", 34, 40], ["sterol", "SIMPLE_CHEMICAL", 34, 40], ["the sterol biosynthesis", "TREATMENT", 30, 53], ["parasite killing", "PROBLEM", 100, 116], ["sterol biosynthesis", "OBSERVATION", 34, 53]]], ["Moreover, when attempts were made to reverse the GA mediated growth inhibition with ergosterol, it could only partially revive the growth.", [["GA", "CHEMICAL", 49, 51], ["ergosterol", "CHEMICAL", 84, 94], ["ergosterol", "CHEMICAL", 84, 94], ["GA", "SIMPLE_CHEMICAL", 49, 51], ["ergosterol", "SIMPLE_CHEMICAL", 84, 94], ["ergosterol", "TREATMENT", 84, 94]]], ["This study clearly indicated that though GA acts by inhibiting LdHMGR enzyme and altering ergosterol levels, yet it is not the sole target for GA.", [["GA", "CHEMICAL", 41, 43], ["ergosterol", "CHEMICAL", 90, 100], ["GA", "CHEMICAL", 143, 145], ["ergosterol", "CHEMICAL", 90, 100], ["GA", "SIMPLE_CHEMICAL", 41, 43], ["LdHMGR enzyme", "GENE_OR_GENE_PRODUCT", 63, 76], ["ergosterol", "SIMPLE_CHEMICAL", 90, 100], ["GA", "SIMPLE_CHEMICAL", 143, 145], ["LdHMGR enzyme", "PROTEIN", 63, 76], ["This study", "TEST", 0, 10], ["GA acts", "PROBLEM", 41, 48], ["LdHMGR enzyme", "TEST", 63, 76], ["altering ergosterol levels", "TEST", 81, 107], ["ergosterol levels", "OBSERVATION", 90, 107]]], ["It was well documented that GA has multiple mechanism of actions and multiple targets in the parasite.", [["GA", "CHEMICAL", 28, 30], ["GA", "SIMPLE_CHEMICAL", 28, 30]]], ["Recent report stated that it inhibits cox-2 enzyme leading to increase NO generation in L. donovani infected macrophages and thus arresting parasite survival (Bhattacharjee et al., 2012) .DiscussionFurther, in order to validate the effect of GA on HMGR enzyme, the effect of GA was tested on wild type and HMGR overexpressing transgenic parasites that were reported in our earlier studies .", [["macrophages", "ANATOMY", 109, 120], ["NO", "CHEMICAL", 71, 73], ["GA", "CHEMICAL", 242, 244], ["GA", "CHEMICAL", 275, 277], ["NO", "CHEMICAL", 71, 73], ["cox-2", "GENE_OR_GENE_PRODUCT", 38, 43], ["NO", "SIMPLE_CHEMICAL", 71, 73], ["L. donovani", "ORGANISM", 88, 99], ["macrophages", "CELL", 109, 120], ["GA", "SIMPLE_CHEMICAL", 242, 244], ["HMGR enzyme", "GENE_OR_GENE_PRODUCT", 248, 259], ["GA", "SIMPLE_CHEMICAL", 275, 277], ["HMGR", "GENE_OR_GENE_PRODUCT", 306, 310], ["cox-2 enzyme", "PROTEIN", 38, 50], ["L. donovani infected macrophages", "CELL_TYPE", 88, 120], ["HMGR enzyme", "PROTEIN", 248, 259], ["HMGR", "PROTEIN", 306, 310], ["L. donovani", "SPECIES", 88, 99], ["L. donovani", "SPECIES", 88, 99], ["cox", "TEST", 38, 41], ["generation in L. donovani infected macrophages", "PROBLEM", 74, 120], ["HMGR enzyme", "TEST", 248, 259], ["GA", "PROBLEM", 275, 277], ["wild type and HMGR overexpressing transgenic parasites", "PROBLEM", 292, 346], ["our earlier studies", "TEST", 369, 388], ["donovani infected macrophages", "OBSERVATION", 91, 120], ["transgenic parasites", "OBSERVATION", 326, 346]]], ["Our results indicated that HMGR overexpressing parasites showed~2 fold resistance towards GA mediated inhibition of promastigotes compared to non-transgenic parasites.", [["GA", "CHEMICAL", 90, 92], ["HMGR", "GENE_OR_GENE_PRODUCT", 27, 31], ["GA", "SIMPLE_CHEMICAL", 90, 92], ["HMGR", "PROTEIN", 27, 31], ["HMGR overexpressing parasites", "PROBLEM", 27, 56], ["2 fold resistance", "PROBLEM", 64, 81], ["GA mediated inhibition of promastigotes", "PROBLEM", 90, 129], ["non-transgenic parasites", "PROBLEM", 142, 166], ["non-transgenic parasites", "OBSERVATION", 142, 166]]], ["Therefore, it is illustrated that episomal expression of HMGR in parasites protects them from GA induced lysis as is evident from the higher concentration of GA required to inhibit the transgenic parasites than the wild type parasites.DiscussionInterference with ergosterol biosynthesis results in disruption of parasite function and molecules involved in this pathway could serve as potential drug targets for antileishmanial chemotherapy (De Souza and Rodrigues, 2009) .", [["GA", "CHEMICAL", 94, 96], ["GA", "CHEMICAL", 158, 160], ["ergosterol", "CHEMICAL", 263, 273], ["ergosterol", "CHEMICAL", 263, 273], ["HMGR", "GENE_OR_GENE_PRODUCT", 57, 61], ["GA", "SIMPLE_CHEMICAL", 94, 96], ["GA", "SIMPLE_CHEMICAL", 158, 160], ["wild type parasites", "ORGANISM", 215, 234], ["ergosterol", "SIMPLE_CHEMICAL", 263, 273], ["HMGR", "PROTEIN", 57, 61], ["HMGR in parasites", "PROBLEM", 57, 74], ["GA induced lysis", "TREATMENT", 94, 110], ["the higher concentration of GA", "PROBLEM", 130, 160], ["the transgenic parasites", "PROBLEM", 181, 205], ["ergosterol biosynthesis", "TREATMENT", 263, 286], ["parasite function", "PROBLEM", 312, 329], ["antileishmanial chemotherapy", "TREATMENT", 411, 439], ["lysis", "OBSERVATION", 105, 110], ["parasite function", "OBSERVATION", 312, 329]]], ["Interestingly, there are reports where Leishmania can survive altered sterol levels.", [["sterol", "CHEMICAL", 70, 76], ["Leishmania", "ORGANISM", 39, 49], ["sterol", "SIMPLE_CHEMICAL", 70, 76], ["Leishmania", "PROBLEM", 39, 49], ["altered sterol levels", "PROBLEM", 62, 83], ["Leishmania", "OBSERVATION", 39, 49], ["sterol levels", "OBSERVATION", 70, 83]]], ["However, changes in sterol profile have been linked to amphotericin B and fluconazole resistance (Mbongo et al., 1998; Roberts et al., 2003) .", [["amphotericin B", "CHEMICAL", 55, 69], ["fluconazole", "CHEMICAL", 74, 85], ["sterol", "CHEMICAL", 20, 26], ["amphotericin B", "CHEMICAL", 55, 69], ["fluconazole", "CHEMICAL", 74, 85], ["sterol", "SIMPLE_CHEMICAL", 20, 26], ["amphotericin B", "SIMPLE_CHEMICAL", 55, 69], ["fluconazole", "SIMPLE_CHEMICAL", 74, 85], ["changes in sterol profile", "PROBLEM", 9, 34], ["amphotericin B", "TREATMENT", 55, 69], ["fluconazole resistance", "TREATMENT", 74, 96]]], ["The alteration of sterol levels could have important implications in drug response because ergosterol is required for action of some drugs.", [["ergosterol", "CHEMICAL", 91, 101], ["sterol", "CHEMICAL", 18, 24], ["ergosterol", "CHEMICAL", 91, 101], ["sterol", "SIMPLE_CHEMICAL", 18, 24], ["ergosterol", "SIMPLE_CHEMICAL", 91, 101], ["The alteration of sterol levels", "PROBLEM", 0, 31], ["ergosterol", "TREATMENT", 91, 101], ["some drugs", "TREATMENT", 128, 138], ["sterol levels", "OBSERVATION", 18, 31]]], ["For example, amphotericin B, a polyene antifungal drug is also used for the treatment of leishmaniasis, which associates, with ergosterol for its action (Croft et al., 2006; Cohen, 1998) .DiscussionIn conclusion, the result of this work extends the investigation of GA as potential candidate for visceral leishmaniasis treatment.", [["visceral", "ANATOMY", 296, 304], ["amphotericin B", "CHEMICAL", 13, 27], ["polyene", "CHEMICAL", 31, 38], ["leishmaniasis", "DISEASE", 89, 102], ["ergosterol", "CHEMICAL", 127, 137], ["GA", "CHEMICAL", 266, 268], ["visceral leishmaniasis", "DISEASE", 296, 318], ["amphotericin B", "CHEMICAL", 13, 27], ["polyene", "CHEMICAL", 31, 38], ["ergosterol", "CHEMICAL", 127, 137], ["amphotericin B", "SIMPLE_CHEMICAL", 13, 27], ["polyene", "SIMPLE_CHEMICAL", 31, 38], ["ergosterol", "SIMPLE_CHEMICAL", 127, 137], ["GA", "SIMPLE_CHEMICAL", 266, 268], ["visceral", "ORGANISM_SUBDIVISION", 296, 304], ["amphotericin B", "TREATMENT", 13, 27], ["a polyene antifungal drug", "TREATMENT", 29, 54], ["leishmaniasis", "PROBLEM", 89, 102], ["ergosterol", "TREATMENT", 127, 137], ["visceral leishmaniasis treatment", "TREATMENT", 296, 328], ["leishmaniasis", "OBSERVATION", 89, 102], ["visceral", "ANATOMY", 296, 304], ["leishmaniasis", "OBSERVATION", 305, 318]]], ["Overall mode of action of GA in vitro studies is via inhibition of HMGR enzyme (rate limiting enzyme of sterol biosynthetic pathway) and depletion of ergosterol levels, which culminates in parasite death.", [["GA", "CHEMICAL", 26, 28], ["ergosterol", "CHEMICAL", 150, 160], ["parasite death", "DISEASE", 189, 203], ["sterol", "CHEMICAL", 104, 110], ["ergosterol", "CHEMICAL", 150, 160], ["GA", "SIMPLE_CHEMICAL", 26, 28], ["HMGR enzyme", "GENE_OR_GENE_PRODUCT", 67, 78], ["sterol", "SIMPLE_CHEMICAL", 104, 110], ["ergosterol", "SIMPLE_CHEMICAL", 150, 160], ["HMGR enzyme", "PROTEIN", 67, 78], ["vitro studies", "TEST", 32, 45], ["HMGR enzyme", "TEST", 67, 78], ["sterol biosynthetic pathway", "TREATMENT", 104, 131], ["depletion of ergosterol levels", "PROBLEM", 137, 167], ["parasite death", "PROBLEM", 189, 203], ["ergosterol levels", "OBSERVATION", 150, 167], ["parasite death", "OBSERVATION", 189, 203]]], ["To the best of our knowledge, this is the first report, which conclusively proves that GA can be used as potential inhibitor of L. donovani HMGR, and is an interesting molecule as it possesses immunomodulatory properties too. was analyzed by performing MTT assay and change in OD measured at 540 nm using 96 well plate reader.", [["GA", "CHEMICAL", 87, 89], ["MTT", "CHEMICAL", 253, 256], ["GA", "SIMPLE_CHEMICAL", 87, 89], ["L. donovani", "ORGANISM", 128, 139], ["HMGR", "GENE_OR_GENE_PRODUCT", 140, 144], ["L. donovani HMGR", "PROTEIN", 128, 144], ["L. donovani", "SPECIES", 128, 139], ["L. donovani", "SPECIES", 128, 139], ["L. donovani HMGR", "TREATMENT", 128, 144], ["MTT assay", "TEST", 253, 262], ["donovani HMGR", "OBSERVATION", 131, 144]]], ["Comparison of the effect of Glycyrrhizic acid on growth profiles of wild type and HMGR overexpressors.", [["Glycyrrhizic acid", "CHEMICAL", 28, 45], ["Glycyrrhizic acid", "CHEMICAL", 28, 45], ["Glycyrrhizic acid", "SIMPLE_CHEMICAL", 28, 45], ["HMGR", "GENE_OR_GENE_PRODUCT", 82, 86], ["HMGR overexpressors", "PROTEIN", 82, 101], ["Glycyrrhizic acid", "TREATMENT", 28, 45], ["wild type and HMGR overexpressors", "TREATMENT", 68, 101]]], ["Promastigotes were incubated with varying concentrations of GA for 48 h and viability was measured using MTT assay.", [["Promastigotes", "ANATOMY", 0, 13], ["GA", "CHEMICAL", 60, 62], ["MTT", "CHEMICAL", 105, 108], ["GA", "SIMPLE_CHEMICAL", 60, 62], ["Promastigotes", "TREATMENT", 0, 13], ["varying concentrations of GA", "TREATMENT", 34, 62], ["MTT assay", "TEST", 105, 114]]], ["Special thanks to Director, NIPER for financial support.", [["financial support", "TREATMENT", 38, 55]]]], "94b65407996f99a14ba3051183535122bc50e392": [["1 The association between screen time and mental health during COVID-19: a cross sectional study Lee Smith 1\u00b1* , Louis Jacob 2\u00b1 , Mike Trott 1 , Anita Yakkundi 3 , Laurie Butler 4 , Yvonne Barnett 4 , Nicola C Armstrong 5 , Daragh McDermott 6 , Felipe Schuch 7 , Jacob Meyer 8 , Rub\u00e9n L\u00f3pez-Bueno 9 , Guillermo F. L\u00f3pez S\u00e1nchez 10 , Declan Bradly 11 , Mark A Therefore, we aimed investigate levels and correlates of screen time during COVID-19 self-isolation in a sample of the UK public, and its association with mental health.Our StudyParticipants were recruited to a a cross-sectional epidemiological online survey, through social media and national media outlets.", [["Laurie Butler", "TREATMENT", 164, 177], ["Yvonne Barnett", "TREATMENT", 182, 196], ["Nicola C Armstrong", "TREATMENT", 201, 219], ["Daragh McDermott", "TREATMENT", 224, 240], ["Felipe Schuch", "TREATMENT", 245, 258], ["Rub\u00e9n L\u00f3pez-Bueno", "TREATMENT", 279, 296], ["L\u00f3pez S\u00e1nchez", "TREATMENT", 314, 327], ["COVID", "TEST", 435, 440]]], ["Participants were directed to a data encrypted website where they indicated their consent to participate The survey was launched on 17 th March 2020 in the United Kingdom and approved by the Anglia Ruskin University Research Ethics Committee.Our StudyParticipants were asked to report the time spent per day (in hours) using a screen and was dichotomized into low and high screen time using the median of responses (six hours).Our StudyMental health was measured using the Beck Anxiety Inventory (BAI) and BeckOur StudyDepression Inventory (BDI).", [["Participants", "SPECIES", 0, 12], ["a screen", "TEST", 325, 333]]], ["These are both 21-item questionnaires with higher BAI and BDI scores indicating more severe anxiety and depressive symptoms.", [["anxiety", "DISEASE", 92, 99], ["depressive symptoms", "DISEASE", 104, 123], ["higher BAI", "PROBLEM", 43, 53], ["BDI scores", "TEST", 58, 68], ["more severe anxiety", "PROBLEM", 80, 99], ["depressive symptoms", "PROBLEM", 104, 123], ["severe", "OBSERVATION_MODIFIER", 85, 91]]], ["Poor mental health was defined as the presence of at least one of the following three criteria: moderate-to-severe anxiety symptoms (BAI score \u226516), moderate-to-severe depressive symptoms (BDI score \u226520) and poor mental wellbeing (SWEMWBS metric score \u226415.8).Our StudyDemographic data collected, included sex, age (in 10-year age bands), marital status (single/separated/divorced/widowed or married/in a domestic partnership), employment status and annual household income (<\u00a315,000, \u00a315,000-<\u00a325,000, \u00a325,000-<\u00a340,000, \u00a340,000-<\u00a360,000, \u2265\u00a360,000).", [["anxiety", "DISEASE", 115, 122], ["depressive symptoms", "DISEASE", 168, 187], ["moderate-to-severe anxiety symptoms", "PROBLEM", 96, 131], ["BAI score \u2265", "TEST", 133, 144], ["moderate-to-severe depressive symptoms", "PROBLEM", 149, 187], ["BDI score", "TEST", 189, 198], ["poor mental wellbeing", "PROBLEM", 208, 229], ["metric score", "TEST", 239, 251], ["moderate", "OBSERVATION_MODIFIER", 96, 104], ["moderate", "OBSERVATION_MODIFIER", 149, 157]]], ["Participants were also asked to indicate which of the four main UK countries they lived in (England, Northern Ireland, Scotland, Wales).", [["Participants", "SPECIES", 0, 12]]], ["Measures of health status were also included, as well as the number of days participants had been in isolation.Our StudyThe association between screen time per day in hours and poor mental health was studied in the overall population and in sex and age groups with adjusted logistic regression models.FindingsNine hundred and thirty-two adults were included in this cross-sectional study.", [["adults", "ORGANISM", 337, 343], ["participants", "SPECIES", 76, 88], ["Our Study", "TEST", 111, 120], ["this cross-sectional study", "TEST", 361, 387]]], ["There were 36.1% of men, and 50.4% of the population was aged between 35 and 64 years.FindingsYounger age (18-34 years), single/separated/divorced/widowed, employment, high annual income (\u2265\u00a360,000), living in England, and current smoking were more common in people with higher screen time per day (\u22656 hours/day) than those with low screen time (<6 hour/days).", [["smoking", "CHEMICAL", 230, 237], ["men", "ORGANISM", 20, 23], ["people", "ORGANISM", 258, 264], ["men", "SPECIES", 20, 23], ["people", "SPECIES", 258, 264]]], ["The number of chronic physical conditions and time spent in moderate-to-vigorous physical activity per day during self-isolation were lower and sitting time per day during self-isolation higher in the high screen time compared to the low screen time per day group.", [["chronic physical conditions", "PROBLEM", 14, 41], ["self-isolation", "TREATMENT", 114, 128], ["self-isolation", "PROBLEM", 172, 186], ["number", "OBSERVATION_MODIFIER", 4, 10], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["moderate", "OBSERVATION_MODIFIER", 60, 68]]], ["The mean (standard deviation)Findingsnumber of hours of screen time per day was 7.2 (3.8) in the overall population, and this was higher in younger adults [8.8 (3.7) hours in adults aged 18-34 years versus 5.2 (2.9) hours in those aged \u226565 years].FindingsAfter adjusting for several potential confounding factors, a positive association between screen time per day in hours and poor mental health in the overall sample (OR=1.07, 95% CI=1.02-1.13) was noted.", [["CI", "TEST", 433, 435], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["The relationship between screen time per day and poor mental health was also found to be significant in women (OR=1.07, 95% CI=1.01-1.14) and adults aged 35-64 years irrespective of sex (OR=1.13, 95%FindingsCI=1.05-1.22).Take-AwaysIn this cross-sectional study of UK adults self-isolating due to COVID-19, being of a younger age, unmarried or single, employed, higher income, living in England, a smoker, having fewer physical conditions and taking lower amounts of MVPA were associated with higher daily screen time.Take-AwaysThis is the first study to investigate the association between screen time and mental health during UK COVID-19 social distancing measures.", [["women", "ORGANISM", 104, 109], ["UK", "ORGANISM", 264, 266], ["women", "SPECIES", 104, 109], ["CI", "TEST", 124, 126], ["FindingsCI", "TEST", 199, 209], ["UK COVID", "TREATMENT", 627, 635], ["social distancing measures", "TREATMENT", 639, 665]]], ["However, findings from the study must be interpreted in light of its limitations.", [["the study", "TEST", 23, 32]]], ["First, participants were asked to self-report their screen time and thus potentially introducing self-reporting bias into the findings.", [["participants", "SPECIES", 7, 19]]], ["Second, analyses were cross-sectional and thus it is not possible to determine trajectories of screen time and mental health during the current pandemic.Take-AwaysThird, since we used a convenience sampling method to recruit participants, there is the possibility of a selection bias.Take-AwaysIn conclusion, public health responses to address screen use and promote good mental health during COVID-19 related social distancing measures are likely required.Take-AwaysFunding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.", [["participants", "SPECIES", 225, 237], ["social distancing measures", "TREATMENT", 410, 436]]]], "PMC7228672": [], "PMC5382314": [["IntroductionAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a progressive upper and lower motor neuron degeneration.", [["lower motor neuron", "ANATOMY", 126, 144], ["IntroductionAmyotrophic lateral sclerosis", "DISEASE", 0, 41], ["ALS", "DISEASE", 43, 46], ["neurodegenerative disease", "DISEASE", 59, 84], ["upper", "ORGANISM_SUBDIVISION", 116, 121], ["neuron", "MULTI-TISSUE_STRUCTURE", 138, 144], ["IntroductionAmyotrophic lateral sclerosis (ALS)", "PROBLEM", 0, 47], ["a fatal neurodegenerative disease", "PROBLEM", 51, 84], ["a progressive upper and lower motor neuron degeneration", "PROBLEM", 102, 157], ["lateral", "OBSERVATION_MODIFIER", 24, 31], ["sclerosis", "OBSERVATION", 32, 41], ["fatal", "OBSERVATION_MODIFIER", 53, 58], ["neurodegenerative disease", "OBSERVATION", 59, 84], ["progressive", "OBSERVATION_MODIFIER", 104, 115], ["upper", "ANATOMY_MODIFIER", 116, 121], ["lower", "ANATOMY_MODIFIER", 126, 131], ["motor neuron degeneration", "OBSERVATION", 132, 157]]], ["ALS is a highly heterogeneous disorder, with phenotypic variability involving a number of clinical aspects such as site of onset, age of onset, rate of progression, nonmotor involvement and response to therapy (Beghi et al., 2011).", [["ALS", "DISEASE", 0, 3], ["a highly heterogeneous disorder", "PROBLEM", 7, 38], ["phenotypic variability", "PROBLEM", 45, 67], ["nonmotor involvement", "PROBLEM", 165, 185], ["therapy", "TREATMENT", 202, 209], ["highly", "OBSERVATION_MODIFIER", 9, 15], ["heterogeneous", "OBSERVATION_MODIFIER", 16, 29], ["disorder", "OBSERVATION", 30, 38], ["phenotypic variability", "OBSERVATION", 45, 67], ["progression", "OBSERVATION_MODIFIER", 152, 163]]], ["This makes it difficult to decipher pathogenesis and to develop therapeutic strategies, also because biomarkers that reflect heterogeneity and may be useful for stratification are missing.", [["therapeutic strategies", "TREATMENT", 64, 86], ["biomarkers", "TEST", 101, 111], ["heterogeneity", "PROBLEM", 125, 138]]], ["A combination of genetic and environmental/exogenous modifying factors are believed to underlie this variability.", [["genetic and environmental/exogenous modifying factors", "TREATMENT", 17, 70]]], ["The identification of the pathways affected by the modifying factors is of great interest, as they may be targets of therapeutic intervention.IntroductionAge is a known risk factor for ALS.", [["ALS", "DISEASE", 185, 188], ["modifying factors", "PROTEIN", 51, 68], ["therapeutic intervention", "TREATMENT", 117, 141], ["ALS", "PROBLEM", 185, 188]]], ["The majority of ALS patients have disease onset between 55 and 75 years of age, however patients with an age of onset <55 years and >75 years do exist and represent, respectively, the 22% and the 16% of all patients, as recently reported in a large multicenter Italian study (Calvo et al., 2016).", [["ALS", "DISEASE", 16, 19], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 88, 96], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 207, 215], ["disease onset", "PROBLEM", 34, 47]]], ["Several factors, both genetic and environmental/exogenous, have been reported to modify age of onset in patients and animal models of ALS.", [["ALS", "DISEASE", 134, 137], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["Several factors", "PROBLEM", 0, 15]]], ["FUS mutations have been frequently associated with early-onset disease in familial and sporadic cases (Chi\u00f2 et al., 2009; H\u00fcbers et al., 2015).", [["FUS", "GENE_OR_GENE_PRODUCT", 0, 3], ["FUS", "PROTEIN", 0, 3], ["FUS mutations", "PROBLEM", 0, 13], ["early-onset disease in familial and sporadic cases", "PROBLEM", 51, 101]]], ["Earlier onset of ALS has been also observed in soldiers and professional soccer players (Haley, 2003; Chi\u00f2 et al., 2005; Pupillo et al., 2012).", [["ALS", "DISEASE", 17, 20]]], ["In these patients, an anticipated onset might be linked to heavy physical exercise, repeated trauma, and/or exposure to as yet unknown toxic agents in genetically predisposed individuals (Beghi and Morrison, 2005; Pupillo et al., 2012; Beghi, 2013).", [["trauma", "DISEASE", 93, 99], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["repeated trauma", "PROBLEM", 84, 99]]], ["A mutant SOD1G93A mouse model of ALS on a 129Sv genetic background has an earlier age of onset than a SOD1G93A mouse model on a C57BL6 genetic background despite an equal expression of the mutant protein (Marino et al., 2015).", [["ALS", "DISEASE", 33, 36], ["SOD1G93A mouse", "ORGANISM", 9, 23], ["ALS", "CANCER", 33, 36], ["SOD1G93A mouse", "ORGANISM", 102, 116], ["mutant protein", "PROTEIN", 189, 203], ["mouse", "SPECIES", 18, 23], ["mouse", "SPECIES", 111, 116], ["mouse", "SPECIES", 18, 23], ["mouse", "SPECIES", 111, 116]]], ["These mice have also faster disease progression and an intrinsic marked down-regulation of specific pathways involved in mitochondrial function and protein quality control (Nardo et al., 2013, 2016; Marino et al., 2015).", [["mitochondrial", "ANATOMY", 121, 134], ["mice", "ORGANISM", 6, 10], ["mitochondrial", "CELLULAR_COMPONENT", 121, 134], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["faster disease progression", "PROBLEM", 21, 47], ["faster", "OBSERVATION_MODIFIER", 21, 27], ["disease", "OBSERVATION", 28, 35], ["marked", "OBSERVATION_MODIFIER", 65, 71], ["mitochondrial function", "OBSERVATION", 121, 143]]], ["Conversely, ApoE2 polymorphism and lower EPHA4 expression have been correlated with delayed age of onset in ALS patients (Li et al., 2004; Van Hoecke et al., 2012).", [["ALS", "DISEASE", 108, 111], ["ApoE2", "GENE_OR_GENE_PRODUCT", 12, 17], ["EPHA4", "GENE_OR_GENE_PRODUCT", 41, 46], ["patients", "ORGANISM", 112, 120], ["ApoE2", "PROTEIN", 12, 17], ["EPHA4", "PROTEIN", 41, 46], ["patients", "SPECIES", 112, 120], ["ApoE2 polymorphism and lower EPHA4 expression", "PROBLEM", 12, 57], ["lower", "ANATOMY_MODIFIER", 35, 40], ["EPHA4", "ANATOMY", 41, 46]]], ["Moreover, in mutant SOD1 mice female showed a later onset than male and this delay further increased with exercise (Veldink et al., 2003).IntroductionSummarizing, different combinations of intrinsic and exogenous factors, that can be hardly discerned, may lead to an anticipated or a delayed onset of the disease.", [["mutant SOD1 mice", "ORGANISM", 13, 29], ["SOD1", "PROTEIN", 20, 24], ["exogenous factors", "PROTEIN", 203, 220], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["IntroductionSummarizing", "TREATMENT", 138, 161], ["intrinsic and exogenous factors", "PROBLEM", 189, 220], ["the disease", "PROBLEM", 301, 312], ["exogenous factors", "OBSERVATION", 203, 220], ["disease", "OBSERVATION", 305, 312]]], ["We wanted to test whether or not modifying factors are converging into common pathogenic pathways leading either to an early or a late disease onset.", [["a late disease onset", "PROBLEM", 128, 148], ["late", "OBSERVATION_MODIFIER", 130, 134], ["disease", "OBSERVATION", 135, 142]]], ["This would imply the identification of phenotypic biomarkers, that can distinguish the two populations of ALS patients, and of relevant pathways to consider in a therapeutic intervention.", [["ALS", "DISEASE", 106, 109], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["phenotypic biomarkers", "TEST", 39, 60], ["a therapeutic intervention", "TREATMENT", 160, 186]]], ["Toward this aim a significant cohort of incident ALS patients with either early (<55 years of age) or late (>75 years of age) disease onset was recruited from population-based Italian registries, and several analyses were performed.", [["ALS", "DISEASE", 49, 52], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["disease onset", "PROBLEM", 126, 139], ["several analyses", "TEST", 200, 216], ["significant", "OBSERVATION_MODIFIER", 18, 29]]], ["We found that an epigenetic rearrangement such as whole-blood DNA methylation could not distinguish the two groups of ALS patients (Tremolizzo et al., 2014).", [["blood", "ANATOMY", 56, 61], ["ALS", "DISEASE", 118, 121], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["an epigenetic rearrangement", "PROBLEM", 14, 41], ["whole-blood DNA methylation", "TREATMENT", 50, 77], ["epigenetic rearrangement", "OBSERVATION", 17, 41]]], ["However, difference in plasma amino acid levels were observed in relation to the age of onset (Cecchi et al., 2014).", [["plasma", "ANATOMY", 23, 29], ["amino acid", "CHEMICAL", 30, 40], ["amino acid", "CHEMICAL", 30, 40], ["plasma", "ORGANISM_SUBSTANCE", 23, 29], ["amino acid", "AMINO_ACID", 30, 40], ["plasma amino acid levels", "TEST", 23, 47]]], ["In this work, we identified protein phenotypic biomarkers in peripheral blood mononuclear cells (PBMC) of the same cohort of patients indicating that protein levels in PBMC could be good biological correlates of the age of onset in ALS.", [["peripheral blood mononuclear cells", "ANATOMY", 61, 95], ["PBMC", "ANATOMY", 97, 101], ["PBMC", "ANATOMY", 168, 172], ["ALS", "DISEASE", 232, 235], ["peripheral blood mononuclear cells", "CELL", 61, 95], ["PBMC", "CELL", 97, 101], ["patients", "ORGANISM", 125, 133], ["PBMC", "CELL", 168, 172], ["peripheral blood mononuclear cells", "CELL_TYPE", 61, 95], ["PBMC", "CELL_TYPE", 97, 101], ["PBMC", "CELL_TYPE", 168, 172], ["patients", "SPECIES", 125, 133], ["protein phenotypic biomarkers", "TEST", 28, 57], ["peripheral blood mononuclear cells", "TEST", 61, 95], ["PBMC", "TEST", 97, 101], ["protein levels", "TEST", 150, 164], ["PBMC", "TEST", 168, 172], ["ALS", "PROBLEM", 232, 235], ["protein phenotypic", "OBSERVATION", 28, 46], ["peripheral", "ANATOMY_MODIFIER", 61, 71], ["blood", "ANATOMY", 72, 77], ["mononuclear cells", "OBSERVATION", 78, 95]]], ["The same phenotypic biomarkers were also analyzed in the two mutant SOD1 mouse models of ALS with early and late disease onset indicating common changes between the sporadic and SOD1-linked forms.", [["ALS", "DISEASE", 89, 92], ["SOD1", "GENE_OR_GENE_PRODUCT", 68, 72], ["mouse", "ORGANISM", 73, 78], ["SOD1", "GENE_OR_GENE_PRODUCT", 178, 182], ["SOD1", "PROTEIN", 68, 72], ["SOD1", "PROTEIN", 178, 182], ["mouse", "SPECIES", 73, 78], ["mouse", "SPECIES", 73, 78], ["The same phenotypic biomarkers", "TEST", 0, 30], ["early and late disease onset", "PROBLEM", 98, 126], ["common changes", "PROBLEM", 138, 152], ["late", "OBSERVATION_MODIFIER", 108, 112], ["disease", "OBSERVATION", 113, 120], ["common", "OBSERVATION_MODIFIER", 138, 144]]], ["These biomarkers are proteins involved in the maintenance of protein homeostasis, or proteostasis.", [["These biomarkers", "TEST", 0, 16], ["protein homeostasis", "PROBLEM", 61, 80], ["proteostasis", "PROBLEM", 85, 97], ["protein homeostasis", "OBSERVATION", 61, 80]]], ["Proteostasis is attained through several quality-control systems that assist protein folding, clear misfolded proteins and respond to protein aggregation, whose major players are molecular chaperones.", [["Proteostasis", "DISEASE", 0, 12], ["misfolded proteins", "PROTEIN", 100, 118], ["molecular chaperones", "PROTEIN", 179, 199], ["Proteostasis", "PROBLEM", 0, 12], ["protein folding", "PROBLEM", 77, 92], ["clear misfolded proteins", "PROBLEM", 94, 118], ["protein aggregation", "PROBLEM", 134, 153]]], ["Interestingly, impaired proteostasis has emerged as a key contributor to the pathogenesis of ALS (Ruegsegger and Saxena, 2016).Antibodies ::: Materials and MethodsThe antibodies for Western and dot blot, used for human and mouse samples, were: rabbit polyclonal anti-peptidyl-prolyl cis-trans isomerase A (PPIA) antibody (1:2500 dilution; Millipore), rabbit polyclonal anti-heat shock protein HSP 90-alpha (HSP90) (1:3000 dilution; Stressgen), rabbit polyclonal anti-78 kDa glucose-regulated protein (GRP78) (1:500 dilution; Santa Cruz Biotechnology Inc.), mouse monoclonal anti-endoplasmic reticulum protein 57 (ERp57) (1:2500 dilution; Stressgen), rabbit monoclonal anti-protein deglycase DJ-1 (DJ-1) (1:1500 dilution; Abcam), mouse monoclonal anti-heat shock cognate 71 kDa protein (HSC70) (1:1000 dilution; Santa Cruz Biotechnology Inc.), rabbit polyclonal anti-TDP-43 (1:2500 dilution; Proteintech), goat anti-mouse or anti-rabbit peroxidase-conjugated secondary antibodies (1:5000; Santa Cruz Biotechnology Inc.).Subjects ::: Materials and MethodsFollowing approval of the protocol by the ethics committees (Comitato Etico Interaziendale A.O.U. San Giovanni Battista di Torino \u2013 A.O.", [["samples", "ANATOMY", 229, 236], ["impaired proteostasis", "DISEASE", 15, 36], ["ALS", "DISEASE", 93, 96], ["glucose", "CHEMICAL", 474, 481], ["anti-TDP-43", "CHEMICAL", 861, 872], ["prolyl", "CHEMICAL", 276, 282], ["glucose", "CHEMICAL", 474, 481], ["human", "ORGANISM", 213, 218], ["mouse", "ORGANISM", 223, 228], ["samples", "CANCER", 229, 236], ["rabbit", "ORGANISM", 244, 250], ["anti-peptidyl-prolyl cis-trans isomerase A", "GENE_OR_GENE_PRODUCT", 262, 304], ["PPIA", "GENE_OR_GENE_PRODUCT", 306, 310], ["rabbit", "ORGANISM", 351, 357], ["anti-heat shock protein HSP 90-alpha", "GENE_OR_GENE_PRODUCT", 369, 405], ["HSP90", "GENE_OR_GENE_PRODUCT", 407, 412], ["rabbit", "ORGANISM", 444, 450], ["glucose-regulated protein", "GENE_OR_GENE_PRODUCT", 474, 499], ["GRP78", "GENE_OR_GENE_PRODUCT", 501, 506], ["mouse", "ORGANISM", 557, 562], ["monoclonal anti-endoplasmic reticulum protein 57", "GENE_OR_GENE_PRODUCT", 563, 611], ["ERp57", "GENE_OR_GENE_PRODUCT", 613, 618], ["rabbit", "ORGANISM", 650, 656], ["DJ-1", "SIMPLE_CHEMICAL", 697, 701], ["Abcam", "GENE_OR_GENE_PRODUCT", 721, 726], ["mouse", "ORGANISM", 729, 734], ["anti-heat shock cognate 71 kDa", "GENE_OR_GENE_PRODUCT", 746, 776], ["HSC70", "GENE_OR_GENE_PRODUCT", 786, 791], ["rabbit", "ORGANISM", 843, 849], ["anti-TDP-43", "SIMPLE_CHEMICAL", 861, 872], ["Proteintech", "SIMPLE_CHEMICAL", 891, 902], ["goat", "ORGANISM", 905, 909], ["anti-rabbit peroxidase", "SIMPLE_CHEMICAL", 924, 946], ["antibodies", "PROTEIN", 167, 177], ["rabbit polyclonal anti-peptidyl-prolyl cis-trans isomerase A (PPIA) antibody", "PROTEIN", 244, 320], ["1:2500 dilution; Millipore", "PROTEIN", 322, 348], ["rabbit polyclonal anti-heat shock protein HSP 90-alpha", "PROTEIN", 351, 405], ["HSP90", "PROTEIN", 407, 412], ["Stressgen", "PROTEIN", 432, 441], ["rabbit polyclonal anti-78 kDa glucose-regulated protein", "PROTEIN", 444, 499], ["GRP78", "PROTEIN", 501, 506], ["Santa Cruz Biotechnology", "PROTEIN", 525, 549], ["mouse monoclonal anti-endoplasmic reticulum protein 57", "PROTEIN", 557, 611], ["ERp57", "PROTEIN", 613, 618], ["Stressgen", "PROTEIN", 638, 647], ["rabbit monoclonal anti-protein deglycase DJ-1 (DJ-1", "PROTEIN", 650, 701], ["Abcam", "PROTEIN", 721, 726], ["mouse monoclonal anti-heat shock cognate 71 kDa protein", "PROTEIN", 729, 784], ["HSC70", "PROTEIN", 786, 791], ["rabbit polyclonal anti-TDP-43", "PROTEIN", 843, 872], ["Proteintech", "PROTEIN", 891, 902], ["goat anti-mouse", "PROTEIN", 905, 920], ["anti-rabbit peroxidase", "PROTEIN", 924, 946], ["conjugated secondary antibodies", "PROTEIN", 947, 978], ["1:5000; Santa Cruz Biotechnology", "PROTEIN", 980, 1012], ["human", "SPECIES", 213, 218], ["mouse", "SPECIES", 223, 228], ["rabbit", "SPECIES", 244, 250], ["rabbit", "SPECIES", 351, 357], ["rabbit", "SPECIES", 444, 450], ["mouse", "SPECIES", 557, 562], ["rabbit", "SPECIES", 650, 656], ["mouse", "SPECIES", 729, 734], ["rabbit", "SPECIES", 843, 849], ["goat", "SPECIES", 905, 909], ["anti-mouse", "SPECIES", 910, 920], ["anti-rabbit", "SPECIES", 924, 935], ["human", "SPECIES", 213, 218], ["mouse", "SPECIES", 223, 228], ["rabbit", "SPECIES", 244, 250], ["rabbit", "SPECIES", 351, 357], ["rabbit", "SPECIES", 444, 450], ["mouse", "SPECIES", 557, 562], ["rabbit", "SPECIES", 650, 656], ["mouse", "SPECIES", 729, 734], ["rabbit", "SPECIES", 843, 849], ["goat", "SPECIES", 905, 909], ["anti-rabbit", "SPECIES", 924, 935], ["impaired proteostasis", "PROBLEM", 15, 36], ["Antibodies", "TEST", 127, 137], ["The antibodies", "TEST", 163, 177], ["dot blot", "TEST", 194, 202], ["human and mouse samples", "TEST", 213, 236], ["rabbit polyclonal anti-peptidyl", "TEST", 244, 275], ["A (PPIA) antibody", "TEST", 303, 320], ["dilution", "TEST", 329, 337], ["Millipore", "TEST", 339, 348], ["rabbit polyclonal anti-heat shock protein HSP", "TEST", 351, 396], ["HSP90", "TEST", 407, 412], ["dilution", "TEST", 422, 430], ["Stressgen", "TEST", 432, 441], ["rabbit polyclonal anti", "TEST", 444, 466], ["glucose", "TEST", 474, 481], ["mouse monoclonal anti-endoplasmic reticulum protein", "TEST", 557, 608], ["Stressgen", "TEST", 638, 647], ["rabbit monoclonal anti-protein deglycase DJ", "TREATMENT", 650, 693], ["mouse monoclonal anti-heat shock", "TREATMENT", 729, 761], ["rabbit polyclonal anti-TDP", "TEST", 843, 869], ["Proteintech", "TEST", 891, 902], ["goat anti-mouse", "TREATMENT", 905, 920], ["anti-rabbit peroxidase", "TEST", 924, 946], ["conjugated secondary antibodies", "PROBLEM", 947, 978], ["the protocol", "TREATMENT", 1075, 1087], ["impaired", "OBSERVATION_MODIFIER", 15, 23], ["proteostasis", "OBSERVATION", 24, 36]]], ["\u201cC.T.O. Maria Adelaide di Torino\u201d, Torino, Italy; Comitato etico degli Spedali Civili di Brescia, Brescia, Italy; Comitato Etico Provinciale di Modena, Modena, Italy) written informed consent was obtained from all participating subjects.", [["Brescia", "ANATOMY", 98, 105]]], ["Patients, enrolled in three Italian population-based registries (Lombardia, Piemonte, Emilia Romagna), were newly diagnosed definite, probable or possible ALS, according to the El Escorial criteria (Brooks, 1994).", [["ALS", "DISEASE", 155, 158], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["ALS", "PROBLEM", 155, 158]]], ["To be eligible, patients had to be \u226455 years of age (early ALS) or \u226575 years of age (late ALS) at diagnosis.", [["ALS", "DISEASE", 59, 62], ["ALS", "DISEASE", 90, 93], ["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["Controls were residency-, sex-, and age-matched (\u00b15 years), randomly chosen within the same hospital of the patient among subjects admitted for surgery for a non-spontaneously evolving disease.", [["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["surgery", "TREATMENT", 144, 151], ["a non-spontaneously evolving disease", "PROBLEM", 156, 192], ["disease", "OBSERVATION", 185, 192]]], ["Subjects enrolled for the discovery phase study were 16 early ALS, 16 late ALS and 32 controls (early and late controls), with demographic and clinical characteristics described in Table 1.", [["ALS", "DISEASE", 62, 65], ["ALS", "DISEASE", 75, 78], ["the discovery phase study", "TEST", 22, 47]]], ["Subjects enrolled in the validation study were 85 ALS patients and 83 controls with demographic and clinical characteristics described in Table 2.", [["ALS", "DISEASE", 50, 53], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["the validation study", "TEST", 21, 41]]], ["A wide, although partial screening for ALS-causative mutations was performed (Tremolizzo et al., 2014).", [["ALS", "DISEASE", 39, 42], ["partial screening", "TEST", 17, 34], ["ALS-causative mutations", "PROBLEM", 39, 62], ["wide", "OBSERVATION_MODIFIER", 2, 6]]], ["Two early ALS cases carried a TARDP mutation (M359V, G368S), one late ALS case carried a SOD1 mutation (D90A) and another one an OPTN mutation (L500P).Mice ::: Materials and MethodsProcedures involving animals and their care were approved by the Institutional Animal Care and Use Committee and were conducted in conformity with the following laws, regulations, and policies governing the care and use of laboratory animals: Italian Governing Law (D.lgs 26/2014; Authorisation n.19/2008-A issued March 6, 2008 by Ministry of Health); Mario Negri Institutional Regulations and Policies providing internal authorization for persons conducting animal experiments (Quality Management System Certificate \u2013 UNI EN ISO 9001:2008 \u2013 Reg.", [["ALS", "DISEASE", 10, 13], ["ALS", "DISEASE", 70, 73], ["TARDP", "GENE_OR_GENE_PRODUCT", 30, 35], ["SOD1", "GENE_OR_GENE_PRODUCT", 89, 93], ["OPTN", "GENE_OR_GENE_PRODUCT", 129, 133], ["Mice", "ORGANISM", 151, 155], ["persons", "ORGANISM", 621, 628], ["TARDP mutation", "DNA", 30, 44], ["SOD1", "PROTEIN", 89, 93], ["Mice", "SPECIES", 151, 155], ["persons", "SPECIES", 621, 628], ["Two early ALS cases", "PROBLEM", 0, 19], ["a TARDP mutation", "PROBLEM", 28, 44], ["a SOD1 mutation", "PROBLEM", 87, 102]]], ["The Statement of Compliance (Assurance) with the Public Health Service (PHS) Policy on Human Care and Use of Laboratory Animals has been recently reviewed (9/9/2014) and will expire on September 30, 2019 (Animal Welfare Assurance #A5023-01).", [["Human", "ORGANISM", 87, 92], ["Human", "SPECIES", 87, 92]]], ["Animals were bred and maintained at the IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan under standard conditions, temperature 21 \u00b1 1\u00b0C, relative humidity 55 \u00b1 10%, 12h light schedule, food and water ad libitum.", [["Animals", "ORGANISM", 0, 7], ["temperature", "TEST", 128, 139], ["relative humidity", "TREATMENT", 150, 167]]], ["Transgenic SOD1G93A mice expressing about 20 copies of mutant human SOD1 with a Gly93Ala substitution (B6SJL-TgSOD1G93A-1Gur) were originally obtained from Jackson Laboratories and maintained on a C57BL/6JOlaHsd (C57) genetic background at Harlan Italy S.R.L., Bresso, Milan, Italy.", [["Gly", "CHEMICAL", 80, 83], ["Transgenic SOD1G93A mice", "ORGANISM", 0, 24], ["human", "ORGANISM", 62, 67], ["SOD1", "GENE_OR_GENE_PRODUCT", 68, 72], ["C57BL/6JOlaHsd (C57)", "ORGANISM", 197, 217], ["mutant human SOD1", "PROTEIN", 55, 72], ["B6SJL", "PROTEIN", 103, 108], ["TgSOD1G93A", "PROTEIN", 109, 119], ["mice", "SPECIES", 20, 24], ["human", "SPECIES", 62, 67], ["mice", "SPECIES", 20, 24], ["human", "SPECIES", 62, 67], ["mutant human SOD1", "PROBLEM", 55, 72], ["a Gly93Ala substitution", "TREATMENT", 78, 101], ["B6SJL", "TEST", 103, 108], ["a C57BL/6JOlaHsd", "TREATMENT", 195, 211]]], ["By crossbreeding C57 SOD1G93A mice with 129S2/SvHsd (129Sv) mice for >15 generations, SOD1G93A mice on a 129Sv homogenous background were generated (Marino et al., 2015).", [["C57 SOD1G93A mice", "ORGANISM", 17, 34], ["129S2/SvHsd (129Sv) mice", "ORGANISM", 40, 64], ["SOD1G93A mice", "ORGANISM", 86, 99], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 60, 64], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 95, 99], ["SvHsd", "TEST", 46, 51]]], ["For biochemical analyses, female mice were deeply anesthetized with ketamine hydrochloride (IMALGENE, 150 mg/kg, Alcyon Italia S.p.A.) and medetomidine hydrochloride (DOMITOR, 2 mg/kg, Alcyon Italia S.p.A.) by intraperitoneal injection and euthanized by decapitation at symptom onset: for 129Sv SOD1G93A mice at 14 weeks of age, and for C57 SOD1G93A mice at 17 weeks of age.", [["intraperitoneal", "ANATOMY", 210, 225], ["ketamine hydrochloride", "CHEMICAL", 68, 90], ["IMALGENE", "CHEMICAL", 92, 100], ["medetomidine hydrochloride", "CHEMICAL", 139, 165], ["DOMITOR", "CHEMICAL", 167, 174], ["ketamine hydrochloride", "CHEMICAL", 68, 90], ["IMALGENE", "CHEMICAL", 92, 100], ["medetomidine hydrochloride", "CHEMICAL", 139, 165], ["DOMITOR", "CHEMICAL", 167, 174], ["mice", "ORGANISM", 33, 37], ["ketamine", "SIMPLE_CHEMICAL", 68, 76], ["hydrochloride", "SIMPLE_CHEMICAL", 77, 90], ["IMALGENE", "SIMPLE_CHEMICAL", 92, 100], ["medetomidine hydrochloride", "SIMPLE_CHEMICAL", 139, 165], ["DOMITOR", "SIMPLE_CHEMICAL", 167, 174], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 210, 225], ["mice", "ORGANISM", 304, 308], ["C57 SOD1G93A mice", "ORGANISM", 337, 354], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 304, 308], ["mice", "SPECIES", 350, 354], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 304, 308], ["mice", "SPECIES", 350, 354], ["biochemical analyses", "TEST", 4, 24], ["ketamine hydrochloride", "TREATMENT", 68, 90], ["IMALGENE", "TREATMENT", 92, 100], ["Alcyon Italia S.p.A.", "TREATMENT", 113, 133], ["medetomidine hydrochloride", "TREATMENT", 139, 165], ["DOMITOR", "TREATMENT", 167, 174], ["Alcyon Italia S.p.A.", "TREATMENT", 185, 205], ["intraperitoneal", "ANATOMY", 210, 225]]], ["The corresponding age-matched nontransgenic mice were used as controls.PBMC Isolation and Protein Extraction ::: Materials and MethodsPeripheral blood mononuclear cells were isolated from peripheral venous blood of human subjects essentially as previously described (Nardo et al., 2011).", [["PBMC", "ANATOMY", 71, 75], ["MethodsPeripheral blood mononuclear cells", "ANATOMY", 127, 168], ["peripheral venous blood", "ANATOMY", 188, 211], ["mice", "ORGANISM", 44, 48], ["PBMC", "CELL", 71, 75], ["MethodsPeripheral blood mononuclear cells", "CELL", 127, 168], ["peripheral venous blood", "ORGANISM_SUBSTANCE", 188, 211], ["human", "ORGANISM", 215, 220], ["PBMC", "CELL_TYPE", 71, 75], ["MethodsPeripheral blood mononuclear cells", "CELL_TYPE", 127, 168], ["mice", "SPECIES", 44, 48], ["human", "SPECIES", 215, 220], ["mice", "SPECIES", 44, 48], ["human", "SPECIES", 215, 220], ["matched nontransgenic mice", "TREATMENT", 22, 48], ["PBMC Isolation", "TREATMENT", 71, 85], ["MethodsPeripheral blood mononuclear cells", "TEST", 127, 168], ["peripheral venous blood of human subjects", "PROBLEM", 188, 229], ["mononuclear cells", "OBSERVATION", 151, 168], ["peripheral", "ANATOMY_MODIFIER", 188, 198], ["venous", "ANATOMY", 199, 205], ["blood", "ANATOMY_MODIFIER", 206, 211]]], ["Briefly, samples of blood were collected in EDTA pre-coated tubes (BD Vacutainer K2EDTA) and PBMC were isolated from EDTA blood by Ficoll-Hypaque (Ficoll-PlaqueTM Plus, GE Healthcare) density gradient centrifugation at 800 \u00d7 g for 30 min at 18\u201320\u00b0C. Mononuclear cells were collected from the interface and washed three times with RPMI 1640 medium (EuroClone).", [["samples", "ANATOMY", 9, 16], ["blood", "ANATOMY", 20, 25], ["PBMC", "ANATOMY", 93, 97], ["blood", "ANATOMY", 122, 127], ["Mononuclear cells", "ANATOMY", 250, 267], ["EDTA", "CHEMICAL", 44, 48], ["EDTA", "CHEMICAL", 117, 121], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["PBMC", "CELL", 93, 97], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["Mononuclear cells", "CELL", 250, 267], ["PBMC", "CELL_TYPE", 93, 97], ["Mononuclear cells", "CELL_TYPE", 250, 267], ["blood", "TEST", 20, 25], ["EDTA pre-coated tubes", "TREATMENT", 44, 65], ["BD Vacutainer K2EDTA", "TREATMENT", 67, 87], ["PBMC", "TREATMENT", 93, 97], ["Ficoll-Hypaque (Ficoll-PlaqueTM Plus, GE Healthcare) density gradient centrifugation", "TREATMENT", 131, 215], ["Mononuclear cells", "TEST", 250, 267], ["RPMI", "TREATMENT", 330, 334], ["PBMC", "ANATOMY", 93, 97]]], ["Platelets were eliminated by an additional wash and centrifugation at 200 \u00d7 g for 10 min.", [["Platelets", "ANATOMY", 0, 9], ["Platelets", "CELL", 0, 9], ["Platelets", "CELL_TYPE", 0, 9], ["Platelets", "TEST", 0, 9], ["an additional wash", "TREATMENT", 29, 47], ["centrifugation", "TREATMENT", 52, 66]]], ["PBMC were stored as pellets at \u201380\u00b0C. PBMC from mice were isolated from blood sampled by intracardiac puncture and collected in EDTA pre-coated vials (BD Vacutainer K2EDTA).", [["PBMC", "ANATOMY", 0, 4], ["PBMC", "ANATOMY", 38, 42], ["blood", "ANATOMY", 72, 77], ["intracardiac", "ANATOMY", 89, 101], ["EDTA", "CHEMICAL", 128, 132], ["PBMC", "CELL", 0, 4], ["PBMC", "CELL", 38, 42], ["mice", "ORGANISM", 48, 52], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["PBMC", "CELL_TYPE", 0, 4], ["PBMC", "CELL_TYPE", 38, 42], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["PBMC", "TREATMENT", 0, 4], ["PBMC", "TREATMENT", 38, 42], ["intracardiac puncture", "TEST", 89, 110], ["BD Vacutainer K2EDTA", "TREATMENT", 151, 171], ["intracardiac", "ANATOMY", 89, 101], ["puncture", "OBSERVATION", 102, 110]]], ["PBMC were isolated from EDTA-blood by Lympholite (Lympholyte-Mammal, Cedarlane) density gradient centrifugation at 1000 \u00d7 g for 25 min at 18\u201320\u00b0C. Mononuclear cells were harvested from the interface and washed once at 800 \u00d7 g for 10 min with RPMI 1640 (EuroClone) supplemented with 2.5 mM EDTA, and stored as pellets at \u201380\u00b0C. Before analysis human and mouse PBMC were lysed in 20 mM Tris-HCl pH 7.5, 0.1% NP40, and 0.1% SDS supplemented with Protease Inhibitors (Sigma), boiled for 5 min and centrifuged at 16.000 \u00d7 g for 10 min at 4\u00b0C. Supernatants were analyzed by Western and dot blot analyses.", [["PBMC", "ANATOMY", 0, 4], ["blood", "ANATOMY", 29, 34], ["Mononuclear cells", "ANATOMY", 147, 164], ["PBMC", "ANATOMY", 359, 363], ["Supernatants", "ANATOMY", 538, 550], ["Lympholite", "CHEMICAL", 38, 48], ["RPMI 1640", "CHEMICAL", 242, 251], ["EuroClone", "CHEMICAL", 253, 262], ["Tris-HCl", "CHEMICAL", 384, 392], ["EDTA", "CHEMICAL", 24, 28], ["EDTA", "CHEMICAL", 289, 293], ["Tris-HCl", "CHEMICAL", 384, 392], ["NP40", "CHEMICAL", 406, 410], ["PBMC", "CELL", 0, 4], ["EDTA", "SIMPLE_CHEMICAL", 24, 28], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["Lympholite", "SIMPLE_CHEMICAL", 38, 48], ["Cedarlane", "SIMPLE_CHEMICAL", 69, 78], ["Mononuclear cells", "CELL", 147, 164], ["EDTA", "SIMPLE_CHEMICAL", 289, 293], ["human", "ORGANISM", 343, 348], ["mouse", "ORGANISM", 353, 358], ["PBMC", "CELL", 359, 363], ["Tris-HCl", "SIMPLE_CHEMICAL", 384, 392], ["NP40", "SIMPLE_CHEMICAL", 406, 410], ["Supernatants", "CELL", 538, 550], ["PBMC", "CELL_TYPE", 0, 4], ["Mononuclear cells", "CELL_TYPE", 147, 164], ["human and mouse PBMC", "CELL_TYPE", 343, 363], ["human", "SPECIES", 343, 348], ["mouse", "SPECIES", 353, 358], ["human", "SPECIES", 343, 348], ["mouse", "SPECIES", 353, 358], ["PBMC", "TREATMENT", 0, 4], ["EDTA", "TEST", 24, 28], ["Lympholite (Lympholyte-Mammal, Cedarlane) density gradient centrifugation", "TREATMENT", 38, 111], ["Mononuclear cells", "PROBLEM", 147, 164], ["RPMI", "TREATMENT", 242, 246], ["2.5 mM EDTA", "TREATMENT", 282, 293], ["mouse PBMC", "TREATMENT", 353, 363], ["Tris", "TEST", 384, 388], ["HCl pH", "TEST", 389, 395], ["Protease Inhibitors", "TREATMENT", 443, 462], ["dot blot analyses", "TEST", 580, 597]]], ["Proteins were quantified by the BCA protein assay (Pierce).Protein Extraction from the Spinal Cord of the Mice ::: Materials and MethodsThe spinal cord was flushed from the vertebral column and sectioned into cervical, thoracic and lumbar segments.", [["Spinal Cord", "ANATOMY", 87, 98], ["spinal cord", "ANATOMY", 140, 151], ["vertebral column", "ANATOMY", 173, 189], ["cervical", "ANATOMY", 209, 217], ["thoracic", "ANATOMY", 219, 227], ["lumbar segments", "ANATOMY", 232, 247], ["Mice", "ORGANISM", 106, 110], ["spinal cord", "ORGAN", 140, 151], ["vertebral column", "MULTI-TISSUE_STRUCTURE", 173, 189], ["cervical", "ORGAN", 209, 217], ["thoracic", "MULTI-TISSUE_STRUCTURE", 219, 227], ["lumbar segments", "MULTI-TISSUE_STRUCTURE", 232, 247], ["Mice", "SPECIES", 106, 110], ["Protein Extraction", "TREATMENT", 59, 77], ["Methods", "TREATMENT", 129, 136], ["Spinal Cord", "ANATOMY", 87, 98], ["Mice", "ANATOMY", 106, 110], ["spinal cord", "ANATOMY", 140, 151], ["flushed", "OBSERVATION", 156, 163], ["vertebral", "ANATOMY", 173, 182], ["column", "ANATOMY_MODIFIER", 183, 189], ["cervical", "ANATOMY_MODIFIER", 209, 217], ["thoracic", "ANATOMY", 219, 227], ["lumbar segments", "ANATOMY", 232, 247]]], ["The samples were immediately frozen on dry-ice and stored at \u201380\u00b0C until analysis.", [["samples", "ANATOMY", 4, 11], ["analysis", "TEST", 73, 81]]], ["Lumbar spinal cords were homogenized by sonication in 1% boiling SDS.", [["Lumbar spinal cords", "ANATOMY", 0, 19], ["Lumbar", "ORGAN", 0, 6], ["spinal cords", "ORGAN", 7, 19], ["spinal cords", "ANATOMY", 7, 19]]], ["Protein homogenates were further boiled for 10 min and centrifuged at 13.500 \u00d7 g for 5 min at 4\u00b0C. Supernatants were analyzed by Western and dot blot analyses.", [["homogenates", "ANATOMY", 8, 19], ["Supernatants", "ANATOMY", 99, 111], ["Supernatants", "CELL", 99, 111], ["Protein homogenates", "PROBLEM", 0, 19], ["dot blot analyses", "TEST", 141, 158]]], ["Proteins were quantified by the BCA protein assay (Pierce).Two-Dimensional Difference in Gel Electrophoresis (2D DIGE) ::: Materials and MethodsPeripheral blood mononuclear cells proteins were prepared for 2D DIGE analysis as follows: four pools of 20 \u03bcg from 16 early ALS, 16 early controls, 16 late ALS, and 16 late controls were methanol-precipitated overnight.", [["MethodsPeripheral blood mononuclear cells", "ANATOMY", 137, 178], ["ALS", "DISEASE", 269, 272], ["ALS", "DISEASE", 301, 304], ["methanol", "CHEMICAL", 332, 340], ["methanol", "CHEMICAL", 332, 340], ["MethodsPeripheral blood mononuclear cells", "CELL", 137, 178], ["methanol", "SIMPLE_CHEMICAL", 332, 340], ["MethodsPeripheral blood mononuclear cells", "CELL_TYPE", 137, 178], ["Gel Electrophoresis", "TEST", 89, 108], ["Materials", "TEST", 123, 132], ["MethodsPeripheral blood mononuclear cells proteins", "TEST", 137, 187], ["2D DIGE analysis", "TEST", 206, 222], ["methanol", "TREATMENT", 332, 340]]], ["Proteins were then dissolved in 30 mM Tris-HCl pH 8.5, 7 M urea, 2 M thiourea, CHAPS 4% (w/v) and Cydye-labeled according to the manufacturer\u2019s instructions (GE Healthcare) with minor modifications.", [["Tris-HCl", "CHEMICAL", 38, 46], ["urea", "CHEMICAL", 59, 63], ["Tris-HCl", "CHEMICAL", 38, 46], ["urea", "CHEMICAL", 59, 63], ["thiourea", "CHEMICAL", 69, 77], ["CHAPS", "CHEMICAL", 79, 84], ["Cydye", "CHEMICAL", 98, 103], ["urea", "SIMPLE_CHEMICAL", 59, 63], ["2 M thiourea", "SIMPLE_CHEMICAL", 65, 77], ["CHAPS", "SIMPLE_CHEMICAL", 79, 84], ["Cydye", "SIMPLE_CHEMICAL", 98, 103], ["Proteins", "TEST", 0, 8], ["Tris", "TEST", 38, 42], ["HCl pH", "TEST", 43, 49], ["urea", "TEST", 59, 63], ["thiourea", "TEST", 69, 77], ["CHAPS", "TEST", 79, 84], ["Cydye", "TEST", 98, 103], ["minor modifications", "TREATMENT", 178, 197]]], ["Briefly, 20 \u03bcg of each pool was labeled with 200 pmol of Cy3 or Cy5 dye for 30 min in ice in the dark.", [["Cy5 dye", "CHEMICAL", 64, 71], ["Cy3", "SIMPLE_CHEMICAL", 57, 60], ["Cy5 dye", "SIMPLE_CHEMICAL", 64, 71], ["Cy3 or Cy5 dye", "TREATMENT", 57, 71]]], ["To exclude preferential labeling of the dyes, each sample was also reverse labeled.", [["sample", "ANATOMY", 51, 57], ["the dyes", "PROBLEM", 36, 44]]], ["As an internal standard, aliquots of each pool were mixed and labeled with Cy2 dye.", [["Cy2 dye", "SIMPLE_CHEMICAL", 75, 82], ["Cy2 dye", "TREATMENT", 75, 82]]], ["Labeled samples were then resuspended in Destreak SolutionTM (GE Healthcare) with IPG buffer pH 3-11 NL 1% v/v (GE Healthcare) and loaded into 11 cm-IPG strips pI range 3-11NL (GE Healthcare).", [["samples", "ANATOMY", 8, 15], ["Labeled samples", "TEST", 0, 15], ["IPG buffer pH", "TREATMENT", 82, 95], ["v (GE Healthcare)", "TREATMENT", 109, 126]]], ["Isoelectrofocusing was done on an IPGphor apparatus (GE Healthcare) with the following protocol: 300 Vhrs at 30 V, 50 Vhrs at 200 V, 1500 Vhrs at 2000 V, 2800 Vhrs of a linear gradient up to 3500 V, 4800 Vhrs at 3500 V, 8500 Vhr of a linear gradient up to 8000 V, and 30000 Vhr at 8000 V. SDS-PAGE was done using Precast Tris-HCl 10% polyacrylamide SDS gel (Biorad).", [["Precast Tris-HCl", "CHEMICAL", 313, 329], ["HCl", "CHEMICAL", 326, 329], ["polyacrylamide", "CHEMICAL", 334, 348], ["polyacrylamide", "SIMPLE_CHEMICAL", 334, 348], ["a linear gradient", "TEST", 167, 184], ["a linear gradient", "TEST", 232, 249], ["SDS", "TEST", 289, 292], ["Precast Tris", "TREATMENT", 313, 325], ["HCl", "TREATMENT", 326, 329], ["polyacrylamide SDS gel", "TREATMENT", 334, 356]]], ["Eight 2D gels were run with the four experimental groups.", [["Eight 2D gels", "TREATMENT", 0, 13]]], ["Each gel contained two experimental groups, one Cy3-labeled, the other Cy5-labeled plus the Cy2-labeled internal standard.", [["Cy3", "SIMPLE_CHEMICAL", 48, 51], ["Cy5", "SIMPLE_CHEMICAL", 71, 74], ["Cy2", "SIMPLE_CHEMICAL", 92, 95]]], ["Gel images were captured by the laser scanner Molecular Imager FX (Bio-Rad).", [["FX", "PROTEIN", 63, 65], ["Bio-Rad", "PROTEIN", 67, 74], ["Gel images", "TEST", 0, 10], ["the laser scanner", "TEST", 28, 45]]], ["Image analysis was done with Progenesis Same Spot software (Nonlinear Dynamics).", [["Image analysis", "TEST", 0, 14]]], ["For each spot the normalized volume was standardized against internal standard spot normal volume.", [["each spot the normalized volume", "TEST", 4, 35], ["normal volume", "OBSERVATION", 84, 97]]], ["The values for each spot in each group were expressed as the mean of the Cy3- and Cy5-labeled analyses.", [["Cy3", "SIMPLE_CHEMICAL", 73, 76], ["Cy5", "SIMPLE_CHEMICAL", 82, 85], ["The values", "TEST", 0, 10], ["the Cy3", "TEST", 69, 76], ["Cy5-labeled analyses", "TEST", 82, 102]]], ["Values for early and late ALS were further normalized to the means values of early and late controls, respectively.", [["ALS", "DISEASE", 26, 29], ["Values", "TEST", 0, 6], ["early and late ALS", "PROBLEM", 11, 29]]], ["Differential spots were considered only those that had a fold change (normalized late ALS/ normalized early ALS) \u22640.8 or \u22651.3.Protein Identification ::: Materials and MethodsDifferential protein spots were located and excised from 2D gels with the EXQuestTM spot cutter (Bio-Rad).", [["ALS", "DISEASE", 108, 111], ["Bio-Rad", "DNA", 271, 278], ["Differential spots", "TEST", 0, 18], ["a fold change", "PROBLEM", 55, 68], ["Differential protein spots", "PROBLEM", 174, 200], ["the EXQuestTM spot cutter", "TREATMENT", 244, 269]]], ["Spots were processed and gel-digested with modified trypsin from bovine pancreas (Roche) and identified by mass spectrometry (MS), as previously described (Nardo et al., 2011).", [["pancreas", "ANATOMY", 72, 80], ["trypsin", "GENE_OR_GENE_PRODUCT", 52, 59], ["bovine", "ORGANISM", 65, 71], ["pancreas", "ORGAN", 72, 80], ["Roche", "ORGANISM_SUBSTANCE", 82, 87], ["trypsin", "PROTEIN", 52, 59], ["bovine", "SPECIES", 65, 71], ["bovine", "SPECIES", 65, 71], ["modified trypsin from bovine pancreas", "TREATMENT", 43, 80], ["pancreas", "ANATOMY", 72, 80], ["mass", "OBSERVATION", 107, 111]]], ["Peptide mass fingerprinting and tandem MS/MS were done on a 4800 MALDI TOF/TOF mass spectrometer (Applied Biosystems).", [["Peptide mass fingerprinting", "PROBLEM", 0, 27], ["tandem MS/MS", "PROBLEM", 32, 44], ["a 4800 MALDI TOF", "TREATMENT", 58, 74], ["mass", "OBSERVATION", 8, 12]]], ["The mass spectra were internally calibrated with trypsin autolysis fragments.", [["trypsin", "GENE_OR_GENE_PRODUCT", 49, 56], ["trypsin", "PROTEIN", 49, 56], ["The mass spectra", "PROBLEM", 0, 16], ["trypsin autolysis fragments", "TREATMENT", 49, 76], ["mass", "OBSERVATION", 4, 8], ["trypsin autolysis", "OBSERVATION", 49, 66], ["fragments", "OBSERVATION_MODIFIER", 67, 76]]], ["The five most abundant precursor ions, out of the exclusion mass list (ions from human keratin and trypsin), were selected for MS/MS analysis.", [["human", "ORGANISM", 81, 86], ["keratin", "GENE_OR_GENE_PRODUCT", 87, 94], ["trypsin", "GENE_OR_GENE_PRODUCT", 99, 106], ["human keratin", "PROTEIN", 81, 94], ["trypsin", "PROTEIN", 99, 106], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["human keratin and trypsin", "TREATMENT", 81, 106], ["MS/MS analysis", "TEST", 127, 141], ["abundant", "OBSERVATION_MODIFIER", 14, 22], ["precursor ions", "OBSERVATION", 23, 37], ["mass", "OBSERVATION", 60, 64]]], ["The combined MS and MS/MS data were submitted by GPS Explorer v.3.6 software (Applied Biosystems) to the MASCOT database search engine (Version 2.1, Matrix Science) and searched with the following parameters: Uniprot_Swissprot 2012x database over all Homo sapiens protein sequences deposited, no fixed modifications, as possible modifications carboamidomethylation of cysteine and oxidation of methionine, 1 missed trypsin cleavage, a mass tolerance of \u00b10.1 Da for the peptide masses and \u00b10.3 Da for the MS/MS fragment ion masses.", [["cysteine", "CHEMICAL", 368, 376], ["methionine", "CHEMICAL", 394, 404], ["cysteine", "CHEMICAL", 368, 376], ["methionine", "CHEMICAL", 394, 404], ["cysteine", "AMINO_ACID", 368, 376], ["methionine", "SIMPLE_CHEMICAL", 394, 404], ["trypsin", "GENE_OR_GENE_PRODUCT", 415, 422], ["Homo sapiens protein sequences", "DNA", 251, 281], ["trypsin", "PROTEIN", 415, 422], ["Homo sapiens", "SPECIES", 251, 263], ["Homo sapiens", "SPECIES", 251, 263], ["The combined MS", "PROBLEM", 0, 15], ["MS/MS data", "TEST", 20, 30], ["Uniprot_Swissprot", "TREATMENT", 209, 226], ["all Homo sapiens protein sequences", "TREATMENT", 247, 281], ["fixed modifications", "TREATMENT", 296, 315], ["modifications carboamidomethylation of cysteine", "TREATMENT", 329, 376], ["methionine", "TREATMENT", 394, 404], ["1 missed trypsin cleavage", "TREATMENT", 406, 431], ["a mass tolerance", "PROBLEM", 433, 449], ["the peptide masses", "PROBLEM", 465, 483], ["the MS", "PROBLEM", 500, 506], ["MS fragment ion masses", "PROBLEM", 507, 529], ["no", "UNCERTAINTY", 293, 295], ["fixed modifications", "OBSERVATION", 296, 315], ["masses", "OBSERVATION", 477, 483], ["masses", "OBSERVATION", 523, 529]]], ["A protein was regarded as identified if the MASCOT protein score, based on the combined MS and MS/MS data, was above the 5% significance threshold for the database (Pappin et al., 1993).Gene Ontology (GO) Analysis ::: Materials and MethodsIdentified proteins were classified on the basis of gene ontology (GO) annotations provided by PANTHER1 (Mi et al., 2013).", [["A protein", "TEST", 0, 9], ["the MASCOT protein score", "TEST", 40, 64], ["the combined MS", "PROBLEM", 75, 90], ["MS/MS data", "TEST", 95, 105], ["the database", "TEST", 151, 163]]], ["PANTHER overrepresentation test was performed with the list of the identified differential proteins against the whole Homo sapiens reference list and against a list of about 800 proteins extracted from published works of 2D-based proteomics of lymphocytes/monocytes (Verhoeckx et al., 2004; Rosengren et al., 2005; Xie et al., 2005; Azkargorta et al., 2006; Han et al., 2006; Huang et al., 2006; Ramirez-Boo et al., 2006; Salonen et al., 2006; Zada et al., 2006; Henrich et al., 2007; Lai et al., 2007; Rakkola et al., 2007; Skopeliti et al., 2007; Vergara et al., 2008).", [["lymphocytes", "ANATOMY", 244, 255], ["monocytes", "ANATOMY", 256, 265], ["lymphocytes", "CELL", 244, 255], ["monocytes", "CELL", 256, 265], ["differential proteins", "PROTEIN", 78, 99], ["Homo sapiens reference list", "DNA", 118, 145], ["800 proteins", "PROTEIN", 174, 186], ["lymphocytes", "CELL_TYPE", 244, 255], ["monocytes", "CELL_TYPE", 256, 265], ["Homo sapiens", "SPECIES", 118, 130], ["Homo sapiens", "SPECIES", 118, 130], ["PANTHER overrepresentation test", "TEST", 0, 31], ["lymphocytes", "TEST", 244, 255], ["monocytes", "TEST", 256, 265], ["Ramirez", "TEST", 396, 403]]], ["PANTHER GO-Slim Biological Process and GO-Slim Molecular Function were used as annotation data sets (version 11.1, released 2016-07-15).Dot Blot Analysis ::: Materials and MethodsDot blot was used in the validation study after verification that the antibody detected specific bands in WB (Supplementary Figure S1).", [["WB", "ANATOMY", 285, 287], ["WB", "PROTEIN", 285, 287], ["MethodsDot blot", "TEST", 172, 187], ["the validation study", "TEST", 200, 220], ["the antibody", "TEST", 245, 257]]], ["Proteins (3 \u03bcg) were directly loaded onto nitrocellulose Trans-Blot transfer 0.2\u20130.45 \u03bcm (Bio-Rad) membranes, depositing each sample on the membrane by vacuum filtration, as described previously (Nardo et al., 2011).", [["membranes", "ANATOMY", 99, 108], ["sample", "ANATOMY", 126, 132], ["membrane", "ANATOMY", 140, 148], ["nitrocellulose", "CHEMICAL", 42, 56], ["membrane", "CELLULAR_COMPONENT", 140, 148], ["Proteins", "TEST", 0, 8], ["Blot transfer", "TEST", 63, 76], ["vacuum filtration", "OBSERVATION", 152, 169]]], ["An internal standard which is a pool of all samples in the analysis (healthy controls and patients) was deposited in triplicates.", [["samples", "ANATOMY", 44, 51], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["the analysis", "TEST", 55, 67], ["internal", "OBSERVATION_MODIFIER", 3, 11], ["standard", "OBSERVATION", 12, 20]]], ["Dot blot membranes were blocked with 3% (w/v) BSA (Sigma) and 0.1% (v/v) Tween 20 in Tris-buffered saline, pH 7.5, incubated with primary antibodies, then with peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology Inc.).", [["membranes", "ANATOMY", 9, 18], ["Tween 20", "CHEMICAL", 73, 81], ["Tris", "CHEMICAL", 85, 89], ["membranes", "CELLULAR_COMPONENT", 9, 18], ["v) BSA", "SIMPLE_CHEMICAL", 43, 49], ["Sigma", "SIMPLE_CHEMICAL", 51, 56], ["Tween 20", "SIMPLE_CHEMICAL", 73, 81], ["Tris-buffered saline", "SIMPLE_CHEMICAL", 85, 105], ["peroxidase", "SIMPLE_CHEMICAL", 160, 170], ["primary antibodies", "PROTEIN", 130, 148], ["peroxidase", "PROTEIN", 160, 170], ["secondary antibodies", "PROTEIN", 182, 202], ["Santa Cruz Biotechnology", "PROTEIN", 204, 228], ["Dot blot membranes", "PROBLEM", 0, 18], ["v/v) Tween", "TREATMENT", 68, 78], ["Tris-buffered saline", "TREATMENT", 85, 105], ["pH", "TEST", 107, 109], ["primary antibodies", "TEST", 130, 148], ["peroxidase", "TEST", 160, 170]]], ["Blots were developed with LuminataTM Forte Western Chemiluminescent HRP Substrate (Millipore) on the ChemiDoc XRS system (Bio-Rad).", [["Blots", "TEST", 0, 5], ["LuminataTM Forte", "TREATMENT", 26, 42], ["the ChemiDoc XRS system", "TEST", 97, 120]]], ["Densitometry was done with Progenesis PG240 v2006 software (Nonlinear Dynamics).", [["Densitometry", "TEST", 0, 12], ["Progenesis", "TREATMENT", 27, 37]]], ["The immunoreactivity of the different proteins was normalized to Ponceau Red staining (Fluka) and to the internal standard of each membrane.Statistical Analysis ::: Materials and MethodsImmunoreactivity values for each protein analyzed in early and late ALS were normalized to the means values of early and late controls, respectively.", [["membrane", "ANATOMY", 131, 139], ["ALS", "DISEASE", 254, 257], ["Ponceau Red", "CHEMICAL", 65, 76], ["Fluka", "CHEMICAL", 87, 92], ["Ponceau Red", "GENE_OR_GENE_PRODUCT", 65, 76], ["Fluka", "SIMPLE_CHEMICAL", 87, 92], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["the different proteins", "PROBLEM", 24, 46], ["Red staining", "TEST", 73, 85], ["MethodsImmunoreactivity values", "TEST", 179, 209], ["each protein", "TEST", 214, 226], ["internal", "ANATOMY_MODIFIER", 105, 113], ["each membrane", "ANATOMY_MODIFIER", 126, 139]]], ["The statistical analysis of the protein expression in the two groups was done by Student\u2019s t-test using PRISM software (GraphPad, San Diego, CA, USA, version 6.01).Identification of Candidate Phenotypic Biomarkers of ALS in PBMC by 2D-DIGE-Based Proteomics ::: ResultsFigure 1A schematically shows the strategy we used to identify and validate phenotypic protein biomarkers of ALS in PBMC.", [["PBMC", "ANATOMY", 224, 228], ["PBMC", "ANATOMY", 384, 388], ["ALS", "DISEASE", 217, 220], ["ALS", "DISEASE", 377, 380], ["PBMC", "CELL", 224, 228], ["PBMC", "CELL", 384, 388], ["PBMC", "CELL_TYPE", 224, 228], ["PBMC", "CELL_TYPE", 384, 388], ["the protein expression", "TEST", 28, 50], ["PRISM software", "TEST", 104, 118], ["Phenotypic Biomarkers", "TEST", 192, 213], ["ALS in PBMC", "PROBLEM", 217, 228], ["2D", "TEST", 232, 234], ["phenotypic protein biomarkers", "TEST", 344, 373], ["ALS in PBMC", "PROBLEM", 377, 388]]], ["In the discovery phase, PBMC of ALS patients with \u226455 years of age (early ALS, EA) or \u226575 years of age (late ALS) at diagnosis and matched early and late controls were analyzed by 2D DIGE.", [["PBMC", "ANATOMY", 24, 28], ["ALS", "DISEASE", 32, 35], ["ALS", "DISEASE", 74, 77], ["ALS", "DISEASE", 109, 112], ["PBMC", "CELL", 24, 28], ["patients", "ORGANISM", 36, 44], ["PBMC", "CELL_TYPE", 24, 28], ["patients", "SPECIES", 36, 44]]], ["The analysis was done with 16 pooled samples for each of the four experimental groups (Table 1).", [["samples", "ANATOMY", 37, 44], ["The analysis", "TEST", 0, 12], ["16 pooled samples", "TREATMENT", 27, 44]]], ["Spot volume values for early and late ALS were normalized to the mean values of early and late controls, respectively.", [["ALS", "DISEASE", 38, 41], ["Spot volume values", "TEST", 0, 18], ["late ALS", "PROBLEM", 33, 41]]], ["Spots were considered differential if fold change (normalized late ALS/normalized early ALS) was \u22640.8 or \u22651.3.", [["ALS", "DISEASE", 67, 70], ["ALS", "DISEASE", 88, 91], ["fold change", "PROBLEM", 38, 49]]], ["A total of 68 differential spots were detected (Figure 1B).", [["differential spots", "TEST", 14, 32], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["From these spots 43 unique proteins were identified by MS as candidate protein biomarkers (Table 3).", [["unique proteins", "TEST", 20, 35], ["protein biomarkers", "TEST", 71, 89]]], ["Some of the proteins were identified in multiple spots at different pI and Mw, which are fragments or post-translationally modified isoforms of the same protein (Supplementary Table S1).", [["fragments", "ANATOMY", 89, 98], ["Supplementary Table S1", "PROTEIN", 162, 184], ["the proteins", "PROBLEM", 8, 20], ["multiple spots at different pI and Mw", "PROBLEM", 40, 77], ["proteins", "OBSERVATION", 12, 20], ["multiple", "OBSERVATION_MODIFIER", 40, 48], ["spots", "OBSERVATION_MODIFIER", 49, 54], ["different pI", "OBSERVATION_MODIFIER", 58, 70], ["Mw", "OBSERVATION_MODIFIER", 75, 77], ["fragments", "OBSERVATION_MODIFIER", 89, 98]]], ["We grouped the differential proteins on the basis of their most recognized function and on GO annotations (Table 3).", [["differential proteins", "PROTEIN", 15, 36]]], ["The overrepresentation test performed with the list of the differential proteins against the Homo sapiens reference list indicated isomerase activity (GO:0016853), associated with PPIA and ERp57, among the most significantly enriched (p = 0.03; fold = 7.8) molecular functions.", [["Homo sapiens", "ORGANISM", 93, 105], ["isomerase", "GENE_OR_GENE_PRODUCT", 131, 140], ["PPIA", "GENE_OR_GENE_PRODUCT", 180, 184], ["ERp57", "GENE_OR_GENE_PRODUCT", 189, 194], ["Homo sapiens reference list", "PROTEIN", 93, 120], ["isomerase", "PROTEIN", 131, 140], ["PPIA", "PROTEIN", 180, 184], ["ERp57", "PROTEIN", 189, 194], ["Homo sapiens", "SPECIES", 93, 105], ["Homo sapiens", "SPECIES", 93, 105], ["The overrepresentation test", "TEST", 0, 27], ["isomerase activity", "PROBLEM", 131, 149], ["PPIA", "TEST", 180, 184], ["ERp57", "TEST", 189, 194], ["fold", "TEST", 245, 249], ["PPIA", "OBSERVATION", 180, 184]]], ["Protein folding (GO:0006457) and response to stress (GO:0006950) were among the most significantly enriched (p < 0.01; fold>4) biological processes identified.", [["Protein folding", "TEST", 0, 15]]], ["The overrepresentation test performed also against a reference list of lymphocyte/monocyte proteins, identified in 2D-based proteomic studies, indicated response to stress as one of the most significantly enriched (p = 0.03; fold = 2.5) biological processes.", [["lymphocyte", "ANATOMY", 71, 81], ["monocyte", "ANATOMY", 82, 90], ["lymphocyte", "CELL", 71, 81], ["monocyte", "CELL", 82, 90], ["lymphocyte/monocyte proteins", "PROTEIN", 71, 99], ["The overrepresentation test", "TEST", 0, 27], ["lymphocyte/monocyte proteins", "TEST", 71, 99], ["proteomic studies", "TEST", 124, 141]]], ["This suggested that proteins associated with these molecular functions and biological processes (Table 3), such as PPIA, HSP90, GRP78, ERp57, and DJ-1, were attracting candidate phenotypic biomarkers to further validate in a larger and well-characterized cohort of patients with early and late disease onset.Validation of Candidate Phenotypic Biomarkers ::: ResultsIn the validation study, we analyzed total protein levels of candidate phenotypic biomarkers, PPIA, HSP90, GRP78, ERp57, and DJ-1, by dot blot analysis in PBMC samples from an independent set of ALS patients (n = 85), n = 38 early ALS and n = 47 late ALS, and matched controls (n = 83), n = 35 early controls and n = 48 late controls (Table 2).", [["PBMC samples", "ANATOMY", 520, 532], ["ALS", "DISEASE", 560, 563], ["ALS", "DISEASE", 596, 599], ["ALS", "DISEASE", 616, 619], ["Table 3", "GENE_OR_GENE_PRODUCT", 97, 104], ["PPIA", "GENE_OR_GENE_PRODUCT", 115, 119], ["HSP90", "GENE_OR_GENE_PRODUCT", 121, 126], ["GRP78", "GENE_OR_GENE_PRODUCT", 128, 133], ["ERp57", "GENE_OR_GENE_PRODUCT", 135, 140], ["DJ-1", "GENE_OR_GENE_PRODUCT", 146, 150], ["patients", "ORGANISM", 265, 273], ["PPIA", "GENE_OR_GENE_PRODUCT", 459, 463], ["HSP90", "GENE_OR_GENE_PRODUCT", 465, 470], ["GRP78", "GENE_OR_GENE_PRODUCT", 472, 477], ["ERp57", "GENE_OR_GENE_PRODUCT", 479, 484], ["DJ-1", "GENE_OR_GENE_PRODUCT", 490, 494], ["PBMC samples", "CANCER", 520, 532], ["patients", "ORGANISM", 564, 572], ["PPIA", "PROTEIN", 115, 119], ["HSP90", "PROTEIN", 121, 126], ["GRP78", "PROTEIN", 128, 133], ["ERp57", "PROTEIN", 135, 140], ["DJ-1", "PROTEIN", 146, 150], ["PPIA", "PROTEIN", 459, 463], ["HSP90", "PROTEIN", 465, 470], ["GRP78", "PROTEIN", 472, 477], ["ERp57", "PROTEIN", 479, 484], ["DJ-1", "PROTEIN", 490, 494], ["PBMC", "CELL_TYPE", 520, 524], ["patients", "SPECIES", 265, 273], ["patients", "SPECIES", 564, 572], ["proteins", "PROBLEM", 20, 28], ["PPIA", "TEST", 115, 119], ["HSP90", "TEST", 121, 126], ["GRP78", "TEST", 128, 133], ["ERp57", "TEST", 135, 140], ["DJ", "TEST", 146, 148], ["early and late disease onset", "PROBLEM", 279, 307], ["the validation study", "TEST", 368, 388], ["total protein levels", "TEST", 402, 422], ["phenotypic biomarkers", "TEST", 436, 457], ["PPIA", "TEST", 459, 463], ["HSP90", "TEST", 465, 470], ["GRP78", "TEST", 472, 477], ["ERp57", "TEST", 479, 484], ["DJ", "TEST", 490, 492], ["dot blot analysis", "TEST", 499, 516], ["PBMC samples", "TEST", 520, 532], ["n", "TEST", 604, 605], ["late ALS", "PROBLEM", 611, 619], ["PPIA", "OBSERVATION", 115, 119], ["late", "OBSERVATION_MODIFIER", 289, 293], ["disease", "OBSERVATION", 294, 301]]], ["Immunoreactivity values for each protein in early and late ALS patients were normalized to the mean values of early and late controls, respectively, similarly to the proteomic analysis.", [["ALS", "DISEASE", 59, 62], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["Immunoreactivity values", "TEST", 0, 23], ["each protein", "TEST", 28, 40], ["the proteomic analysis", "TEST", 162, 184]]], ["We found that PPIA, HSP90, GRP78, and DJ-1 were significantly lower in early ALS than in late ALS, and therefore can be considered phenotypic biomarkers (Figures 2A\u2013C,E), while ERp57 did not change (Figure 2D).", [["ALS", "DISEASE", 77, 80], ["ALS", "DISEASE", 94, 97], ["PPIA", "GENE_OR_GENE_PRODUCT", 14, 18], ["HSP90", "GENE_OR_GENE_PRODUCT", 20, 25], ["GRP78", "GENE_OR_GENE_PRODUCT", 27, 32], ["DJ-1", "GENE_OR_GENE_PRODUCT", 38, 42], ["ER", "GENE_OR_GENE_PRODUCT", 177, 179], ["PPIA", "PROTEIN", 14, 18], ["HSP90", "PROTEIN", 20, 25], ["GRP78", "PROTEIN", 27, 32], ["DJ-1", "PROTEIN", 38, 42], ["ER", "PROTEIN", 177, 179], ["PPIA", "TEST", 14, 18], ["HSP90", "TEST", 20, 25], ["GRP78", "TEST", 27, 32], ["DJ", "TEST", 38, 40], ["phenotypic biomarkers", "TEST", 131, 152], ["Figures", "TEST", 154, 161], ["PPIA", "OBSERVATION", 14, 18]]], ["Moreover, PPIA, HSP90, GRP78, and DJ-1 were similarly regulated, with a decreased level in early ALS compared to early controls and an opposite tendency in late ALS (Supplementary Figures S2A\u2013C,E), suggesting that early ALS patients have some defects in the response to stress pathways.", [["ALS", "DISEASE", 97, 100], ["ALS", "DISEASE", 161, 164], ["ALS", "DISEASE", 220, 223], ["PPIA", "GENE_OR_GENE_PRODUCT", 10, 14], ["HSP90", "GENE_OR_GENE_PRODUCT", 16, 21], ["GRP78", "GENE_OR_GENE_PRODUCT", 23, 28], ["DJ-1", "GENE_OR_GENE_PRODUCT", 34, 38], ["patients", "ORGANISM", 224, 232], ["PPIA", "PROTEIN", 10, 14], ["HSP90", "PROTEIN", 16, 21], ["GRP78", "PROTEIN", 23, 28], ["DJ-1", "PROTEIN", 34, 38], ["patients", "SPECIES", 224, 232], ["PPIA", "TEST", 10, 14], ["HSP90", "TEST", 16, 21], ["GRP78", "TEST", 23, 28], ["DJ", "TEST", 34, 36], ["a decreased level", "PROBLEM", 70, 87], ["early ALS", "PROBLEM", 91, 100], ["an opposite tendency in late ALS", "PROBLEM", 132, 164], ["early ALS patients", "PROBLEM", 214, 232], ["some defects", "PROBLEM", 238, 250], ["stress pathways", "PROBLEM", 270, 285], ["PPIA", "OBSERVATION", 10, 14], ["DJ", "ANATOMY", 34, 36], ["decreased", "OBSERVATION_MODIFIER", 72, 81], ["opposite", "OBSERVATION_MODIFIER", 135, 143], ["tendency", "OBSERVATION_MODIFIER", 144, 152], ["defects", "OBSERVATION", 243, 250]]], ["In the same validation analysis, we measured another chaperone protein, HSC70, and TDP-43, both not differential in the 2D-DIGE analysis, but up-regulated in PBMC of a cohort of ALS patients with a mean age of onset of 62 \u00b1 10 years, previously reported in a work by our laboratory (Nardo et al., 2011).", [["PBMC", "ANATOMY", 158, 162], ["ALS", "DISEASE", 178, 181], ["HSC70", "GENE_OR_GENE_PRODUCT", 72, 77], ["TDP-43", "GENE_OR_GENE_PRODUCT", 83, 89], ["PBMC", "CELL", 158, 162], ["patients", "ORGANISM", 182, 190], ["chaperone protein", "PROTEIN", 53, 70], ["HSC70", "PROTEIN", 72, 77], ["TDP-43", "PROTEIN", 83, 89], ["PBMC", "CELL_TYPE", 158, 162], ["patients", "SPECIES", 182, 190], ["another chaperone protein", "TEST", 45, 70], ["HSC70", "TEST", 72, 77], ["TDP", "TEST", 83, 86], ["the 2D-DIGE analysis", "TEST", 116, 136]]], ["We found that HSC70 could not distinguish early from late ALS (Figure 2F), but it was up-regulated in late ALS compared to controls (Supplementary Figure S2F).", [["ALS", "DISEASE", 58, 61], ["ALS", "DISEASE", 107, 110], ["HSC70", "GENE_OR_GENE_PRODUCT", 14, 19], ["HSC70", "PROTEIN", 14, 19], ["HSC70", "TEST", 14, 19], ["could not distinguish", "UNCERTAINTY", 20, 41]]], ["We confirmed that total TDP-43 protein levels in PBMC underscores disease (Figure 2G), in fact it was higher in both early and late ALS compared to controls, but could not discriminate early ALS from late ALS (Figure 2H).", [["PBMC", "ANATOMY", 49, 53], ["ALS", "DISEASE", 132, 135], ["ALS", "DISEASE", 191, 194], ["ALS", "DISEASE", 205, 208], ["TDP-43", "GENE_OR_GENE_PRODUCT", 24, 30], ["PBMC", "CELL", 49, 53], ["PBMC", "CELL_TYPE", 49, 53], ["total TDP", "TEST", 18, 27], ["protein levels", "TEST", 31, 45], ["PBMC", "TEST", 49, 53], ["disease", "PROBLEM", 66, 73], ["early ALS", "PROBLEM", 185, 194], ["late ALS", "PROBLEM", 200, 208], ["higher", "OBSERVATION_MODIFIER", 102, 108]]], ["It has to be noted that in our assay the total TDP-43 protein level comprise the 43-kDa full-length and fragmented forms (Supplementary Figure S1A).Validation of Candidate Phenotypic Biomarkers ::: ResultsThe experimental set up of the analysis has strengths and limitations.", [["TDP-43", "GENE_OR_GENE_PRODUCT", 47, 53], ["TDP-43 protein", "PROTEIN", 47, 61], ["the total TDP", "TEST", 37, 50], ["protein level", "TEST", 54, 67], ["the analysis", "TEST", 232, 244]]], ["The major strengths are the population base and the enrolment of patients with newly diagnosed ALS.", [["ALS", "DISEASE", 95, 98], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["newly diagnosed ALS", "PROBLEM", 79, 98], ["major", "OBSERVATION_MODIFIER", 4, 9], ["strengths", "OBSERVATION_MODIFIER", 10, 19], ["population", "OBSERVATION_MODIFIER", 28, 38], ["base", "OBSERVATION_MODIFIER", 39, 43]]], ["Our patients are a fairly representative sample of an incident ALS population.", [["ALS", "DISEASE", 63, 66], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["an incident ALS population", "PROBLEM", 51, 77]]], ["The major limitation is the small sample size.", [["major", "OBSERVATION_MODIFIER", 4, 9], ["limitation", "OBSERVATION_MODIFIER", 10, 20], ["small", "OBSERVATION_MODIFIER", 28, 33], ["sample", "OBSERVATION_MODIFIER", 34, 40], ["size", "OBSERVATION_MODIFIER", 41, 45]]], ["The analysis may thus be underpowered for some differences to achieve statistical significance.", [["The analysis", "TEST", 0, 12]]], ["Then, we did not adjust our data for multiple comparisons.", [["multiple comparisons", "TEST", 37, 57]]], ["Thus, we cannot exclude that some of the associations are chance findings.", [["cannot exclude", "UNCERTAINTY", 9, 23]]], ["However, due to the exploratory nature of the analysis, we deliberately decided not to use the Bonferroni correction for multiple testing.Analysis of Phenotypic Biomarkers in Two SOD1G93A Mouse Models with Different Age of Onset ::: ResultsWe also analyzed total protein levels of the candidate phenotypic biomarkers, PPIA, HSP90, GRP78, ERp57, and DJ-1 in PBMC of two SOD1G93A mouse models, 129Sv SOD1G93A and C57 SOD1G93A mice and corresponding non-transgenic controls by dot blot analysis.", [["PBMC", "ANATOMY", 357, 361], ["PPIA", "GENE_OR_GENE_PRODUCT", 318, 322], ["HSP90", "GENE_OR_GENE_PRODUCT", 324, 329], ["GRP78", "GENE_OR_GENE_PRODUCT", 331, 336], ["ERp57", "GENE_OR_GENE_PRODUCT", 338, 343], ["DJ-1", "GENE_OR_GENE_PRODUCT", 349, 353], ["PBMC", "CELL", 357, 361], ["SOD1G93A", "ORGANISM", 369, 377], ["mouse", "ORGANISM", 378, 383], ["129Sv SOD1G93A", "ORGANISM", 392, 406], ["C57 SOD1G93A mice", "ORGANISM", 411, 428], ["SOD", "PROTEIN", 179, 182], ["PPIA", "PROTEIN", 318, 322], ["HSP90", "PROTEIN", 324, 329], ["GRP78", "PROTEIN", 331, 336], ["ERp57", "PROTEIN", 338, 343], ["DJ-1", "PROTEIN", 349, 353], ["PBMC", "CELL_TYPE", 357, 361], ["Mouse", "SPECIES", 188, 193], ["mouse", "SPECIES", 378, 383], ["mice", "SPECIES", 424, 428], ["mouse", "SPECIES", 378, 383], ["mice", "SPECIES", 424, 428], ["the analysis", "TEST", 42, 54], ["the Bonferroni correction", "TREATMENT", 91, 116], ["multiple testing", "TEST", 121, 137], ["Phenotypic Biomarkers", "TEST", 150, 171], ["total protein levels", "TEST", 257, 277], ["phenotypic biomarkers", "TEST", 295, 316], ["PPIA", "TEST", 318, 322], ["HSP90", "TEST", 324, 329], ["GRP78", "TEST", 331, 336], ["ERp57", "TEST", 338, 343], ["DJ", "TEST", 349, 351], ["PBMC", "TEST", 357, 361], ["dot blot analysis", "TEST", 474, 491]]], ["These mice despite having equal SOD1G93A expression have a different disease phenotype, because of the different genetic background (Marino et al., 2015).", [["mice", "ORGANISM", 6, 10], ["SOD1G93A", "GENE_OR_GENE_PRODUCT", 32, 40], ["SOD1G93A", "PROTEIN", 32, 40], ["mice", "SPECIES", 6, 10], ["mice", "SPECIES", 6, 10], ["a different disease phenotype", "PROBLEM", 57, 86]]], ["In particular, 129Sv and C57 SOD1G93A mice have symptom onset at 14 and 17 weeks of age, respectively, thus representing our mouse models of early (129Sv) and late (C57) disease onset.", [["C57 SOD1G93A mice", "ORGANISM", 25, 42], ["mouse", "ORGANISM", 125, 130], ["mice", "SPECIES", 38, 42], ["mouse", "SPECIES", 125, 130], ["mice", "SPECIES", 38, 42], ["mouse", "SPECIES", 125, 130], ["symptom onset", "PROBLEM", 48, 61], ["late (C57) disease onset", "PROBLEM", 159, 183]]], ["Similarly, to the human samples, immunoreactivity values for each protein in early and late mouse models were normalized to the mean values of the corresponding non-transgenic controls.", [["samples", "ANATOMY", 24, 31], ["human", "ORGANISM", 18, 23], ["samples", "CANCER", 24, 31], ["mouse", "ORGANISM", 92, 97], ["human", "SPECIES", 18, 23], ["mouse", "SPECIES", 92, 97], ["human", "SPECIES", 18, 23], ["mouse", "SPECIES", 92, 97], ["the human samples", "TEST", 14, 31], ["immunoreactivity values", "TEST", 33, 56], ["each protein", "TEST", 61, 73], ["non-transgenic controls", "OBSERVATION", 161, 184]]], ["We found that PPIA and HSP90 were significantly lower in early SOD1G93A mice than in late SOD1G93A mice, as much as in the human samples (Figures 3A,B), and there was a significant lower level of the two proteins in the early SOD1G93A mice compared to their non-transgenic controls (Supplementary Figures S3A,B).", [["samples", "ANATOMY", 129, 136], ["PPIA", "GENE_OR_GENE_PRODUCT", 14, 18], ["HSP90", "GENE_OR_GENE_PRODUCT", 23, 28], ["SOD1G93A mice", "ORGANISM", 63, 76], ["SOD1G93A mice", "ORGANISM", 90, 103], ["human", "ORGANISM", 123, 128], ["B", "GENE_OR_GENE_PRODUCT", 149, 150], ["SOD1G93A mice", "ORGANISM", 226, 239], ["B", "GENE_OR_GENE_PRODUCT", 309, 310], ["PPIA", "PROTEIN", 14, 18], ["HSP90", "PROTEIN", 23, 28], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 99, 103], ["human", "SPECIES", 123, 128], ["mice", "SPECIES", 235, 239], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 99, 103], ["human", "SPECIES", 123, 128], ["mice", "SPECIES", 235, 239], ["PPIA", "TEST", 14, 18], ["HSP90", "TEST", 23, 28], ["PPIA", "OBSERVATION", 14, 18], ["significantly", "OBSERVATION_MODIFIER", 34, 47], ["lower", "OBSERVATION_MODIFIER", 48, 53], ["significant", "OBSERVATION_MODIFIER", 169, 180], ["lower", "OBSERVATION_MODIFIER", 181, 186]]], ["DJ-1 had a similar behavior but it did not reach statistical significance (Figure 3E and Supplementary Figure S3E).", [["DJ-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["DJ-1", "DNA", 0, 4]]], ["GRP78 was instead significantly higher in early SOD1G93A mice than in late SOD1G93A mice (Figure 3C), in contrast with the human samples, with an increased level in the early SOD1G93A mice compared to controls (Supplementary Figure S3C).", [["samples", "ANATOMY", 129, 136], ["GRP78", "GENE_OR_GENE_PRODUCT", 0, 5], ["SOD1G93A mice", "ORGANISM", 48, 61], ["SOD1G93A mice", "ORGANISM", 75, 88], ["human", "ORGANISM", 123, 128], ["samples", "CANCER", 129, 136], ["SOD1G93A mice", "ORGANISM", 175, 188], ["GRP78", "PROTEIN", 0, 5], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 84, 88], ["human", "SPECIES", 123, 128], ["mice", "SPECIES", 184, 188], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 84, 88], ["human", "SPECIES", 123, 128], ["mice", "SPECIES", 184, 188], ["GRP78", "TEST", 0, 5], ["the human samples", "TEST", 119, 136], ["an increased level", "PROBLEM", 143, 161], ["significantly", "OBSERVATION_MODIFIER", 18, 31], ["higher", "OBSERVATION_MODIFIER", 32, 38], ["increased", "OBSERVATION_MODIFIER", 146, 155]]], ["ERp57 was not significantly different in late and early SOD1G93A mice, as much as in the human samples (Figure 3D), but it was significantly lower in late SOD1G93A mice compared to controls (Supplementary Figure S3D).", [["samples", "ANATOMY", 95, 102], ["ERp57", "GENE_OR_GENE_PRODUCT", 0, 5], ["SOD1G93A mice", "ORGANISM", 56, 69], ["human", "ORGANISM", 89, 94], ["samples", "CANCER", 95, 102], ["SOD1G93A mice", "ORGANISM", 155, 168], ["ERp57", "PROTEIN", 0, 5], ["mice", "SPECIES", 65, 69], ["human", "SPECIES", 89, 94], ["mice", "SPECIES", 164, 168], ["mice", "SPECIES", 65, 69], ["human", "SPECIES", 89, 94], ["mice", "SPECIES", 164, 168], ["ERp", "TEST", 0, 3], ["not significantly different", "OBSERVATION_MODIFIER", 10, 37]]], ["Finally, TDP-43 was not significantly different in early and late SOD1G93A mice, as in the human samples (Figure 3F), but was not different compared to corresponding nontransgenic controls, in contrast with the human samples (Supplementary Figure S3F).Analysis of Phenotypic Biomarkers in Two SOD1G93A Mouse Models with Different Age of Onset ::: ResultsTotal protein levels of PPIA, HSP90, GRP78, DJ-1, and TDP-43 were also measured in lumbar spinal cord homogenates from the early and late SOD1G93A mice at disease onset and relative age-matched nontransgenic controls by dot blot analysis (Figure 4 and Supplementary Figure S4).", [["samples", "ANATOMY", 97, 104], ["samples", "ANATOMY", 217, 224], ["lumbar spinal cord homogenates", "ANATOMY", 437, 467], ["TDP-43", "GENE_OR_GENE_PRODUCT", 9, 15], ["SOD1G93A mice", "ORGANISM", 66, 79], ["human", "ORGANISM", 91, 96], ["human", "ORGANISM", 211, 216], ["PPIA", "GENE_OR_GENE_PRODUCT", 378, 382], ["HSP90", "GENE_OR_GENE_PRODUCT", 384, 389], ["GRP78", "GENE_OR_GENE_PRODUCT", 391, 396], ["DJ-1", "GENE_OR_GENE_PRODUCT", 398, 402], ["TDP-43", "GENE_OR_GENE_PRODUCT", 408, 414], ["lumbar spinal cord homogenates", "TISSUE", 437, 467], ["mice", "ORGANISM", 501, 505], ["SOD", "PROTEIN", 293, 296], ["PPIA", "PROTEIN", 378, 382], ["HSP90", "PROTEIN", 384, 389], ["GRP78", "PROTEIN", 391, 396], ["DJ-1", "PROTEIN", 398, 402], ["TDP-43", "PROTEIN", 408, 414], ["mice", "SPECIES", 75, 79], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 211, 216], ["Mouse", "SPECIES", 302, 307], ["mice", "SPECIES", 501, 505], ["mice", "SPECIES", 75, 79], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 211, 216], ["TDP", "TEST", 9, 12], ["the human samples", "TEST", 207, 224], ["Phenotypic Biomarkers", "TEST", 264, 285], ["Total protein levels", "TEST", 354, 374], ["PPIA", "TEST", 378, 382], ["HSP90", "TEST", 384, 389], ["GRP78", "TEST", 391, 396], ["DJ", "TEST", 398, 400], ["TDP", "TEST", 408, 411], ["dot blot analysis", "TEST", 574, 591], ["significantly different", "OBSERVATION_MODIFIER", 24, 47], ["lumbar", "ANATOMY_MODIFIER", 437, 443], ["spinal cord", "ANATOMY", 444, 455]]], ["PPIA, HSP90, GRP78 and DJ-1 were significantly lower in early SOD1G93A mice than in late SOD1G93A mice (Figures 4A\u2013C,E) and were similarly regulated to PBMC isolated from patients (Supplementary Figures S4A\u2013E), indicating that also early SOD1G93A mice have some defects in the response to stress pathways, as already reported (Nardo et al., 2013, 2016; Marino et al., 2015).", [["PBMC", "ANATOMY", 152, 156], ["PPIA", "GENE_OR_GENE_PRODUCT", 0, 4], ["HSP90", "GENE_OR_GENE_PRODUCT", 6, 11], ["GRP78", "GENE_OR_GENE_PRODUCT", 13, 18], ["DJ-1", "GENE_OR_GENE_PRODUCT", 23, 27], ["SOD1G93A mice", "ORGANISM", 62, 75], ["SOD1G93A mice", "ORGANISM", 89, 102], ["PBMC", "CELL", 152, 156], ["patients", "ORGANISM", 171, 179], ["SOD1G93A mice", "ORGANISM", 238, 251], ["PPIA", "PROTEIN", 0, 4], ["HSP90", "PROTEIN", 6, 11], ["GRP78", "PROTEIN", 13, 18], ["DJ-1", "PROTEIN", 23, 27], ["PBMC", "CELL_TYPE", 152, 156], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 98, 102], ["patients", "SPECIES", 171, 179], ["mice", "SPECIES", 247, 251], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 247, 251], ["PPIA", "TEST", 0, 4], ["HSP90", "TEST", 6, 11], ["GRP78", "TEST", 13, 18], ["DJ", "TEST", 23, 25], ["PBMC", "TEST", 152, 156], ["some defects", "PROBLEM", 257, 269], ["defects", "OBSERVATION", 262, 269]]], ["ERp57 and TDP-43 were not different in the two conditions as in the human samples (Figures 4D,F).", [["samples", "ANATOMY", 74, 81], ["ERp57", "GENE_OR_GENE_PRODUCT", 0, 5], ["TDP-43", "GENE_OR_GENE_PRODUCT", 10, 16], ["human", "ORGANISM", 68, 73], ["ERp57", "PROTEIN", 0, 5], ["TDP-43", "PROTEIN", 10, 16], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["ERp57", "TEST", 0, 5], ["TDP", "TEST", 10, 13], ["the human samples", "TEST", 64, 81], ["not different", "OBSERVATION_MODIFIER", 22, 35]]], ["These data confirmed a previous work where no differences in total soluble TDP-43 were found between the SOD1G93A mice and respective Ntg littermates and between the two mouse strains (Marino et al., 2015).", [["TDP-43", "GENE_OR_GENE_PRODUCT", 75, 81], ["SOD1G93A mice", "ORGANISM", 105, 118], ["Ntg littermates", "ORGANISM", 134, 149], ["mouse", "ORGANISM", 170, 175], ["TDP-43", "PROTEIN", 75, 81], ["mice", "SPECIES", 114, 118], ["mouse", "SPECIES", 170, 175], ["mice", "SPECIES", 114, 118], ["mouse", "SPECIES", 170, 175], ["total soluble TDP", "TEST", 61, 78], ["Ntg littermates", "TREATMENT", 134, 149]]], ["In conclusion, we observed a similar regulation of these proteins, in PBMC of patients and PBMC and spinal cord of mice (Table 4).DiscussionThe molecular determinants of ALS heterogeneity are still poorly understood.", [["PBMC", "ANATOMY", 70, 74], ["PBMC", "ANATOMY", 91, 95], ["spinal cord", "ANATOMY", 100, 111], ["ALS", "DISEASE", 170, 173], ["PBMC", "CELL", 70, 74], ["patients", "ORGANISM", 78, 86], ["PBMC", "CELL", 91, 95], ["spinal cord", "ORGAN", 100, 111], ["mice", "ORGANISM", 115, 119], ["PBMC", "CELL_TYPE", 70, 74], ["PBMC", "CELL_TYPE", 91, 95], ["patients", "SPECIES", 78, 86], ["mice", "SPECIES", 115, 119], ["mice", "SPECIES", 115, 119], ["PBMC", "TEST", 91, 95], ["ALS heterogeneity", "PROBLEM", 170, 187], ["spinal cord", "ANATOMY", 100, 111]]], ["An anticipated or a delayed onset of the disease may be caused by various combinations of intrinsic and exogenous factors converging into common pathogenic pathways that underlie different susceptibility to ALS and eventually lead to a different prognosis.", [["ALS", "DISEASE", 207, 210], ["exogenous factors", "PROTEIN", 104, 121], ["the disease", "PROBLEM", 37, 48], ["intrinsic and exogenous factors", "PROBLEM", 90, 121], ["disease", "OBSERVATION", 41, 48], ["may be caused", "UNCERTAINTY", 49, 62]]], ["Here we report the identification of protein biomarkers in PBMC that can discriminate ALS patients with an early disease onset from those with a late disease onset.", [["PBMC", "ANATOMY", 59, 63], ["ALS", "DISEASE", 86, 89], ["PBMC", "CELL", 59, 63], ["patients", "ORGANISM", 90, 98], ["PBMC", "CELL_TYPE", 59, 63], ["patients", "SPECIES", 90, 98], ["protein biomarkers in PBMC", "PROBLEM", 37, 63], ["an early disease onset", "PROBLEM", 104, 126], ["a late disease onset", "PROBLEM", 143, 163], ["early", "OBSERVATION_MODIFIER", 107, 112], ["disease", "OBSERVATION", 113, 120], ["late", "OBSERVATION_MODIFIER", 145, 149], ["disease", "OBSERVATION", 150, 157]]], ["The identified phenotypic biomarkers have in common a high expression in CNS where they have an important role in protein folding, as foldases and/or classical molecular chaperones, and are upregulated by a variety of stressors.", [["CNS", "ANATOMY", 73, 76], ["CNS", "ANATOMICAL_SYSTEM", 73, 76], ["foldases", "GENE_OR_GENE_PRODUCT", 134, 142], ["foldases", "PROTEIN", 134, 142], ["classical molecular chaperones", "PROTEIN", 150, 180], ["phenotypic biomarkers", "TEST", 15, 36], ["high expression", "OBSERVATION_MODIFIER", 54, 69], ["protein folding", "OBSERVATION", 114, 129]]], ["They participate at different levels and in different ways in the maintenance of proteostasis, whose deficit has shown to generate protein misfolding and aggregation and facilitate the development of several neurodegenerative diseases, including ALS (Ruegsegger and Saxena, 2016).", [["neurodegenerative diseases", "DISEASE", 208, 234], ["ALS", "DISEASE", 246, 249], ["whose deficit", "PROBLEM", 95, 108], ["protein misfolding and aggregation", "PROBLEM", 131, 165], ["several neurodegenerative diseases", "PROBLEM", 200, 234], ["several", "OBSERVATION_MODIFIER", 200, 207], ["neurodegenerative", "OBSERVATION_MODIFIER", 208, 225], ["diseases", "OBSERVATION", 226, 234]]], ["These phenotypic biomarkers are: PPIA, HSP90, GRP78, and DJ-1.DiscussionPolyclonal anti-peptidyl-prolyl cis-trans isomerase A is ubiquitously expressed, with the highest expression in neurons and motor neurons (Lauranzano et al., 2015).", [["neurons", "ANATOMY", 184, 191], ["motor neurons", "ANATOMY", 196, 209], ["anti-peptidyl", "CHEMICAL", 83, 96], ["prolyl", "CHEMICAL", 97, 103], ["PPIA", "GENE_OR_GENE_PRODUCT", 33, 37], ["HSP90", "GENE_OR_GENE_PRODUCT", 39, 44], ["GRP78", "GENE_OR_GENE_PRODUCT", 46, 51], ["DJ-1", "GENE_OR_GENE_PRODUCT", 57, 61], ["anti-peptidyl-prolyl cis-trans isomerase A", "GENE_OR_GENE_PRODUCT", 83, 125], ["neurons", "CELL", 184, 191], ["motor neurons", "CELL", 196, 209], ["PPIA", "PROTEIN", 33, 37], ["HSP90", "PROTEIN", 39, 44], ["GRP78", "PROTEIN", 46, 51], ["DJ-1", "PROTEIN", 57, 61], ["Polyclonal anti-peptidyl-prolyl cis-trans isomerase A", "PROTEIN", 72, 125], ["neurons", "CELL_TYPE", 184, 191], ["motor neurons", "CELL_TYPE", 196, 209], ["These phenotypic biomarkers", "TEST", 0, 27], ["PPIA", "TEST", 33, 37], ["HSP90", "TEST", 39, 44], ["GRP78", "TEST", 46, 51], ["DJ", "TEST", 57, 59], ["PPIA", "OBSERVATION", 33, 37], ["neurons", "ANATOMY", 184, 191], ["motor neurons", "ANATOMY", 196, 209]]], ["It is a peptidylprolyl cis/trans isomerase and, as a foldase, it accelerates the rate-limiting steps along the folding pathway, but it also acts as a classical molecular chaperone (Fischer et al., 1989; Freskgard et al., 1992).", [["peptidylprolyl", "CHEMICAL", 8, 22], ["peptidylprolyl cis/trans isomerase", "GENE_OR_GENE_PRODUCT", 8, 42], ["peptidylprolyl cis/trans isomerase", "PROTEIN", 8, 42], ["foldase", "PROTEIN", 53, 60]]], ["We originally identified it as a candidate protein biomarker in PBMC of ALS patients with classical disease onset, where it is upregulated also in association with disease progression (Nardo et al., 2011).", [["PBMC", "ANATOMY", 64, 68], ["ALS", "DISEASE", 72, 75], ["PBMC", "CELL", 64, 68], ["patients", "ORGANISM", 76, 84], ["PBMC", "CELL_TYPE", 64, 68], ["patients", "SPECIES", 76, 84], ["protein biomarker", "TEST", 43, 60], ["classical disease onset", "PROBLEM", 90, 113], ["disease progression", "PROBLEM", 164, 183]]], ["We next found that mutant SOD1 and TDP-43 are substrates of PPIA (Lauranzano et al., 2015).", [["SOD1", "GENE_OR_GENE_PRODUCT", 26, 30], ["TDP-43", "GENE_OR_GENE_PRODUCT", 35, 41], ["PPIA", "GENE_OR_GENE_PRODUCT", 60, 64], ["mutant SOD1", "PROTEIN", 19, 30], ["TDP-43", "PROTEIN", 35, 41], ["PPIA", "PROTEIN", 60, 64], ["mutant SOD1", "PROBLEM", 19, 30], ["TDP", "TEST", 35, 38], ["PPIA", "PROBLEM", 60, 64]]], ["In fact, in absence of PPIA increased levels of mutant SOD1 and TDP-43 were recovered in the aggregates isolated from the spinal cord of SOD1G93A mice that had also an anticipation of the onset and an acceleration of the disease progression.DiscussionHSP90 is one of the most abundant and conserved cytosolic heat shock proteins.", [["spinal cord", "ANATOMY", 122, 133], ["cytosolic", "ANATOMY", 299, 308], ["DiscussionHSP90", "CHEMICAL", 241, 256], ["PPIA", "GENE_OR_GENE_PRODUCT", 23, 27], ["SOD1", "GENE_OR_GENE_PRODUCT", 55, 59], ["TDP-43", "GENE_OR_GENE_PRODUCT", 64, 70], ["spinal cord", "ORGAN", 122, 133], ["SOD1G93A mice", "ORGANISM", 137, 150], ["cytosolic heat shock proteins", "GENE_OR_GENE_PRODUCT", 299, 328], ["PPIA", "PROTEIN", 23, 27], ["mutant SOD1", "PROTEIN", 48, 59], ["TDP-43", "PROTEIN", 64, 70], ["DiscussionHSP90", "PROTEIN", 241, 256], ["cytosolic heat shock proteins", "PROTEIN", 299, 328], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 146, 150], ["PPIA increased levels of mutant SOD1", "PROBLEM", 23, 59], ["TDP", "TEST", 64, 67], ["the disease progression", "PROBLEM", 217, 240], ["conserved cytosolic heat shock proteins", "PROBLEM", 289, 328], ["PPIA", "OBSERVATION", 23, 27], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["spinal cord", "ANATOMY", 122, 133], ["acceleration", "OBSERVATION_MODIFIER", 201, 213], ["disease", "OBSERVATION", 221, 228], ["progression", "OBSERVATION_MODIFIER", 229, 240], ["cytosolic heat", "OBSERVATION", 299, 313], ["shock proteins", "OBSERVATION", 314, 328]]], ["It is responsible for the correct folding of a number of newly synthesized proteins and for the refolding of misfolded proteins associated with neurodegenerative diseases, including TDP-43 (Basso et al., 2009; Daturpalli et al., 2013; Carlomagno et al., 2014; Schirmer et al., 2016).", [["neurodegenerative diseases", "DISEASE", 144, 170], ["TDP", "DISEASE", 182, 185], ["TDP-43", "GENE_OR_GENE_PRODUCT", 182, 188], ["misfolded proteins", "PROTEIN", 109, 127], ["newly synthesized proteins", "PROBLEM", 57, 83], ["misfolded proteins", "PROBLEM", 109, 127], ["neurodegenerative diseases", "PROBLEM", 144, 170], ["TDP", "TEST", 182, 185], ["neurodegenerative diseases", "OBSERVATION", 144, 170]]], ["Accordingly, we found it entrapped in the aggregates isolated from the spinal cord of SOD1G93A mice already at a presymptomatic stage of the disease and from spinal cord tissues of sporadic ALS patients (Basso et al., 2009).DiscussionGRP78 is a major ER chaperone and a key regulator of the unfolded protein response.", [["spinal cord", "ANATOMY", 71, 82], ["spinal cord tissues", "ANATOMY", 158, 177], ["ALS", "DISEASE", 190, 193], ["spinal cord", "ORGAN", 71, 82], ["SOD1G93A mice", "ORGANISM", 86, 99], ["spinal cord tissues", "TISSUE", 158, 177], ["patients", "ORGANISM", 194, 202], ["DiscussionGRP78", "GENE_OR_GENE_PRODUCT", 224, 239], ["ER", "GENE_OR_GENE_PRODUCT", 251, 253], ["DiscussionGRP78", "PROTEIN", 224, 239], ["ER chaperone", "PROTEIN", 251, 263], ["mice", "SPECIES", 95, 99], ["patients", "SPECIES", 194, 202], ["mice", "SPECIES", 95, 99], ["the disease", "PROBLEM", 137, 148], ["the unfolded protein response", "PROBLEM", 287, 316], ["entrapped", "OBSERVATION", 25, 34], ["aggregates", "OBSERVATION", 42, 52], ["spinal cord", "ANATOMY", 71, 82], ["disease", "OBSERVATION", 141, 148], ["spinal cord", "ANATOMY", 158, 169], ["sporadic", "OBSERVATION_MODIFIER", 181, 189], ["protein response", "OBSERVATION", 300, 316]]], ["Disturbance of ER homeostasis is a common feature of ALS and defects in ER chaperones caused motor dysfunction in experimental models of ALS (Atkin et al., 2008; Saxena et al., 2009; Woehlbier et al., 2016).", [["ER", "ANATOMY", 72, 74], ["ALS", "DISEASE", 53, 56], ["motor dysfunction", "DISEASE", 93, 110], ["ALS", "DISEASE", 137, 140], ["ER", "GENE_OR_GENE_PRODUCT", 15, 17], ["ER", "GENE_OR_GENE_PRODUCT", 72, 74], ["ER", "PROTEIN", 15, 17], ["ER chaperones", "PROTEIN", 72, 85], ["ALS and defects in ER chaperones", "PROBLEM", 53, 85], ["motor dysfunction", "PROBLEM", 93, 110], ["defects", "OBSERVATION", 61, 68], ["motor dysfunction", "OBSERVATION", 93, 110]]], ["Loss of one copy of SIL1, a GRP78 cofactor, anticipated disease onset and reduced life span in the SOD1G93A mouse model (Fil\u00e9zac de L\u2019Etang et al., 2015), however, the precise role of GRP78 in ALS remains to be determined.", [["ALS", "DISEASE", 193, 196], ["SIL1", "GENE_OR_GENE_PRODUCT", 20, 24], ["GRP78", "GENE_OR_GENE_PRODUCT", 28, 33], ["SOD1G93A mouse", "ORGANISM", 99, 113], ["GRP78", "GENE_OR_GENE_PRODUCT", 184, 189], ["SIL1", "PROTEIN", 20, 24], ["GRP78 cofactor", "PROTEIN", 28, 42], ["GRP78", "PROTEIN", 184, 189], ["mouse", "SPECIES", 108, 113], ["mouse", "SPECIES", 108, 113], ["a GRP78 cofactor", "PROBLEM", 26, 42], ["anticipated disease onset", "PROBLEM", 44, 69], ["reduced life span", "PROBLEM", 74, 91]]], ["In Alzheimer\u2019s disease, studies in vitro indicated that it may be part of the defense mechanisms of the cell by inhibiting the generation of amyloid-\u03b2 peptides (Yang et al., 1998; Hoshino et al., 2007).DiscussionDJ-1 is a multifunctional stress response protein with a strong and homogenous expression in all CNS regions (Bader et al., 2005).", [["cell", "ANATOMY", 104, 108], ["CNS regions", "ANATOMY", 309, 320], ["Alzheimer\u2019s disease", "DISEASE", 3, 22], ["cell", "CELL", 104, 108], ["amyloid-\u03b2 peptides", "GENE_OR_GENE_PRODUCT", 141, 159], ["DiscussionDJ-1", "GENE_OR_GENE_PRODUCT", 202, 216], ["DiscussionDJ-1", "PROTEIN", 202, 216], ["multifunctional stress response protein", "PROTEIN", 222, 261], ["Alzheimer\u2019s disease", "PROBLEM", 3, 22], ["a multifunctional stress response protein", "PROBLEM", 220, 261], ["Alzheimer", "OBSERVATION", 3, 12], ["homogenous", "OBSERVATION_MODIFIER", 280, 290], ["expression", "OBSERVATION", 291, 301], ["all", "ANATOMY_MODIFIER", 305, 308], ["CNS", "ANATOMY", 309, 312], ["regions", "ANATOMY_MODIFIER", 313, 320]]], ["DJ-1 mutations cause early onset autosomal recessive Parkinson\u2019s disease (Bonifati et al., 2003).", [["autosomal recessive Parkinson\u2019s disease", "DISEASE", 33, 72], ["DJ-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["DJ-1 mutations", "DNA", 0, 14], ["DJ", "TEST", 0, 2], ["early onset autosomal recessive Parkinson\u2019s disease", "PROBLEM", 21, 72], ["autosomal", "OBSERVATION_MODIFIER", 33, 42], ["recessive", "OBSERVATION_MODIFIER", 43, 52], ["Parkinson\u2019s", "OBSERVATION", 53, 64]]], ["It is a chaperone for alpha synuclein and was shown to be protective against oxidative stress by upregulating HSP70 (Shendelman et al., 2004; Zhou et al., 2006; Batelli et al., 2008).", [["alpha synuclein", "CHEMICAL", 22, 37], ["alpha synuclein", "GENE_OR_GENE_PRODUCT", 22, 37], ["HSP70", "GENE_OR_GENE_PRODUCT", 110, 115], ["alpha synuclein", "PROTEIN", 22, 37], ["HSP70", "PROTEIN", 110, 115], ["alpha synuclein", "TREATMENT", 22, 37]]], ["In the SOD1G93A mouse model increased oxidized/inactive DJ-1 forms were found in brain tissues and knocking out DJ-1 has led to an accelerated disease course and shortened survival time (Lev et al., 2009, 2015).DiscussionInterestingly, we found that PPIA, HSP90, GRP78, and DJ-1 are present at lower levels in PBMC from patients with an early onset disease, and have a similar behavior in PBMC and spinal cord of an early onset SOD1G93A mouse model, in which defects in protein quality control have been previously observed (Marino et al., 2015).", [["brain tissues", "ANATOMY", 81, 94], ["PBMC", "ANATOMY", 310, 314], ["PBMC", "ANATOMY", 389, 393], ["spinal cord", "ANATOMY", 398, 409], ["SOD1G93A mouse", "ORGANISM", 7, 21], ["DJ-1", "GENE_OR_GENE_PRODUCT", 56, 60], ["brain tissues", "TISSUE", 81, 94], ["DJ-1", "GENE_OR_GENE_PRODUCT", 112, 116], ["PPIA", "GENE_OR_GENE_PRODUCT", 250, 254], ["HSP90", "GENE_OR_GENE_PRODUCT", 256, 261], ["GRP78", "GENE_OR_GENE_PRODUCT", 263, 268], ["DJ-1", "GENE_OR_GENE_PRODUCT", 274, 278], ["PBMC", "CELL", 310, 314], ["patients", "ORGANISM", 320, 328], ["PBMC", "CELL", 389, 393], ["spinal cord", "ORGAN", 398, 409], ["mouse", "ORGANISM", 437, 442], ["DJ", "PROTEIN", 56, 58], ["DJ-1", "PROTEIN", 112, 116], ["PPIA", "PROTEIN", 250, 254], ["HSP90", "PROTEIN", 256, 261], ["GRP78", "PROTEIN", 263, 268], ["DJ-1", "PROTEIN", 274, 278], ["PBMC", "CELL_TYPE", 310, 314], ["PBMC", "CELL_TYPE", 389, 393], ["mouse", "SPECIES", 16, 21], ["patients", "SPECIES", 320, 328], ["mouse", "SPECIES", 437, 442], ["mouse", "SPECIES", 16, 21], ["mouse", "SPECIES", 437, 442], ["increased oxidized/inactive DJ", "PROBLEM", 28, 58], ["an accelerated disease course", "PROBLEM", 128, 157], ["PPIA", "TEST", 250, 254], ["HSP90", "TEST", 256, 261], ["GRP78", "TEST", 263, 268], ["DJ", "TEST", 274, 276], ["an early onset disease", "PROBLEM", 334, 356], ["a similar behavior in PBMC and spinal cord", "PROBLEM", 367, 409], ["defects in protein quality control", "PROBLEM", 459, 493], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["oxidized", "OBSERVATION_MODIFIER", 38, 46], ["inactive DJ", "OBSERVATION", 47, 58], ["brain tissues", "ANATOMY", 81, 94], ["accelerated", "OBSERVATION_MODIFIER", 131, 142], ["disease", "OBSERVATION", 143, 150], ["PPIA", "OBSERVATION", 250, 254], ["PBMC", "ANATOMY", 310, 314], ["early", "OBSERVATION_MODIFIER", 337, 342], ["onset", "OBSERVATION_MODIFIER", 343, 348], ["disease", "OBSERVATION", 349, 356], ["spinal cord", "ANATOMY", 398, 409], ["early", "OBSERVATION_MODIFIER", 416, 421], ["defects", "OBSERVATION", 459, 466], ["protein quality", "OBSERVATION", 470, 485]]], ["These proteins, both in patient PBMC and mouse samples, are less upregulated in early ALS than in late ALS, and for PPIA this is evident already at a presymptomatic stage of the disease in the soluble fraction of the mouse spinal cord (Marino et al., 2015).", [["PBMC", "ANATOMY", 32, 36], ["samples", "ANATOMY", 47, 54], ["spinal cord", "ANATOMY", 223, 234], ["ALS", "DISEASE", 86, 89], ["ALS", "DISEASE", 103, 106], ["patient", "ORGANISM", 24, 31], ["PBMC", "CELL", 32, 36], ["mouse", "ORGANISM", 41, 46], ["PPIA", "GENE_OR_GENE_PRODUCT", 116, 120], ["mouse", "ORGANISM", 217, 222], ["spinal cord", "ORGAN", 223, 234], ["PBMC", "CELL_TYPE", 32, 36], ["PPIA", "PROTEIN", 116, 120], ["patient", "SPECIES", 24, 31], ["mouse", "SPECIES", 41, 46], ["mouse", "SPECIES", 217, 222], ["mouse", "SPECIES", 41, 46], ["mouse", "SPECIES", 217, 222], ["These proteins", "TEST", 0, 14], ["mouse samples", "TEST", 41, 54], ["PPIA", "PROBLEM", 116, 120], ["the disease", "PROBLEM", 174, 185], ["less upregulated", "OBSERVATION_MODIFIER", 60, 76], ["disease", "OBSERVATION", 178, 185], ["mouse", "ANATOMY_MODIFIER", 217, 222], ["spinal cord", "ANATOMY", 223, 234]]], ["The bases of these differences in early and late-onset disease are solely genetic and yet unknown in the case of the SOD1G93A mouse models, but exogenous factors cannot be excluded in the patients.", [["SOD1G93A mouse", "ORGANISM", 117, 131], ["patients", "ORGANISM", 188, 196], ["exogenous factors", "PROTEIN", 144, 161], ["mouse", "SPECIES", 126, 131], ["patients", "SPECIES", 188, 196], ["mouse", "SPECIES", 126, 131], ["exogenous factors", "PROBLEM", 144, 161], ["bases", "ANATOMY_MODIFIER", 4, 9], ["differences", "OBSERVATION_MODIFIER", 19, 30], ["early", "OBSERVATION_MODIFIER", 34, 39], ["late", "OBSERVATION_MODIFIER", 44, 48], ["-onset", "OBSERVATION_MODIFIER", 48, 54], ["disease", "OBSERVATION", 55, 62], ["cannot be excluded", "UNCERTAINTY", 162, 180]]], ["For example, it has been reported that exposure to certain toxins lead to GRP78 downregulation (Yang et al., 2000; Namba et al., 2010).ConclusionThese data suggest that a failure in the response to stress and a reduced ability to upregulate protective proteins may increase susceptibility to ALS.", [["ALS", "DISEASE", 292, 295], ["GRP78", "GENE_OR_GENE_PRODUCT", 74, 79], ["GRP78", "PROTEIN", 74, 79], ["GRP78 downregulation", "PROBLEM", 74, 94], ["a failure", "PROBLEM", 169, 178], ["stress", "PROBLEM", 198, 204], ["a reduced ability", "PROBLEM", 209, 226], ["protective proteins", "TREATMENT", 241, 260], ["failure", "OBSERVATION", 171, 178]]], ["This is in agreement with the fact that vulnerable motor neurons have a high threshold for induction of the protective heat shock response and a higher sensitivity to ER stress (Batulan et al., 2003; Saxena et al., 2009).", [["motor neurons", "ANATOMY", 51, 64], ["shock", "DISEASE", 124, 129], ["motor neurons", "CELL", 51, 64], ["ER", "GENE_OR_GENE_PRODUCT", 167, 169], ["motor neurons", "CELL_TYPE", 51, 64], ["ER", "PROTEIN", 167, 169], ["vulnerable motor neurons", "PROBLEM", 40, 64], ["the protective heat shock response", "PROBLEM", 104, 138]]], ["A protein signature comprising a panel of proteins involved in proteostasis may underline a subset of patients more susceptible to the disease and may help to stratify patients for more targeted ALS clinical trials.", [["ALS", "DISEASE", 195, 198], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 168, 176], ["A protein signature", "TEST", 0, 19], ["a panel", "TEST", 31, 38], ["the disease", "PROBLEM", 131, 142]]], ["These observations further strengthen the notion that proteostasis maintenance by the ubiquitin\u2013proteasome system, autophagy and ER, is a central issue in ALS, and therapeutic approaches aiming at boosting the protein quality control system might be a promising therapeutic strategy.", [["ALS", "DISEASE", 155, 158], ["ER", "GENE_OR_GENE_PRODUCT", 129, 131], ["ER", "PROTEIN", 129, 131], ["proteostasis maintenance", "TREATMENT", 54, 78], ["a central issue in ALS", "PROBLEM", 136, 158], ["therapeutic approaches", "TREATMENT", 164, 186], ["the protein quality control system", "TREATMENT", 206, 240]]], ["Arimoclomol, a small molecule that acts as a co-inducer of the heat shock response by prolonging HSF1 activation and upregulating a number of proteins such as HSP60, HSP70, HSP90, and GRP94, has shown to be effective in several experimental models of motor neuron degeneration including the SOD1G93A mouse (Kalmar et al., 2014).", [["motor neuron", "ANATOMY", 251, 263], ["Arimoclomol", "CHEMICAL", 0, 11], ["shock", "DISEASE", 68, 73], ["motor neuron degeneration", "DISEASE", 251, 276], ["Arimoclomol", "CHEMICAL", 0, 11], ["Arimoclomol", "SIMPLE_CHEMICAL", 0, 11], ["HSF1", "GENE_OR_GENE_PRODUCT", 97, 101], ["HSP60", "GENE_OR_GENE_PRODUCT", 159, 164], ["HSP70", "GENE_OR_GENE_PRODUCT", 166, 171], ["HSP90", "GENE_OR_GENE_PRODUCT", 173, 178], ["GRP94", "GENE_OR_GENE_PRODUCT", 184, 189], ["motor neuron", "MULTI-TISSUE_STRUCTURE", 251, 263], ["SOD1G93A mouse", "ORGANISM", 291, 305], ["HSF1", "PROTEIN", 97, 101], ["HSP60", "PROTEIN", 159, 164], ["HSP70", "PROTEIN", 166, 171], ["HSP90", "PROTEIN", 173, 178], ["GRP94", "PROTEIN", 184, 189], ["mouse", "SPECIES", 300, 305], ["mouse", "SPECIES", 300, 305], ["Arimoclomol", "TREATMENT", 0, 11], ["a small molecule", "PROBLEM", 13, 29], ["the heat shock response", "PROBLEM", 59, 82], ["prolonging HSF1 activation", "PROBLEM", 86, 112], ["HSP60", "TEST", 159, 164], ["HSP70", "TEST", 166, 171], ["HSP90", "TEST", 173, 178], ["GRP94", "TEST", 184, 189], ["motor neuron degeneration", "PROBLEM", 251, 276], ["small molecule", "OBSERVATION", 15, 29], ["motor neuron degeneration", "OBSERVATION", 251, 276]]], ["A Phase II clinical trial in ALS patients has shown that the drug is safe and well tolerated (Cudkowicz et al., 2008) and is now under investigation in a PhaseII/III clinical trial in SOD1 positive familial ALS patients (ClinicalTrials.gov identifier: NCT00706147).", [["ALS", "DISEASE", 29, 32], ["ALS", "DISEASE", 207, 210], ["patients", "ORGANISM", 33, 41], ["SOD1", "GENE_OR_GENE_PRODUCT", 184, 188], ["patients", "ORGANISM", 211, 219], ["SOD1", "PROTEIN", 184, 188], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 211, 219]]], ["Colchicine, a FDA-approved drug that was identified by a high-throughput screening as enhancer of the expression of HSPB8, a key player of the protein quality control system, has demonstrated to facilitate the removal of TDP-43 aggregates by autophagy (Crippa et al., 2016).ConclusionFinally, this work confirmed that PBMC are valuable clinical samples since they reflect traits of the disease observed in the central nervous system and that total TDP-43 protein level in PBMC can discriminate ALS patients from healthy controls, as observed in a previous work using the same assay (Nardo et al., 2011).", [["PBMC", "ANATOMY", 318, 322], ["samples", "ANATOMY", 345, 352], ["central nervous system", "ANATOMY", 410, 432], ["PBMC", "ANATOMY", 472, 476], ["Colchicine", "CHEMICAL", 0, 10], ["TDP", "DISEASE", 221, 224], ["ALS", "DISEASE", 494, 497], ["Colchicine", "CHEMICAL", 0, 10], ["Colchicine", "SIMPLE_CHEMICAL", 0, 10], ["HSPB8", "GENE_OR_GENE_PRODUCT", 116, 121], ["TDP-43", "GENE_OR_GENE_PRODUCT", 221, 227], ["PBMC", "CELL", 318, 322], ["central nervous system", "ANATOMICAL_SYSTEM", 410, 432], ["TDP-43", "GENE_OR_GENE_PRODUCT", 448, 454], ["PBMC", "CELL", 472, 476], ["patients", "ORGANISM", 498, 506], ["HSPB8", "PROTEIN", 116, 121], ["PBMC", "CELL_TYPE", 318, 322], ["PBMC", "CELL_TYPE", 472, 476], ["patients", "SPECIES", 498, 506], ["Colchicine", "TREATMENT", 0, 10], ["the removal of TDP", "TREATMENT", 206, 224], ["PBMC", "PROBLEM", 318, 322], ["the disease", "PROBLEM", 382, 393], ["total TDP", "TEST", 442, 451], ["protein level", "TEST", 455, 468], ["disease", "OBSERVATION", 386, 393], ["central", "ANATOMY_MODIFIER", 410, 417], ["nervous system", "ANATOMY", 418, 432]]], ["We also further confirmed that the experimental setting in which both 129Sv and C57 SOD1G93A mouse strains are examined is useful to study disease susceptibility and test novel therapeutic approaches aimed at addressing disease heterogeneity.Ethics StatementThis study was carried out in accordance with the GCP recommendations with written informed consent from all subjects.", [["C57 SOD1G93A mouse", "ORGANISM", 80, 98], ["mouse", "SPECIES", 93, 98], ["mouse", "SPECIES", 93, 98], ["disease susceptibility", "PROBLEM", 139, 161], ["test", "TEST", 166, 170], ["disease heterogeneity", "PROBLEM", 220, 241], ["This study", "TEST", 258, 268]]], ["The protocol was approved by the Ethics Committees of the participating institutions.Ethics StatementProcedures involving animals and their care were conducted in conformity with the following laws, regulations, and policies governing the care and use of laboratory animals: Italian Governing Law (D.lgs 26/2014; Authorisation n.19/2008-A issued March 6, 2008 by Ministry of Health); Mario Negri Institutional Regulations and Policies providing internal authorization for persons conducting animal experiments (Quality Management System Certificate \u2013 UNI EN ISO 9001:2008 \u2013 Reg.", [["persons", "ORGANISM", 472, 479], ["persons", "SPECIES", 472, 479], ["The protocol", "TREATMENT", 0, 12]]], ["The Statement of Compliance (Assurance) with the Public Health Service (PHS) Policy on Human Care and Use of Laboratory Animals has been recently reviewed (9/9/2014) and will expire on September 30, 2019 (Animal Welfare Assurance #A5023-01).Author ContributionsStudy concept and design: EB, CB, VB.", [["Human", "ORGANISM", 87, 92], ["Human", "SPECIES", 87, 92], ["VB", "ANATOMY", 295, 297]]], ["Acquisition, analysis, or interpretation of data: all authors.", [["Acquisition, analysis", "TEST", 0, 21]]], ["Critical revision of the manuscript: EB, CB.Conflict of Interest StatementThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [["revision", "OBSERVATION", 9, 17], ["EB", "ANATOMY", 37, 39], ["CB", "ANATOMY", 41, 43]]]], "dbaadf88453c3640afca1a0cd1204e411c5da70d": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 12 million people worldwide with over 500,000 deaths.", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["SARS-CoV-2", "CHEMICAL", 61, 71], ["deaths", "DISEASE", 137, 143], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["people", "ORGANISM", 102, 108], ["people", "SPECIES", 102, 108], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["infected", "OBSERVATION_MODIFIER", 77, 85]]], ["It has been shown to severely impact the respiratory, cardiovascular, neurologic, and renal organ systems [1] .", [["respiratory", "ANATOMY", 41, 52], ["cardiovascular", "ANATOMY", 54, 68], ["neurologic", "ANATOMY", 70, 80], ["renal organ", "ANATOMY", 86, 97], ["respiratory, cardiovascular, neurologic, and renal organ systems", "DISEASE", 41, 105], ["cardiovascular", "ANATOMICAL_SYSTEM", 54, 68], ["renal organ", "MULTI-TISSUE_STRUCTURE", 86, 97], ["severely", "OBSERVATION_MODIFIER", 21, 29], ["respiratory", "ANATOMY", 41, 52], ["renal organ", "ANATOMY", 86, 97]]], ["To the best of our knowledge, no study has highlighted the impact this novel virus has on the parathyroid gland so far.", [["parathyroid gland", "ANATOMY", 94, 111], ["parathyroid gland", "ORGAN", 94, 111], ["study", "TEST", 33, 38], ["this novel virus", "PROBLEM", 66, 82], ["virus", "OBSERVATION", 77, 82], ["parathyroid gland", "ANATOMY", 94, 111]]], ["We present a case of a 46-year-old Hispanic male with no significant past medical history who presented to the ED with complaints of worsening shortness of breath of one-week duration.", [["shortness of breath", "DISEASE", 143, 162], ["worsening shortness of breath", "PROBLEM", 133, 162], ["worsening", "OBSERVATION_MODIFIER", 133, 142]]], ["The patient was found to be coronavirus disease 2019 (COVID-19)-positive, resulting in acute hypoxic respiratory failure.", [["respiratory", "ANATOMY", 101, 112], ["coronavirus disease", "DISEASE", 28, 47], ["respiratory failure", "DISEASE", 101, 120], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["coronavirus disease", "PROBLEM", 28, 47], ["COVID", "TEST", 54, 59], ["acute hypoxic respiratory failure", "PROBLEM", 87, 120], ["coronavirus", "OBSERVATION", 28, 39], ["acute", "OBSERVATION_MODIFIER", 87, 92], ["hypoxic", "OBSERVATION_MODIFIER", 93, 100], ["respiratory failure", "OBSERVATION", 101, 120]]], ["During the second half of his hospital stay, the patient was found to have hypoparathyroidism as well as elevated phosphate levels.", [["hypoparathyroidism", "DISEASE", 75, 93], ["phosphate", "CHEMICAL", 114, 123], ["phosphate", "CHEMICAL", 114, 123], ["patient", "ORGANISM", 49, 56], ["phosphate", "SIMPLE_CHEMICAL", 114, 123], ["patient", "SPECIES", 49, 56], ["hypoparathyroidism", "PROBLEM", 75, 93], ["elevated phosphate levels", "PROBLEM", 105, 130], ["hypoparathyroidism", "OBSERVATION", 75, 93]]], ["Differentials for the aforementioned disorders were ruled out and the only deducible explanation was heightened inflammatory response caused by the novel virus.Case PresentationOur patient was a 46-year-old Hispanic male with no significant past medical history who presented to the ED with complaints of worsening shortness of breath of one-week duration.", [["shortness of breath", "DISEASE", 315, 334], ["patient", "ORGANISM", 181, 188], ["patient", "SPECIES", 181, 188], ["the aforementioned disorders", "PROBLEM", 18, 46], ["heightened inflammatory response", "PROBLEM", 101, 133], ["the novel virus", "PROBLEM", 144, 159], ["worsening shortness of breath", "PROBLEM", 305, 334], ["worsening", "OBSERVATION_MODIFIER", 305, 314]]], ["The patient also endorsed fever, chills, body aches, and dry cough.", [["body", "ANATOMY", 41, 45], ["fever", "DISEASE", 26, 31], ["chills", "DISEASE", 33, 39], ["body aches", "DISEASE", 41, 51], ["dry cough", "DISEASE", 57, 66], ["patient", "ORGANISM", 4, 11], ["body", "ORGANISM_SUBDIVISION", 41, 45], ["aches", "ORGANISM_SUBDIVISION", 46, 51], ["patient", "SPECIES", 4, 11], ["fever", "PROBLEM", 26, 31], ["chills", "PROBLEM", 33, 39], ["body aches", "PROBLEM", 41, 51], ["dry cough", "PROBLEM", 57, 66], ["fever", "OBSERVATION", 26, 31], ["chills", "OBSERVATION", 33, 39], ["dry", "OBSERVATION_MODIFIER", 57, 60], ["cough", "OBSERVATION", 61, 66]]], ["Vital signs on presentation were as follows: temperature: 99.4 F, blood pressure (BP): 123/84 mmHg, and respiratory rate (RR) of 25 breaths/minute with an O 2 saturation of 90% on room air.Case PresentationPhysical examination was unremarkable apart from decreased breath sounds bilaterally.", [["blood", "ANATOMY", 66, 71], ["O 2", "CHEMICAL", 155, 158], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["Vital signs", "TEST", 0, 11], ["temperature", "TEST", 45, 56], ["blood pressure", "TEST", 66, 80], ["BP", "TEST", 82, 84], ["respiratory rate", "TEST", 104, 120], ["RR", "TEST", 122, 124], ["an O 2 saturation", "TEST", 152, 169], ["Case PresentationPhysical examination", "TEST", 189, 226], ["decreased breath sounds bilaterally", "PROBLEM", 255, 290], ["unremarkable", "OBSERVATION", 231, 243], ["decreased", "OBSERVATION_MODIFIER", 255, 264], ["breath sounds", "OBSERVATION", 265, 278], ["bilaterally", "ANATOMY_MODIFIER", 279, 290]]], ["Labs were significant for elevated aspartate aminotransferase (AST) at 67 u/l (normal range: 15-41 u/l) and alanine aminotransferase (ALT) at 84 u/l (normal range: 17-63 u/l).", [["aspartate", "CHEMICAL", 35, 44], ["alanine", "CHEMICAL", 108, 115], ["aspartate", "CHEMICAL", 35, 44], ["alanine", "CHEMICAL", 108, 115], ["Labs", "GENE_OR_GENE_PRODUCT", 0, 4], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 35, 61], ["AST", "SIMPLE_CHEMICAL", 63, 66], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 108, 132], ["ALT", "SIMPLE_CHEMICAL", 134, 137], ["aspartate aminotransferase", "PROTEIN", 35, 61], ["AST", "PROTEIN", 63, 66], ["alanine aminotransferase", "PROTEIN", 108, 132], ["ALT", "PROTEIN", 134, 137], ["Labs", "TEST", 0, 4], ["elevated aspartate aminotransferase", "PROBLEM", 26, 61], ["AST", "TEST", 63, 66], ["u/l", "TEST", 74, 77], ["u/l", "TEST", 99, 102], ["alanine aminotransferase", "TEST", 108, 132], ["ALT", "TEST", 134, 137], ["u/l", "TEST", 145, 148]]], ["Other lab findings included alkaline phosphatase (ALP) of 225 u/L (normal range: 38-126 u/l), sodium (Na) of 134 mmol/l (normal range: 136-144 mmol/l), potassium (K) of 3.9 mmol/l (normal range: 3.6-5.1 mmol/l).", [["sodium", "CHEMICAL", 94, 100], ["Na", "CHEMICAL", 102, 104], ["potassium", "CHEMICAL", 152, 161], ["K", "CHEMICAL", 163, 164], ["sodium", "CHEMICAL", 94, 100], ["Na", "CHEMICAL", 102, 104], ["potassium", "CHEMICAL", 152, 161], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 28, 48], ["ALP", "GENE_OR_GENE_PRODUCT", 50, 53], ["sodium", "SIMPLE_CHEMICAL", 94, 100], ["potassium", "SIMPLE_CHEMICAL", 152, 161], ["alkaline phosphatase", "PROTEIN", 28, 48], ["ALP", "PROTEIN", 50, 53], ["Other lab findings", "TEST", 0, 18], ["alkaline phosphatase", "TEST", 28, 48], ["ALP", "TEST", 50, 53], ["u/L", "TEST", 62, 65], ["u/l", "TEST", 88, 91], ["sodium", "TEST", 94, 100], ["Na", "TEST", 102, 104], ["mmol", "TEST", 113, 117], ["potassium", "TEST", 152, 161], ["K", "TEST", 163, 164]]], ["A posteroanterior (PA) and lateral chest X-ray demonstrated multifocal pneumonia (Figures 1, 2) .", [["pneumonia", "DISEASE", 71, 80], ["A posteroanterior (PA) and lateral chest X-ray", "TEST", 0, 46], ["multifocal pneumonia", "PROBLEM", 60, 80], ["posteroanterior", "ANATOMY_MODIFIER", 2, 17], ["lateral", "ANATOMY_MODIFIER", 27, 34], ["chest", "ANATOMY", 35, 40], ["multifocal", "OBSERVATION_MODIFIER", 60, 70], ["pneumonia", "OBSERVATION", 71, 80]]], ["The patient received hydroxychloroquine and azithromycin in the ED.", [["hydroxychloroquine", "CHEMICAL", 21, 39], ["azithromycin", "CHEMICAL", 44, 56], ["hydroxychloroquine", "CHEMICAL", 21, 39], ["azithromycin", "CHEMICAL", 44, 56], ["patient", "ORGANISM", 4, 11], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 21, 39], ["azithromycin", "SIMPLE_CHEMICAL", 44, 56], ["patient", "SPECIES", 4, 11], ["hydroxychloroquine", "TREATMENT", 21, 39], ["azithromycin", "TREATMENT", 44, 56]]], ["He was initially placed on a 4L nasal cannula with oxygen saturation improvement to 93%.", [["nasal", "ANATOMY", 32, 37], ["oxygen", "CHEMICAL", 51, 57], ["oxygen", "CHEMICAL", 51, 57], ["He", "ORGANISM", 0, 2], ["oxygen", "SIMPLE_CHEMICAL", 51, 57], ["a 4L nasal cannula", "TREATMENT", 27, 45], ["oxygen saturation", "TEST", 51, 68]]], ["The patient's saturation decreased to 70% and was placed on non-rebreather with an oxygen saturation of 88%.", [["oxygen", "CHEMICAL", 83, 89], ["oxygen", "CHEMICAL", 83, 89], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 83, 89], ["patient", "SPECIES", 4, 11], ["The patient's saturation", "TEST", 0, 24], ["non-rebreather", "TREATMENT", 60, 74], ["an oxygen saturation", "TEST", 80, 100]]], ["Hence, he was placed on continuous positive airway pressure (CPAP) therapy with an improvement of oxygen saturation to 96%.", [["airway", "ANATOMY", 44, 50], ["oxygen", "CHEMICAL", 98, 104], ["oxygen", "CHEMICAL", 98, 104], ["airway", "MULTI-TISSUE_STRUCTURE", 44, 50], ["oxygen", "SIMPLE_CHEMICAL", 98, 104], ["continuous positive airway pressure", "TREATMENT", 24, 59], ["CPAP) therapy", "TREATMENT", 61, 74], ["oxygen saturation", "TEST", 98, 115], ["oxygen saturation", "OBSERVATION", 98, 115]]], ["He was admitted to the medical floors for oxygen support and further evaluation.", [["oxygen", "CHEMICAL", 42, 48], ["oxygen", "CHEMICAL", 42, 48], ["He", "ORGANISM", 0, 2], ["oxygen", "SIMPLE_CHEMICAL", 42, 48], ["oxygen support", "TREATMENT", 42, 56], ["further evaluation", "TEST", 61, 79]]], ["Of note, the patient tested positive with polymerase chain reaction (PCR) nasal swab for SARS-CoV-2.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["SARS-CoV", "SPECIES", 89, 97], ["polymerase chain reaction", "PROBLEM", 42, 67], ["PCR", "TEST", 69, 72], ["nasal swab", "TEST", 74, 84], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97]]], ["He was continued on azithromycin and hydroxychloroquine on the medical floor.", [["azithromycin", "CHEMICAL", 20, 32], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["azithromycin", "CHEMICAL", 20, 32], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["He", "ORGANISM", 0, 2], ["azithromycin", "SIMPLE_CHEMICAL", 20, 32], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 37, 55], ["azithromycin", "TREATMENT", 20, 32], ["hydroxychloroquine", "TREATMENT", 37, 55]]], ["His respiratory status deteriorated within one week of hospitalization, and he was upgraded to the ICU and subsequently intubated for respiratory support and airway protection.", [["respiratory", "ANATOMY", 4, 15], ["respiratory", "ANATOMY", 134, 145], ["airway", "ANATOMY", 158, 164], ["airway", "MULTI-TISSUE_STRUCTURE", 158, 164], ["intubated", "TREATMENT", 120, 129], ["respiratory support", "TREATMENT", 134, 153], ["airway protection", "TREATMENT", 158, 175], ["respiratory", "ANATOMY", 4, 15], ["respiratory support", "OBSERVATION", 134, 153], ["airway", "ANATOMY", 158, 164]]], ["His ICU course was complicated by a septic shock from an unknown source initially started on broad-spectrum coverage, meropenem for seven days.", [["septic shock", "DISEASE", 36, 48], ["meropenem", "CHEMICAL", 118, 127], ["meropenem", "CHEMICAL", 118, 127], ["meropenem", "SIMPLE_CHEMICAL", 118, 127], ["a septic shock", "PROBLEM", 34, 48], ["broad-spectrum coverage", "TREATMENT", 93, 116], ["meropenem", "TREATMENT", 118, 127], ["septic shock", "OBSERVATION", 36, 48]]], ["The patient continued spiking intermittent fevers and repeat sepsis workup revealed Pseudomonas urinary tract infection, which was treated with ciprofloxacin.", [["urinary tract", "ANATOMY", 96, 109], ["fevers", "DISEASE", 43, 49], ["sepsis", "DISEASE", 61, 67], ["Pseudomonas urinary tract infection", "DISEASE", 84, 119], ["ciprofloxacin", "CHEMICAL", 144, 157], ["ciprofloxacin", "CHEMICAL", 144, 157], ["patient", "ORGANISM", 4, 11], ["Pseudomonas", "ORGANISM", 84, 95], ["urinary tract", "ORGANISM_SUBDIVISION", 96, 109], ["ciprofloxacin", "SIMPLE_CHEMICAL", 144, 157], ["patient", "SPECIES", 4, 11], ["spiking intermittent fevers", "PROBLEM", 22, 49], ["repeat sepsis workup", "TEST", 54, 74], ["Pseudomonas urinary tract infection", "PROBLEM", 84, 119], ["ciprofloxacin", "TREATMENT", 144, 157], ["intermittent", "OBSERVATION_MODIFIER", 30, 42], ["fevers", "OBSERVATION", 43, 49], ["sepsis", "OBSERVATION", 61, 67], ["Pseudomonas", "OBSERVATION_MODIFIER", 84, 95], ["urinary tract", "ANATOMY", 96, 109], ["infection", "OBSERVATION", 110, 119]]], ["The patient was also noted to have marked elevation of D-dimer levels at >5,000.", [["patient", "ORGANISM", 4, 11], ["D-dimer", "SIMPLE_CHEMICAL", 55, 62], ["D-dimer", "PROTEIN", 55, 62], ["patient", "SPECIES", 4, 11], ["marked elevation of D-dimer levels", "PROBLEM", 35, 69], ["marked", "OBSERVATION_MODIFIER", 35, 41], ["elevation", "OBSERVATION", 42, 51], ["D-dimer", "OBSERVATION_MODIFIER", 55, 62]]], ["The venous duplex was unremarkable with a transthoracic echocardiogram showing right heart strain.", [["venous duplex", "ANATOMY", 4, 17], ["right heart", "ANATOMY", 79, 90], ["venous duplex", "MULTI-TISSUE_STRUCTURE", 4, 17], ["heart", "ORGAN", 85, 90], ["The venous duplex", "TEST", 0, 17], ["a transthoracic echocardiogram", "TEST", 40, 70], ["right heart strain", "PROBLEM", 79, 97], ["venous", "ANATOMY", 4, 10], ["unremarkable", "OBSERVATION", 22, 34], ["right", "ANATOMY_MODIFIER", 79, 84], ["heart", "ANATOMY", 85, 90], ["strain", "OBSERVATION", 91, 97]]], ["The patient at that point was unstable for CT angiography (CTA) of the chest; hence, he was empirically started on therapeutic anticoagulation.", [["chest", "ANATOMY", 71, 76], ["patient", "ORGANISM", 4, 11], ["chest", "ORGAN", 71, 76], ["patient", "SPECIES", 4, 11], ["CT angiography", "TEST", 43, 57], ["CTA) of the chest", "TEST", 59, 76], ["therapeutic anticoagulation", "TREATMENT", 115, 142], ["chest", "ANATOMY", 71, 76]]], ["Hematology was consulted given hospital protocol at that time for tocilizumab and convalescent plasma consideration.", [["plasma", "ANATOMY", 95, 101], ["tocilizumab", "SIMPLE_CHEMICAL", 66, 77], ["plasma", "ORGANISM_SUBSTANCE", 95, 101], ["hospital protocol", "TREATMENT", 31, 48], ["tocilizumab", "TREATMENT", 66, 77]]], ["The patient received tocilizumab twice as well as convalescent plasma.", [["plasma", "ANATOMY", 63, 69], ["tocilizumab", "CHEMICAL", 21, 32], ["patient", "ORGANISM", 4, 11], ["tocilizumab", "SIMPLE_CHEMICAL", 21, 32], ["convalescent", "ORGANISM", 50, 62], ["plasma", "ORGANISM_SUBSTANCE", 63, 69], ["patient", "SPECIES", 4, 11], ["tocilizumab", "TREATMENT", 21, 32], ["convalescent plasma", "TREATMENT", 50, 69]]], ["Of note, by the time remdesivir was available at our hospital, the patient had already been retested negative for the novel virus.Case PresentationHospital course was further complicated by transient thrombocytopenia for which hematology service was already on board, and anticoagulation was suspended.", [["thrombocytopenia", "DISEASE", 200, 216], ["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["the novel virus", "PROBLEM", 114, 129], ["transient thrombocytopenia", "PROBLEM", 190, 216], ["anticoagulation", "TREATMENT", 272, 287], ["transient", "OBSERVATION_MODIFIER", 190, 199], ["thrombocytopenia", "OBSERVATION", 200, 216]]], ["He received a total of six units of platelets with significant improvement in his platelet count.", [["platelets", "ANATOMY", 36, 45], ["platelet", "ANATOMY", 82, 90], ["platelets", "CELL", 36, 45], ["platelet", "CELL", 82, 90], ["platelets", "CELL_TYPE", 36, 45], ["platelets", "TREATMENT", 36, 45], ["his platelet count", "TEST", 78, 96], ["significant", "OBSERVATION_MODIFIER", 51, 62], ["improvement", "OBSERVATION_MODIFIER", 63, 74], ["platelet count", "OBSERVATION", 82, 96]]], ["The patient at that time became stable, and CTA of the chest showed no pulmonary embolism.", [["chest", "ANATOMY", 55, 60], ["pulmonary", "ANATOMY", 71, 80], ["pulmonary embolism", "DISEASE", 71, 89], ["patient", "ORGANISM", 4, 11], ["chest", "ORGAN", 55, 60], ["pulmonary", "ORGAN", 71, 80], ["patient", "SPECIES", 4, 11], ["CTA of the chest", "TEST", 44, 60], ["pulmonary embolism", "PROBLEM", 71, 89], ["stable", "OBSERVATION", 32, 38], ["chest", "ANATOMY", 55, 60], ["no", "UNCERTAINTY", 68, 70], ["pulmonary", "ANATOMY", 71, 80], ["embolism", "OBSERVATION", 81, 89]]], ["Unfortunately, hospital stay was complicated by yet another infection, Pseudomonas pneumonia, for which he received meropenem and ciprofloxacin.", [["infection", "DISEASE", 60, 69], ["Pseudomonas pneumonia", "DISEASE", 71, 92], ["meropenem", "CHEMICAL", 116, 125], ["ciprofloxacin", "CHEMICAL", 130, 143], ["meropenem", "CHEMICAL", 116, 125], ["ciprofloxacin", "CHEMICAL", 130, 143], ["meropenem", "SIMPLE_CHEMICAL", 116, 125], ["ciprofloxacin", "SIMPLE_CHEMICAL", 130, 143], ["another infection", "PROBLEM", 52, 69], ["Pseudomonas pneumonia", "PROBLEM", 71, 92], ["meropenem", "TREATMENT", 116, 125], ["ciprofloxacin", "TREATMENT", 130, 143], ["infection", "OBSERVATION", 60, 69], ["Pseudomonas", "OBSERVATION_MODIFIER", 71, 82], ["pneumonia", "OBSERVATION", 83, 92]]], ["Eventually, the patient underwent a tracheostomy after one month of intubation and was then downgraded to the medical floors for further management.", [["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23], ["a tracheostomy", "TREATMENT", 34, 48], ["intubation", "TREATMENT", 68, 78], ["further management", "TREATMENT", 129, 147], ["tracheostomy", "OBSERVATION", 36, 48]]], ["As he remained on a tracheostomy-to-ventilator initially, he started spiking intermittent fevers and pan cultures were performed, and tracheostomy culture grew carbapenem-resistant Enterobacteriaceae (CRE)-Klebsiella pneumonia sensitive to amikacin.", [["fevers", "DISEASE", 90, 96], ["carbapenem", "CHEMICAL", 160, 170], ["Enterobacteriaceae", "CHEMICAL", 181, 199], ["pneumonia", "DISEASE", 217, 226], ["amikacin", "CHEMICAL", 240, 248], ["carbapenem", "CHEMICAL", 160, 170], ["amikacin", "CHEMICAL", 240, 248], ["carbapenem-resistant Enterobacteriaceae", "SIMPLE_CHEMICAL", 160, 199], ["amikacin", "SIMPLE_CHEMICAL", 240, 248], ["a tracheostomy", "TREATMENT", 18, 32], ["ventilator", "TREATMENT", 36, 46], ["spiking intermittent fevers", "PROBLEM", 69, 96], ["pan cultures", "TEST", 101, 113], ["tracheostomy culture", "TEST", 134, 154], ["carbapenem", "TEST", 160, 170], ["resistant Enterobacteriaceae (CRE", "PROBLEM", 171, 204], ["Klebsiella pneumonia", "PROBLEM", 206, 226], ["amikacin", "TREATMENT", 240, 248], ["Klebsiella pneumonia", "OBSERVATION", 206, 226]]], ["The infectious disease unit was consulted and the patient was started on amikacin and ceftazidime-avibactam for 10 days.", [["infectious disease", "DISEASE", 4, 22], ["amikacin", "CHEMICAL", 73, 81], ["ceftazidime-avibactam", "CHEMICAL", 86, 107], ["amikacin", "CHEMICAL", 73, 81], ["ceftazidime", "CHEMICAL", 86, 97], ["avibactam", "CHEMICAL", 98, 107], ["patient", "ORGANISM", 50, 57], ["amikacin", "SIMPLE_CHEMICAL", 73, 81], ["ceftazidime-avibactam", "SIMPLE_CHEMICAL", 86, 107], ["patient", "SPECIES", 50, 57], ["amikacin", "TREATMENT", 73, 81], ["ceftazidime", "TREATMENT", 86, 97], ["avibactam", "TREATMENT", 98, 107], ["infectious", "OBSERVATION", 4, 14]]], ["The patient also developed diarrhea that coincided with the spiking of fevers and Clostridioides difficile toxin was detected, and he was treated with oral vancomycin.", [["oral", "ANATOMY", 151, 155], ["diarrhea", "DISEASE", 27, 35], ["fevers", "DISEASE", 71, 77], ["Clostridioides difficile", "DISEASE", 82, 106], ["vancomycin", "CHEMICAL", 156, 166], ["vancomycin", "CHEMICAL", 156, 166], ["patient", "ORGANISM", 4, 11], ["Clostridioides difficile toxin", "SIMPLE_CHEMICAL", 82, 112], ["oral", "ORGANISM_SUBDIVISION", 151, 155], ["vancomycin", "SIMPLE_CHEMICAL", 156, 166], ["patient", "SPECIES", 4, 11], ["Clostridioides difficile", "SPECIES", 82, 106], ["Clostridioides difficile", "SPECIES", 82, 106], ["diarrhea", "PROBLEM", 27, 35], ["fevers", "PROBLEM", 71, 77], ["Clostridioides difficile toxin", "PROBLEM", 82, 112], ["oral vancomycin", "TREATMENT", 151, 166], ["diarrhea", "OBSERVATION", 27, 35], ["fevers", "OBSERVATION", 71, 77]]], ["Postcourse of antibiotics, the patient stopped spiking fevers with a resolution of diarrhea.", [["fevers", "DISEASE", 55, 61], ["diarrhea", "DISEASE", 83, 91], ["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["antibiotics", "TREATMENT", 14, 25], ["spiking fevers", "PROBLEM", 47, 61], ["diarrhea", "PROBLEM", 83, 91], ["diarrhea", "OBSERVATION", 83, 91]]], ["He passed weaning and was placed on a trach collar with an improvement in oxygen requirements.Case PresentationOnce the patient was downgraded to medical floors, he was noted to have unexplained hyperphosphatemia during the second month of hospitalization, with phosphorus levels elevated to 6.9 mg/dl (normal range: 2.4-4.7 mg/dl).", [["oxygen", "CHEMICAL", 74, 80], ["hyperphosphatemia", "DISEASE", 195, 212], ["phosphorus", "CHEMICAL", 262, 272], ["oxygen", "CHEMICAL", 74, 80], ["phosphorus", "CHEMICAL", 262, 272], ["oxygen", "SIMPLE_CHEMICAL", 74, 80], ["patient", "ORGANISM", 120, 127], ["phosphorus", "SIMPLE_CHEMICAL", 262, 272], ["patient", "SPECIES", 120, 127], ["a trach collar", "TREATMENT", 36, 50], ["oxygen requirements", "TREATMENT", 74, 93], ["unexplained hyperphosphatemia", "PROBLEM", 183, 212], ["phosphorus levels", "TEST", 262, 279], ["improvement", "OBSERVATION_MODIFIER", 59, 70], ["oxygen requirements", "OBSERVATION", 74, 93], ["hyperphosphatemia", "OBSERVATION", 195, 212]]], ["Blood work during that timeframe revealed the following: Na: 138 mmol/l, K: 4.4 mmol/l, chloride (Cl): 96 mmol/l (normal range: 101-111 mmol/l), bicarbonate: 30 mmol/l (normal range: 22-32 mmol/l), blood urea nitrogen (BUN): 8 mg/dl (normal range: 8-20 mg/dl), creatinine: 0.223 mg/dl (normal range: 0.7-1.2 mg/dl), glucose: 99 mg/dl (normal range: 74-118 mg/dl), phosphorus: 5.8 mg/dl with albumin of 2.9 g/dl, and calcium level was normal at 9.2 mg/dl.", [["Blood", "ANATOMY", 0, 5], ["blood", "ANATOMY", 198, 203], ["Na", "CHEMICAL", 57, 59], ["Cl", "CHEMICAL", 98, 100], ["bicarbonate", "CHEMICAL", 145, 156], ["blood urea nitrogen", "CHEMICAL", 198, 217], ["creatinine", "CHEMICAL", 261, 271], ["glucose", "CHEMICAL", 316, 323], ["phosphorus", "CHEMICAL", 364, 374], ["calcium", "CHEMICAL", 416, 423], ["Na", "CHEMICAL", 57, 59], ["chloride", "CHEMICAL", 88, 96], ["Cl", "CHEMICAL", 98, 100], ["bicarbonate", "CHEMICAL", 145, 156], ["urea", "CHEMICAL", 204, 208], ["nitrogen", "CHEMICAL", 209, 217], ["creatinine", "CHEMICAL", 261, 271], ["glucose", "CHEMICAL", 316, 323], ["phosphorus", "CHEMICAL", 364, 374], ["calcium", "CHEMICAL", 416, 423], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["chloride", "SIMPLE_CHEMICAL", 88, 96], ["Cl", "SIMPLE_CHEMICAL", 98, 100], ["bicarbonate", "SIMPLE_CHEMICAL", 145, 156], ["blood", "ORGANISM_SUBSTANCE", 198, 203], ["urea nitrogen", "SIMPLE_CHEMICAL", 204, 217], ["BUN", "SIMPLE_CHEMICAL", 219, 222], ["creatinine", "SIMPLE_CHEMICAL", 261, 271], ["glucose", "SIMPLE_CHEMICAL", 316, 323], ["phosphorus", "SIMPLE_CHEMICAL", 364, 374], ["albumin", "GENE_OR_GENE_PRODUCT", 391, 398], ["calcium", "SIMPLE_CHEMICAL", 416, 423], ["Blood work", "TEST", 0, 10], ["Na", "TEST", 57, 59], ["mmol", "TEST", 65, 69], ["K", "TEST", 73, 74], ["mmol", "TEST", 80, 84], ["chloride", "TEST", 88, 96], ["Cl", "TEST", 98, 100], ["mmol", "TEST", 106, 110], ["bicarbonate", "TEST", 145, 156], ["blood urea nitrogen", "TEST", 198, 217], ["BUN", "TEST", 219, 222], ["creatinine", "TEST", 261, 271], ["glucose", "TEST", 316, 323], ["phosphorus", "TEST", 364, 374], ["mg/dl", "TEST", 380, 385], ["albumin", "TEST", 391, 398], ["dl", "TEST", 408, 410], ["calcium level", "TEST", 416, 429]]], ["Complete blood count (CBC) revealed hemoglobin of 10.2 mg/dl, hematocrit of 32%, white blood cell count of 11.1 k/ul, and platelets of 359 K. Parathyroid hormone (PTH) levels of 8 pg/ml were observed and repeat levels the next day for confirmation revealed a level of 10 pg/ml (normal range: 12-88 pg/ml).", [["blood", "ANATOMY", 9, 14], ["white blood cell", "ANATOMY", 81, 97], ["platelets", "ANATOMY", 122, 131], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 36, 46], ["blood cell", "CELL", 87, 97], ["platelets", "CELL", 122, 131], ["Parathyroid hormone", "GENE_OR_GENE_PRODUCT", 142, 161], ["PTH", "GENE_OR_GENE_PRODUCT", 163, 166], ["hemoglobin", "PROTEIN", 36, 46], ["platelets", "CELL_TYPE", 122, 131], ["Complete blood count", "TEST", 0, 20], ["CBC", "TEST", 22, 25], ["hemoglobin", "TEST", 36, 46], ["hematocrit", "TEST", 62, 72], ["white blood cell count", "TEST", 81, 103], ["k/ul", "TEST", 112, 116], ["platelets", "TEST", 122, 131], ["Parathyroid hormone (PTH) levels", "TEST", 142, 174], ["repeat levels", "TEST", 204, 217], ["confirmation", "TEST", 235, 247]]], ["Vitamin D level obtained was low (7 ng/dl) (normal range: 30-100 ng/dl), magnesium level was 1.9 mg/dl (normal range: 1.8-2.5 mg/dl), and creatine phosphokinase (CPK) level was 64 u/l (normal range: 38-174 u/l).", [["Vitamin D", "CHEMICAL", 0, 9], ["magnesium", "CHEMICAL", 73, 82], ["creatine", "CHEMICAL", 138, 146], ["Vitamin D", "CHEMICAL", 0, 9], ["magnesium", "CHEMICAL", 73, 82], ["creatine", "CHEMICAL", 138, 146], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["magnesium", "SIMPLE_CHEMICAL", 73, 82], ["creatine phosphokinase", "GENE_OR_GENE_PRODUCT", 138, 160], ["CPK", "GENE_OR_GENE_PRODUCT", 162, 165], ["creatine phosphokinase", "PROTEIN", 138, 160], ["CPK", "PROTEIN", 162, 165], ["Vitamin D level", "TEST", 0, 15], ["magnesium level", "TEST", 73, 88], ["creatine phosphokinase", "TEST", 138, 160], ["CPK", "TEST", 162, 165], ["u/l", "TEST", 180, 183]]], ["As vitamin D levels were low, the patient was started on 50,000 units of ergocalciferol once a week.", [["vitamin D", "CHEMICAL", 3, 12], ["ergocalciferol", "CHEMICAL", 73, 87], ["vitamin D", "CHEMICAL", 3, 12], ["ergocalciferol", "CHEMICAL", 73, 87], ["vitamin D", "SIMPLE_CHEMICAL", 3, 12], ["patient", "ORGANISM", 34, 41], ["ergocalciferol", "SIMPLE_CHEMICAL", 73, 87], ["patient", "SPECIES", 34, 41], ["vitamin D levels", "TEST", 3, 19], ["ergocalciferol", "TREATMENT", 73, 87]]], ["Parathyroid hormone-related peptide (PTHrP) levels were obtained to rule out paraneoplastic syndrome as a cause of decreased PTH levels.", [["paraneoplastic syndrome", "DISEASE", 77, 100], ["Parathyroid hormone-related peptide", "GENE_OR_GENE_PRODUCT", 0, 35], ["PTHrP", "GENE_OR_GENE_PRODUCT", 37, 42], ["PTH", "GENE_OR_GENE_PRODUCT", 125, 128], ["PTHrP", "PROTEIN", 37, 42], ["Parathyroid hormone", "TEST", 0, 19], ["peptide (PTHrP) levels", "TEST", 28, 50], ["paraneoplastic syndrome", "PROBLEM", 77, 100], ["decreased PTH levels", "PROBLEM", 115, 135], ["paraneoplastic syndrome", "OBSERVATION", 77, 100], ["decreased", "OBSERVATION", 115, 124]]], ["However, it was found to be low at 10.", [["low", "OBSERVATION_MODIFIER", 28, 31]]], ["He was started on calcium acetate 1,334 mg three times a day for hyperphosphatemia.", [["calcium acetate", "CHEMICAL", 18, 33], ["hyperphosphatemia", "DISEASE", 65, 82], ["calcium acetate", "CHEMICAL", 18, 33], ["He", "ORGANISM", 0, 2], ["calcium acetate", "SIMPLE_CHEMICAL", 18, 33], ["calcium acetate", "TREATMENT", 18, 33], ["hyperphosphatemia", "PROBLEM", 65, 82], ["hyperphosphatemia", "OBSERVATION", 65, 82]]], ["Phosphorus levels remained elevated, and sevelamer was added on discharge after he was weaned off oxygen and cleared by physical therapy.Case PresentationOne month following discharge, repeat labs were obtained showing calcium of 9.5 mg/dl, creatinine of 0.75 mg/dl, albumin of 4.1 g/dl, K of 4.5 mmol/l, phosphorus of 5.4 mg/dl, and PTH of 9 pg/dl.", [["Phosphorus", "CHEMICAL", 0, 10], ["sevelamer", "CHEMICAL", 41, 50], ["oxygen", "CHEMICAL", 98, 104], ["calcium", "CHEMICAL", 219, 226], ["creatinine", "CHEMICAL", 241, 251], ["phosphorus", "CHEMICAL", 305, 315], ["Phosphorus", "CHEMICAL", 0, 10], ["sevelamer", "CHEMICAL", 41, 50], ["oxygen", "CHEMICAL", 98, 104], ["calcium", "CHEMICAL", 219, 226], ["creatinine", "CHEMICAL", 241, 251], ["phosphorus", "CHEMICAL", 305, 315], ["Phosphorus", "SIMPLE_CHEMICAL", 0, 10], ["sevelamer", "SIMPLE_CHEMICAL", 41, 50], ["oxygen", "SIMPLE_CHEMICAL", 98, 104], ["calcium", "SIMPLE_CHEMICAL", 219, 226], ["creatinine", "SIMPLE_CHEMICAL", 241, 251], ["albumin", "GENE_OR_GENE_PRODUCT", 267, 274], ["phosphorus", "SIMPLE_CHEMICAL", 305, 315], ["PTH", "SIMPLE_CHEMICAL", 334, 337], ["Phosphorus levels", "TEST", 0, 17], ["elevated", "PROBLEM", 27, 35], ["sevelamer", "TREATMENT", 41, 50], ["oxygen", "TREATMENT", 98, 104], ["repeat labs", "TEST", 185, 196], ["calcium", "TEST", 219, 226], ["dl", "TEST", 237, 239], ["creatinine", "TEST", 241, 251], ["albumin", "TEST", 267, 274], ["dl", "TEST", 284, 286], ["K", "TEST", 288, 289], ["phosphorus", "TEST", 305, 315], ["dl", "TEST", 326, 328], ["PTH", "TEST", 334, 337], ["elevated", "OBSERVATION_MODIFIER", 27, 35]]], ["A summary of the patient's labs can be found in Table 1 Two of the most common etiologies of hypoparathyroidism are either postsurgical following a thyroidectomy, parathyroidectomy, or radical neck dissection, all of which were ruled out in our patient, or autoimmune polyglandular syndromes [5] .", [["neck", "ANATOMY", 193, 197], ["hypoparathyroidism", "DISEASE", 93, 111], ["autoimmune polyglandular syndromes", "DISEASE", 257, 291], ["patient", "ORGANISM", 17, 24], ["neck", "ORGAN", 193, 197], ["patient", "ORGANISM", 245, 252], ["patient", "SPECIES", 17, 24], ["patient", "SPECIES", 245, 252], ["the patient's labs", "TEST", 13, 31], ["hypoparathyroidism", "PROBLEM", 93, 111], ["a thyroidectomy", "TREATMENT", 146, 161], ["parathyroidectomy", "TREATMENT", 163, 180], ["radical neck dissection", "TREATMENT", 185, 208], ["autoimmune polyglandular syndromes", "PROBLEM", 257, 291], ["hypoparathyroidism", "OBSERVATION", 93, 111], ["thyroidectomy", "OBSERVATION", 148, 161], ["parathyroidectomy", "OBSERVATION", 163, 180], ["radical", "OBSERVATION_MODIFIER", 185, 192], ["neck", "ANATOMY", 193, 197], ["dissection", "OBSERVATION", 198, 208]]], ["The latter is often associated either with cutaneous manifestations such as vitiligo or chronic mucocutaneous candidiasis, or with primary adrenal insufficiency.", [["cutaneous", "ANATOMY", 43, 52], ["adrenal", "ANATOMY", 139, 146], ["vitiligo", "DISEASE", 76, 84], ["mucocutaneous candidiasis", "DISEASE", 96, 121], ["primary adrenal insufficiency", "DISEASE", 131, 160], ["adrenal", "ORGAN", 139, 146], ["cutaneous manifestations", "PROBLEM", 43, 67], ["vitiligo", "PROBLEM", 76, 84], ["chronic mucocutaneous candidiasis", "PROBLEM", 88, 121], ["primary adrenal insufficiency", "PROBLEM", 131, 160], ["chronic", "OBSERVATION_MODIFIER", 88, 95], ["mucocutaneous candidiasis", "OBSERVATION", 96, 121], ["adrenal", "ANATOMY", 139, 146], ["insufficiency", "OBSERVATION", 147, 160]]], ["In our case, the patient did not show any of these manifestations.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24], ["these manifestations", "PROBLEM", 45, 65]]], ["Other possible etiologies include radiation-induced destruction of the parathyroid gland, excessive accumulation of iron, and copper or infiltration of the parathyroid gland by granulomatous diseases or metastatic disease [5] .", [["parathyroid gland", "ANATOMY", 71, 88], ["parathyroid gland", "ANATOMY", 156, 173], ["granulomatous", "ANATOMY", 177, 190], ["destruction of the parathyroid gland", "DISEASE", 52, 88], ["iron", "CHEMICAL", 116, 120], ["copper", "CHEMICAL", 126, 132], ["granulomatous diseases", "DISEASE", 177, 199], ["iron", "CHEMICAL", 116, 120], ["copper", "CHEMICAL", 126, 132], ["parathyroid gland", "ORGAN", 71, 88], ["iron", "SIMPLE_CHEMICAL", 116, 120], ["copper", "SIMPLE_CHEMICAL", 126, 132], ["parathyroid gland", "ORGAN", 156, 173], ["radiation-induced destruction of the parathyroid gland", "PROBLEM", 34, 88], ["excessive accumulation of iron", "PROBLEM", 90, 120], ["copper or infiltration of the parathyroid gland", "PROBLEM", 126, 173], ["granulomatous diseases", "PROBLEM", 177, 199], ["metastatic disease", "PROBLEM", 203, 221], ["possible", "UNCERTAINTY", 6, 14], ["radiation", "OBSERVATION", 34, 43], ["destruction", "OBSERVATION", 52, 63], ["parathyroid gland", "ANATOMY", 71, 88], ["excessive", "OBSERVATION_MODIFIER", 90, 99], ["accumulation", "OBSERVATION_MODIFIER", 100, 112], ["iron", "OBSERVATION_MODIFIER", 116, 120], ["copper", "OBSERVATION_MODIFIER", 126, 132], ["infiltration", "OBSERVATION", 136, 148], ["parathyroid gland", "ANATOMY", 156, 173], ["granulomatous", "OBSERVATION_MODIFIER", 177, 190], ["metastatic", "OBSERVATION", 203, 213]]], ["Many of these etiologies were ruled out in our patient.Case PresentationComplex genetic defects and several gene mutations have been documented to cause abnormal growth of the gland leading to inappropriate biosynthesis and secretion of PTH.", [["gland", "ANATOMY", 176, 181], ["patient", "ORGANISM", 47, 54], ["gland", "ORGAN", 176, 181], ["PTH", "GENE_OR_GENE_PRODUCT", 237, 240], ["patient", "SPECIES", 47, 54], ["Case PresentationComplex genetic defects", "PROBLEM", 55, 95], ["several gene mutations", "PROBLEM", 100, 122], ["abnormal growth of the gland", "PROBLEM", 153, 181], ["inappropriate biosynthesis", "PROBLEM", 193, 219], ["secretion of PTH", "PROBLEM", 224, 240], ["etiologies", "OBSERVATION", 14, 24], ["defects", "OBSERVATION", 88, 95], ["growth", "OBSERVATION_MODIFIER", 162, 168], ["gland", "ANATOMY", 176, 181]]], ["One common example is mutations in the calcium-sensing receptor (CaSR), which follows an autosomal dominant pattern [5] .", [["calcium", "CHEMICAL", 39, 46], ["calcium", "CHEMICAL", 39, 46], ["calcium-sensing receptor", "GENE_OR_GENE_PRODUCT", 39, 63], ["CaSR", "GENE_OR_GENE_PRODUCT", 65, 69], ["calcium-sensing receptor", "PROTEIN", 39, 63], ["CaSR", "PROTEIN", 65, 69], ["mutations", "PROBLEM", 22, 31], ["the calcium", "TEST", 35, 46], ["mutations", "OBSERVATION", 22, 31]]], ["A key feature of these genetic disorders is hypocalcemia.", [["genetic disorders", "DISEASE", 23, 40], ["hypocalcemia", "DISEASE", 44, 56], ["these genetic disorders", "PROBLEM", 17, 40], ["hypocalcemia", "PROBLEM", 44, 56], ["hypocalcemia", "OBSERVATION", 44, 56]]], ["It was unlikely that the patient carried these genetic defects given his age and the normal calcium levels.Case PresentationAdditionally, PTHrp levels were normal, effectively excluding an underlying malignancy that could lead to low PTH levels.", [["calcium", "CHEMICAL", 92, 99], ["malignancy", "DISEASE", 200, 210], ["calcium", "CHEMICAL", 92, 99], ["patient", "ORGANISM", 25, 32], ["calcium", "SIMPLE_CHEMICAL", 92, 99], ["PTHrp", "GENE_OR_GENE_PRODUCT", 138, 143], ["malignancy", "CANCER", 200, 210], ["PTH", "GENE_OR_GENE_PRODUCT", 234, 237], ["PTHrp", "PROTEIN", 138, 143], ["patient", "SPECIES", 25, 32], ["these genetic defects", "PROBLEM", 41, 62], ["PTHrp levels", "TEST", 138, 150], ["an underlying malignancy", "PROBLEM", 186, 210], ["low PTH levels", "PROBLEM", 230, 244], ["malignancy", "OBSERVATION", 200, 210]]], ["We were leaning towards hypoparathyroidism causing hyperphosphatemia given that the kidney function was intact and the patient had a daily intake of only 1,200 mg of phosphorous.Case PresentationTo date, there have been some reports linking SARS-CoV-2 to widespread tissue injury; however, there has been no report on the effect of the parathyroid gland [1] .", [["kidney", "ANATOMY", 84, 90], ["tissue", "ANATOMY", 266, 272], ["parathyroid gland", "ANATOMY", 336, 353], ["hypoparathyroidism", "DISEASE", 24, 42], ["hyperphosphatemia", "DISEASE", 51, 68], ["phosphorous", "CHEMICAL", 166, 177], ["tissue injury", "DISEASE", 266, 279], ["phosphorous", "CHEMICAL", 166, 177], ["kidney", "ORGAN", 84, 90], ["patient", "ORGANISM", 119, 126], ["phosphorous", "SIMPLE_CHEMICAL", 166, 177], ["SARS-CoV-2", "ORGANISM", 241, 251], ["tissue", "TISSUE", 266, 272], ["parathyroid gland", "ORGAN", 336, 353], ["patient", "SPECIES", 119, 126], ["hypoparathyroidism", "PROBLEM", 24, 42], ["hyperphosphatemia", "PROBLEM", 51, 68], ["the kidney function", "TEST", 80, 99], ["phosphorous", "TREATMENT", 166, 177], ["widespread tissue injury", "PROBLEM", 255, 279], ["hyperphosphatemia", "OBSERVATION", 51, 68], ["kidney", "ANATOMY", 84, 90], ["intact", "OBSERVATION", 104, 110], ["widespread tissue", "OBSERVATION_MODIFIER", 255, 272], ["injury", "OBSERVATION", 273, 279], ["parathyroid gland", "ANATOMY", 336, 353]]], ["Because of the widespread organ injury and damage, COVID-19 may likely contribute to inflammation of the parathyroid gland.", [["organ", "ANATOMY", 26, 31], ["parathyroid gland", "ANATOMY", 105, 122], ["organ injury", "DISEASE", 26, 38], ["COVID-19", "CHEMICAL", 51, 59], ["inflammation", "DISEASE", 85, 97], ["organ", "ORGAN", 26, 31], ["COVID-19", "GENE_OR_GENE_PRODUCT", 51, 59], ["parathyroid gland", "ORGAN", 105, 122], ["the widespread organ injury", "PROBLEM", 11, 38], ["damage", "PROBLEM", 43, 49], ["COVID", "TEST", 51, 56], ["inflammation of the parathyroid gland", "PROBLEM", 85, 122], ["widespread", "OBSERVATION_MODIFIER", 15, 25], ["organ", "ANATOMY", 26, 31], ["injury", "OBSERVATION", 32, 38], ["may likely contribute to", "UNCERTAINTY", 60, 84], ["inflammation", "OBSERVATION", 85, 97], ["parathyroid gland", "ANATOMY", 105, 122]]], ["Our findings of hypoparathyroidism and elevated serum phosphate levels have implications when it comes to the management of patients with SARS-CoV-2.", [["serum", "ANATOMY", 48, 53], ["hypoparathyroidism", "DISEASE", 16, 34], ["phosphate", "CHEMICAL", 54, 63], ["SARS", "DISEASE", 138, 142], ["phosphate", "CHEMICAL", 54, 63], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["phosphate", "SIMPLE_CHEMICAL", 54, 63], ["patients", "ORGANISM", 124, 132], ["CoV-2", "ORGANISM", 143, 148], ["patients", "SPECIES", 124, 132], ["hypoparathyroidism", "PROBLEM", 16, 34], ["elevated serum phosphate levels", "PROBLEM", 39, 70], ["SARS", "PROBLEM", 138, 142], ["CoV", "TEST", 143, 146], ["hypoparathyroidism", "OBSERVATION", 16, 34], ["elevated", "OBSERVATION_MODIFIER", 39, 47], ["serum phosphate", "OBSERVATION_MODIFIER", 48, 63]]], ["Further studies are necessary to elaborate and to confirm the causative relationship between SARS-CoV-2 and the reported hyperphosphatemia manifestations of COVID-19 and to determine whether or not it is necessary to monitor the levels of PTH, serum phosphorus, and serum calcium in affected patients.ConclusionsHypoparathyroidism is usually associated with genetic or postsurgical factors.", [["serum", "ANATOMY", 244, 249], ["serum", "ANATOMY", 266, 271], ["hyperphosphatemia", "DISEASE", 121, 138], ["phosphorus", "CHEMICAL", 250, 260], ["calcium", "CHEMICAL", 272, 279], ["Hypoparathyroidism", "DISEASE", 312, 330], ["COVID-19", "CHEMICAL", 157, 165], ["phosphorus", "CHEMICAL", 250, 260], ["calcium", "CHEMICAL", 272, 279], ["SARS-CoV-2", "ORGANISM", 93, 103], ["PTH", "GENE_OR_GENE_PRODUCT", 239, 242], ["serum", "ORGANISM_SUBSTANCE", 244, 249], ["phosphorus", "SIMPLE_CHEMICAL", 250, 260], ["serum", "ORGANISM_SUBSTANCE", 266, 271], ["calcium", "SIMPLE_CHEMICAL", 272, 279], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 292, 300], ["SARS-CoV", "SPECIES", 93, 101], ["Further studies", "TEST", 0, 15], ["SARS", "TEST", 93, 97], ["CoV", "TEST", 98, 101], ["hyperphosphatemia manifestations", "PROBLEM", 121, 153], ["COVID", "TEST", 157, 162], ["PTH", "TEST", 239, 242], ["serum phosphorus", "TEST", 244, 260], ["serum calcium", "TEST", 266, 279], ["Hypoparathyroidism", "PROBLEM", 312, 330], ["genetic or postsurgical factors", "PROBLEM", 358, 389], ["hyperphosphatemia", "OBSERVATION", 121, 138], ["Hypoparathyroidism", "OBSERVATION", 312, 330], ["usually associated with", "UNCERTAINTY", 334, 357], ["postsurgical", "OBSERVATION", 369, 381]]], ["Other causes include autoimmune and infiltrative processes.", [["autoimmune and infiltrative processes", "PROBLEM", 21, 58], ["autoimmune", "OBSERVATION", 21, 31], ["infiltrative", "OBSERVATION_MODIFIER", 36, 48]]], ["Our patient had a prolonged course of hospitalization, which could have predisposed him to multiple electrolyte abnormalities.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["multiple electrolyte abnormalities", "PROBLEM", 91, 125], ["multiple", "OBSERVATION_MODIFIER", 91, 99], ["electrolyte abnormalities", "OBSERVATION", 100, 125]]], ["However, he had persistent hyperphosphatemia and low PTH levels throughout his hospital course and after discharge.", [["hyperphosphatemia", "DISEASE", 27, 44], ["PTH", "SIMPLE_CHEMICAL", 53, 56], ["persistent hyperphosphatemia", "PROBLEM", 16, 44], ["low PTH levels", "PROBLEM", 49, 63], ["persistent", "OBSERVATION_MODIFIER", 16, 26], ["hyperphosphatemia", "OBSERVATION", 27, 44], ["low PTH", "OBSERVATION_MODIFIER", 49, 56]]], ["However, it is unknown whether this is related to COVID-19 infection.Additional Information DisclosuresHuman subjects: Consent was obtained by all participants in this study.Conflicts of interest:In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.", [["infection", "DISEASE", 59, 68], ["COVID-19", "GENE_OR_GENE_PRODUCT", 50, 58], ["Human", "ORGANISM", 103, 108], ["Human", "SPECIES", 103, 108], ["participants", "SPECIES", 147, 159], ["COVID-19 infection", "PROBLEM", 50, 68], ["this study", "TEST", 163, 173], ["financial support", "TREATMENT", 342, 359], ["infection", "OBSERVATION", 59, 68]]]], "PMC7243428": [["IntroductionThe outbreak of COVID-19 is the most global crisis with the heaviest and most immediate impact on people\u2019s lives around the world since World War II.", [["COVID-19", "CHEMICAL", 28, 36], ["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116], ["COVID", "TEST", 28, 33], ["global", "OBSERVATION_MODIFIER", 49, 55], ["crisis", "OBSERVATION", 56, 62]]], ["Its societal and economic impact is hard to quantify, but in all aspects enormous.", [["societal", "OBSERVATION_MODIFIER", 4, 12], ["hard to quantify", "OBSERVATION_MODIFIER", 36, 52]]], ["Therefore, the COVID-19 crisis has dominated the political agenda of governments around the globe for the past months.", [["the COVID", "TEST", 11, 20], ["crisis", "PROBLEM", 24, 30], ["political agenda", "OBSERVATION", 49, 65], ["globe", "ANATOMY", 92, 97]]], ["Especially the crisis\u2019 immediate character differentiates it from the ongoing climate crisis.", [["the crisis", "PROBLEM", 11, 21], ["the ongoing climate crisis", "PROBLEM", 66, 92], ["crisis", "OBSERVATION", 15, 21]]], ["This circumstance calls for swift analyses of governmental action with a global perspective.IntroductionOur paper contributes to this need by providing a brief, timely, and Euro-Asian comparative perspective on COVID-19 with a focus on the interface of government and economy: We analyzed selected Asian and European countries along the degree of strictness when shutting down economic and social life: China, which has reacted with an unprecedented lockdown, especially in Wuhan, where the corona-virus was first detected; South Korea, which has been strict in detecting and isolating confirmed cases but which has refrained from locking down the economy; France, which has highly limited social and economic freedom; and finally Germany, which has taken a more liberal approach of locking down the economy.IntroductionSpeedy governmental reaction not only saves lives but can also be a savior of extreme economic downturn.", [["COVID", "TREATMENT", 211, 216], ["strictness", "PROBLEM", 347, 357]]], ["However, the level of strictness in government-responses to Corona is an ambiguous variable: On the one hand, a healthy economy is doubtlessly dependent on healthy people; hence, strict measures can safeguard the economy.", [["people", "ORGANISM", 164, 170], ["people", "SPECIES", 164, 170], ["strict measures", "TREATMENT", 179, 194]]], ["On the other hand, extreme strictness can strangulate the economy and contribute to a severe economic downturn, recession, or even long-term depression.", [["depression", "DISEASE", 141, 151], ["extreme strictness", "PROBLEM", 19, 37], ["a severe economic downturn", "PROBLEM", 84, 110], ["recession", "PROBLEM", 112, 121], ["long-term depression", "PROBLEM", 131, 151], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["long-term", "OBSERVATION_MODIFIER", 131, 140]]], ["Finding the right balance is key and a demanding task that benefits from comparisons such as the one provided by this paper.China ::: Responses to COVID-19 and economic impact in Asia: China and South KoreaAs the first known region to be hit with the outbreak of COVID-19, the economic impact on Asia is severe especially due to the disruption of all key industries.", [["COVID-19", "CHEMICAL", 263, 271], ["COVID", "TEST", 147, 152], ["COVID", "TEST", 263, 268], ["right", "ANATOMY_MODIFIER", 12, 17], ["hit", "OBSERVATION", 238, 241]]], ["The International Monetary Fund (IMF) calls COVID-19 worse than the global financial crisis (GFC) of 2007/2008, estimating that growth in Asia is expected to stall at 0% in 2020.", [["COVID", "TEST", 44, 49], ["growth", "OBSERVATION_MODIFIER", 128, 134]]], ["This makes it the worst year in the last 60 years and under-performing than both the GFC (4.7%) and the Asian financial crisis (1.3%) of 1997 (Rhee 2020).", [["GFC", "DISEASE", 85, 88], ["the GFC", "TEST", 81, 88]]], ["Since the initial coronavirus infections began picking up in Wuhan, Hubei Province, in December 2019, China has implemented a quarantine and lockdown in Wuhan, with a level of strictness in limiting economic and social life that is unprecedented.", [["coronavirus infections", "DISEASE", 18, 40], ["coronavirus", "ORGANISM", 18, 29], ["coronavirus", "SPECIES", 18, 29], ["the initial coronavirus infections", "PROBLEM", 6, 40], ["coronavirus", "OBSERVATION_MODIFIER", 18, 29], ["infections", "OBSERVATION", 30, 40]]], ["Due to the high population density and rising number of infections and death toll, the Chinese Government rolled out quickly a comprehensive response that includes heavy restrictions on people\u2019s movements, closedowns of restaurant and shops, technology-enabled scanning, and checking tools, which managed to control the pandemic and move ahead of \u201ccurve\u201d of the virus headway.China ::: Responses to COVID-19 and economic impact in Asia: China and South KoreaAs much as these measures were meant to save lives, and actually have done so, they have severe consequences on China\u2019s economy.", [["infections", "DISEASE", 56, 66], ["death", "DISEASE", 71, 76], ["people", "ORGANISM", 186, 192], ["people", "SPECIES", 186, 192], ["the high population density", "PROBLEM", 7, 34], ["infections", "PROBLEM", 56, 66], ["COVID", "TEST", 399, 404], ["high", "OBSERVATION_MODIFIER", 11, 15], ["population", "OBSERVATION_MODIFIER", 16, 26], ["density", "OBSERVATION", 27, 34], ["rising", "OBSERVATION_MODIFIER", 39, 45], ["number", "OBSERVATION_MODIFIER", 46, 52], ["infections", "OBSERVATION", 56, 66]]], ["The short-term direct effect is confirmed by the official data from China\u2019s National Bureau of Statistics (CNBS), showing that the country\u2019s gross domestic product (GDP) in the first quarter of 2020 shrank 6.8% year on year.", [["short-term", "OBSERVATION_MODIFIER", 4, 14]]], ["The low manufacturing activity is attributed to the uncertainties and sluggish demand in the domestic and international market, where orders have been canceled or postponed.", [["The low manufacturing activity", "PROBLEM", 0, 30], ["low", "OBSERVATION_MODIFIER", 4, 7], ["manufacturing activity", "OBSERVATION", 8, 30], ["sluggish", "OBSERVATION_MODIFIER", 70, 78]]], ["Equally, the restaurant sector is under serious threat; large scale chains and small size family-run outlets have seen their businesses shut and running out of cash for paying staff members.", [["large scale chains", "PROBLEM", 56, 74], ["small", "OBSERVATION_MODIFIER", 79, 84], ["size", "OBSERVATION_MODIFIER", 85, 89]]], ["Both sectors are a major source of employment, particularly among the country\u2019s 288 million floating population, internal migrant workers (a third of the total workforce), who became the most vulnerable group to the economic decline.", [["economic", "OBSERVATION_MODIFIER", 216, 224], ["decline", "OBSERVATION", 225, 232]]], ["Without readily available \u201csafety nets\u201d through social securities for most of the migrant workers, China\u2019s labor market pressure with an estimation of 70 million jobless workers will have profound socioeconomic effects and even unrests in China.China ::: Responses to COVID-19 and economic impact in Asia: China and South KoreaMoreover, the pandemic reveals some concerning repercussion of the COVID-19 for China.", [["profound socioeconomic effects", "PROBLEM", 188, 218], ["COVID", "TEST", 268, 273], ["the COVID", "TEST", 390, 399]]], ["One being the attempt by major economies to reduce the trade dependencies and over-reliance on China\u2019s manufacturing role in key industries, for instance, the production of personal protection equipment (PPE), by shifting such production out of China back to home countries.", [["the trade dependencies", "PROBLEM", 51, 73], ["personal protection equipment", "TREATMENT", 173, 202], ["trade dependencies", "OBSERVATION", 55, 73]]], ["Another consideration for this important move is the potential escalation of the bilateral trade conflict and increasing volatile political tensions between China and the USA.", [["the bilateral trade conflict", "PROBLEM", 77, 105], ["bilateral", "ANATOMY_MODIFIER", 81, 90], ["trade conflict", "OBSERVATION", 91, 105], ["volatile", "OBSERVATION_MODIFIER", 121, 129], ["political tensions", "OBSERVATION", 130, 148]]], ["As China\u2019s increasing labor costs in recent years have already been off-putting for some foreign investors, the bold move by the US and Japanese governments in offering financial incentives for reshoring manufacturing from China may have a long-term cascading structural effect on China\u2019s economy and domino effect on other countries in Europe and elsewhere.China ::: Responses to COVID-19 and economic impact in Asia: China and South KoreaChina\u2019s economic and political powers have shifted significantly from the GFC and SARS periods, now occupying an ever more crucial position for global manufacturing, supply chain, and governance.", [["SARS", "DISEASE", 522, 526], ["reshoring manufacturing", "TREATMENT", 194, 217], ["COVID", "TEST", 381, 386], ["political powers", "TREATMENT", 461, 477], ["domino effect", "OBSERVATION", 301, 314]]], ["As China overcomes the \u201cCOVID-19 curve\u201d and slowly returns to a \u201cnew normal\u201d period of production daily life, we can expect to see China increase public sector spending and reinforce investment on 5G telecommunication, big data, cloud computing, e-commerce, online education, and advanced medicine manufacturing industries that have played a vital role in combating COVID-19 epidemic.China ::: Responses to COVID-19 and economic impact in Asia: China and South KoreaHowever, even in the case of strong government fiscal stimulus injection, China is unlikely to shoulder the decline of the GDP and helps with the global recession in the same way as it did during the GFC a decade ago.", [["GDP", "CHEMICAL", 589, 592], ["GDP", "CHEMICAL", 589, 592], ["GDP", "SIMPLE_CHEMICAL", 589, 592], ["the \u201cCOVID", "TREATMENT", 19, 29], ["advanced medicine manufacturing industries", "TREATMENT", 280, 322], ["COVID", "TEST", 366, 371], ["COVID", "TEST", 407, 412], ["strong government fiscal stimulus injection", "TREATMENT", 495, 538], ["the GDP", "PROBLEM", 585, 592], ["the global recession", "PROBLEM", 608, 628], ["recession", "OBSERVATION", 619, 628]]], ["While an immediate reshoring from China on a large scale is not foreseen, China cannot afford this potential decoupling process and needs to restructure its industrial composition, incentivize higher domestic consumption, and reconsider its strategy for overseas investment\u2014all this amid growing uncertainties, greater scrutiny, and a potentially hostile environment.", [["a large scale", "TREATMENT", 43, 56]]], ["While we wait for the eventual containment of the novel Coronavirus and cooling down of \u201cpoliticizing\u201d over the virus crisis, we will likely face a new configuration of China in both global economy and governance, in a post-COVID-19 world.South Korea ::: Responses to COVID-19 and economic impact in Asia: China and South KoreaCompared to China, South Korea has taken quite a more liberal path: While the country seeks to trace every Corona-case with large-scale testing and very strictly isolates all confirmed cases with the help of digital support, there has never been any lockdown like in most other countries in Europe, Asia, and indeed most other countries worldwide.", [["the novel Coronavirus", "TREATMENT", 46, 67], ["the virus crisis", "PROBLEM", 108, 124], ["COVID", "TEST", 268, 273], ["large-scale testing", "TEST", 451, 470], ["digital support", "TREATMENT", 535, 550], ["new", "OBSERVATION_MODIFIER", 148, 151]]], ["Restaurants, schools, and shops all remain open in the southern part of the East Asian peninsula.", [["open", "OBSERVATION", 43, 47]]], ["Many other nations with as many cases have reacted with harsh and strict lockdowns, such as China, France, Italy, or Spain: The Coronavirus Government Response Tracker of the University of Oxford has confirmed the positive relationship between number of COVID-19 cases and strictness of governmental response (Oxford University 2020).South Korea ::: Responses to COVID-19 and economic impact in Asia: China and South KoreaThe South Korean path seems to be successful: By end of April 2020, no new domestics cases of COVID-19 were detected (EU Observer 2020).", [["COVID", "TEST", 254, 259], ["COVID", "TEST", 363, 368], ["COVID", "TEST", 516, 521]]], ["Respectively, the impact on the South Korean economy is by comparison rather limited: Although the South Korean economy is going through its worst time since the 1997-Asian financial crisis, it is expected to shrink by merely 1.2% as expected by the IMF (Hankyoreh 2020), while most other countries have rates of 5% and more.South Korea ::: Responses to COVID-19 and economic impact in Asia: China and South KoreaSouth Korea benefits from two advantages: One was the learning effect from previous respiratory epidemics, such as MERS.", [["respiratory epidemics", "DISEASE", 497, 518], ["COVID", "TEST", 354, 359], ["previous respiratory epidemics", "PROBLEM", 488, 518], ["respiratory epidemics", "OBSERVATION", 497, 518]]], ["The country is highly routinized and knowledgeable when it comes to the \u201cepidemic-logistics,\u201d with innovative solutions such as drive-through-testing.", [["innovative solutions", "TREATMENT", 99, 119]]], ["Such skepticism may be in order: The Bertelsmann Foundation\u2019s Sustainable Governance Indicators consider the South Korean data protection authority not to be very effective (Klatt 2020), which is important input in light of the much-discussed General Data Protection Regulation of the European Union.France ::: Responses to COVID-19 and economic impact in Europe: France and GermanyTo contrast the rather liberal South Korean pathway, France is an example of a highly strict governmental response to the Coronavirus.", [["COVID", "TEST", 324, 329], ["the Coronavirus", "PROBLEM", 500, 515]]], ["When COVID-19 made its first victims in France, the social climate had been under tension for 2 years already, notably due to the demonstrations of the so-called Yellow Vests as well as opposition to the pension reform carried out by President Macron by a diverse group of hospital staff, professors, researchers, and civil servants.France ::: Responses to COVID-19 and economic impact in Europe: France and GermanyNotwithstanding such societal climate, France indeed could not react as, e.g., Germany or South Korea did, because it did not have the necessary logistical capacity either to promote mass testing (only 45 public laboratories accredited in the country) or to massively produce masks.", [["COVID-19", "DNA", 5, 13], ["COVID", "TEST", 357, 362], ["mass testing", "TEST", 598, 610], ["mass", "OBSERVATION", 598, 602]]], ["Rather than explicitly setting the goal of scaling up testing until capacities became sufficient, the government appointed an 11-member scientific council and argued that systematic testing was not needed.", [["scaling up testing", "TEST", 43, 61], ["systematic testing", "TEST", 171, 189]]], ["The recommendations and political injunctions that followed were contradictory and created a feeling of confusion: Maintaining the first round of municipal elections (March 15) while enforcing the closure of schools (March 12) and then total lockdown (March 17).", [["confusion", "DISEASE", 104, 113], ["political injunctions", "TREATMENT", 24, 45], ["confusion", "PROBLEM", 104, 113]]], ["Lagadec established that disaster communication should avoid confronting the population with a double-bind situation through dissonant incentives (Lagadec 2009).", [["a double-bind situation", "TREATMENT", 93, 116]]], ["However, the French policy was only reversed on March 28, with the aim of managing a way out from the lockdown.France ::: Responses to COVID-19 and economic impact in Europe: France and GermanyDuring the first 55 days of lockdown, the INSEE (the French statistical office) estimated the loss of economic activity linked to COVID-19 at \u2212 33%, a decrease in consumption of \u2212 32%, and a loss of private salaried employment at \u2212 2.3% (i.e., more than 450,000 net job losses) with regions more exposed than others and variations across sectors (INSEE 2020).Germany ::: Responses to COVID-19 and economic impact in Europe: France and GermanyBy comparison to other European and Asian countries, and despite variations caused by the 16 different federal states, the overall level of strictness is rather moderate in Germany: German citizens may still leave their homes for activities other than just grocery shopping.", [["strictness", "DISEASE", 775, 785], ["COVID", "TEST", 135, 140], ["the loss of economic activity", "PROBLEM", 283, 312], ["COVID", "TEST", 323, 328], ["private salaried employment", "TREATMENT", 392, 419], ["COVID", "TEST", 577, 582], ["decrease", "OBSERVATION_MODIFIER", 344, 352], ["moderate", "OBSERVATION_MODIFIER", 796, 804]]], ["The exceptional character of the lockdown and the ensuing limitation of individual freedom are emphasized in German Corona-debates, not least due to the traumatic experiences of the Nazi-past and the totalitarian former East German communist regime.", [["traumatic", "OBSERVATION", 153, 162]]], ["Especially chancellor Merkel, herself from Eastern Germany, has communicated the measures with a caution that Germans have rewarded with high levels of trust in her and the incumbent government (Ehni 2020).Germany ::: Responses to COVID-19 and economic impact in Europe: France and GermanyThe COVID-19-impact on the German economy is enormous: Exports are in \u201cfree fall,\u201d the economy is expected to shrink over 6% (Deutsche Welle 2020), and over 10 million employees are on short-term work, a government-supported policy to avoid layoffs in crisis times (Xinhua Net 2020).", [["COVID", "TEST", 231, 236], ["The COVID", "TEST", 289, 298], ["enormous", "OBSERVATION_MODIFIER", 334, 342]]], ["Nonetheless, Germany is probably one of the best equipped to deal with the crisis: The incumbent government\u2019s policy of a \u201cBlack Zero,\u201d which some have named a \u201cnational obsession with a balanced budget\u201d (Deutsche Welle 2019), now pays off: With a balanced budget prior to Corona, Germany is likely to \u201cafford\u201d the unprecedented 350-bn-heavy \u201cCorona Protective Shield\u201d (Federal Ministry of Finance 2020) that shall save everyone, from the so-called \u201cSolo Self-employed\u201d over SMEs to large corporations such as Lufthansa\u2014the latter alone shall receive 5.5 bn EUR from the Federal government (Tagesschau 2020).Germany ::: Responses to COVID-19 and economic impact in Europe: France and GermanyDespite the relative consensus of the German population that the lockdown is necessary to save lives, voices are becoming louder since end of April that the government must give a perspective on a lockdown-exit-strategy.", [["COVID", "TEST", 633, 638], ["a lockdown-exit-strategy", "TREATMENT", 886, 910], ["crisis", "OBSERVATION", 75, 81]]], ["Such voices with moderate tones were coming from more business-prone political parties, such as the Liberal Democrats, as well as from working parents, who are stuck at home with their children since kindergartens are still closed and schools are only partially open.", [["children", "ORGANISM", 185, 193], ["children", "SPECIES", 185, 193], ["moderate tones", "PROBLEM", 17, 31]]], ["Every crisis also offers chances: Thus, COVID-19 has given a real boost in digitizing especially workplaces in Germany, which will certainly be helpful for the German economy in the long-run.Discussion and conclusionThe pandemic has done nothing less but turning the lives of people all over the world upside down.", [["COVID-19", "CHEMICAL", 40, 48], ["people", "ORGANISM", 276, 282], ["people", "SPECIES", 276, 282]]], ["After all, a major depression may also cost further lives.", [["depression", "DISEASE", 19, 29], ["a major depression", "PROBLEM", 11, 29]]], ["The paper has shown that striking such a balance is an incredibly difficult task: While China has things by now under control, the economic consequences for China but also for the global economy are severe.", [["severe", "OBSERVATION_MODIFIER", 199, 205]]], ["South Korea seems to be the role model in containing the virus and keeping the economy as untouched as possible, with its combination of strict testing and isolating, while refraining from lockdown.", [["the virus", "PROBLEM", 53, 62], ["strict testing", "TEST", 137, 151]]], ["France, which has faced its extraordinarily high infection and death rates with a very severe lockdown for weeks already, has just announced a relief of restrictions\u2014not least because the economic consequences are likely to be disastrous.", [["infection", "DISEASE", 49, 58], ["death", "DISEASE", 63, 68], ["high infection", "PROBLEM", 44, 58], ["death rates", "PROBLEM", 63, 74], ["a very severe lockdown", "PROBLEM", 80, 102], ["disastrous", "PROBLEM", 227, 237], ["extraordinarily", "OBSERVATION_MODIFIER", 28, 43], ["high", "OBSERVATION_MODIFIER", 44, 48], ["infection", "OBSERVATION", 49, 58], ["likely to be", "UNCERTAINTY", 214, 226], ["disastrous", "OBSERVATION", 227, 237]]], ["Export-oriented Germany may experience a similar impact but is in a better position to finance measures against the downturn and has left more liberties in the first place for its society and economy.Discussion and conclusionDespite the above differences across responses to Corona, one thing is striking, namely, that governments across Asia, Europe, and indeed worldwide almost show a concerted action when it comes to the timing of taking measures against the common global threat of the virus: Almost all governmental responses to COVID-19, especially those related to lockdowns, were announced around mid-March.", [["COVID-19", "DNA", 535, 543], ["COVID", "TEST", 535, 540], ["left", "ANATOMY_MODIFIER", 133, 137]]], ["This may be a hint that this truly global crisis has after all been met with quite a global response.", [["global", "OBSERVATION_MODIFIER", 35, 41], ["crisis", "OBSERVATION", 42, 48]]]], "PMC7094621": [["Looking backWhen my collaborators and I began to investigate mechanisms of animal virus entry in 1976, several key concepts were already known [1].", [["animal virus entry", "PROBLEM", 75, 93]]], ["Some of them had been established with T-even bacteriophages, which at the time had been studied in much greater detail than animal viruses.", [["T-even bacteriophages", "PROBLEM", 39, 60], ["viruses", "OBSERVATION", 132, 139]]], ["The phages were known to have proteins that bound to cell surface \u201creceptors\u201d on specific host bacteria.", [["cell surface", "ANATOMY", 53, 65], ["cell", "CELL", 53, 57], ["cell surface \u201creceptors", "PROTEIN", 53, 76], ["proteins that bound", "PROBLEM", 30, 49], ["cell surface", "TEST", 53, 65], ["specific host bacteria", "PROBLEM", 81, 103]]], ["Interaction with the receptors triggered conformational changes in the virus particles.", [["conformational changes in the virus particles", "PROBLEM", 41, 86]]], ["The result was perforation of the bacterial cell wall and ejection of the viral DNA genome and some proteins into the cytosol.Looking backBeing much simpler in structure and composition, animal viruses were not likely to use a bacteriophage-like ejection mechanism.", [["cell wall", "ANATOMY", 44, 53], ["cytosol", "ANATOMY", 118, 125], ["cell wall", "TISSUE", 44, 53], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["cytosol", "CELLULAR_COMPONENT", 118, 125], ["viral DNA genome", "DNA", 74, 90], ["perforation of the bacterial cell wall", "PROBLEM", 15, 53], ["the viral DNA genome", "TREATMENT", 70, 90], ["animal viruses", "PROBLEM", 187, 201], ["a bacteriophage", "TREATMENT", 225, 240], ["perforation", "OBSERVATION", 15, 26], ["bacterial cell", "OBSERVATION", 34, 48], ["wall", "ANATOMY_MODIFIER", 49, 53], ["viral DNA genome", "OBSERVATION", 74, 90], ["cytosol", "ANATOMY", 118, 125], ["back", "ANATOMY", 134, 138], ["viruses", "OBSERVATION", 194, 201]]], ["However, influenza and paramyxoviruses were known to use sialic acid residues as receptors, and have sialidase activity for receptor destruction [2].", [["influenza", "DISEASE", 9, 18], ["sialic acid", "CHEMICAL", 57, 68], ["sialic acid", "CHEMICAL", 57, 68], ["paramyxoviruses", "ORGANISM", 23, 38], ["sialic acid", "SIMPLE_CHEMICAL", 57, 68], ["sialidase", "GENE_OR_GENE_PRODUCT", 101, 110], ["sialidase", "PROTEIN", 101, 110], ["influenza", "PROBLEM", 9, 18], ["paramyxoviruses", "PROBLEM", 23, 38], ["sialic acid residues", "TREATMENT", 57, 77], ["sialidase activity", "TREATMENT", 101, 119], ["receptor destruction", "PROBLEM", 124, 144]]], ["It was generally assumed that other animal viruses used a variety of receptors explaining the observed differences in cell tropism and host range.", [["cell", "ANATOMY", 118, 122], ["cell", "CELL", 118, 122], ["other animal viruses", "PROBLEM", 30, 50], ["a variety of receptors", "TREATMENT", 56, 78], ["viruses", "OBSERVATION", 43, 50], ["cell tropism", "OBSERVATION", 118, 130]]], ["Identification of additional receptors took place later: The HIV virus receptor CD4 on T cells and the Epstein\u2013Barr virus receptor CR2 on B cells were identified in 1984 [3], [4], the poliovirus receptor CD155 in 1989 [5], and the coxsackie adenovirus virus receptor in 1997 [6].Looking backThe major controversy in the emerging field of animal virus entry at the time was whether viruses\u2014once bound to their receptors\u2014penetrated directly through the plasma membrane or only after endocytosis (called \u201cviropexis\u201d at the time) [7].", [["T cells", "ANATOMY", 87, 94], ["B cells", "ANATOMY", 138, 145], ["plasma membrane", "ANATOMY", 451, 466], ["HIV virus", "ORGANISM", 61, 70], ["CD4", "GENE_OR_GENE_PRODUCT", 80, 83], ["T cells", "CELL", 87, 94], ["Epstein\u2013Barr virus", "ORGANISM", 103, 121], ["CR2", "GENE_OR_GENE_PRODUCT", 131, 134], ["B cells", "CELL", 138, 145], ["CD155", "GENE_OR_GENE_PRODUCT", 204, 209], ["coxsackie adenovirus virus", "ORGANISM", 231, 257], ["animal virus", "ORGANISM", 338, 350], ["plasma membrane", "CELLULAR_COMPONENT", 451, 466], ["HIV virus receptor CD4", "PROTEIN", 61, 83], ["T cells", "CELL_TYPE", 87, 94], ["Epstein\u2013Barr virus receptor CR2", "PROTEIN", 103, 134], ["B cells", "CELL_TYPE", 138, 145], ["poliovirus receptor CD155", "PROTEIN", 184, 209], ["coxsackie adenovirus virus receptor", "PROTEIN", 231, 266], ["HIV", "SPECIES", 61, 64], ["coxsackie adenovirus virus", "SPECIES", 231, 257], ["HIV virus", "SPECIES", 61, 70], ["Epstein\u2013Barr virus", "SPECIES", 103, 121], ["coxsackie adenovirus virus", "SPECIES", 231, 257], ["The HIV virus receptor", "TEST", 57, 79], ["T cells", "TEST", 87, 94], ["the Epstein", "TEST", 99, 110], ["B cells", "TEST", 138, 145], ["the poliovirus receptor CD155", "TEST", 180, 209], ["the coxsackie adenovirus virus receptor", "TEST", 227, 266], ["viruses\u2014once bound", "PROBLEM", 381, 399], ["viropexis", "TREATMENT", 502, 511], ["back", "ANATOMY", 287, 291], ["major", "OBSERVATION_MODIFIER", 295, 300], ["controversy", "OBSERVATION", 301, 312]]], ["Envelope glycoproteins in members of the paramyxovirus family were known to possess cell\u2013cell fusion activity [8].", [["cell\u2013cell", "ANATOMY", 84, 93], ["paramyxovirus", "ORGANISM", 41, 54], ["cell\u2013cell", "CELL", 84, 93], ["Envelope glycoproteins", "PROTEIN", 0, 22], ["paramyxovirus family", "PROTEIN", 41, 61], ["Envelope glycoproteins", "TREATMENT", 0, 22], ["the paramyxovirus family", "TREATMENT", 37, 61]]], ["This suggested that penetration of enveloped viruses relied on fusion of the viral membrane with the plasma membrane.", [["membrane", "ANATOMY", 83, 91], ["plasma membrane", "ANATOMY", 101, 116], ["membrane", "CELLULAR_COMPONENT", 83, 91], ["plasma membrane", "CELLULAR_COMPONENT", 101, 116], ["penetration of enveloped viruses", "PROBLEM", 20, 52], ["fusion", "TREATMENT", 63, 69], ["the viral membrane", "TREATMENT", 73, 91], ["the plasma membrane", "TREATMENT", 97, 116], ["penetration", "OBSERVATION_MODIFIER", 20, 31], ["enveloped", "OBSERVATION_MODIFIER", 35, 44], ["viruses", "OBSERVATION", 45, 52], ["viral membrane", "OBSERVATION", 77, 91], ["plasma membrane", "OBSERVATION", 101, 116]]], ["However, other mechanisms could not be excluded [9].", [["could not be excluded", "UNCERTAINTY", 26, 47]]], ["The endocytic pathway was dismissed by many as a mechanism that cells employed to defend themselves by destruction of viruses in lysosomes.Looking backThe available data were confusing and contradictory.", [["cells", "ANATOMY", 64, 69], ["lysosomes", "ANATOMY", 129, 138], ["cells", "CELL", 64, 69], ["lysosomes", "CELLULAR_COMPONENT", 129, 138], ["destruction of viruses in lysosomes", "PROBLEM", 103, 138], ["endocytic pathway", "OBSERVATION", 4, 21], ["viruses", "OBSERVATION", 118, 125], ["back", "ANATOMY", 147, 151]]], ["To take an example, vesicular stomatitis virus was shown by electron microscopy (EM) to undergo endocytosis in L cells through what we now recognize as clathrin-coated pits and vesicles [10], [11].", [["L cells", "ANATOMY", 111, 118], ["vesicles", "ANATOMY", 177, 185], ["vesicular stomatitis", "DISEASE", 20, 40], ["vesicular stomatitis virus", "ORGANISM", 20, 46], ["L cells", "CELL", 111, 118], ["clathrin", "GENE_OR_GENE_PRODUCT", 152, 160], ["vesicles", "CELLULAR_COMPONENT", 177, 185], ["[11]", "SIMPLE_CHEMICAL", 192, 196], ["L cells", "CELL_TYPE", 111, 118], ["clathrin", "PROTEIN", 152, 160], ["vesicular stomatitis virus", "SPECIES", 20, 46], ["vesicular stomatitis virus", "PROBLEM", 20, 46], ["electron microscopy", "TEST", 60, 79], ["endocytosis in L cells", "TREATMENT", 96, 118]]], ["Equally convincing-looking electron micrographs showed direct fusion of the viral envelope with the L cell plasma membrane [12].Looking backIt was known, moreover, that some viruses underwent a stepwise uncoating process during entry culminating in the release of the genome.", [["L cell plasma membrane", "ANATOMY", 100, 122], ["L cell", "CELLULAR_COMPONENT", 100, 106], ["plasma membrane", "CELLULAR_COMPONENT", 107, 122], ["genome", "CELLULAR_COMPONENT", 268, 274], ["electron micrographs", "TEST", 27, 47], ["direct fusion of the viral envelope", "PROBLEM", 55, 90], ["some viruses", "PROBLEM", 169, 181], ["a stepwise uncoating process", "TREATMENT", 192, 220], ["viral envelope", "OBSERVATION", 76, 90], ["back", "ANATOMY", 136, 140], ["viruses", "OBSERVATION", 174, 181]]], ["This insight was based primarily on picorna virus work [13].", [["picorna virus", "ORGANISM", 36, 49]]], ["After association with cells, these viruses could be shown to undergo what was called \u201ceclipse,\u201d that is, a series of conformational changes before the viral RNA was released.", [["cells", "ANATOMY", 23, 28], ["cells", "CELL", 23, 28], ["viral RNA", "RNA", 152, 161], ["cells", "PROBLEM", 23, 28], ["these viruses", "PROBLEM", 30, 43], ["conformational changes", "PROBLEM", 118, 140], ["the viral RNA", "PROBLEM", 148, 161], ["viral RNA", "OBSERVATION", 152, 161]]], ["Incoming adenovirus capsids were known to associate with microtubules and with nuclear pore complexes followed by delivery of the genome into the nucleus [14].Looking backHowever, as commented by Sam Dales, one of the pioneers, all these facts were \u201cestablished with only a modest degree of credibility\u201d [15].", [["microtubules", "ANATOMY", 57, 69], ["nuclear pore complexes", "ANATOMY", 79, 101], ["nucleus", "ANATOMY", 146, 153], ["adenovirus capsids", "ORGANISM", 9, 27], ["microtubules", "CELLULAR_COMPONENT", 57, 69], ["genome", "CELLULAR_COMPONENT", 130, 136], ["nucleus", "CELLULAR_COMPONENT", 146, 153], ["microtubules", "PROTEIN", 57, 69], ["nuclear pore complexes", "PROTEIN", 79, 101], ["Incoming adenovirus capsids", "PROBLEM", 0, 27], ["nuclear pore complexes", "TREATMENT", 79, 101], ["nucleus", "ANATOMY", 146, 153]]], ["The main problem was that most of the studies relied on EM.", [["the studies", "TEST", 34, 45], ["main", "OBSERVATION_MODIFIER", 4, 8], ["problem", "OBSERVATION", 9, 16]]], ["With EM, it was not possible to distinguish between productive and non-productive entry pathways and infective and non-infective particles.", [["productive and non-productive entry pathways", "PROBLEM", 52, 96], ["infective and non-infective particles", "PROBLEM", 101, 138], ["infective", "OBSERVATION_MODIFIER", 101, 110], ["non-infective particles", "OBSERVATION", 115, 138]]], ["For many viruses, the high particle to plaque-forming unit (a measure of virus infectivity) ratio makes analysis of entry difficult still today.", [["plaque", "ANATOMY", 39, 45], ["many viruses", "PROBLEM", 4, 16], ["virus infectivity", "PROBLEM", 73, 90], ["viruses", "OBSERVATION", 9, 16], ["high particle", "OBSERVATION_MODIFIER", 22, 35]]], ["In the early 1980s, it was in addition hard to obtain funding as major agencies had written off virus entry as \u201cunsolvable.\u201dLooking backOnly by combining morphological and biochemical methods with perturbants and inhibitors that affected the pathway to productive infection did it become possible to make progress.", [["infection", "DISEASE", 264, 273], ["perturbants", "TREATMENT", 197, 208], ["inhibitors", "TREATMENT", 213, 223], ["productive infection", "PROBLEM", 253, 273], ["productive", "OBSERVATION_MODIFIER", 253, 263], ["infection", "OBSERVATION", 264, 273]]], ["In our own early experiments, we used weak bases such as ammonium chloride and chloroquine as perturbants [16].", [["ammonium chloride", "CHEMICAL", 57, 74], ["chloroquine", "CHEMICAL", 79, 90], ["ammonium chloride", "CHEMICAL", 57, 74], ["chloroquine", "CHEMICAL", 79, 90], ["ammonium chloride", "SIMPLE_CHEMICAL", 57, 74], ["chloroquine", "SIMPLE_CHEMICAL", 79, 90], ["weak bases", "TREATMENT", 38, 48], ["ammonium chloride", "TREATMENT", 57, 74], ["chloroquine", "TREATMENT", 79, 90]]], ["Only later was it established that they raise the pH of acidic organelles in the cell [18].", [["organelles", "ANATOMY", 63, 73], ["cell", "ANATOMY", 81, 85], ["acidic organelles", "CELLULAR_COMPONENT", 56, 73], ["cell", "CELL", 81, 85]]], ["The virus families affected turned out to be those in which penetration was triggered by low pH.Looking backIn combination with cell entry and in vitro fusion experiments, the inhibitors allowed us to demonstrate that endocytosis is essential for entry of several enveloped virus families and that fusion activity of the envelope proteins is triggered by low pH [16], [19].", [["cell", "ANATOMY", 128, 132], ["cell", "CELL", 128, 132], ["envelope proteins", "PROTEIN", 321, 338], ["low pH", "PROBLEM", 89, 95], ["cell entry", "TREATMENT", 128, 138], ["vitro fusion experiments", "TREATMENT", 146, 170], ["the inhibitors", "TREATMENT", 172, 186], ["several enveloped virus families", "PROBLEM", 256, 288], ["fusion activity", "PROBLEM", 298, 313], ["the envelope proteins", "PROBLEM", 317, 338], ["low pH", "PROBLEM", 355, 361], ["virus", "OBSERVATION", 4, 9], ["back", "ANATOMY", 104, 108]]], ["It became clear that to understand virus entry, it was critical to learn about cell biology and membrane biology.", [["cell", "ANATOMY", 79, 83], ["membrane", "ANATOMY", 96, 104], ["cell", "CELL", 79, 83], ["membrane", "CELLULAR_COMPONENT", 96, 104]]], ["Also, it was evident that viruses could serve as useful tools and model systems to study cellular phenomena such as endocytosis, membrane trafficking, and membrane fusion.In the main stream of virus researchToday, entry studies constitute a major subfield in virology as illustrated by the collection of reviews and primary publications in this volume, and by more than 1500 reviews and 20,000 publications in the literature.", [["cellular", "ANATOMY", 89, 97], ["membrane", "ANATOMY", 129, 137], ["membrane", "ANATOMY", 155, 163], ["cellular", "CELL", 89, 97], ["membrane", "CELLULAR_COMPONENT", 129, 137], ["membrane", "CELLULAR_COMPONENT", 155, 163], ["viruses", "PROBLEM", 26, 33], ["cellular phenomena", "PROBLEM", 89, 107], ["endocytosis", "PROBLEM", 116, 127], ["membrane trafficking", "PROBLEM", 129, 149], ["membrane fusion", "TREATMENT", 155, 170], ["entry studies", "TEST", 214, 227], ["this volume", "TEST", 340, 351], ["viruses", "OBSERVATION", 26, 33], ["membrane trafficking", "OBSERVATION", 129, 149], ["membrane fusion", "OBSERVATION", 155, 170], ["main", "OBSERVATION_MODIFIER", 178, 182], ["virus", "OBSERVATION", 193, 198]]], ["The entry of hundreds of viruses has been analyzed in tissue culture cells and increasingly in vivo.", [["tissue culture cells", "ANATOMY", 54, 74], ["tissue culture cells", "CELL", 54, 74], ["tissue culture cells", "CELL_LINE", 54, 74], ["viruses", "PROBLEM", 25, 32], ["tissue culture cells", "TEST", 54, 74], ["viruses", "OBSERVATION", 25, 32], ["culture cells", "OBSERVATION", 61, 74]]], ["The methods used range from detailed structural biology of receptor/virus interactions to live cell imaging of incoming viruses, loss-of-function screens, and mathematical modeling.", [["cell", "ANATOMY", 95, 99], ["cell", "CELL", 95, 99], ["receptor/virus interactions", "TREATMENT", 59, 86], ["live cell imaging", "TEST", 90, 107], ["incoming viruses", "PROBLEM", 111, 127]]], ["The level of detailed information available is impressive.In the main stream of virus researchMy purpose in this review is to describe the general framework of current concepts in the field.", [["main", "OBSERVATION_MODIFIER", 65, 69], ["stream", "OBSERVATION_MODIFIER", 70, 76], ["virus", "OBSERVATION", 80, 85]]], ["Since there are numerous reviews and book chapters on this topic as well as on individual viruses and virus families, I will focus on a few novel issues.In the main stream of virus researchRegarding the old controversy mentioned above, we now know that the majority of virus species use endocytosis.", [["virus", "PROBLEM", 175, 180], ["virus species", "PROBLEM", 269, 282], ["main", "OBSERVATION_MODIFIER", 160, 164], ["stream", "OBSERVATION_MODIFIER", 165, 171], ["virus", "OBSERVATION", 175, 180], ["virus", "OBSERVATION", 269, 274]]], ["Several different endocytic mechanisms can be used (Table 1).", [["endocytic mechanisms", "OBSERVATION", 18, 38]]], ["However, some enveloped viruses can penetrate directly through the plasma membrane by membrane fusion.", [["plasma membrane", "ANATOMY", 67, 82], ["membrane", "ANATOMY", 86, 94], ["plasma membrane", "CELLULAR_COMPONENT", 67, 82], ["membrane", "CELLULAR_COMPONENT", 86, 94], ["some enveloped viruses", "PROBLEM", 9, 31], ["membrane fusion", "TREATMENT", 86, 101], ["enveloped", "OBSERVATION_MODIFIER", 14, 23], ["viruses", "OBSERVATION", 24, 31], ["plasma membrane", "OBSERVATION", 67, 82], ["membrane fusion", "OBSERVATION", 86, 101]]], ["Being pH independent, such fusion reactions are triggered by interactions with one or more cell surface receptors.", [["cell surface", "ANATOMY", 91, 103], ["cell", "CELL", 91, 95], ["cell surface receptors", "PROTEIN", 91, 113], ["such fusion reactions", "PROBLEM", 22, 43], ["pH independent", "OBSERVATION_MODIFIER", 6, 20]]], ["HIV-1, a lentivirus, needs two cell surface receptors that induce successive changes in the conformation of the fusion-active glycoprotein.", [["cell surface", "ANATOMY", 31, 43], ["HIV-1", "ORGANISM", 0, 5], ["lentivirus", "ORGANISM", 9, 19], ["cell", "CELL", 31, 35], ["cell surface receptors", "PROTEIN", 31, 53], ["fusion-active glycoprotein", "PROTEIN", 112, 138], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "TEST", 0, 3], ["a lentivirus", "PROBLEM", 7, 19], ["two cell surface receptors", "TREATMENT", 27, 53], ["successive changes", "PROBLEM", 66, 84], ["the fusion", "TREATMENT", 108, 118], ["active glycoprotein", "PROBLEM", 119, 138], ["lentivirus", "OBSERVATION", 9, 19], ["fusion", "OBSERVATION", 112, 118], ["active", "OBSERVATION_MODIFIER", 119, 125], ["glycoprotein", "OBSERVATION", 126, 138]]], ["In the case of paramyxoviruses and herpes viruses, fusion is usually triggered by interactions between receptor-binding viral spike glycoproteins and distinct metastable viral fusion proteins [20].", [["herpes viruses", "DISEASE", 35, 49], ["paramyxoviruses", "ORGANISM", 15, 30], ["herpes viruses", "ORGANISM", 35, 49], ["receptor-binding viral spike glycoproteins", "GENE_OR_GENE_PRODUCT", 103, 145], ["receptor-binding viral spike glycoproteins", "PROTEIN", 103, 145], ["metastable viral fusion proteins", "PROTEIN", 159, 191], ["paramyxoviruses", "PROBLEM", 15, 30], ["herpes viruses", "PROBLEM", 35, 49], ["fusion", "TREATMENT", 51, 57], ["receptor-binding viral spike glycoproteins", "TREATMENT", 103, 145], ["distinct metastable viral fusion proteins", "PROBLEM", 150, 191], ["paramyxoviruses", "OBSERVATION", 15, 30], ["herpes viruses", "OBSERVATION", 35, 49], ["metastable", "OBSERVATION_MODIFIER", 159, 169], ["viral fusion", "OBSERVATION", 170, 182]]], ["For the fusion activation mechanism, different models are being discussed [21].In the main stream of virus researchSince direct fusion at the plasma membrane and endocytosis and intracellular fusion occur in parallel, it is not always easy to determine how much each of them contributes to infection [22].", [["plasma membrane", "ANATOMY", 142, 157], ["intracellular", "ANATOMY", 178, 191], ["infection", "DISEASE", 290, 299], ["plasma membrane", "CELLULAR_COMPONENT", 142, 157], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 178, 191], ["the fusion activation mechanism", "TREATMENT", 4, 35], ["virus", "PROBLEM", 101, 106], ["direct fusion", "TREATMENT", 121, 134], ["endocytosis", "PROBLEM", 162, 173], ["intracellular fusion", "TREATMENT", 178, 198], ["infection", "PROBLEM", 290, 299], ["fusion", "OBSERVATION", 8, 14], ["main", "OBSERVATION_MODIFIER", 86, 90], ["stream", "OBSERVATION_MODIFIER", 91, 97], ["virus", "OBSERVATION", 101, 106], ["intracellular fusion", "OBSERVATION", 178, 198], ["infection", "OBSERVATION", 290, 299]]], ["For example, HIV-1 is able to fuse at the cell surface and intracellularly, but there is evidence that fusion at the plasma membrane does not progress beyond the lipid-mixing stage [23].", [["cell surface", "ANATOMY", 42, 54], ["plasma membrane", "ANATOMY", 117, 132], ["HIV-1", "ORGANISM", 13, 18], ["cell surface", "CELLULAR_COMPONENT", 42, 54], ["plasma membrane", "CELLULAR_COMPONENT", 117, 132], ["HIV-1", "SPECIES", 13, 18], ["HIV-1", "SPECIES", 13, 18], ["HIV", "PROBLEM", 13, 16], ["fusion at the plasma membrane", "PROBLEM", 103, 132], ["fusion", "OBSERVATION", 103, 109]]], ["The same is true for influenza A virus when fusion at the plasma membrane is induced by low pH [24].", [["plasma membrane", "ANATOMY", 58, 73], ["influenza A virus", "ORGANISM", 21, 38], ["plasma membrane", "CELLULAR_COMPONENT", 58, 73], ["influenza A virus", "SPECIES", 21, 38], ["influenza A virus", "SPECIES", 21, 38], ["influenza A virus", "PROBLEM", 21, 38], ["low pH", "PROBLEM", 88, 94]]], ["Here, capsid release and uncoating fail to occur.", [["capsid release", "TREATMENT", 6, 20]]], ["Thus, conclusive demonstration that fusion at the plasma membrane actually leads to infection is still pending for many viruses.Entry in several stepsFor viruses that enter by endocytosis, the pathways are complex.", [["plasma membrane", "ANATOMY", 50, 65], ["infection", "DISEASE", 84, 93], ["plasma membrane", "CELLULAR_COMPONENT", 50, 65], ["fusion at the plasma membrane", "PROBLEM", 36, 65], ["infection", "PROBLEM", 84, 93], ["many viruses", "PROBLEM", 115, 127], ["viruses", "PROBLEM", 154, 161], ["fusion", "OBSERVATION", 36, 42], ["infection", "OBSERVATION", 84, 93], ["several steps", "OBSERVATION_MODIFIER", 137, 150], ["viruses", "OBSERVATION", 154, 161], ["complex", "OBSERVATION_MODIFIER", 206, 213]]], ["The viruses depend on the dynamics of the plasma membrane, membrane trafficking, signaling, endosome maturation, and a variety of other cell functions [25].", [["plasma membrane", "ANATOMY", 42, 57], ["membrane", "ANATOMY", 59, 67], ["endosome", "ANATOMY", 92, 100], ["cell", "ANATOMY", 136, 140], ["plasma membrane", "CELLULAR_COMPONENT", 42, 57], ["membrane", "CELLULAR_COMPONENT", 59, 67], ["endosome", "CELLULAR_COMPONENT", 92, 100], ["cell", "CELL", 136, 140], ["The viruses", "PROBLEM", 0, 11], ["viruses", "OBSERVATION", 4, 11], ["membrane trafficking", "OBSERVATION", 59, 79], ["endosome maturation", "OBSERVATION", 92, 111]]], ["The overall program can usually be broken down into consecutive steps: (1) attachment to the cell surface; (2) lateral movement along the plasma membrane and receptor clustering; (3) activation of cellular signaling pathways; (4) endocytosis and transport to secondary organelles; (5) penetration by membrane fusion, lysis, or channel/pore formation; (6) intracellular transport into the nucleus or location within the cytoplasm; and (7) partial or complete uncoating of the virus particles or capsids in the cytosol, at the nuclear pore, or in the nucleoplasm.Entry in several stepsIt is important to realize that the steps listed above leave a lot of room for variability.", [["cell surface", "ANATOMY", 93, 105], ["plasma membrane", "ANATOMY", 138, 153], ["cellular", "ANATOMY", 197, 205], ["organelles", "ANATOMY", 269, 279], ["membrane", "ANATOMY", 300, 308], ["pore", "ANATOMY", 335, 339], ["intracellular", "ANATOMY", 355, 368], ["nucleus", "ANATOMY", 388, 395], ["cytoplasm", "ANATOMY", 419, 428], ["cytosol", "ANATOMY", 509, 516], ["nuclear pore", "ANATOMY", 525, 537], ["nucleoplasm", "ANATOMY", 549, 560], ["cell surface", "CELLULAR_COMPONENT", 93, 105], ["plasma membrane", "CELLULAR_COMPONENT", 138, 153], ["cellular", "CELL", 197, 205], ["organelles", "CELLULAR_COMPONENT", 269, 279], ["membrane", "CELLULAR_COMPONENT", 300, 308], ["pore", "CELLULAR_COMPONENT", 335, 339], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 355, 368], ["nucleus", "CELLULAR_COMPONENT", 388, 395], ["cytoplasm", "ORGANISM_SUBSTANCE", 419, 428], ["cytosol", "CELLULAR_COMPONENT", 509, 516], ["nuclear pore", "CELLULAR_COMPONENT", 525, 537], ["nucleoplasm", "CELLULAR_COMPONENT", 549, 560], ["the cell surface", "TEST", 89, 105], ["lateral movement", "TEST", 111, 127], ["cellular signaling pathways", "PROBLEM", 197, 224], ["membrane fusion", "TREATMENT", 300, 315], ["lysis", "TREATMENT", 317, 322], ["channel/pore formation", "TREATMENT", 327, 349], ["the virus particles", "PROBLEM", 471, 490], ["capsids", "PROBLEM", 494, 501], ["plasma membrane", "ANATOMY", 138, 153], ["nucleus", "ANATOMY", 388, 395], ["nuclear pore", "OBSERVATION_MODIFIER", 525, 537], ["nucleoplasm", "OBSERVATION", 549, 560], ["several steps", "OBSERVATION_MODIFIER", 570, 583]]], ["The receptors on the cell surface are generally different between viruses, the signaling pathways are distinct, several different endocytic machineries can be activated, and there are many mechanisms of penetration.", [["cell surface", "ANATOMY", 21, 33], ["cell surface", "CELLULAR_COMPONENT", 21, 33], ["penetration", "PROBLEM", 203, 214], ["cell surface", "OBSERVATION_MODIFIER", 21, 33], ["different", "OBSERVATION_MODIFIER", 48, 57], ["viruses", "OBSERVATION", 66, 73], ["distinct", "OBSERVATION_MODIFIER", 102, 110], ["endocytic machineries", "OBSERVATION", 130, 151], ["penetration", "OBSERVATION_MODIFIER", 203, 214]]], ["Uncoating has been studied in detail for just a few viruses, but what has been learned is that the processes are variable, complicated, and full of surprises [26], [27], [28].Receptors and membrane domainsAmong the most important virus\u2013host interactions are those between the incoming virus and receptors and co-receptors in the plasma membrane.", [["membrane", "ANATOMY", 189, 197], ["plasma membrane", "ANATOMY", 329, 344], ["membrane", "CELLULAR_COMPONENT", 189, 197], ["plasma membrane", "CELLULAR_COMPONENT", 329, 344], ["membrane domains", "PROTEIN", 189, 205], ["co-receptors", "PROTEIN", 309, 321], ["a few viruses", "PROBLEM", 46, 59], ["Receptors and membrane domains", "PROBLEM", 175, 205], ["viruses", "OBSERVATION", 52, 59], ["membrane domains", "OBSERVATION", 189, 205], ["plasma membrane", "ANATOMY", 329, 344]]], ["Some of the contacts provide attachment only, while others promote signaling, induce plasma membrane ruffling, activate endocytosis, and trigger changes in the viral particle [28].", [["plasma membrane", "ANATOMY", 85, 100], ["plasma membrane", "CELLULAR_COMPONENT", 85, 100], ["plasma membrane ruffling", "PROBLEM", 85, 109], ["activate endocytosis", "PROBLEM", 111, 131], ["trigger changes", "PROBLEM", 137, 152]]], ["For many viruses, these early events are defining features for species and cell tropism in vivo and in tissue culture [29].", [["cell", "ANATOMY", 75, 79], ["tissue culture", "ANATOMY", 103, 117], ["cell", "CELL", 75, 79], ["tissue", "TISSUE", 103, 109], ["many viruses", "PROBLEM", 4, 16], ["species", "PROBLEM", 63, 70], ["cell tropism", "PROBLEM", 75, 87], ["tissue culture", "TEST", 103, 117], ["viruses", "OBSERVATION", 9, 16], ["cell tropism", "OBSERVATION", 75, 87]]], ["While the presence of attachment factors and receptors alone does not guarantee infection, it is clear that cells that do not support binding of a virus cannot be infected.Receptors and membrane domainsThat infection is limited to specific tissues and cell types and has many consequences.", [["cells", "ANATOMY", 108, 113], ["membrane", "ANATOMY", 186, 194], ["tissues", "ANATOMY", 240, 247], ["cell", "ANATOMY", 252, 256], ["infection", "DISEASE", 80, 89], ["infection", "DISEASE", 207, 216], ["cells", "CELL", 108, 113], ["membrane", "CELLULAR_COMPONENT", 186, 194], ["tissues", "TISSUE", 240, 247], ["cell", "CELL", 252, 256], ["attachment factors", "PROTEIN", 22, 40], ["membrane domains", "PROTEIN", 186, 202], ["attachment factors", "PROBLEM", 22, 40], ["infection", "PROBLEM", 80, 89], ["a virus", "PROBLEM", 145, 152], ["Receptors and membrane domains", "PROBLEM", 172, 202], ["That infection", "PROBLEM", 202, 216], ["infection", "OBSERVATION", 80, 89], ["virus", "OBSERVATION", 147, 152], ["membrane domains", "OBSERVATION", 186, 202], ["infection", "OBSERVATION", 207, 216], ["cell types", "OBSERVATION", 252, 262]]], ["For example, it determines the pathogenesis of disease, it limits the damage caused by the infection on the host, and it defines mechanisms of transmission.", [["infection", "DISEASE", 91, 100], ["disease", "PROBLEM", 47, 54], ["the damage", "PROBLEM", 66, 76], ["the infection", "PROBLEM", 87, 100], ["disease", "OBSERVATION", 47, 54], ["infection", "OBSERVATION", 91, 100]]], ["In addition, the receptors hold the key to many downstream events in entry such as signaling, endocytosis, penetration, and uncoating.Receptors and membrane domainsWithout discussing the role of receptors during virus entry\u2014a huge topic by itself\u2014in further depth, there is one emerging aspect that I would like mention.", [["membrane", "ANATOMY", 148, 156], ["membrane", "CELLULAR_COMPONENT", 148, 156], ["membrane domains", "PROTEIN", 148, 164], ["penetration", "PROBLEM", 107, 118], ["Receptors and membrane domains", "PROBLEM", 134, 164], ["membrane domains", "OBSERVATION", 148, 164]]], ["It is related to the fact that the plasma membrane contains a dynamic mosaic of domains and microclusters of different size and composition [30], [31].", [["plasma membrane", "ANATOMY", 35, 50], ["plasma membrane", "CELLULAR_COMPONENT", 35, 50], ["microclusters", "CELLULAR_COMPONENT", 92, 105], ["the plasma membrane", "TEST", 31, 50], ["plasma membrane", "OBSERVATION", 35, 50], ["dynamic mosaic", "OBSERVATION", 62, 76], ["different", "OBSERVATION_MODIFIER", 109, 118], ["size", "OBSERVATION_MODIFIER", 119, 123]]], ["Being multivalent, viruses are likely to have a higher probability of binding to microdomains that contain pre-clustered receptors, and to induce further clustering or remodeling of such domains.", [["microdomains", "ANATOMY", 81, 93], ["pre-clustered receptors", "PROTEIN", 107, 130], ["pre-clustered receptors", "TREATMENT", 107, 130], ["remodeling of such domains", "PROBLEM", 168, 194], ["viruses", "OBSERVATION", 19, 26]]], ["The outcome may result in formation of \u201cplatforms\u201d that can trigger virus modification, endocytosis, signaling, and other events [32].Receptors and membrane domainsThe issue of microdomains is particularly relevant for a wide range of viruses including HIV-1, human cytomegalovirus, human papilloma virus, hepatitis C, influenza, and corona viruses, that depend on tetraspanins such as CD9, CD63, CD81, and CD151 for efficient infection [33].", [["membrane", "ANATOMY", 148, 156], ["microdomains", "ANATOMY", 177, 189], ["human cytomegalovirus", "DISEASE", 260, 281], ["human papilloma virus", "DISEASE", 283, 304], ["hepatitis C", "DISEASE", 306, 317], ["influenza", "DISEASE", 319, 328], ["infection", "DISEASE", 427, 436], ["membrane", "CELLULAR_COMPONENT", 148, 156], ["HIV-1", "ORGANISM", 253, 258], ["human cytomegalovirus", "ORGANISM", 260, 281], ["human papilloma virus", "ORGANISM", 283, 304], ["hepatitis C", "ORGANISM", 306, 317], ["influenza", "ORGANISM", 319, 328], ["corona viruses", "ORGANISM", 334, 348], ["tetraspanins", "GENE_OR_GENE_PRODUCT", 365, 377], ["CD9", "GENE_OR_GENE_PRODUCT", 386, 389], ["CD63", "GENE_OR_GENE_PRODUCT", 391, 395], ["CD81", "GENE_OR_GENE_PRODUCT", 397, 401], ["CD151", "GENE_OR_GENE_PRODUCT", 407, 412], ["membrane domains", "PROTEIN", 148, 164], ["tetraspanins", "PROTEIN", 365, 377], ["CD9", "PROTEIN", 386, 389], ["CD63", "PROTEIN", 391, 395], ["CD81", "PROTEIN", 397, 401], ["CD151", "PROTEIN", 407, 412], ["HIV-1", "SPECIES", 253, 258], ["human", "SPECIES", 260, 265], ["human", "SPECIES", 283, 288], ["papilloma virus", "SPECIES", 289, 304], ["HIV-1", "SPECIES", 253, 258], ["human cytomegalovirus", "SPECIES", 260, 281], ["human papilloma virus", "SPECIES", 283, 304], ["\u201cplatforms", "PROBLEM", 39, 49], ["virus modification", "PROBLEM", 68, 86], ["Receptors and membrane domains", "PROBLEM", 134, 164], ["a wide range of viruses", "PROBLEM", 219, 242], ["HIV", "TEST", 253, 256], ["human cytomegalovirus", "PROBLEM", 260, 281], ["human papilloma virus", "PROBLEM", 283, 304], ["hepatitis C", "PROBLEM", 306, 317], ["influenza", "PROBLEM", 319, 328], ["corona viruses", "PROBLEM", 334, 348], ["tetraspanins", "TREATMENT", 365, 377], ["CD9", "TEST", 386, 389], ["CD63", "TEST", 391, 395], ["CD81", "TEST", 397, 401], ["CD151", "TEST", 407, 412], ["efficient infection", "PROBLEM", 417, 436], ["membrane domains", "OBSERVATION", 148, 164], ["microdomains", "OBSERVATION", 177, 189], ["cytomegalovirus", "OBSERVATION", 266, 281], ["papilloma virus", "OBSERVATION", 289, 304], ["corona viruses", "ANATOMY", 334, 348]]], ["In the plasma membrane, tetraspanins are known to organize locally into dynamic, ordered clusters and microdomains (tetraspanin-enriched microdomains) that contain, in addition to tetraspanins, selections of surface proteins [34], [35].", [["plasma membrane", "ANATOMY", 7, 22], ["microdomains", "ANATOMY", 102, 114], ["microdomains", "ANATOMY", 137, 149], ["surface", "ANATOMY", 208, 215], ["plasma membrane", "CELLULAR_COMPONENT", 7, 22], ["tetraspanins", "GENE_OR_GENE_PRODUCT", 24, 36], ["microdomains", "CELLULAR_COMPONENT", 102, 114], ["tetraspanin", "GENE_OR_GENE_PRODUCT", 116, 127], ["microdomains", "CELLULAR_COMPONENT", 137, 149], ["tetraspanins", "GENE_OR_GENE_PRODUCT", 180, 192], ["tetraspanins", "PROTEIN", 24, 36], ["tetraspanin-enriched microdomains", "PROTEIN", 116, 149], ["tetraspanins", "PROTEIN", 180, 192], ["surface proteins", "PROTEIN", 208, 224], ["microdomains (tetraspanin-enriched microdomains", "TREATMENT", 102, 149], ["surface proteins", "TEST", 208, 224], ["plasma membrane", "ANATOMY", 7, 22]]], ["Tetraspanin-enriched microdomains play a role in cell adhesion, migration, fusion, signaling, vesicle traffic, and other processes.", [["microdomains", "ANATOMY", 21, 33], ["cell", "ANATOMY", 49, 53], ["vesicle", "ANATOMY", 94, 101], ["Tetraspanin", "CHEMICAL", 0, 11], ["Tetraspanin", "GENE_OR_GENE_PRODUCT", 0, 11], ["microdomains", "CELLULAR_COMPONENT", 21, 33], ["cell", "CELL", 49, 53], ["vesicle", "CELLULAR_COMPONENT", 94, 101], ["Tetraspanin", "PROTEIN", 0, 11], ["Tetraspanin-enriched microdomains", "TREATMENT", 0, 33], ["a role in cell adhesion", "TREATMENT", 39, 62], ["migration, fusion", "TREATMENT", 64, 81], ["enriched microdomains", "OBSERVATION", 12, 33], ["cell adhesion", "OBSERVATION", 49, 62], ["vesicle traffic", "OBSERVATION", 94, 109]]], ["Also in virus infection, they seem to have multiple functions including receptor presentation, exposure of viruses to proteolytic activators, signaling, clathrin-independent endocytosis, and post-endocytic events such as endosome maturation [33].", [["endosome", "ANATOMY", 221, 229], ["infection", "DISEASE", 14, 23], ["clathrin", "GENE_OR_GENE_PRODUCT", 153, 161], ["endosome", "CELLULAR_COMPONENT", 221, 229], ["proteolytic activators", "PROTEIN", 118, 140], ["clathrin", "PROTEIN", 153, 161], ["virus infection", "PROBLEM", 8, 23], ["receptor presentation", "PROBLEM", 72, 93], ["viruses", "PROBLEM", 107, 114], ["proteolytic activators", "PROBLEM", 118, 140], ["clathrin-independent endocytosis", "PROBLEM", 153, 185], ["post-endocytic events", "PROBLEM", 191, 212], ["virus infection", "OBSERVATION", 8, 23]]], ["It is not clear to what extent viruses actually interact with tetraspanins directly.Receptors and membrane domainsRecent work on Middle East respiratory syndrome virus illustrates some of the consequences of tetraspanins in infection.", [["membrane", "ANATOMY", 98, 106], ["Middle East respiratory syndrome virus", "DISEASE", 129, 167], ["infection", "DISEASE", 224, 233], ["tetraspanins", "GENE_OR_GENE_PRODUCT", 62, 74], ["membrane", "CELLULAR_COMPONENT", 98, 106], ["Middle East respiratory syndrome virus", "ORGANISM", 129, 167], ["tetraspanins", "GENE_OR_GENE_PRODUCT", 208, 220], ["tetraspanins", "PROTEIN", 62, 74], ["membrane domains", "PROTEIN", 98, 114], ["tetraspanins", "PROTEIN", 208, 220], ["Middle East respiratory syndrome virus", "SPECIES", 129, 167], ["Receptors and membrane domains", "PROBLEM", 84, 114], ["Recent work on Middle East respiratory syndrome virus", "PROBLEM", 114, 167], ["tetraspanins in infection", "PROBLEM", 208, 233], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15], ["membrane domains", "OBSERVATION", 98, 114], ["Middle", "ANATOMY_MODIFIER", 129, 135], ["respiratory syndrome", "OBSERVATION", 141, 161], ["infection", "OBSERVATION", 224, 233]]], ["In addition to its bona fide receptor (DPP2), this corona virus requires exposure to protease; either a TTSP family member on the plasma membrane or cathepsins in endolysosomes.", [["plasma membrane", "ANATOMY", 130, 145], ["bona fide receptor", "GENE_OR_GENE_PRODUCT", 19, 37], ["DPP2", "GENE_OR_GENE_PRODUCT", 39, 43], ["corona virus", "ORGANISM", 51, 63], ["TTSP", "GENE_OR_GENE_PRODUCT", 104, 108], ["plasma membrane", "CELLULAR_COMPONENT", 130, 145], ["cathepsins", "GENE_OR_GENE_PRODUCT", 149, 159], ["bona fide receptor", "PROTEIN", 19, 37], ["DPP2", "PROTEIN", 39, 43], ["protease", "PROTEIN", 85, 93], ["TTSP family member", "PROTEIN", 104, 122], ["cathepsins", "PROTEIN", 149, 159], ["this corona virus", "PROBLEM", 46, 63], ["protease", "TREATMENT", 85, 93], ["the plasma membrane", "TREATMENT", 126, 145], ["cathepsins in endolysosomes", "TREATMENT", 149, 176]]], ["These cleave the viral fusion protein and activate membrane fusion.", [["membrane", "ANATOMY", 51, 59], ["membrane", "CELLULAR_COMPONENT", 51, 59], ["viral fusion protein", "PROTEIN", 17, 37], ["the viral fusion protein", "TREATMENT", 13, 37], ["activate membrane fusion", "TREATMENT", 42, 66], ["viral fusion", "OBSERVATION", 17, 29], ["membrane fusion", "OBSERVATION", 51, 66]]], ["Studies with mouse lung-adapted Middle East respiratory syndrome virus in tissue culture and in vivo show that infection efficiency is elevated by tetraspanin CD9 because it links the DPP2 and TMPRSS2 (a TTPS protease) into a ternary complex [36].", [["lung", "ANATOMY", 19, 23], ["tissue culture", "ANATOMY", 74, 88], ["respiratory syndrome", "DISEASE", 44, 64], ["infection", "DISEASE", 111, 120], ["mouse", "ORGANISM", 13, 18], ["lung", "ORGAN", 19, 23], ["-adapted Middle East respiratory syndrome virus", "ORGANISM", 23, 70], ["tissue culture", "CELL", 74, 88], ["tetraspanin", "GENE_OR_GENE_PRODUCT", 147, 158], ["CD9", "GENE_OR_GENE_PRODUCT", 159, 162], ["DPP2", "GENE_OR_GENE_PRODUCT", 184, 188], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 193, 200], ["TTPS protease", "GENE_OR_GENE_PRODUCT", 204, 217], ["tetraspanin CD9", "PROTEIN", 147, 162], ["DPP2", "PROTEIN", 184, 188], ["TMPRSS2", "PROTEIN", 193, 200], ["TTPS protease", "PROTEIN", 204, 217], ["ternary complex", "PROTEIN", 226, 241], ["mouse", "SPECIES", 13, 18], ["mouse", "SPECIES", 13, 18], ["Middle East respiratory syndrome virus", "SPECIES", 32, 70], ["Studies", "TEST", 0, 7], ["mouse lung", "PROBLEM", 13, 23], ["Middle East respiratory syndrome virus", "PROBLEM", 32, 70], ["tissue culture", "TEST", 74, 88], ["infection efficiency", "PROBLEM", 111, 131], ["tetraspanin CD9", "TREATMENT", 147, 162], ["the DPP2", "TEST", 180, 188], ["TMPRSS2", "TEST", 193, 200], ["a TTPS protease", "TREATMENT", 202, 217], ["lung", "ANATOMY", 19, 23], ["Middle", "ANATOMY_MODIFIER", 32, 38], ["respiratory syndrome", "OBSERVATION", 44, 64], ["infection", "OBSERVATION", 111, 120]]], ["That these entry factors are associated with each other and concentrated in microdomains ensures rapid processing of incoming virus, efficient infection, and higher virulence.", [["microdomains", "ANATOMY", 76, 88], ["infection", "DISEASE", 143, 152], ["entry factors", "PROTEIN", 11, 24], ["incoming virus", "PROBLEM", 117, 131], ["efficient infection", "PROBLEM", 133, 152], ["higher virulence", "PROBLEM", 158, 174], ["infection", "OBSERVATION", 143, 152], ["higher", "OBSERVATION_MODIFIER", 158, 164], ["virulence", "OBSERVATION_MODIFIER", 165, 174]]], ["Clinical isolates of the related human coronavirus-229E also require CD9.", [["human", "ORGANISM", 33, 38], ["coronavirus-229E", "ORGANISM", 39, 55], ["CD9", "GENE_OR_GENE_PRODUCT", 69, 72], ["CD9", "PROTEIN", 69, 72], ["human", "SPECIES", 33, 38], ["coronavirus", "SPECIES", 39, 50], ["human coronavirus-229E", "SPECIES", 33, 55], ["the related human coronavirus", "PROBLEM", 21, 50]]], ["Unlike tissue culture adapted strains, they prefer activation by TMPRSS2 on the cell surface over activation by cathepsin L in late endocytic compartments [37].", [["tissue culture", "ANATOMY", 7, 21], ["cell surface", "ANATOMY", 80, 92], ["endocytic compartments", "ANATOMY", 132, 154], ["tissue culture", "CELL", 7, 21], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 65, 72], ["cell surface", "CELLULAR_COMPONENT", 80, 92], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 112, 123], ["TMPRSS2", "PROTEIN", 65, 72], ["cathepsin L", "PROTEIN", 112, 123], ["tissue culture", "TEST", 7, 21]]], ["A likely explanation is that by elevating the concentration of receptor and TMPRSS2 locally, CD9 promotes early activation, which in turn allows entry without passage into late endocytic compartments.", [["endocytic compartments", "ANATOMY", 177, 199], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 76, 83], ["CD9", "GENE_OR_GENE_PRODUCT", 93, 96], ["endocytic compartments", "CELLULAR_COMPONENT", 177, 199], ["TMPRSS2", "PROTEIN", 76, 83], ["CD9", "PROTEIN", 93, 96], ["receptor and TMPRSS2 locally", "TREATMENT", 63, 91], ["likely explanation is", "UNCERTAINTY", 2, 23], ["endocytic compartments", "OBSERVATION", 177, 199]]], ["The virus avoids inactivation, exposure to interferon induced factors, and detection by Toll-like receptors that can activate cellular innate immunity.Endocytosis and endosomesIt was initially thought that viruses serve as passive cargo for ongoing cellular endocytic processes.", [["cellular", "ANATOMY", 126, 134], ["endosomes", "ANATOMY", 167, 176], ["cellular", "ANATOMY", 249, 257], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 88, 107], ["cellular", "CELL", 126, 134], ["endosomes", "CELLULAR_COMPONENT", 167, 176], ["cellular", "CELL", 249, 257], ["interferon induced factors", "PROTEIN", 43, 69], ["Toll-like receptors", "PROTEIN", 88, 107], ["The virus avoids inactivation", "PROBLEM", 0, 29], ["interferon induced factors", "TREATMENT", 43, 69], ["Endocytosis and endosomes", "PROBLEM", 151, 176], ["viruses", "PROBLEM", 206, 213], ["ongoing cellular endocytic processes", "PROBLEM", 241, 277], ["virus", "OBSERVATION", 4, 9], ["endosomes", "OBSERVATION", 167, 176], ["viruses", "OBSERVATION", 206, 213], ["cellular endocytic processes", "OBSERVATION", 249, 277]]], ["It is now apparent that a majority of them trigger internalization by activating endocytic processes such as macro- and micropinocytosis or by inducing clathrin coat formation [22], [38], [39].", [["clathrin", "GENE_OR_GENE_PRODUCT", 152, 160], ["clathrin", "PROTEIN", 152, 160], ["activating endocytic processes", "PROBLEM", 70, 100], ["macro- and micropinocytosis", "PROBLEM", 109, 136], ["inducing clathrin coat formation", "PROBLEM", 143, 175]]], ["They do this by activating signaling pathways through direct or indirect contacts with cell surface molecules and structures.Endocytosis and endosomesIn the case of macropinocytosis, activation involves receptor tyrosine kinases, integrins, and other signaling receptors via exposed phosphatidyl serine (PS) in the viral envelope membrane.", [["cell surface", "ANATOMY", 87, 99], ["endosomes", "ANATOMY", 141, 150], ["membrane", "ANATOMY", 330, 338], ["tyrosine", "CHEMICAL", 212, 220], ["phosphatidyl serine", "CHEMICAL", 283, 302], ["tyrosine", "CHEMICAL", 212, 220], ["phosphatidyl serine", "CHEMICAL", 283, 302], ["cell surface molecules", "CELLULAR_COMPONENT", 87, 109], ["endosomes", "CELLULAR_COMPONENT", 141, 150], ["receptor tyrosine kinases", "GENE_OR_GENE_PRODUCT", 203, 228], ["integrins", "GENE_OR_GENE_PRODUCT", 230, 239], ["phosphatidyl serine", "SIMPLE_CHEMICAL", 283, 302], ["PS", "SIMPLE_CHEMICAL", 304, 306], ["membrane", "CELLULAR_COMPONENT", 330, 338], ["cell surface molecules", "PROTEIN", 87, 109], ["receptor tyrosine kinases", "PROTEIN", 203, 228], ["integrins", "PROTEIN", 230, 239], ["signaling receptors", "PROTEIN", 251, 270], ["Endocytosis and endosomes", "PROBLEM", 125, 150], ["macropinocytosis", "PROBLEM", 165, 181], ["receptor tyrosine kinases", "TREATMENT", 203, 228], ["integrins", "TREATMENT", 230, 239], ["exposed phosphatidyl serine", "TREATMENT", 275, 302], ["endosomes", "OBSERVATION", 141, 150], ["macropinocytosis", "OBSERVATION", 165, 181], ["viral", "OBSERVATION", 315, 320], ["envelope membrane", "OBSERVATION", 321, 338]]], ["The PS is recognized by PS-binding proteins such as members of the TIM/TAM family [39].", [["PS-binding proteins", "GENE_OR_GENE_PRODUCT", 24, 43], ["TIM", "GENE_OR_GENE_PRODUCT", 67, 70], ["TAM", "GENE_OR_GENE_PRODUCT", 71, 74], ["PS-binding proteins", "PROTEIN", 24, 43], ["TIM", "PROTEIN", 67, 70], ["TAM family", "PROTEIN", 71, 81]]], ["Transmembrane signals can be also triggered by receptor clustering and perhaps by induction of membrane curvature.", [["membrane", "ANATOMY", 95, 103], ["membrane", "CELLULAR_COMPONENT", 95, 103], ["Transmembrane signals", "TEST", 0, 21], ["receptor clustering", "PROBLEM", 47, 66], ["membrane curvature", "OBSERVATION", 95, 113]]], ["Comprehensive loss-of-function screens (e.g., siRNA, CRISPR-Cas9, etc.) and other studies indicate that hundreds of cellular proteins are involved in the complex signaling, membrane deformation, and vesicle scission events [40], [41].Endocytosis and endosomesWhen endocytosis first emerged as a mechanism of virus entry, little was known about the pathway from the primary endocytic vesicles to the final destination, the lysosome.", [["cellular", "ANATOMY", 116, 124], ["membrane", "ANATOMY", 173, 181], ["vesicle", "ANATOMY", 199, 206], ["endosomes", "ANATOMY", 250, 259], ["endocytic vesicles", "ANATOMY", 373, 391], ["lysosome", "ANATOMY", 422, 430], ["CRISPR-Cas9", "GENE_OR_GENE_PRODUCT", 53, 64], ["cellular", "CELL", 116, 124], ["membrane", "CELLULAR_COMPONENT", 173, 181], ["vesicle", "CELLULAR_COMPONENT", 199, 206], ["endosomes", "CELLULAR_COMPONENT", 250, 259], ["endocytic vesicles", "CELLULAR_COMPONENT", 373, 391], ["lysosome", "CELLULAR_COMPONENT", 422, 430], ["CRISPR", "DNA", 53, 59], ["cellular proteins", "PROTEIN", 116, 133], ["siRNA", "TEST", 46, 51], ["CRISPR", "TEST", 53, 59], ["other studies", "TEST", 76, 89], ["cellular proteins", "PROBLEM", 116, 133], ["membrane deformation", "PROBLEM", 173, 193], ["vesicle scission events", "PROBLEM", 199, 222], ["Endocytosis and endosomes", "PROBLEM", 234, 259], ["virus entry", "PROBLEM", 308, 319], ["cellular proteins", "OBSERVATION", 116, 133], ["membrane deformation", "OBSERVATION", 173, 193], ["vesicle scission", "OBSERVATION", 199, 215], ["endosomes", "OBSERVATION", 250, 259], ["lysosome", "OBSERVATION", 422, 430]]], ["To those of us who followed viruses after endocytosis, it was clear that coated vesicles did not deliver the virus particles and other cargo directly to lysosomes but rather to uncoated, large vacuoles largely devoid of luminal material.", [["vesicles", "ANATOMY", 80, 88], ["lysosomes", "ANATOMY", 153, 162], ["vacuoles", "ANATOMY", 193, 201], ["luminal material", "ANATOMY", 220, 236], ["luminal", "CHEMICAL", 220, 227], ["vesicles", "CELLULAR_COMPONENT", 80, 88], ["lysosomes", "CELLULAR_COMPONENT", 153, 162], ["vacuoles", "CELLULAR_COMPONENT", 193, 201], ["luminal material", "CELLULAR_COMPONENT", 220, 236], ["endocytosis", "PROBLEM", 42, 53], ["coated vesicles", "PROBLEM", 73, 88], ["the virus particles", "TREATMENT", 105, 124], ["large vacuoles", "PROBLEM", 187, 201], ["large", "OBSERVATION_MODIFIER", 187, 192], ["vacuoles", "OBSERVATION", 193, 201], ["luminal material", "OBSERVATION", 220, 236]]], ["We started calling these endosomes, a term still used today for these important organelles [43].", [["endosomes", "ANATOMY", 25, 34], ["organelles", "ANATOMY", 80, 90], ["endosomes", "CELLULAR_COMPONENT", 25, 34]]], ["We could later demonstrate that being acidic they were sites of virus penetration [44].PenetrationThe transfer of a virus or a capsid through a membrane into the cytosol constitutes a critical step in the entry program.", [["membrane", "ANATOMY", 144, 152], ["cytosol", "ANATOMY", 162, 169], ["membrane", "CELLULAR_COMPONENT", 144, 152], ["cytosol", "CELLULAR_COMPONENT", 162, 169], ["virus penetration", "PROBLEM", 64, 81], ["a virus", "PROBLEM", 114, 121]]], ["When the particle has reached the right location within the cell, the viral particle or components of the virus execute the penetration process often with assistance from cellular factors [25].", [["cell", "ANATOMY", 60, 64], ["cellular", "ANATOMY", 171, 179], ["cell", "CELL", 60, 64], ["cellular", "CELL", 171, 179], ["cellular factors", "PROTEIN", 171, 187], ["the viral particle", "PROBLEM", 66, 84], ["the virus", "PROBLEM", 102, 111], ["right", "ANATOMY_MODIFIER", 34, 39], ["cell", "ANATOMY", 60, 64], ["viral particle", "OBSERVATION", 70, 84], ["virus", "OBSERVATION", 106, 111]]], ["The location can be the plasma membrane, the organelles of the endocytic network (early endosome, late endosome, maturing endosome, recycling endosome, macropinosome, and endolysosome), or an organelle connected through membrane traffic with the endocytic network such as trans-Golgi network and endoplasmic reticulum.PenetrationMost commonly, the cues that trigger penetration include low pH in endocytic vacuoles, specific molecular interactions with receptors, proteolytic cleavages, and interaction with molecular chaperones [28].", [["plasma membrane", "ANATOMY", 24, 39], ["organelles", "ANATOMY", 45, 55], ["endocytic network", "ANATOMY", 63, 80], ["early endosome", "ANATOMY", 82, 96], ["late endosome", "ANATOMY", 98, 111], ["endosome", "ANATOMY", 122, 130], ["recycling endosome", "ANATOMY", 132, 150], ["macropinosome", "ANATOMY", 152, 165], ["endolysosome", "ANATOMY", 171, 183], ["organelle", "ANATOMY", 192, 201], ["membrane", "ANATOMY", 220, 228], ["endocytic network", "ANATOMY", 246, 263], ["Golgi network", "ANATOMY", 278, 291], ["endoplasmic reticulum", "ANATOMY", 296, 317], ["endocytic vacuoles", "ANATOMY", 396, 414], ["plasma membrane", "CELLULAR_COMPONENT", 24, 39], ["organelles", "CELLULAR_COMPONENT", 45, 55], ["endocytic network", "CELLULAR_COMPONENT", 63, 80], ["early endosome", "CELLULAR_COMPONENT", 82, 96], ["late endosome", "CELLULAR_COMPONENT", 98, 111], ["maturing endosome", "CELLULAR_COMPONENT", 113, 130], ["recycling endosome", "CELLULAR_COMPONENT", 132, 150], ["macropinosome", "CELLULAR_COMPONENT", 152, 165], ["endolysosome", "CELLULAR_COMPONENT", 171, 183], ["organelle", "CELLULAR_COMPONENT", 192, 201], ["membrane", "CELLULAR_COMPONENT", 220, 228], ["endocytic network", "CELLULAR_COMPONENT", 246, 263], ["Golgi network", "CELLULAR_COMPONENT", 278, 291], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 296, 317], ["endocytic vacuoles", "CELLULAR_COMPONENT", 396, 414], ["macropinosome", "PROTEIN", 152, 165], ["endolysosome", "PROTEIN", 171, 183], ["trans-Golgi network", "PROTEIN", 272, 291], ["molecular chaperones", "PROTEIN", 508, 528], ["low pH in endocytic vacuoles", "PROBLEM", 386, 414], ["receptors", "TREATMENT", 453, 462], ["proteolytic cleavages", "TREATMENT", 464, 485], ["endocytic network", "OBSERVATION", 63, 80], ["endoplasmic reticulum", "OBSERVATION", 296, 317]]], ["The cues induce changes in the viruses or in metastable viral proteins activating the penetration modus.", [["metastable viral proteins", "PROTEIN", 45, 70], ["the viruses", "PROBLEM", 27, 38], ["metastable viral proteins", "PROBLEM", 45, 70], ["the penetration modus", "PROBLEM", 82, 103], ["viruses", "OBSERVATION", 31, 38], ["metastable", "OBSERVATION_MODIFIER", 45, 55], ["viral proteins", "OBSERVATION", 56, 70], ["penetration modus", "OBSERVATION", 86, 103]]], ["Enveloped viruses penetrate by membrane fusion, non-enveloped virus by membrane lysis or by the formation of transmembrane pores of different sizes.PenetrationViral membrane fusion proteins were the first fusogenic proteins identified and analyzed [45].", [["membrane", "ANATOMY", 31, 39], ["membrane", "ANATOMY", 71, 79], ["transmembrane pores", "ANATOMY", 109, 128], ["membrane", "ANATOMY", 165, 173], ["membrane", "CELLULAR_COMPONENT", 31, 39], ["non-enveloped virus", "ORGANISM", 48, 67], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["transmembrane pores", "CELLULAR_COMPONENT", 109, 128], ["PenetrationViral membrane fusion proteins", "PROTEIN", 148, 189], ["fusogenic proteins", "PROTEIN", 205, 223], ["membrane fusion", "TREATMENT", 31, 46], ["non-enveloped virus", "PROBLEM", 48, 67], ["membrane lysis", "TREATMENT", 71, 85], ["PenetrationViral membrane fusion proteins", "PROBLEM", 148, 189], ["viruses", "OBSERVATION", 10, 17], ["membrane fusion", "OBSERVATION", 31, 46], ["membrane lysis", "OBSERVATION", 71, 85], ["transmembrane pores", "OBSERVATION", 109, 128], ["different", "OBSERVATION_MODIFIER", 132, 141], ["sizes", "OBSERVATION_MODIFIER", 142, 147], ["fusion proteins", "OBSERVATION", 174, 189]]], ["Detailed studies over many years have provided evidence for a general mechanism of action, in which the fusion proteins first bind to the target membrane and bridge the gap between the two membranes.", [["membrane", "ANATOMY", 145, 153], ["membranes", "ANATOMY", 189, 198], ["membrane", "CELLULAR_COMPONENT", 145, 153], ["membranes", "CELLULAR_COMPONENT", 189, 198], ["fusion proteins", "PROTEIN", 104, 119], ["Detailed studies", "TEST", 0, 16], ["the fusion proteins", "TREATMENT", 100, 119], ["two membranes", "ANATOMY_MODIFIER", 185, 198]]], ["By undergoing further conformational changes, they force the two bilayer surfaces locally together resulting in hemifusion followed by full fusion and stalk-pore formation [46], [47].PenetrationWhen cellular fusion proteins were later identified and analyzed in presynaptic vesicle fusion and other intracellular fusion events, it was found that they work by a similar mechanism [48].", [["stalk-pore", "ANATOMY", 151, 161], ["cellular", "ANATOMY", 199, 207], ["presynaptic vesicle", "ANATOMY", 262, 281], ["intracellular", "ANATOMY", 299, 312], ["cellular", "CELL", 199, 207], ["presynaptic vesicle", "CELLULAR_COMPONENT", 262, 281], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 299, 312], ["cellular fusion proteins", "PROTEIN", 199, 223], ["further conformational changes", "PROBLEM", 14, 44], ["PenetrationWhen cellular fusion proteins", "PROBLEM", 183, 223], ["presynaptic vesicle fusion", "TREATMENT", 262, 288], ["other intracellular fusion events", "PROBLEM", 293, 326], ["fusion proteins", "OBSERVATION", 208, 223], ["vesicle fusion", "OBSERVATION", 274, 288], ["intracellular fusion", "OBSERVATION", 299, 319]]], ["It is now clear that some cellular proteins involved in cell\u2013cell fusion events, in fact, represent structural homologs of class I and II viral fusogens [49].", [["cellular", "ANATOMY", 26, 34], ["cell\u2013cell", "ANATOMY", 56, 65], ["cellular", "CELL", 26, 34], ["cell\u2013cell", "CELL", 56, 65], ["class I", "GENE_OR_GENE_PRODUCT", 123, 130], ["cellular proteins", "PROTEIN", 26, 43], ["some cellular proteins", "PROBLEM", 21, 43], ["cell\u2013cell fusion events", "PROBLEM", 56, 79], ["clear", "OBSERVATION", 10, 15], ["cellular proteins", "OBSERVATION", 26, 43], ["cell\u2013cell fusion", "OBSERVATION", 56, 72]]], ["Syncytins that form syncytiothrophoblasts during placenta development are derived from retroviral class I viral proteins [50], [51].", [["syncytiothrophoblasts", "ANATOMY", 20, 41], ["placenta", "ANATOMY", 49, 57], ["Syncytins", "GENE_OR_GENE_PRODUCT", 0, 9], ["placenta", "ORGAN", 49, 57], ["Syncytins", "PROTEIN", 0, 9], ["retroviral class I viral proteins", "PROTEIN", 87, 120], ["Syncytins", "TREATMENT", 0, 9], ["viral proteins", "TEST", 106, 120]]], ["The FF proteins involved in cell\u2013cell fusion in nematodes are structural homologs of class II viral proteins.", [["cell\u2013cell", "ANATOMY", 28, 37], ["FF", "GENE_OR_GENE_PRODUCT", 4, 6], ["cell\u2013cell", "GENE_OR_GENE_PRODUCT", 28, 37], ["class II viral proteins", "GENE_OR_GENE_PRODUCT", 85, 108], ["FF proteins", "PROTEIN", 4, 15], ["class II viral proteins", "PROTEIN", 85, 108], ["The FF proteins", "TEST", 0, 15], ["cell\u2013cell fusion", "TREATMENT", 28, 44], ["class II viral proteins", "PROBLEM", 85, 108], ["cell\u2013cell fusion", "OBSERVATION", 28, 44]]], ["Most recently, HAP2 in unicellular eukaryotes and flowering plants has been found to fuse gametes.", [["gametes", "ANATOMY", 90, 97], ["HAP2", "CHEMICAL", 15, 19], ["HAP2", "GENE_OR_GENE_PRODUCT", 15, 19], ["gametes", "CELLULAR_COMPONENT", 90, 97], ["HAP2", "PROTEIN", 15, 19], ["unicellular eukaryotes", "OBSERVATION", 23, 45], ["flowering plants", "OBSERVATION", 50, 66]]], ["It has a structure similar to class II viral fusion proteins [52], [53].The role of endosome maturationThe endosomal network comprises organelles with multiple functions, cellular locations, and properties.", [["endosome", "ANATOMY", 84, 92], ["endosomal network", "ANATOMY", 107, 124], ["organelles", "ANATOMY", 135, 145], ["cellular", "ANATOMY", 171, 179], ["endosome", "CELLULAR_COMPONENT", 84, 92], ["endosomal network", "CELLULAR_COMPONENT", 107, 124], ["organelles", "CELLULAR_COMPONENT", 135, 145], ["cellular", "CELL", 171, 179], ["class II viral fusion proteins", "PROTEIN", 30, 60], ["II viral fusion proteins", "TEST", 36, 60], ["viral fusion", "OBSERVATION", 39, 51], ["endosome maturation", "OBSERVATION", 84, 103]]], ["Due to the logistics of the network, organelles do not represent fixed entities: they undergo a variety of fusion/fission events and a complex maturation process that alters their characteristics dramatically [54], [55].", [["organelles", "ANATOMY", 37, 47], ["organelles", "CELLULAR_COMPONENT", 37, 47], ["fusion/fission events", "TREATMENT", 107, 128], ["a complex maturation process", "PROBLEM", 133, 161]]], ["In addition to gradual drop in intraluminal pH of endosomes, the process involves intraluminal vesicle formation, transport to the perinuclear region, Rab-switching, phosphatidyl inositolphosphate conversion, acquisition of lysosomal proteins and hydrolases and many other changes before they finally fuse with lysosomes.The role of endosome maturationAn incoming virus particle is therefore exposed to a continuously changing environment, and it has to respond to it properly.", [["intraluminal", "ANATOMY", 31, 43], ["endosomes", "ANATOMY", 50, 59], ["intraluminal vesicle", "ANATOMY", 82, 102], ["perinuclear region", "ANATOMY", 131, 149], ["lysosomal", "ANATOMY", 224, 233], ["lysosomes", "ANATOMY", 311, 320], ["endosome", "ANATOMY", 333, 341], ["phosphatidyl inositolphosphate", "CHEMICAL", 166, 196], ["phosphatidyl inositolphosphate", "CHEMICAL", 166, 196], ["intraluminal", "IMMATERIAL_ANATOMICAL_ENTITY", 31, 43], ["endosomes", "CELLULAR_COMPONENT", 50, 59], ["intraluminal vesicle", "CELLULAR_COMPONENT", 82, 102], ["perinuclear region", "CELLULAR_COMPONENT", 131, 149], ["Rab-", "GENE_OR_GENE_PRODUCT", 151, 155], ["phosphatidyl inositolphosphate", "SIMPLE_CHEMICAL", 166, 196], ["lysosomes", "CELLULAR_COMPONENT", 311, 320], ["endosome", "CELLULAR_COMPONENT", 333, 341], ["lysosomal proteins", "PROTEIN", 224, 242], ["hydrolases", "PROTEIN", 247, 257], ["gradual drop in intraluminal pH of endosomes", "PROBLEM", 15, 59], ["intraluminal vesicle formation", "PROBLEM", 82, 112], ["phosphatidyl inositolphosphate conversion", "TREATMENT", 166, 207], ["lysosomal proteins", "TREATMENT", 224, 242], ["hydrolases", "TREATMENT", 247, 257], ["An incoming virus particle", "PROBLEM", 352, 378], ["gradual", "OBSERVATION_MODIFIER", 15, 22], ["drop", "OBSERVATION_MODIFIER", 23, 27], ["intraluminal", "ANATOMY_MODIFIER", 31, 43], ["pH of endosomes", "OBSERVATION", 44, 59], ["intraluminal", "ANATOMY_MODIFIER", 82, 94], ["vesicle formation", "OBSERVATION", 95, 112], ["perinuclear", "ANATOMY_MODIFIER", 131, 142], ["lysosomal proteins", "OBSERVATION", 224, 242], ["endosome maturation", "OBSERVATION", 333, 352], ["virus particle", "OBSERVATION", 364, 378]]], ["When the trigger for membrane fusion and penetration involves low pH, the threshold pH is the main factor defining the location and timing of the penetration event [56], [57], [58].", [["membrane", "ANATOMY", 21, 29], ["membrane", "CELLULAR_COMPONENT", 21, 29], ["membrane fusion", "TREATMENT", 21, 36], ["low pH", "PROBLEM", 62, 68], ["the threshold pH", "TEST", 70, 86]]], ["Rhabdo- and alphaviruses undergo acid-activated fusion in early endosomes where the pH is about 6.2.", [["early endosomes", "ANATOMY", 58, 73], ["alphaviruses", "ORGANISM", 12, 24], ["early endosomes", "CELLULAR_COMPONENT", 58, 73], ["Rhabdo", "PROBLEM", 0, 6], ["alphaviruses", "TREATMENT", 12, 24], ["acid-activated fusion", "TREATMENT", 33, 54], ["the pH", "TEST", 80, 86], ["acid-activated fusion", "OBSERVATION", 33, 54]]], ["When the threshold pH is below 6.0 as it is for influenza A virus, delivery to late compartments is required.", [["late compartments", "ANATOMY", 79, 96], ["influenza A virus", "ORGANISM", 48, 65], ["influenza A virus", "SPECIES", 48, 65], ["the threshold pH", "TEST", 5, 21], ["influenza A virus", "PROBLEM", 48, 65]]], ["For such late penetrating viruses timing becomes critical because the viruses risk inactivation by proteases prior to penetration [59].The role of endosome maturationThe pH in endosomes is regulated in complex ways by cellular factors [60].", [["endosome", "ANATOMY", 147, 155], ["endosomes", "ANATOMY", 176, 185], ["cellular", "ANATOMY", 218, 226], ["endosome", "CELLULAR_COMPONENT", 147, 155], ["endosomes", "CELLULAR_COMPONENT", 176, 185], ["cellular", "CELL", 218, 226], ["proteases", "PROTEIN", 99, 108], ["cellular factors", "PROTEIN", 218, 234], ["such late penetrating viruses timing", "PROBLEM", 4, 40], ["the viruses risk inactivation", "PROBLEM", 66, 95], ["penetrating", "OBSERVATION_MODIFIER", 14, 25], ["viruses", "OBSERVATION", 26, 33], ["endosome maturation", "OBSERVATION", 147, 166]]], ["Interesting, new studies suggest that some incoming viruses can take advantage of cellular factors to adjust their pH threshold so that fusion can occur earlier [61].", [["cellular", "ANATOMY", 82, 90], ["cellular", "CELL", 82, 90], ["cellular factors", "PROTEIN", 82, 98], ["new studies", "TEST", 13, 24], ["some incoming viruses", "PROBLEM", 38, 59], ["their pH threshold", "TREATMENT", 109, 127], ["viruses", "OBSERVATION", 52, 59]]], ["For Lassa virus, this occurs when the virus interacts with an intracellular receptor, LAMP1, a glycoprotein in the endosome/macropinosome membrane [62].", [["intracellular", "ANATOMY", 62, 75], ["endosome", "ANATOMY", 115, 123], ["macropinosome membrane", "ANATOMY", 124, 146], ["Lassa virus", "ORGANISM", 4, 15], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 62, 75], ["LAMP1", "GENE_OR_GENE_PRODUCT", 86, 91], ["endosome", "CELLULAR_COMPONENT", 115, 123], ["macropinosome membrane", "CELLULAR_COMPONENT", 124, 146], ["intracellular receptor", "PROTEIN", 62, 84], ["LAMP1", "PROTEIN", 86, 91], ["glycoprotein", "PROTEIN", 95, 107], ["Lassa virus", "SPECIES", 4, 15], ["Lassa virus", "SPECIES", 4, 15], ["Lassa virus", "PROBLEM", 4, 15], ["the virus", "PROBLEM", 34, 43], ["a glycoprotein in the endosome/macropinosome membrane", "TREATMENT", 93, 146]]], ["Other viruses have been shown to depend on UVRAG, a cellular protein that controls SNARE complex assembly in homotypic late endosome fusion and delays lysosomal delivery of cargo and possibly exposure to immune recognition [63].The role of endosome maturationLate penetrating viruses are generally dependent on proper maturation of endosomes and macropinosomes.", [["cellular", "ANATOMY", 52, 60], ["late endosome", "ANATOMY", 119, 132], ["lysosomal", "ANATOMY", 151, 160], ["endosome", "ANATOMY", 240, 248], ["endosomes", "ANATOMY", 332, 341], ["UVRAG", "GENE_OR_GENE_PRODUCT", 43, 48], ["cellular", "CELL", 52, 60], ["SNARE", "GENE_OR_GENE_PRODUCT", 83, 88], ["late endosome", "CELLULAR_COMPONENT", 119, 132], ["lysosomal", "CELLULAR_COMPONENT", 151, 160], ["endosome", "CELLULAR_COMPONENT", 240, 248], ["endosomes", "CELLULAR_COMPONENT", 332, 341], ["macropinosomes", "CELLULAR_COMPONENT", 346, 360], ["UVRAG", "PROTEIN", 43, 48], ["cellular protein", "PROTEIN", 52, 68], ["SNARE complex", "PROTEIN", 83, 96], ["macropinosomes", "PROTEIN", 346, 360], ["Other viruses", "PROBLEM", 0, 13], ["a cellular protein", "TREATMENT", 50, 68], ["homotypic late endosome fusion", "TREATMENT", 109, 139], ["lysosomal delivery of cargo", "TREATMENT", 151, 178], ["endosome maturationLate penetrating viruses", "PROBLEM", 240, 283], ["viruses", "OBSERVATION", 6, 13], ["endosome fusion", "OBSERVATION", 124, 139], ["penetrating viruses", "OBSERVATION", 264, 283], ["dependent", "OBSERVATION_MODIFIER", 298, 307]]], ["This means that perturbations that inhibit the process of endosome conversion to late endosome (or multivesicular body) block infection.", [["endosome", "ANATOMY", 58, 66], ["late endosome", "ANATOMY", 81, 94], ["multivesicular body", "ANATOMY", 99, 118], ["infection", "DISEASE", 126, 135], ["endosome", "CELLULAR_COMPONENT", 58, 66], ["late endosome", "CELLULAR_COMPONENT", 81, 94], ["multivesicular body", "CELLULAR_COMPONENT", 99, 118], ["endosome conversion", "TREATMENT", 58, 77], ["late endosome", "PROBLEM", 81, 94], ["multivesicular body) block infection", "PROBLEM", 99, 135], ["multivesicular", "ANATOMY_MODIFIER", 99, 113], ["body", "ANATOMY", 114, 118], ["infection", "OBSERVATION", 126, 135]]], ["Treatments that affect any component in endosome/macropinosome maturation program can cause entry inhibition because events during maturation are tightly coordinated and interdependent.", [["endosome", "ANATOMY", 40, 48], ["macropinosome", "ANATOMY", 49, 62], ["endosome", "CELLULAR_COMPONENT", 40, 48], ["macropinosome", "CELLULAR_COMPONENT", 49, 62], ["Treatments", "TREATMENT", 0, 10], ["endosome/macropinosome maturation program", "TREATMENT", 40, 81], ["entry inhibition", "PROBLEM", 92, 108]]], ["In our work with influenza A virus, we observed that interference with endosome movement along microtubules or with intraluminal vesicle formation by the ESCRT complexes prevents proper penetration and capsid uncoating [64], [65], [66].Variation and redundancyIn many recent studies, it is shown that mechanisms and virus cell interactions during entry are more flexible and variable than anticipated from results obtained using tissue culture-adapted virus strains and standard tissue culture cell lines.", [["endosome", "ANATOMY", 71, 79], ["microtubules", "ANATOMY", 95, 107], ["intraluminal vesicle", "ANATOMY", 116, 136], ["cell", "ANATOMY", 322, 326], ["tissue culture cell lines", "ANATOMY", 479, 504], ["influenza A virus", "ORGANISM", 17, 34], ["endosome", "CELLULAR_COMPONENT", 71, 79], ["microtubules", "CELLULAR_COMPONENT", 95, 107], ["intraluminal vesicle", "CELLULAR_COMPONENT", 116, 136], ["ESCRT", "GENE_OR_GENE_PRODUCT", 154, 159], ["virus cell", "CELL", 316, 326], ["tissue culture cell lines", "CELL", 479, 504], ["ESCRT complexes", "PROTEIN", 154, 169], ["standard tissue culture cell lines", "CELL_LINE", 470, 504], ["influenza A virus", "SPECIES", 17, 34], ["influenza A virus", "SPECIES", 17, 34], ["influenza A virus", "PROBLEM", 17, 34], ["intraluminal vesicle formation", "PROBLEM", 116, 146], ["the ESCRT complexes", "TREATMENT", 150, 169], ["proper penetration", "PROBLEM", 179, 197], ["Variation and redundancy", "PROBLEM", 236, 260], ["virus cell interactions", "PROBLEM", 316, 339], ["tissue culture", "TEST", 429, 443], ["adapted virus strains", "TREATMENT", 444, 465], ["standard tissue culture cell lines", "TREATMENT", 470, 504], ["intraluminal", "ANATOMY_MODIFIER", 116, 128], ["vesicle formation", "OBSERVATION", 129, 146], ["ESCRT complexes", "OBSERVATION", 154, 169], ["redundancy", "OBSERVATION_MODIFIER", 250, 260], ["virus cell", "OBSERVATION", 316, 326], ["cell lines", "OBSERVATION", 494, 504]]], ["It turns out that many viruses can use alternative receptors and entry mechanisms depending on cell type and virus strain.", [["cell", "ANATOMY", 95, 99], ["cell type", "CELL", 95, 104], ["many viruses", "PROBLEM", 18, 30], ["alternative receptors", "TREATMENT", 39, 60], ["entry mechanisms", "PROBLEM", 65, 81], ["cell type and virus strain", "PROBLEM", 95, 121], ["viruses", "OBSERVATION", 23, 30]]], ["For the same virus, entry into highly polarized cell types such as neurons and endothelial cells is, for example, often different from entry into non-polarized cells like fibroblast and T cells.", [["cell", "ANATOMY", 48, 52], ["neurons", "ANATOMY", 67, 74], ["endothelial cells", "ANATOMY", 79, 96], ["cells", "ANATOMY", 160, 165], ["fibroblast", "ANATOMY", 171, 181], ["T cells", "ANATOMY", 186, 193], ["cell", "CELL", 48, 52], ["neurons", "CELL", 67, 74], ["endothelial cells", "CELL", 79, 96], ["cells", "CELL", 160, 165], ["fibroblast", "CELL", 171, 181], ["T cells", "CELL", 186, 193], ["neurons", "CELL_TYPE", 67, 74], ["endothelial cells", "CELL_TYPE", 79, 96], ["non-polarized cells", "CELL_TYPE", 146, 165], ["fibroblast", "CELL_TYPE", 171, 181], ["T cells", "CELL_TYPE", 186, 193], ["the same virus", "PROBLEM", 4, 18], ["neurons and endothelial cells", "PROBLEM", 67, 96], ["fibroblast and T cells", "PROBLEM", 171, 193], ["highly polarized", "OBSERVATION_MODIFIER", 31, 47], ["cell types", "OBSERVATION", 48, 58], ["endothelial cells", "OBSERVATION", 79, 96], ["non-polarized cells", "OBSERVATION", 146, 165], ["fibroblast", "OBSERVATION_MODIFIER", 171, 181]]], ["During evolution, viruses have apparently adjusted and fine-tuned their properties to match the life style, physiology, anatomy, and biology of host organisms and host cells.", [["cells", "ANATOMY", 168, 173], ["host cells", "CELL", 163, 173], ["host cells", "CELL_TYPE", 163, 173], ["viruses", "PROBLEM", 18, 25], ["viruses", "OBSERVATION", 18, 25], ["host cells", "OBSERVATION", 163, 173]]], ["Flexibility, plasticity, and the existence of parallel and alternative pathways are true manifestations of viral life style and a serious challenge in future studies.Variation and redundancyBefore approaching the issue of redundancy in more detail, it may be useful to consider some examples.", [["viral life style", "TREATMENT", 107, 123], ["future studies", "TEST", 151, 165], ["Variation and redundancy", "PROBLEM", 166, 190], ["redundancy", "OBSERVATION_MODIFIER", 180, 190], ["redundancy", "OBSERVATION", 222, 232]]], ["From a large number of relevant reports in the literature, I have highlighted some in Table 2.", [["large", "OBSERVATION_MODIFIER", 7, 12], ["number", "OBSERVATION_MODIFIER", 13, 19]]], ["They illustrate various aspects of the phenomenon.Variation and redundancyThus, instead of a single fixed entry program, many viruses can utilize alternative receptors and entry pathways [69], [78], [80].", [["Variation and redundancy", "PROBLEM", 50, 74], ["a single fixed entry program", "TREATMENT", 91, 119], ["many viruses", "PROBLEM", 121, 133], ["redundancy", "OBSERVATION_MODIFIER", 64, 74]]], ["The mechanisms can occur in parallel in the same cells, or they may operate in different cell types, host species, and under different conditions.", [["cells", "ANATOMY", 49, 54], ["cell", "ANATOMY", 89, 93], ["cells", "CELL", 49, 54], ["cell", "CELL", 89, 93], ["different cell types", "OBSERVATION", 79, 99]]], ["Some viruses carry separate surface proteins that allow them to bind to different receptors [69].", [["surface", "ANATOMY", 28, 35], ["surface proteins", "PROTEIN", 28, 44], ["Some viruses carry separate surface proteins", "PROBLEM", 0, 44], ["viruses", "OBSERVATION", 5, 12]]], ["Also, like gD in herpes simplex virus, a single surface protein may bind to multiple receptors [81].Variation and redundancySome viruses that can fuse directly at the plasma membrane may in addition employ different forms of endocytosis.", [["surface", "ANATOMY", 48, 55], ["plasma membrane", "ANATOMY", 167, 182], ["herpes simplex virus", "DISEASE", 17, 37], ["gD", "GENE_OR_GENE_PRODUCT", 11, 13], ["herpes simplex virus", "ORGANISM", 17, 37], ["plasma membrane", "CELLULAR_COMPONENT", 167, 182], ["gD", "PROTEIN", 11, 13], ["herpes simplex virus", "SPECIES", 17, 37], ["herpes simplex virus", "SPECIES", 17, 37], ["gD in herpes simplex virus", "PROBLEM", 11, 37], ["a single surface protein", "TREATMENT", 39, 63], ["Variation and redundancy", "PROBLEM", 100, 124], ["Some viruses", "PROBLEM", 124, 136], ["endocytosis", "PROBLEM", 225, 236], ["gD", "OBSERVATION_MODIFIER", 11, 13], ["herpes simplex virus", "OBSERVATION", 17, 37], ["redundancy", "OBSERVATION_MODIFIER", 114, 124], ["viruses", "OBSERVATION", 129, 136], ["plasma membrane", "ANATOMY", 167, 182], ["endocytosis", "OBSERVATION", 225, 236]]], ["Epstein\u2013Barr virus is a good example; a receptor on B cells mediates entry by direct fusion, while another one in epithelial cells leads to micropinocytosis and acid-independent intracellular fusion [67].", [["B cells", "ANATOMY", 52, 59], ["epithelial cells", "ANATOMY", 114, 130], ["intracellular", "ANATOMY", 178, 191], ["Epstein\u2013Barr virus", "ORGANISM", 0, 18], ["B cells", "CELL", 52, 59], ["epithelial cells", "CELL", 114, 130], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 178, 191], ["B cells", "CELL_TYPE", 52, 59], ["epithelial cells", "CELL_TYPE", 114, 130], ["Epstein\u2013Barr virus", "SPECIES", 0, 18], ["Epstein\u2013Barr virus", "PROBLEM", 0, 18], ["a receptor on B cells", "TREATMENT", 38, 59], ["direct fusion", "TREATMENT", 78, 91], ["micropinocytosis", "PROBLEM", 140, 156], ["acid-independent intracellular fusion", "PROBLEM", 161, 198], ["Barr virus", "OBSERVATION", 8, 18], ["epithelial cells", "OBSERVATION", 114, 130], ["intracellular fusion", "OBSERVATION", 178, 198]]], ["Generally, influenza A virus internalization in tissue culture cells occurs by parallel clathrin-mediated endocytosis and micropinocytosis [70].", [["tissue culture cells", "ANATOMY", 48, 68], ["influenza A virus", "ORGANISM", 11, 28], ["tissue culture cells", "CELL", 48, 68], ["clathrin", "GENE_OR_GENE_PRODUCT", 88, 96], ["tissue culture cells", "CELL_LINE", 48, 68], ["clathrin", "PROTEIN", 88, 96], ["influenza A virus", "SPECIES", 11, 28], ["influenza", "PROBLEM", 11, 20], ["tissue culture cells", "TEST", 48, 68], ["parallel clathrin", "PROBLEM", 79, 96], ["mediated endocytosis", "PROBLEM", 97, 117], ["micropinocytosis", "PROBLEM", 122, 138]]], ["Sometimes, the activation of penetration by alternative cues, such as low pH or proteolytic cleavage, depend on cell line or virus strain [37].", [["cell line", "ANATOMY", 112, 121], ["cell line", "CELL", 112, 121], ["low pH", "PROBLEM", 70, 76], ["proteolytic cleavage", "TREATMENT", 80, 100], ["cell line", "TREATMENT", 112, 121], ["virus strain", "PROBLEM", 125, 137], ["cell line", "OBSERVATION", 112, 121]]], ["The pathway by which the virus negotiates the endocytic network in the cell may involve alternative routes and penetration compartments as shown by the rhinovirus example in Table 2[79].Variation and redundancyViruses continue to evolve by adapting to changing conditions and host cells.", [["cell", "ANATOMY", 71, 75], ["cells", "ANATOMY", 281, 286], ["cell", "CELL", 71, 75], ["host cells", "CELL", 276, 286], ["host cells", "CELL_TYPE", 276, 286], ["the virus", "PROBLEM", 21, 30], ["Variation and redundancy", "PROBLEM", 186, 210], ["Viruses", "PROBLEM", 210, 217], ["endocytic network", "OBSERVATION", 46, 63], ["redundancy", "OBSERVATION_MODIFIER", 200, 210], ["host cells", "OBSERVATION", 276, 286]]], ["This happens for example during adaptation to tissue culture or vaccine production [82], [83].", [["tissue culture", "ANATOMY", 46, 60], ["tissue", "TISSUE", 46, 52], ["tissue culture", "TEST", 46, 60], ["vaccine production", "PROBLEM", 64, 82]]], ["For RNA viruses, the mechanism usually involves accumulation of adaptive mutations and enrichment of mutant quasi-species with better fitness [84].", [["RNA viruses", "PROBLEM", 4, 15], ["adaptive mutations", "PROBLEM", 64, 82], ["mutant quasi-species", "PROBLEM", 101, 121], ["RNA viruses", "OBSERVATION", 4, 15], ["adaptive mutations", "OBSERVATION", 64, 82]]], ["Adaptation may not only manifest itself by increased binding to attachment factors such as heparin sulfate proteoglycans, but also by receptor switching and changes in host range [85].", [["heparin sulfate", "CHEMICAL", 91, 106], ["heparin sulfate proteoglycans", "GENE_OR_GENE_PRODUCT", 91, 120], ["attachment factors", "PROTEIN", 64, 82], ["heparin sulfate proteoglycans", "PROTEIN", 91, 120], ["attachment factors", "PROBLEM", 64, 82], ["heparin sulfate proteoglycans", "TREATMENT", 91, 120]]], ["As viruses acquire properties that make them more efficient in tissue culture, they usually lose infectivity in primary target cells and pathogenicity.Ubiquitous attachment factorsMany viruses make use of attachment factors and receptors that are widely or ubiquitously expressed [86].", [["tissue culture", "ANATOMY", 63, 77], ["cells", "ANATOMY", 127, 132], ["tissue culture", "CELL", 63, 77], ["cells", "CELL", 127, 132], ["primary target cells", "CELL_TYPE", 112, 132], ["attachment factors", "PROTEIN", 162, 180], ["attachment factors", "PROTEIN", 205, 223], ["tissue culture", "TEST", 63, 77], ["pathogenicity", "PROBLEM", 137, 150], ["Ubiquitous attachment factors", "PROBLEM", 151, 180], ["target cells", "OBSERVATION", 120, 132], ["viruses", "OBSERVATION", 185, 192]]], ["By possessing sialic acid binding glycoproteins, paramyxo- and myxoviruses provide extreme examples of this.", [["sialic acid", "CHEMICAL", 14, 25], ["sialic acid", "CHEMICAL", 14, 25], ["sialic acid", "SIMPLE_CHEMICAL", 14, 25], ["sialic acid binding glycoproteins", "PROTEIN", 14, 47], ["possessing sialic acid binding glycoproteins", "TREATMENT", 3, 47], ["paramyxo", "TREATMENT", 49, 57], ["myxoviruses", "TREATMENT", 63, 74]]], ["Since sialic acid is present on practically all cell types and hundreds of cell surface glycoproteins and lipids, these viruses can bind almost everywhere.", [["cell", "ANATOMY", 48, 52], ["cell surface", "ANATOMY", 75, 87], ["sialic acid", "CHEMICAL", 6, 17], ["sialic acid", "CHEMICAL", 6, 17], ["sialic acid", "SIMPLE_CHEMICAL", 6, 17], ["cell", "CELL", 48, 52], ["cell surface glycoproteins", "CELLULAR_COMPONENT", 75, 101], ["lipids", "CELLULAR_COMPONENT", 106, 112], ["cell surface glycoproteins", "PROTEIN", 75, 101], ["sialic acid", "PROBLEM", 6, 17], ["cell surface glycoproteins", "TREATMENT", 75, 101], ["lipids", "TREATMENT", 106, 112], ["sialic acid", "OBSERVATION", 6, 17]]], ["Cell and tissue tropism is, however, often still limited due to requirements for specific glycosidic linkages and modifications of the sialic acids as well as to cell factors such as proteases required for activation of fusion proteins and to host immune responses [87], [88], [89].", [["Cell", "ANATOMY", 0, 4], ["tissue", "ANATOMY", 9, 15], ["cell", "ANATOMY", 162, 166], ["sialic acids", "CHEMICAL", 135, 147], ["sialic acids", "CHEMICAL", 135, 147], ["Cell", "CELL", 0, 4], ["tissue", "TISSUE", 9, 15], ["sialic acids", "SIMPLE_CHEMICAL", 135, 147], ["cell", "CELL", 162, 166], ["cell factors", "PROTEIN", 162, 174], ["proteases", "PROTEIN", 183, 192], ["fusion proteins", "PROTEIN", 220, 235], ["specific glycosidic linkages", "TREATMENT", 81, 109], ["the sialic acids", "TREATMENT", 131, 147], ["proteases", "TREATMENT", 183, 192], ["activation of fusion proteins", "TREATMENT", 206, 235], ["tissue tropism", "OBSERVATION", 9, 23]]], ["For influenza virus, there is evidence that attachment to sialic acid alone is not sufficient for infection; one or more specific co-receptors are required [73].", [["influenza virus", "DISEASE", 4, 19], ["sialic acid", "CHEMICAL", 58, 69], ["infection", "DISEASE", 98, 107], ["sialic acid", "CHEMICAL", 58, 69], ["influenza virus", "ORGANISM", 4, 19], ["sialic acid", "SIMPLE_CHEMICAL", 58, 69], ["influenza virus", "SPECIES", 4, 19], ["influenza virus", "SPECIES", 4, 19], ["influenza virus", "PROBLEM", 4, 19], ["sialic acid alone", "TREATMENT", 58, 75], ["infection", "PROBLEM", 98, 107], ["infection", "OBSERVATION", 98, 107]]], ["Through these supplementary interactions, the virus may activate downstream receptor tyrosine kinases or other signaling- and endocytosis-activating receptors [90].Ubiquitous attachment factorsGlycosaminoglycans (GAGs) constitute widely distributed glycoconjugates that serve as attachment factors for many different enveloped and non-enveloped viruses in cell culture and in tissues [91].", [["cell culture", "ANATOMY", 356, 368], ["tissues", "ANATOMY", 376, 383], ["tyrosine", "CHEMICAL", 85, 93], ["tyrosine", "CHEMICAL", 85, 93], ["receptor tyrosine kinases", "GENE_OR_GENE_PRODUCT", 76, 101], ["Glycosaminoglycans", "GENE_OR_GENE_PRODUCT", 193, 211], ["GAGs", "GENE_OR_GENE_PRODUCT", 213, 217], ["cell", "CELL", 356, 360], ["tissues", "TISSUE", 376, 383], ["downstream receptor tyrosine kinases", "PROTEIN", 65, 101], ["endocytosis-activating receptors", "PROTEIN", 126, 158], ["attachment factors", "PROTEIN", 175, 193], ["Glycosaminoglycans", "PROTEIN", 193, 211], ["GAGs", "PROTEIN", 213, 217], ["attachment factors", "PROTEIN", 279, 297], ["the virus", "TREATMENT", 42, 51], ["downstream receptor tyrosine kinases", "TREATMENT", 65, 101], ["Glycosaminoglycans (GAGs)", "TREATMENT", 193, 218], ["widely distributed glycoconjugates", "PROBLEM", 230, 264], ["attachment factors", "PROBLEM", 279, 297], ["many different enveloped", "PROBLEM", 302, 326], ["non-enveloped viruses", "PROBLEM", 331, 352], ["cell culture", "TEST", 356, 368]]], ["Although GAGs are generally not absolutely required for infection, they play a significant role in increasing efficiency and influencing cell specificity.", [["cell", "ANATOMY", 137, 141], ["infection", "DISEASE", 56, 65], ["GAGs", "GENE_OR_GENE_PRODUCT", 9, 13], ["cell", "CELL", 137, 141], ["infection", "PROBLEM", 56, 65], ["increasing efficiency", "PROBLEM", 99, 120], ["infection", "OBSERVATION", 56, 65]]], ["In many cases, interaction with these highly negatively charged and heterogeneous surface glycoconjugates is promoted by clusters of positive charges in viral surface proteins.", [["surface glycoconjugates", "ANATOMY", 82, 105], ["surface", "ANATOMY", 159, 166], ["viral surface proteins", "PROTEIN", 153, 175], ["heterogeneous surface glycoconjugates", "PROBLEM", 68, 105], ["positive charges in viral surface proteins", "PROBLEM", 133, 175], ["heterogeneous", "OBSERVATION_MODIFIER", 68, 81], ["positive charges", "OBSERVATION", 133, 149]]], ["Binding to GAGs is usually followed by association with cognate receptors and co-receptors for productive entry [69].", [["GAGs", "GENE_OR_GENE_PRODUCT", 11, 15], ["cognate receptors", "PROTEIN", 56, 73], ["co-receptors", "PROTEIN", 78, 90]]], ["Increased binding to GAGs often occurs during adaptation of RNA viruses to tissue culture cells, and it often involves loss of pathogenicity [83], [92].Viral glycans interact with cellular receptorsSome cell types carry lectin molecules that capture viruses that have specific glycans.", [["tissue culture cells", "ANATOMY", 75, 95], ["cellular", "ANATOMY", 180, 188], ["cell", "ANATOMY", 203, 207], ["GAGs", "GENE_OR_GENE_PRODUCT", 21, 25], ["tissue culture cells", "CELL", 75, 95], ["cellular", "CELL", 180, 188], ["cell", "CELL", 203, 207], ["tissue culture cells", "CELL_TYPE", 75, 95], ["cellular receptors", "PROTEIN", 180, 198], ["lectin molecules", "PROTEIN", 220, 236], ["Increased binding to GAGs", "PROBLEM", 0, 25], ["RNA viruses", "PROBLEM", 60, 71], ["tissue culture cells", "TEST", 75, 95], ["loss of pathogenicity", "PROBLEM", 119, 140], ["Viral glycans", "PROBLEM", 152, 165], ["cellular receptors", "TREATMENT", 180, 198], ["lectin molecules", "PROBLEM", 220, 236], ["capture viruses", "PROBLEM", 242, 257], ["cell types", "OBSERVATION", 203, 213]]], ["The awkwardly named \u201cdendritic cell specific intercellular adhesion molecule-3 (ICAM-3) grabbing nonintegrin\u201d (DC-SIGN) is one of these lectins [93].", [["dendritic cell", "ANATOMY", 21, 35], ["dendritic cell specific intercellular adhesion molecule-3", "GENE_OR_GENE_PRODUCT", 21, 78], ["ICAM-3", "GENE_OR_GENE_PRODUCT", 80, 86], ["nonintegrin", "GENE_OR_GENE_PRODUCT", 97, 108], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 111, 118], ["dendritic cell specific intercellular adhesion molecule-3 (ICAM-3) grabbing nonintegrin\u201d", "PROTEIN", 21, 109], ["DC", "PROTEIN", 111, 113], ["SIGN", "PROTEIN", 114, 118], ["intercellular adhesion molecule", "TEST", 45, 76], ["ICAM", "TEST", 80, 84], ["these lectins", "TEST", 130, 143], ["dendritic cell", "OBSERVATION", 21, 35], ["intercellular adhesion", "OBSERVATION", 45, 67]]], ["It binds and internalizes a broad range of viruses that carry high mannose N-linked glycans in their envelope glycoproteins.", [["mannose", "CHEMICAL", 67, 74], ["N", "CHEMICAL", 75, 76], ["mannose N-linked glycans", "PROTEIN", 67, 91], ["envelope glycoproteins", "PROTEIN", 101, 123], ["a broad range of viruses", "PROBLEM", 26, 50], ["broad", "OBSERVATION_MODIFIER", 28, 33], ["viruses", "OBSERVATION", 43, 50]]], ["Viruses introduced into the skin through insect bites and other mechanisms take advantage of DC-SIGN in dendritic cells to promote dissemination from peripheral tissues to lymphoid organs [94].", [["skin", "ANATOMY", 28, 32], ["DC", "ANATOMY", 93, 95], ["dendritic cells", "ANATOMY", 104, 119], ["peripheral tissues", "ANATOMY", 150, 168], ["lymphoid organs", "ANATOMY", 172, 187], ["insect bites", "DISEASE", 41, 53], ["skin", "ORGAN", 28, 32], ["DC-SIGN", "CELL", 93, 100], ["dendritic cells", "CELL", 104, 119], ["peripheral tissues", "TISSUE", 150, 168], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 172, 187], ["DC", "CELL_TYPE", 93, 95], ["SIGN", "PROTEIN", 96, 100], ["dendritic cells", "CELL_TYPE", 104, 119], ["Viruses", "TREATMENT", 0, 7], ["dendritic cells", "PROBLEM", 104, 119], ["skin", "ANATOMY", 28, 32], ["dendritic cells", "OBSERVATION", 104, 119], ["peripheral", "ANATOMY_MODIFIER", 150, 160], ["tissues", "ANATOMY", 161, 168], ["lymphoid organs", "OBSERVATION", 172, 187]]], ["We have observed DC-SIGN clustering by surface-bound bunya viruses in real time followed by internalization via clathrin-mediated endocytosis [76].", [["DC", "ANATOMY", 17, 19], ["surface", "ANATOMY", 39, 46], ["SIGN", "GENE_OR_GENE_PRODUCT", 20, 24], ["clathrin", "GENE_OR_GENE_PRODUCT", 112, 120], ["DC", "CELL_TYPE", 17, 19], ["SIGN", "PROTEIN", 20, 24], ["clathrin", "PROTEIN", 112, 120], ["bound bunya viruses", "PROBLEM", 47, 66]]], ["In this case, the lectin not only serves as an attachment factor but as an authentic receptor.Viral heterogeneityDifferent physical forms of virus particles such as filamentous versus spherical may in some cases lead to different entry mechanisms.", [["lectin", "GENE_OR_GENE_PRODUCT", 18, 24], ["lectin", "PROTEIN", 18, 24], ["attachment factor", "PROTEIN", 47, 64], ["Viral heterogeneity", "PROBLEM", 94, 113], ["virus particles", "PROBLEM", 141, 156], ["heterogeneity", "OBSERVATION", 100, 113], ["virus particles", "OBSERVATION", 141, 156]]], ["Influenza viruses occur in two forms: spherical and filamentous.", [["Influenza viruses", "DISEASE", 0, 17], ["Influenza viruses", "ORGANISM", 0, 17], ["Influenza viruses", "PROBLEM", 0, 17], ["viruses", "OBSERVATION", 10, 17], ["spherical", "OBSERVATION_MODIFIER", 38, 47], ["filamentous", "OBSERVATION_MODIFIER", 52, 63]]], ["While the spherical particles mainly enter via clathrin-mediated endocytosis and micropinocytosis, the larger filamentous forms use macropinocytosis [95], [96].", [["clathrin", "GENE_OR_GENE_PRODUCT", 47, 55], ["clathrin", "PROTEIN", 47, 55], ["micropinocytosis", "PROBLEM", 81, 97], ["macropinocytosis", "TEST", 132, 148], ["spherical", "OBSERVATION_MODIFIER", 10, 19], ["particles", "OBSERVATION_MODIFIER", 20, 29], ["endocytosis", "OBSERVATION_MODIFIER", 65, 76], ["larger", "OBSERVATION_MODIFIER", 103, 109], ["filamentous", "OBSERVATION_MODIFIER", 110, 121]]], ["The particles are presumably too large to use the other two mechanisms.", [["particles", "OBSERVATION", 4, 13], ["presumably", "UNCERTAINTY", 18, 28], ["too large", "OBSERVATION_MODIFIER", 29, 38]]], ["A consideration seldom addressed in virus entry studies is the possibility that virus aggregates may enter cells by mechanisms other than single particles [97], [98].", [["cells", "ANATOMY", 107, 112], ["cells", "CELL", 107, 112], ["virus entry studies", "TEST", 36, 55], ["virus aggregates", "PROBLEM", 80, 96]]], ["Aggregates may exist in the inoculum or they may form on the cell surface during high multiplicity infection.SummaryIt has been possible to uncover many of the basic pathways and mechanisms that viruses use to enter cells.", [["cell surface", "ANATOMY", 61, 73], ["cells", "ANATOMY", 216, 221], ["infection", "DISEASE", 99, 108], ["cell surface", "CELLULAR_COMPONENT", 61, 73], ["cells", "CELL", 216, 221], ["high multiplicity infection", "PROBLEM", 81, 108], ["inoculum", "OBSERVATION", 28, 36], ["high multiplicity", "OBSERVATION_MODIFIER", 81, 98], ["infection", "OBSERVATION", 99, 108]]], ["Some are now understood in remarkable detail at a cellular and even atomic level.", [["cellular", "ANATOMY", 50, 58], ["cellular", "CELL", 50, 58]]], ["Progress has been possible through the use of multidisciplinary approaches involving methods and concepts from epidemiology, medicine, cell biology, biochemistry, structural biology, systems biology, and so on.SummaryHowever, the deceptive simplicity in structure and composition of viral particles and the limited size of viral genomes conceal a remarkable, built-in complexity that allows viruses to exploit and manipulate host cells and organisms in many sophisticated ways.", [["cell", "ANATOMY", 135, 139], ["cells", "ANATOMY", 430, 435], ["cell", "CELL", 135, 139], ["host cells", "CELL", 425, 435], ["viral genomes", "DNA", 323, 336], ["host cells", "CELL_TYPE", 425, 435], ["multidisciplinary approaches", "TREATMENT", 46, 74], ["viral particles", "PROBLEM", 283, 298], ["viral genomes conceal", "PROBLEM", 323, 344], ["viruses", "PROBLEM", 391, 398], ["host cells", "PROBLEM", 425, 435], ["organisms", "PROBLEM", 440, 449], ["deceptive", "OBSERVATION_MODIFIER", 230, 239], ["simplicity", "OBSERVATION", 240, 250], ["viral particles", "OBSERVATION", 283, 298], ["size", "OBSERVATION_MODIFIER", 315, 319], ["viral genomes", "OBSERVATION", 323, 336]]], ["During cell entry, they profit from deep insights into the broad spectrum of signals and conduits by which cells in multicellular organisms interact with each other and the outside world.", [["cell", "ANATOMY", 7, 11], ["cells", "ANATOMY", 107, 112], ["cell", "CELL", 7, 11], ["cells", "CELL", 107, 112], ["conduits", "TREATMENT", 89, 97], ["conduits", "OBSERVATION", 89, 97], ["multicellular organisms", "OBSERVATION", 116, 139]]], ["Receptors, signaling, endocytosis, and intracellular trafficking are all part of a refined machinery that viruses take advantage of.", [["intracellular", "ANATOMY", 39, 52], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 52], ["endocytosis", "PROBLEM", 22, 33], ["intracellular trafficking", "PROBLEM", 39, 64], ["endocytosis", "OBSERVATION_MODIFIER", 22, 33], ["intracellular trafficking", "OBSERVATION", 39, 64]]], ["Viruses make use of their \u201cinsider information\u201d not only for entry and replication but also to avoid cellular defenses, to support different routes of transmission from organism to organism and between tissues in the body, to provide back-up systems, and to expand and adjust tropism.", [["cellular", "ANATOMY", 101, 109], ["tissues", "ANATOMY", 202, 209], ["body", "ANATOMY", 217, 221], ["cellular", "CELL", 101, 109], ["tissues", "TISSUE", 202, 209], ["body", "ORGANISM_SUBDIVISION", 217, 221], ["cellular defenses", "PROBLEM", 101, 118], ["tropism", "PROBLEM", 276, 283], ["body", "ANATOMY", 217, 221]]], ["That virus/host cell interactions during entry are often redundant and adaptable is a challenge for our efforts to develop antiviral strategies.", [["cell", "ANATOMY", 16, 20], ["host cell", "CELL", 11, 20], ["That virus/host cell interactions", "PROBLEM", 0, 33], ["antiviral strategies", "TREATMENT", 123, 143], ["host cell interactions", "OBSERVATION", 11, 33]]], ["However, it is an inherent part of the life-style of many viruses.", [["many", "OBSERVATION_MODIFIER", 53, 57], ["viruses", "OBSERVATION", 58, 65]]]], "c8a0f5e2ba471fc1199c55215da4c93248418a26": [["In France, as in most countries, strict strategies were implemented in cancer hospitals to reduce the spread of coronavirus (COVID-19), but to maintain as much as possible the capacity of oncology health services [1, 2] .", [["cancer", "ANATOMY", 71, 77], ["cancer", "DISEASE", 71, 77], ["coronavirus", "DISEASE", 112, 123], ["cancer", "CANCER", 71, 77], ["coronavirus", "ORGANISM", 112, 123], ["strict strategies", "TREATMENT", 33, 50], ["coronavirus", "PROBLEM", 112, 123]]], ["These strategies included the reduction of elective services, an emphasis on remote visits, and the use of personal protective equipment [3] [4] [5] [6] [7] .", [["[3] [4] [5] [6] [7]", "SIMPLE_CHEMICAL", 137, 156], ["elective services", "TREATMENT", 43, 60], ["personal protective equipment", "TREATMENT", 107, 136]]], ["International radiation therapy (RT) academic societies proposed to restrict the indications for treatment [8] , to delay as long as possible the start of non-urgent treatments and to prefer hypofractionated regimens [9] [10] [11] [12] [13] [14] [15] [16] .", [["[9] [10] [11] [12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 217, 255], ["International radiation therapy (RT) academic societies", "TREATMENT", 0, 55], ["treatment", "TREATMENT", 97, 106], ["non-urgent treatments", "TREATMENT", 155, 176], ["hypofractionated regimens", "TREATMENT", 191, 216], ["radiation therapy", "OBSERVATION", 14, 31]]], ["To our knowledge, none of these recommendations anticipated how to handle the load of delayed treatments after the lockdown.", [["delayed treatments", "TREATMENT", 86, 104], ["the lockdown", "TREATMENT", 111, 123]]], ["However, the successful management of cancer treatments during lockdown undoubtedly correlates with the successful management of post-lockdown activity overload.", [["cancer", "ANATOMY", 38, 44], ["cancer", "DISEASE", 38, 44], ["cancer", "CANCER", 38, 44], ["cancer treatments", "TREATMENT", 38, 55], ["the successful management", "TREATMENT", 100, 125], ["post-lockdown activity overload", "PROBLEM", 129, 160], ["cancer", "OBSERVATION", 38, 44], ["activity overload", "OBSERVATION", 143, 160]]]], "9f62ec5480a164c459db8fd34012963ea217cfe2": [["IntroductionCoronavirus disease 2019 (COVID- 19) is an official name applied by the World Health Organization (WHO), referring to a recently emerged disease that has now become the pandemic of the twenty-first century.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID- 19", "CHEMICAL", 38, 47], ["IntroductionCoronavirus disease 2019 (COVID- 19", "SPECIES", 0, 47], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31], ["disease", "OBSERVATION", 149, 156]]], ["The responsible virus was named as \"severe acute respiratory syndrome coronavirus 2\" (SARS-CoV-2).", [["acute respiratory syndrome coronavirus", "DISEASE", 43, 81], ["\"severe acute respiratory syndrome coronavirus", "SPECIES", 35, 81], ["SARS-CoV-2", "SPECIES", 86, 96], ["The responsible virus", "PROBLEM", 0, 21], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 36, 81], ["CoV", "TEST", 91, 94], ["virus", "OBSERVATION", 16, 21], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["respiratory syndrome", "OBSERVATION", 49, 69]]], ["The virus causing COVID \u221219 is a SARS-like coronavirus with a 29,903 bp single-stranded RNA (ss-RNA) [1] .IntroductionHuman coronaviruses (HCoV) were identified as one of the main causes of acute upper respiratory tract infections (URTI) in the 1960s [2] .", [["upper respiratory tract", "ANATOMY", 196, 219], ["COVID \u221219", "CHEMICAL", 18, 27], ["SARS-like coronavirus", "DISEASE", 33, 54], ["upper respiratory tract infections", "DISEASE", 196, 230], ["URTI", "DISEASE", 232, 236], ["COVID \u221219", "GENE_OR_GENE_PRODUCT", 18, 27], ["SARS-like coronavirus", "ORGANISM", 33, 54], ["IntroductionHuman coronaviruses", "ORGANISM", 106, 137], ["HCoV", "ORGANISM", 139, 143], ["upper respiratory", "ORGANISM_SUBDIVISION", 196, 213], ["tract", "ORGANISM_SUBDIVISION", 214, 219], ["COVID \u221219", "DNA", 18, 27], ["29,903 bp single-stranded RNA", "DNA", 62, 91], ["coronaviruses", "SPECIES", 124, 137], ["COVID \u221219", "SPECIES", 18, 27], ["HCoV", "SPECIES", 139, 143], ["The virus", "PROBLEM", 0, 9], ["COVID", "TEST", 18, 23], ["a SARS-like coronavirus", "PROBLEM", 31, 54], ["bp", "TEST", 69, 71], ["IntroductionHuman coronaviruses (HCoV", "TREATMENT", 106, 143], ["acute upper respiratory tract infections", "PROBLEM", 190, 230], ["virus", "OBSERVATION", 4, 9], ["main", "OBSERVATION_MODIFIER", 175, 179], ["acute", "OBSERVATION_MODIFIER", 190, 195], ["upper", "ANATOMY_MODIFIER", 196, 201], ["respiratory tract", "ANATOMY", 202, 219], ["infections", "OBSERVATION", 220, 230]]], ["Later, various coronavirus species, including HCoV-NL63, associated with acute laryngotracheitis (croup), were identified [2, 3] .", [["acute laryngotracheitis", "DISEASE", 73, 96], ["croup", "DISEASE", 98, 103], ["coronavirus", "ORGANISM", 15, 26], ["HCoV-NL63", "ORGANISM", 46, 55], ["HCoV", "SPECIES", 46, 50], ["various coronavirus species", "PROBLEM", 7, 34], ["HCoV", "TEST", 46, 50], ["acute laryngotracheitis", "PROBLEM", 73, 96], ["coronavirus species", "OBSERVATION", 15, 34], ["associated with", "UNCERTAINTY", 57, 72], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["laryngotracheitis", "OBSERVATION", 79, 96]]], ["A coronavirus belonging to the 2b \u03b2coronavirus group was detected in 2002 as the cause of severe lower respiratory tract infection (LRTI) in China, named as a severe acute respiratory syndrome (SARS) [4] .", [["lower respiratory tract", "ANATOMY", 97, 120], ["lower respiratory tract infection", "DISEASE", 97, 130], ["LRTI", "DISEASE", 132, 136], ["acute respiratory syndrome", "DISEASE", 166, 192], ["SARS", "DISEASE", 194, 198], ["coronavirus", "ORGANISM", 2, 13], ["2b \u03b2coronavirus", "ORGANISM", 31, 46], ["lower", "ORGANISM_SUBDIVISION", 97, 102], ["respiratory tract", "ORGANISM_SUBDIVISION", 103, 120], ["A coronavirus", "SPECIES", 0, 13], ["A coronavirus belonging", "PROBLEM", 0, 23], ["severe lower respiratory tract infection", "PROBLEM", 90, 130], ["a severe acute respiratory syndrome", "PROBLEM", 157, 192], ["coronavirus", "OBSERVATION", 2, 13], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["lower", "ANATOMY_MODIFIER", 97, 102], ["respiratory tract", "ANATOMY", 103, 120], ["infection", "OBSERVATION", 121, 130], ["severe", "OBSERVATION_MODIFIER", 159, 165], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["respiratory syndrome", "OBSERVATION", 172, 192]]], ["In 2012, another coronavirus belonging to the 2c \u03b2-coronavirus group caused a highly pathogenic LRTI in Saudi Arabia, named Middle East respiratory syndrome (MERS), which became epidemic mainly in the Middle East [5, 6] .", [["LRTI", "DISEASE", 96, 100], ["Middle East respiratory syndrome", "DISEASE", 124, 156], ["MERS", "DISEASE", 158, 162], ["coronavirus", "ORGANISM", 17, 28], ["2c \u03b2-coronavirus", "ORGANISM", 46, 62], ["coronavirus", "SPECIES", 17, 28], ["Middle East respiratory syndrome", "PROBLEM", 124, 156], ["epidemic", "PROBLEM", 178, 186], ["pathogenic", "OBSERVATION_MODIFIER", 85, 95], ["LRTI", "OBSERVATION", 96, 100], ["Middle", "ANATOMY_MODIFIER", 124, 130], ["respiratory syndrome", "OBSERVATION", 136, 156], ["epidemic", "OBSERVATION_MODIFIER", 178, 186], ["Middle", "ANATOMY_MODIFIER", 201, 207]]], ["In these newly emerged groups of coronaviruses, although the main site of involvement in the lower respiratory tract, mild symptoms of URTI have been reported in MERS and SARS [7, 8] .IntroductionSinonasal symptoms in an URTI are due to generalized mucosal edema that is also the reason for olfactory loss encountered during the acute phase of an URTI [9] .", [["lower respiratory tract", "ANATOMY", 93, 116], ["Sinonasal", "ANATOMY", 196, 205], ["mucosal", "ANATOMY", 249, 256], ["olfactory", "ANATOMY", 291, 300], ["URTI", "DISEASE", 135, 139], ["SARS", "DISEASE", 171, 175], ["URTI", "DISEASE", 221, 225], ["edema", "DISEASE", 257, 262], ["olfactory loss", "DISEASE", 291, 305], ["URTI", "DISEASE", 347, 351], ["coronaviruses", "ORGANISM", 33, 46], ["lower", "ORGANISM_SUBDIVISION", 93, 98], ["respiratory tract", "ORGANISM_SUBDIVISION", 99, 116], ["mucosal edema", "PATHOLOGICAL_FORMATION", 249, 262], ["olfactory", "ORGAN", 291, 300], ["coronaviruses", "PROBLEM", 33, 46], ["involvement in the lower respiratory tract", "PROBLEM", 74, 116], ["mild symptoms", "PROBLEM", 118, 131], ["URTI", "PROBLEM", 135, 139], ["Sinonasal symptoms", "PROBLEM", 196, 214], ["an URTI", "PROBLEM", 218, 225], ["generalized mucosal edema", "PROBLEM", 237, 262], ["olfactory loss", "PROBLEM", 291, 305], ["coronaviruses", "OBSERVATION", 33, 46], ["main", "OBSERVATION_MODIFIER", 61, 65], ["involvement", "OBSERVATION", 74, 85], ["lower", "ANATOMY_MODIFIER", 93, 98], ["respiratory tract", "ANATOMY", 99, 116], ["mild", "OBSERVATION_MODIFIER", 118, 122], ["generalized", "OBSERVATION_MODIFIER", 237, 248], ["mucosal", "ANATOMY", 249, 256], ["edema", "OBSERVATION", 257, 262]]], ["However, the olfactory loss may also occur following the resolution of sinonasal symptoms, the entity known as post-viral olfactory loss [10] .", [["olfactory", "ANATOMY", 13, 22], ["sinonasal", "ANATOMY", 71, 80], ["olfactory", "ANATOMY", 122, 131], ["olfactory loss", "DISEASE", 13, 27], ["post-viral olfactory loss", "DISEASE", 111, 136], ["olfactory", "ORGAN", 13, 22], ["sinonasal", "ORGAN", 71, 80], ["olfactory", "ORGAN", 122, 131], ["the olfactory loss", "PROBLEM", 9, 27], ["sinonasal symptoms", "PROBLEM", 71, 89], ["post-viral olfactory loss", "PROBLEM", 111, 136], ["olfactory loss", "OBSERVATION", 13, 27]]], ["Although there are more than 200 subtypes of viruses associated with URTI, not all of which have been studied concerning olfactory loss, influenza or parainfluenza viruses, rhinovirus, picornavirus, human coronavirus, and Epstein-Barr virus are among those that have been mentioned as the cause of post-viral olfactory loss [11] [12] [13] .", [["olfactory", "ANATOMY", 121, 130], ["olfactory", "ANATOMY", 309, 318], ["URTI", "DISEASE", 69, 73], ["olfactory loss", "DISEASE", 121, 135], ["influenza or parainfluenza viruses", "DISEASE", 137, 171], ["human coronavirus", "DISEASE", 199, 216], ["post-viral olfactory loss", "DISEASE", 298, 323], ["olfactory", "ORGAN", 121, 130], ["parainfluenza viruses", "ORGANISM", 150, 171], ["rhinovirus", "ORGANISM", 173, 183], ["human coronavirus", "ORGANISM", 199, 216], ["Epstein-Barr virus", "ORGANISM", 222, 240], ["olfactory", "ORGAN", 309, 318], ["parainfluenza", "SPECIES", 150, 163], ["human", "SPECIES", 199, 204], ["coronavirus", "SPECIES", 205, 216], ["parainfluenza viruses", "SPECIES", 150, 171], ["human coronavirus", "SPECIES", 199, 216], ["Epstein-Barr virus", "SPECIES", 222, 240], ["viruses", "PROBLEM", 45, 52], ["URTI", "PROBLEM", 69, 73], ["olfactory loss", "PROBLEM", 121, 135], ["influenza", "PROBLEM", 137, 146], ["parainfluenza viruses", "PROBLEM", 150, 171], ["rhinovirus", "PROBLEM", 173, 183], ["picornavirus", "PROBLEM", 185, 197], ["human coronavirus", "PROBLEM", 199, 216], ["Epstein-Barr virus", "PROBLEM", 222, 240], ["post-viral olfactory loss", "PROBLEM", 298, 323], ["viruses", "OBSERVATION", 45, 52], ["olfactory loss", "OBSERVATION", 121, 135], ["parainfluenza viruses", "OBSERVATION", 150, 171], ["Barr virus", "OBSERVATION", 230, 240]]], ["Olfactory loss has been identified in very limited case reports in SARS, which was not associated with sinonasal symptoms [14] .", [["Olfactory", "ANATOMY", 0, 9], ["sinonasal", "ANATOMY", 103, 112], ["Olfactory loss", "DISEASE", 0, 14], ["SARS", "DISEASE", 67, 71], ["Olfactory", "ORGAN", 0, 9], ["sinonasal", "ORGAN", 103, 112], ["Olfactory loss", "PROBLEM", 0, 14], ["SARS", "PROBLEM", 67, 71], ["sinonasal symptoms", "PROBLEM", 103, 121], ["loss", "OBSERVATION", 10, 14], ["very", "OBSERVATION_MODIFIER", 38, 42]]], ["It has been suggested that the virus can infect the brain via the nasal cavity epithelium and olfactory pathway in animals infected by MERS-CoV and SARS-CoV [15] .IntroductionSince the outbreak of the COVID-19 in Iran, plenty of patients with olfactory loss have been reported by the otolaryngologists.", [["brain", "ANATOMY", 52, 57], ["nasal cavity epithelium", "ANATOMY", 66, 89], ["olfactory", "ANATOMY", 243, 252], ["SARS", "DISEASE", 148, 152], ["olfactory loss", "DISEASE", 243, 257], ["brain", "ORGAN", 52, 57], ["nasal cavity epithelium", "TISSUE", 66, 89], ["olfactory", "ORGAN", 94, 103], ["MERS-CoV", "ORGANISM", 135, 143], ["SARS-CoV", "ORGANISM", 148, 156], ["patients", "ORGANISM", 229, 237], ["olfactory", "ORGAN", 243, 252], ["patients", "SPECIES", 229, 237], ["MERS-CoV", "SPECIES", 135, 143], ["SARS-CoV", "SPECIES", 148, 156], ["the virus", "PROBLEM", 27, 36], ["the COVID", "TEST", 197, 206], ["olfactory loss", "PROBLEM", 243, 257], ["brain", "ANATOMY", 52, 57], ["nasal cavity", "ANATOMY", 66, 78], ["olfactory loss", "OBSERVATION", 243, 257]]], ["The objective of this study was to investigate the frequency of the olfactory impairment and the rate of recovery, together with any accompanying URTI (sinonasal symptoms) during the recent COVID-19 pandemic.MethodsThis prospective descriptive study was performed on hospitalized patients with COVID-19 from February to March 2020, randomly sampled from the COVID care wards of a tertiary referral hospital (Hazrat Rasool Akram Hospital) in Tehran, Iran.", [["olfactory", "ANATOMY", 68, 77], ["sinonasal", "ANATOMY", 152, 161], ["olfactory impairment", "DISEASE", 68, 88], ["URTI", "DISEASE", 146, 150], ["olfactory", "ORGAN", 68, 77], ["sinonasal", "ORGAN", 152, 161], ["patients", "ORGANISM", 280, 288], ["patients", "SPECIES", 280, 288], ["this study", "TEST", 17, 27], ["the olfactory impairment", "PROBLEM", 64, 88], ["any accompanying URTI (sinonasal symptoms", "PROBLEM", 129, 170], ["the recent COVID", "TEST", 179, 195], ["pandemic", "PROBLEM", 199, 207], ["descriptive study", "TEST", 232, 249]]], ["The protocol of the study was approved by the Institutional Review Board and ethics committee of Iran University of Medical Sciences (code number 1399.052).", [["the study", "TEST", 16, 25]]], ["The study protocol was in accordance with the 1964 Helsinki declaration and its later amendments comparable ethical standards.", [["The study protocol", "TEST", 0, 18]]], ["Written informed consent was obtained from all participants.Study participantsOne hundred adult patients under the age of 80, having positive throat swab specimens in the evaluation of reverse transcriptase-polymerase chain reaction, were enrolled in the study.", [["throat swab specimens", "ANATOMY", 142, 163], ["patients", "ORGANISM", 96, 104], ["reverse transcriptase", "PROTEIN", 185, 206], ["participants", "SPECIES", 47, 59], ["participants", "SPECIES", 66, 78], ["patients", "SPECIES", 96, 104], ["positive throat swab specimens", "PROBLEM", 133, 163], ["the evaluation", "TEST", 167, 181], ["reverse transcriptase-polymerase chain reaction", "PROBLEM", 185, 232], ["the study", "TEST", 251, 260]]], ["Patients with COVID-19 were diagnosed according to the WHO interim guideline [16, 17] .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["COVID", "TEST", 14, 19]]], ["Patients with wellknown neurodegenerative diseases, including Parkinson's disease or dementia, history of olfactory dysfunction, as well as those with severe respiratory distress or under mechanical ventilation, were excluded from the study.Data collectionThe demographic characteristics (age and sex), comorbidities, previous chronic sinonasal disease or related surgery, seasonal allergy, smoking habits, time of disease onset, and the first symptom(s) at the onset, and those added later, were asked from the patients.", [["olfactory", "ANATOMY", 106, 115], ["respiratory", "ANATOMY", 158, 169], ["sinonasal", "ANATOMY", 335, 344], ["neurodegenerative diseases", "DISEASE", 24, 50], ["Parkinson's disease", "DISEASE", 62, 81], ["dementia", "DISEASE", 85, 93], ["olfactory dysfunction", "DISEASE", 106, 127], ["respiratory distress", "DISEASE", 158, 178], ["chronic sinonasal disease", "DISEASE", 327, 352], ["allergy", "DISEASE", 382, 389], ["Patients", "ORGANISM", 0, 8], ["olfactory", "ORGAN", 106, 115], ["patients", "ORGANISM", 512, 520], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 512, 520], ["wellknown neurodegenerative diseases", "PROBLEM", 14, 50], ["Parkinson's disease", "PROBLEM", 62, 81], ["dementia", "PROBLEM", 85, 93], ["olfactory dysfunction", "PROBLEM", 106, 127], ["severe respiratory distress", "PROBLEM", 151, 178], ["mechanical ventilation", "TREATMENT", 188, 210], ["the study", "TEST", 231, 240], ["Data collection", "TEST", 241, 256], ["comorbidities", "PROBLEM", 303, 316], ["previous chronic sinonasal disease", "PROBLEM", 318, 352], ["related surgery", "TREATMENT", 356, 371], ["seasonal allergy", "PROBLEM", 373, 389], ["disease onset", "PROBLEM", 415, 428], ["the first symptom", "PROBLEM", 434, 451], ["neurodegenerative", "OBSERVATION_MODIFIER", 24, 41], ["diseases", "OBSERVATION", 42, 50], ["dementia", "OBSERVATION", 85, 93], ["olfactory dysfunction", "OBSERVATION", 106, 127], ["severe", "OBSERVATION_MODIFIER", 151, 157], ["respiratory", "ANATOMY", 158, 169], ["distress", "OBSERVATION", 170, 178], ["mechanical ventilation", "OBSERVATION", 188, 210], ["chronic", "OBSERVATION_MODIFIER", 327, 334], ["sinonasal disease", "OBSERVATION", 335, 352]]], ["The oxygen saturation, assessed by a pulse oximeter, was also recorded.", [["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["The oxygen saturation", "TEST", 0, 21], ["a pulse oximeter", "TEST", 35, 51], ["oxygen saturation", "OBSERVATION", 4, 21]]], ["Laboratory results, including leukocyte and lymphocyte count, c-reactive protein (CRP), erythrocyte sedimentation rate, aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen (BUN), and creatinine, were recorded from the electronic medical records of the hospital.", [["leukocyte", "ANATOMY", 30, 39], ["lymphocyte", "ANATOMY", 44, 54], ["erythrocyte", "ANATOMY", 88, 99], ["blood", "ANATOMY", 186, 191], ["aspartate", "CHEMICAL", 120, 129], ["alanine", "CHEMICAL", 154, 161], ["blood urea nitrogen", "CHEMICAL", 186, 205], ["creatinine", "CHEMICAL", 217, 227], ["aspartate", "CHEMICAL", 120, 129], ["alanine", "CHEMICAL", 154, 161], ["urea", "CHEMICAL", 192, 196], ["nitrogen", "CHEMICAL", 197, 205], ["creatinine", "CHEMICAL", 217, 227], ["leukocyte", "CELL", 30, 39], ["lymphocyte", "CELL", 44, 54], ["c-reactive protein", "GENE_OR_GENE_PRODUCT", 62, 80], ["CRP", "GENE_OR_GENE_PRODUCT", 82, 85], ["erythrocyte", "CELL", 88, 99], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 120, 146], ["AST", "SIMPLE_CHEMICAL", 148, 151], ["alanine aminotransferase", "SIMPLE_CHEMICAL", 154, 178], ["ALT", "SIMPLE_CHEMICAL", 180, 183], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["urea nitrogen", "SIMPLE_CHEMICAL", 192, 205], ["BUN", "SIMPLE_CHEMICAL", 207, 210], ["creatinine", "SIMPLE_CHEMICAL", 217, 227], ["c-reactive protein", "PROTEIN", 62, 80], ["CRP", "PROTEIN", 82, 85], ["aspartate aminotransferase", "PROTEIN", 120, 146], ["AST", "PROTEIN", 148, 151], ["alanine aminotransferase", "PROTEIN", 154, 178], ["ALT", "PROTEIN", 180, 183], ["leukocyte", "TEST", 30, 39], ["lymphocyte count", "TEST", 44, 60], ["c-reactive protein", "TEST", 62, 80], ["CRP", "TEST", 82, 85], ["erythrocyte sedimentation rate", "TEST", 88, 118], ["aspartate aminotransferase", "TEST", 120, 146], ["AST", "TEST", 148, 151], ["alanine aminotransferase", "TEST", 154, 178], ["ALT", "TEST", 180, 183], ["blood urea nitrogen", "TEST", 186, 205], ["BUN", "TEST", 207, 210], ["creatinine", "TEST", 217, 227]]], ["Fever was defined as an axillary temperature of \u2265 37.5\u00b0C.Data collectionThe radiological assessment of all the patients was carried out using chest computed tomographic (CT) scans.", [["axillary", "ANATOMY", 24, 32], ["Fever", "DISEASE", 0, 5], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["Fever", "PROBLEM", 0, 5], ["an axillary temperature", "TEST", 21, 44], ["The radiological assessment", "TEST", 72, 99], ["chest computed tomographic (CT) scans", "TEST", 142, 179], ["axillary", "ANATOMY", 24, 32], ["chest", "ANATOMY", 142, 147]]], ["The patients were interviewed regarding sinonasal symptoms.", [["sinonasal", "ANATOMY", 40, 49], ["patients", "ORGANISM", 4, 12], ["sinonasal", "ORGAN", 40, 49], ["patients", "SPECIES", 4, 12], ["sinonasal symptoms", "PROBLEM", 40, 58]]], ["Seven prominent symptoms including needing to blow the nose, sneeze, rhinorrhea, postnasal discharge, thick nasal discharge, facial pain over sinuses, and nasal congestion/obstruction were evaluated using 7 Likert scale questions (five-point scale; 0: no complaint, 5: extreme severe problem).", [["nose", "ANATOMY", 55, 59], ["nasal", "ANATOMY", 108, 113], ["facial", "ANATOMY", 125, 131], ["sinuses", "ANATOMY", 142, 149], ["nasal", "ANATOMY", 155, 160], ["sneeze", "DISEASE", 61, 67], ["rhinorrhea", "DISEASE", 69, 79], ["facial pain", "DISEASE", 125, 136], ["nasal congestion", "DISEASE", 155, 171], ["obstruction", "DISEASE", 172, 183], ["nose", "ORGANISM_SUBDIVISION", 55, 59], ["nasal", "ORGANISM_SUBDIVISION", 108, 113], ["sinuses", "MULTI-TISSUE_STRUCTURE", 142, 149], ["nasal", "ORGANISM_SUBDIVISION", 155, 160], ["Seven prominent symptoms", "PROBLEM", 0, 24], ["sneeze", "PROBLEM", 61, 67], ["rhinorrhea", "PROBLEM", 69, 79], ["postnasal discharge", "PROBLEM", 81, 100], ["thick nasal discharge", "PROBLEM", 102, 123], ["facial pain over sinuses", "PROBLEM", 125, 149], ["nasal congestion", "PROBLEM", 155, 171], ["obstruction", "PROBLEM", 172, 183], ["extreme severe problem", "PROBLEM", 269, 291], ["prominent", "OBSERVATION_MODIFIER", 6, 15], ["symptoms", "OBSERVATION", 16, 24], ["nose", "ANATOMY", 55, 59], ["rhinorrhea", "OBSERVATION", 69, 79], ["postnasal", "ANATOMY", 81, 90], ["nasal", "ANATOMY", 108, 113], ["facial", "ANATOMY", 125, 131], ["pain", "OBSERVATION", 132, 136], ["sinuses", "ANATOMY", 142, 149], ["nasal", "ANATOMY", 155, 160], ["congestion", "OBSERVATION", 161, 171], ["obstruction", "OBSERVATION", 172, 183]]], ["The group with sinonasal symptoms was defined considering the sum of the Likert score when the change in each one was higher than 1 (very mild).", [["sinonasal", "ANATOMY", 15, 24], ["sinonasal", "ORGAN", 15, 24], ["sinonasal symptoms", "PROBLEM", 15, 33]]], ["The same questions were applied when the patients were called for follow-up.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49]]], ["The patients were asked to score according to the most severe symptoms they had since the disease onset (and not the severity sensed at the time of the interview).", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["the most severe symptoms", "PROBLEM", 46, 70], ["the disease onset", "PROBLEM", 86, 103]]], ["The highest score was adopted for each patient.", [["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46]]], ["The severity of COVID-19 was defined for the patients according to the international guidelines for communityacquired pneumonia [18] .", [["pneumonia", "DISEASE", 118, 127], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["COVID", "TEST", 16, 21], ["communityacquired pneumonia", "PROBLEM", 100, 127], ["pneumonia", "OBSERVATION", 118, 127]]], ["The throat swab specimens of patients were analyzed using the SARS-CoV-2 nucleic acid detection kit.", [["throat swab specimens", "ANATOMY", 4, 25], ["nucleic acid", "CHEMICAL", 73, 85], ["throat swab specimens", "ORGANISM_SUBSTANCE", 4, 25], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 62, 70], ["The throat swab specimens", "TEST", 0, 25], ["the SARS", "TEST", 58, 66], ["CoV", "TEST", 67, 70], ["throat", "ANATOMY", 4, 10]]], ["(LightMix\u00ae Sarbeco V E-gene plus EAV control 530/660).Statistical analysisCharacteristics were summarized as mean \u00b1 standard deviation (SD) for quantitative variables and as a percentage for qualitative variables, respectively.", [["Sarbeco V E-", "GENE_OR_GENE_PRODUCT", 11, 23], ["LightMix\u00ae Sarbeco V E-gene plus EAV control", "TREATMENT", 1, 44], ["Statistical analysis", "TEST", 54, 74], ["quantitative variables", "TEST", 144, 166]]], ["Inter-group comparison of categorical and quantitative variables was performed with Fisher's exact test and t test, respectively.", [["Fisher's exact test", "TEST", 84, 103], ["t test", "TEST", 108, 114]]], ["P values less than 0.05 were set as statistically significant levels.ResultsOne hundred hospitalized patients who had SARS-CoV2 infection were eligible to be included in the study.", [["SARS-CoV2 infection", "DISEASE", 118, 137], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["P values", "TEST", 0, 8], ["SARS", "PROBLEM", 118, 122], ["CoV2 infection", "PROBLEM", 123, 137], ["the study", "TEST", 170, 179], ["infection", "OBSERVATION", 128, 137]]], ["Ninety-two patients completed the follow-up and hence were analyzed (3 patients were not interested with follow-up, 2 patients did not answer the phone after several attempts, one had a wrong telephone number registered in the medical record, one patient deceased after admission to another hospital, and one patient had a cerebrovascular accident a few days after being discharged from the hospital).", [["cerebrovascular", "ANATOMY", 323, 338], ["cerebrovascular accident", "DISEASE", 323, 347], ["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 71, 79], ["patients", "ORGANISM", 118, 126], ["patient", "ORGANISM", 247, 254], ["patient", "ORGANISM", 309, 316], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 118, 126], ["patient", "SPECIES", 247, 254], ["patient", "SPECIES", 309, 316], ["cerebrovascular", "ANATOMY", 323, 338]]], ["The mean follow-up duration was 20.10 \u00b1 7.42 days, and 71 (77.2%) patients had more than 2-week follow-up.Clinical, radiological, and laboratory findingsAccording to the international guidelines for communityacquired pneumonia, 72 (78.3%) patients had mild and 20 patients (21.7%) had moderate pneumonia.", [["pneumonia", "DISEASE", 217, 226], ["pneumonia", "DISEASE", 294, 303], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 239, 247], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 239, 247], ["patients", "SPECIES", 264, 272], ["laboratory findings", "TEST", 134, 153], ["communityacquired pneumonia", "PROBLEM", 199, 226], ["mild and 20 patients", "PROBLEM", 252, 272], ["moderate pneumonia", "PROBLEM", 285, 303], ["pneumonia", "OBSERVATION", 217, 226], ["mild", "OBSERVATION_MODIFIER", 252, 256], ["moderate", "OBSERVATION_MODIFIER", 285, 293], ["pneumonia", "OBSERVATION", 294, 303]]], ["In the patients with mild pneumonia, the mean leukocyte and lymphocyte count were 6095.07 \u00b1 3669/\u03bcl and 1066.76 \u00b1 542/\u03bcl, respectively.", [["leukocyte", "ANATOMY", 46, 55], ["lymphocyte", "ANATOMY", 60, 70], ["pneumonia", "DISEASE", 26, 35], ["patients", "ORGANISM", 7, 15], ["leukocyte", "CELL", 46, 55], ["lymphocyte", "CELL", 60, 70], ["patients", "SPECIES", 7, 15], ["mild pneumonia", "PROBLEM", 21, 35], ["the mean leukocyte", "TEST", 37, 55], ["lymphocyte count", "TEST", 60, 76], ["mild", "OBSERVATION_MODIFIER", 21, 25], ["pneumonia", "OBSERVATION", 26, 35], ["mean leukocyte", "OBSERVATION", 41, 55], ["lymphocyte count", "OBSERVATION", 60, 76]]], ["In the patients with moderate pneumonia, the mean leukocyte count and lymphocyte count were 5940 \u00b1 2880/\u03bcl and 939.17 \u00b1 441/\u03bcl, respectively.", [["leukocyte", "ANATOMY", 50, 59], ["lymphocyte", "ANATOMY", 70, 80], ["pneumonia", "DISEASE", 30, 39], ["patients", "ORGANISM", 7, 15], ["leukocyte", "CELL", 50, 59], ["lymphocyte", "CELL", 70, 80], ["patients", "SPECIES", 7, 15], ["moderate pneumonia", "PROBLEM", 21, 39], ["the mean leukocyte count", "TEST", 41, 65], ["lymphocyte count", "TEST", 70, 86], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["pneumonia", "OBSERVATION", 30, 39], ["mean leukocyte count", "OBSERVATION", 45, 65], ["lymphocyte count", "OBSERVATION", 70, 86]]], ["The mean age in mild group was 50.75 \u00b1 12.31 while in the moderate group it was 60.85 \u00b1 13.82 years.", [["mean", "OBSERVATION_MODIFIER", 4, 8], ["mild", "OBSERVATION_MODIFIER", 16, 20], ["moderate", "OBSERVATION_MODIFIER", 58, 66]]], ["There was a significant difference between the severity of pneumonia and age (p = 0.002).", [["pneumonia", "DISEASE", 59, 68], ["pneumonia", "PROBLEM", 59, 68], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34], ["severity", "OBSERVATION_MODIFIER", 47, 55], ["pneumonia", "OBSERVATION", 59, 68]]], ["The severity of pneumonia and mean leukocyte and lymphocyte count had no association with sinonasal symptoms or olfactory loss.", [["leukocyte", "ANATOMY", 35, 44], ["lymphocyte", "ANATOMY", 49, 59], ["sinonasal", "ANATOMY", 90, 99], ["olfactory", "ANATOMY", 112, 121], ["pneumonia", "DISEASE", 16, 25], ["olfactory loss", "DISEASE", 112, 126], ["leukocyte", "CELL", 35, 44], ["lymphocyte", "CELL", 49, 59], ["sinonasal", "ORGAN", 90, 99], ["olfactory", "ORGAN", 112, 121], ["pneumonia", "PROBLEM", 16, 25], ["mean leukocyte", "TEST", 30, 44], ["lymphocyte count", "TEST", 49, 65], ["sinonasal symptoms", "PROBLEM", 90, 108], ["olfactory loss", "PROBLEM", 112, 126], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["pneumonia", "OBSERVATION", 16, 25], ["mean leukocyte", "OBSERVATION", 30, 44], ["lymphocyte count", "OBSERVATION", 49, 65], ["no association with", "UNCERTAINTY", 70, 89], ["olfactory loss", "OBSERVATION", 112, 126]]], ["The details of demographic data, comorbidities, and laboratory findings of the patients are all presented in Table 1 .", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["demographic data", "TEST", 15, 31], ["comorbidities", "PROBLEM", 33, 46]]], ["In 95.7% of our patients, CRP was higher than the normal level, which was not significantly different in patients with or without sinonasal symptoms or olfactory loss.", [["sinonasal", "ANATOMY", 130, 139], ["olfactory", "ANATOMY", 152, 161], ["olfactory loss", "DISEASE", 152, 166], ["patients", "ORGANISM", 16, 24], ["CRP", "GENE_OR_GENE_PRODUCT", 26, 29], ["patients", "ORGANISM", 105, 113], ["sinonasal", "ORGAN", 130, 139], ["olfactory", "ORGAN", 152, 161], ["CRP", "PROTEIN", 26, 29], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 105, 113], ["CRP", "TEST", 26, 29], ["sinonasal symptoms", "PROBLEM", 130, 148], ["olfactory loss", "PROBLEM", 152, 166], ["significantly different", "OBSERVATION_MODIFIER", 78, 101], ["olfactory loss", "OBSERVATION", 152, 166]]], ["The CT chest scans of patients were compatible with ground-glass opacity in 71.2%, consolidation in 21.9%, and crazy paving pattern in 6.8%.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["The CT chest scans", "TEST", 0, 18], ["ground-glass opacity", "PROBLEM", 52, 72], ["consolidation", "PROBLEM", 83, 96], ["crazy paving pattern", "TEST", 111, 131], ["chest", "ANATOMY", 7, 12], ["glass opacity", "OBSERVATION", 59, 72], ["consolidation", "OBSERVATION", 83, 96], ["21.9%", "OBSERVATION_MODIFIER", 100, 105]]], ["The mean of oxygen blood saturation was 91.81% \u00b1 4.34.Sinonasal symptomsSinonasal symptoms were found in 39 (42.39%) patients.", [["blood", "ANATOMY", 19, 24], ["Sinonasal", "ANATOMY", 54, 63], ["Sinonasal", "ANATOMY", 72, 81], ["oxygen", "CHEMICAL", 12, 18], ["Sinonasal symptoms", "DISEASE", 72, 90], ["oxygen", "CHEMICAL", 12, 18], ["oxygen", "SIMPLE_CHEMICAL", 12, 18], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["patients", "ORGANISM", 117, 125], ["patients", "SPECIES", 117, 125], ["oxygen blood saturation", "TEST", 12, 35], ["Sinonasal symptoms", "PROBLEM", 54, 72], ["Sinonasal symptoms", "PROBLEM", 72, 90]]], ["Although the most common presenting symptoms were myalgia and fever, each in more than one-third of the patients, rhinorrhea was among the first symptom in 3 (3.26%) of the cases.", [["myalgia", "DISEASE", 50, 57], ["fever", "DISEASE", 62, 67], ["rhinorrhea", "DISEASE", 114, 124], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["the most common presenting symptoms", "PROBLEM", 9, 44], ["myalgia", "PROBLEM", 50, 57], ["fever", "PROBLEM", 62, 67], ["rhinorrhea", "PROBLEM", 114, 124], ["myalgia", "OBSERVATION", 50, 57], ["fever", "OBSERVATION", 62, 67], ["rhinorrhea", "OBSERVATION", 114, 124]]], ["Considering the severity, 12 patients (13.04%) had sinonasal symptoms with a Likert score of 4 or more.", [["sinonasal", "ANATOMY", 51, 60], ["patients", "ORGANISM", 29, 37], ["sinonasal", "ORGAN", 51, 60], ["patients", "SPECIES", 29, 37], ["sinonasal symptoms", "PROBLEM", 51, 69], ["a Likert score", "TEST", 75, 89]]], ["The patients' manifestations, including sinonasal symptoms and olfaction, are presented in Table 2 .", [["sinonasal", "ANATOMY", 40, 49], ["patients", "ORGANISM", 4, 12], ["sinonasal", "ORGAN", 40, 49], ["patients", "SPECIES", 4, 12], ["The patients' manifestations", "PROBLEM", 0, 28], ["sinonasal symptoms", "PROBLEM", 40, 58], ["olfaction", "PROBLEM", 63, 72]]], ["Patients with sinonasal symptoms had a lower age (p = 0.01) patients with diabetes mellitus had a lesser chance of presenting with sinonasal symptoms (p = 0.03).", [["sinonasal", "ANATOMY", 14, 23], ["sinonasal", "ANATOMY", 131, 140], ["sinonasal symptoms", "DISEASE", 14, 32], ["diabetes mellitus", "DISEASE", 74, 91], ["sinonasal symptoms", "DISEASE", 131, 149], ["Patients", "ORGANISM", 0, 8], ["sinonasal", "ORGAN", 14, 23], ["patients", "ORGANISM", 60, 68], ["sinonasal", "ORGAN", 131, 140], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 60, 68], ["sinonasal symptoms", "PROBLEM", 14, 32], ["diabetes mellitus", "PROBLEM", 74, 91], ["sinonasal symptoms", "PROBLEM", 131, 149]]], ["However, patients with diabetes mellitus (DM) were significantly younger (59.86 \u00b1 12.23 vs. 50.77 \u00b1 12.89, p = 0.004).", [["diabetes mellitus", "DISEASE", 23, 40], ["DM", "DISEASE", 42, 44], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["diabetes mellitus", "PROBLEM", 23, 40], ["DM", "PROBLEM", 42, 44], ["p", "TEST", 107, 108]]], ["There was no significant difference in the other demographic data, comorbidities, and laboratory findings between those who had sinonasal symptoms comparing to others.Olfactory lossThe olfactory loss was reported by 22 (23.91%) patients, of whom 6 (6.52%) patients reported it as the first symptom of their disease.", [["sinonasal", "ANATOMY", 128, 137], ["Olfactory", "ANATOMY", 167, 176], ["olfactory", "ANATOMY", 185, 194], ["Olfactory loss", "DISEASE", 167, 181], ["olfactory loss", "DISEASE", 185, 199], ["Olfactory", "ORGAN", 167, 176], ["olfactory", "ORGAN", 185, 194], ["patients", "ORGANISM", 228, 236], ["patients", "ORGANISM", 256, 264], ["patients", "SPECIES", 228, 236], ["patients", "SPECIES", 256, 264], ["comorbidities", "PROBLEM", 67, 80], ["sinonasal symptoms", "PROBLEM", 128, 146], ["Olfactory lossThe olfactory loss", "PROBLEM", 167, 199], ["their disease", "PROBLEM", 301, 314], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["loss", "OBSERVATION", 177, 181], ["olfactory loss", "OBSERVATION", 185, 199], ["disease", "OBSERVATION", 307, 314]]], ["Anosmia was reported by 9 (40.9%) and hyposmia by 13 (59.1%), respectively.", [["Anosmia", "DISEASE", 0, 7], ["hyposmia", "DISEASE", 38, 46], ["Anosmia", "PROBLEM", 0, 7], ["hyposmia", "TEST", 38, 46]]], ["Two patients reported hyperosmia.", [["hyperosmia", "DISEASE", 22, 32], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["hyperosmia", "PROBLEM", 22, 32], ["hyperosmia", "OBSERVATION", 22, 32]]], ["Fifteen patients (16.3%) reported simultaneous taste impairment.", [["taste impairment", "DISEASE", 47, 63], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["simultaneous taste impairment", "PROBLEM", 34, 63]]], ["The frequency and severity of sinonasal symptoms and the olfactory and taste impairment (based on the Likert scale) are shown in Table 3 .", [["sinonasal", "ANATOMY", 30, 39], ["olfactory", "ANATOMY", 57, 66], ["taste impairment", "DISEASE", 71, 87], ["sinonasal", "ORGAN", 30, 39], ["olfactory", "ORGAN", 57, 66], ["sinonasal symptoms", "PROBLEM", 30, 48], ["the olfactory and taste impairment", "PROBLEM", 53, 87], ["the Likert scale", "TEST", 98, 114]]], ["There was no significant difference in the demographic data, comorbidities, and laboratory findings between those who had olfactory loss comparing to others.", [["olfactory", "ANATOMY", 122, 131], ["olfactory loss", "DISEASE", 122, 136], ["olfactory", "ORGAN", 122, 131], ["the demographic data", "TEST", 39, 59], ["comorbidities", "PROBLEM", 61, 74], ["olfactory loss", "PROBLEM", 122, 136], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["In the 22 patients with olfactory loss, the median (mean \u00b1 SD) time of the onset of olfactory was 3 days (3.41 \u00b1 2.46) after the onset of COVID-19 symptoms.", [["olfactory", "ANATOMY", 24, 33], ["olfactory", "ANATOMY", 84, 93], ["olfactory loss", "DISEASE", 24, 38], ["patients", "ORGANISM", 10, 18], ["olfactory", "ORGAN", 24, 33], ["olfactory", "ORGAN", 84, 93], ["patients", "SPECIES", 10, 18], ["olfactory loss", "PROBLEM", 24, 38], ["COVID-19 symptoms", "PROBLEM", 138, 155]]], ["The olfactory loss lasted for a median of 8 (10.73 \u00b1 8.26) days and completely resolved in 21 (95.45%) patients (mean follow-up for 22 patients with olfactory impairment was 20.63 \u00b1 5.95, ranging from 10 to 30 days).", [["olfactory", "ANATOMY", 4, 13], ["olfactory", "ANATOMY", 149, 158], ["olfactory loss", "DISEASE", 4, 18], ["olfactory impairment", "DISEASE", 149, 169], ["olfactory", "ORGAN", 4, 13], ["patients", "ORGANISM", 103, 111], ["patients", "ORGANISM", 135, 143], ["olfactory", "ORGAN", 149, 158], ["patients", "SPECIES", 103, 111], ["patients", "SPECIES", 135, 143], ["The olfactory loss", "PROBLEM", 0, 18], ["olfactory impairment", "PROBLEM", 149, 169], ["olfactory loss", "OBSERVATION", 4, 18]]], ["One patient with anosmia remained symptomatic 30 days after the onset of the symptom.", [["anosmia", "DISEASE", 17, 24], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["anosmia", "PROBLEM", 17, 24], ["symptomatic", "PROBLEM", 34, 45], ["the symptom", "PROBLEM", 73, 84], ["symptomatic", "OBSERVATION_MODIFIER", 34, 45]]], ["However, he had shown some degree of improvement at that time (Likert score = 2).Olfactory lossAmong 22 patients with olfactory loss, 9 patients had no sinonasal symptoms.", [["Olfactory", "ANATOMY", 81, 90], ["olfactory", "ANATOMY", 118, 127], ["sinonasal", "ANATOMY", 152, 161], ["Olfactory loss", "DISEASE", 81, 95], ["olfactory loss", "DISEASE", 118, 132], ["Olfactory", "ORGAN", 81, 90], ["patients", "ORGANISM", 104, 112], ["olfactory", "ORGAN", 118, 127], ["patients", "ORGANISM", 136, 144], ["sinonasal", "CANCER", 152, 161], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 136, 144], ["Likert score", "TEST", 63, 75], ["Olfactory loss", "PROBLEM", 81, 95], ["olfactory loss", "PROBLEM", 118, 132], ["sinonasal symptoms", "PROBLEM", 152, 170], ["improvement", "OBSERVATION", 37, 48], ["no", "UNCERTAINTY", 149, 151]]], ["Likewise, among 39 patients with sinonasal symptoms, 26 patients did not have any olfactory complain.", [["sinonasal", "ANATOMY", 33, 42], ["olfactory", "ANATOMY", 82, 91], ["sinonasal symptoms", "DISEASE", 33, 51], ["patients", "ORGANISM", 19, 27], ["sinonasal", "ORGAN", 33, 42], ["patients", "ORGANISM", 56, 64], ["olfactory", "ORGAN", 82, 91], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 56, 64], ["sinonasal symptoms", "PROBLEM", 33, 51]]], ["There was no significant relation between olfactory loss and upper respiratory tract involvement (p = 0.07).DiscussionThe present study followed 92 hospitalized COVID-19 patients for around 3 weeks after the start of their disease symptoms.", [["olfactory", "ANATOMY", 42, 51], ["upper respiratory tract", "ANATOMY", 61, 84], ["olfactory loss", "DISEASE", 42, 56], ["olfactory", "ORGAN", 42, 51], ["upper respiratory", "ORGANISM_SUBDIVISION", 61, 78], ["tract", "ORGANISM_SUBDIVISION", 79, 84], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["olfactory loss", "PROBLEM", 42, 56], ["upper respiratory tract involvement", "PROBLEM", 61, 96], ["The present study", "TEST", 118, 135], ["their disease symptoms", "PROBLEM", 217, 239], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["olfactory loss", "OBSERVATION", 42, 56], ["upper", "ANATOMY_MODIFIER", 61, 66], ["respiratory tract", "ANATOMY", 67, 84]]], ["The olfactory loss was reported by almost 24% of the patients.", [["olfactory", "ANATOMY", 4, 13], ["olfactory loss", "DISEASE", 4, 18], ["olfactory", "ORGAN", 4, 13], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["The olfactory loss", "PROBLEM", 0, 18], ["olfactory loss", "OBSERVATION", 4, 18]]], ["URTI symptoms were present in 42% of the patients (severe form only in around 13% of the patients), which did not correlate with the olfactory loss.", [["olfactory", "ANATOMY", 133, 142], ["URTI symptoms", "DISEASE", 0, 13], ["olfactory loss", "DISEASE", 133, 147], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 89, 97], ["olfactory", "ORGAN", 133, 142], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 89, 97], ["URTI symptoms", "PROBLEM", 0, 13], ["the olfactory loss", "PROBLEM", 129, 147], ["olfactory loss", "OBSERVATION", 133, 147]]], ["Patients with sinonasal symptoms were significantly younger.", [["sinonasal", "ANATOMY", 14, 23], ["sinonasal symptoms", "DISEASE", 14, 32], ["Patients", "ORGANISM", 0, 8], ["sinonasal", "ORGAN", 14, 23], ["Patients", "SPECIES", 0, 8], ["sinonasal symptoms", "PROBLEM", 14, 32]]], ["Until April 3, 2020, there have been 3,917,366 and 106,220 laboratory-confirmed cases of COVID-19 globally and in Iran, respectively [20] .", [["COVID", "TEST", 89, 94]]], ["There is accumulating evidence from all around the world, revealing the association of olfactory loss with the COVID-19 pandemic.", [["olfactory", "ANATOMY", 87, 96], ["olfactory loss", "DISEASE", 87, 101], ["olfactory", "ORGAN", 87, 96], ["olfactory loss", "PROBLEM", 87, 101], ["the COVID", "TEST", 107, 116], ["pandemic", "PROBLEM", 120, 128], ["olfactory loss", "OBSERVATION", 87, 101]]], ["The reported frequency of olfactory impairment in recent peer-reviewed or not peer-reviewed studies varies greatly [21, 22] .", [["olfactory", "ANATOMY", 26, 35], ["olfactory impairment", "DISEASE", 26, 46], ["olfactory", "ORGAN", 26, 35], ["olfactory impairment", "PROBLEM", 26, 46], ["impairment", "OBSERVATION", 36, 46]]], ["This wide range may be due to various factors including study design (i.e., retrospective [22] , prospective [23] , online survey [24, 25] study population, subdivided in hospitalized patients [21, 22, 26] , out-patient setting [27] , and mixed [23, 28] ; regional differences in population (racial diversity) [23] and use of olfactory tests and the test being used [21, 28] .", [["olfactory", "ANATOMY", 326, 335], ["patients", "ORGANISM", 184, 192], ["patient", "ORGANISM", 212, 219], ["patients", "SPECIES", 184, 192], ["patient", "SPECIES", 212, 219], ["study design", "TEST", 56, 68], ["study population", "TEST", 139, 155], ["regional differences in population", "PROBLEM", 256, 290], ["olfactory tests", "TEST", 326, 341], ["the test", "TEST", 346, 354], ["may be due to", "UNCERTAINTY", 16, 29]]], ["For instance, Giacomelli et al. [26] found that when being asked, 33.9% of hospitalized patients with COVID-19 reported olfactory and/or taste disorder.", [["olfactory", "ANATOMY", 120, 129], ["COVID", "DISEASE", 102, 107], ["olfactory and/or taste disorder", "DISEASE", 120, 151], ["patients", "ORGANISM", 88, 96], ["olfactory", "ORGAN", 120, 129], ["patients", "SPECIES", 88, 96], ["COVID", "TEST", 102, 107], ["taste disorder", "PROBLEM", 137, 151]]], ["While Mao et al. [22] , collecting the data from medical electronic records, reported 5.1% of the hospitalized patients had a complaint of hyposmia.DiscussionOlfactory clefts are narrow upper parts of nasal cavities containing olfactory epithelium with olfactory receptor neurons necessary for olfaction [29] .", [["nasal cavities", "ANATOMY", 201, 215], ["olfactory epithelium", "ANATOMY", 227, 247], ["olfactory receptor neurons", "ANATOMY", 253, 279], ["hyposmia", "DISEASE", 139, 147], ["DiscussionOlfactory clefts", "DISEASE", 148, 174], ["patients", "ORGANISM", 111, 119], ["upper parts", "ORGANISM_SUBDIVISION", 186, 197], ["nasal cavities", "MULTI-TISSUE_STRUCTURE", 201, 215], ["olfactory epithelium", "TISSUE", 227, 247], ["olfactory receptor neurons", "CELL", 253, 279], ["patients", "SPECIES", 111, 119], ["hyposmia", "PROBLEM", 139, 147], ["DiscussionOlfactory clefts", "PROBLEM", 148, 174], ["narrow upper parts of nasal cavities", "PROBLEM", 179, 215], ["hyposmia", "OBSERVATION", 139, 147], ["clefts", "OBSERVATION", 168, 174], ["narrow", "OBSERVATION_MODIFIER", 179, 185], ["upper", "ANATOMY_MODIFIER", 186, 191], ["parts", "ANATOMY_MODIFIER", 192, 197], ["nasal cavities", "ANATOMY", 201, 215], ["olfactory epithelium", "OBSERVATION", 227, 247]]], ["Various pathologies, including common viral URTI, can cause prominent mucosal edema and subsequent obstruction in the middle and the lower parts of the nasal cavities, hindering the odors to reach the olfactory cleft [29] .", [["mucosal", "ANATOMY", 70, 77], ["lower parts", "ANATOMY", 133, 144], ["nasal cavities", "ANATOMY", 152, 166], ["olfactory cleft", "ANATOMY", 201, 216], ["viral URTI", "DISEASE", 38, 48], ["edema", "DISEASE", 78, 83], ["mucosal edema", "PATHOLOGICAL_FORMATION", 70, 83], ["nasal cavities", "MULTI-TISSUE_STRUCTURE", 152, 166], ["Various pathologies", "PROBLEM", 0, 19], ["common viral URTI", "PROBLEM", 31, 48], ["prominent mucosal edema", "PROBLEM", 60, 83], ["subsequent obstruction in the middle and the lower parts of the nasal cavities", "PROBLEM", 88, 166], ["pathologies", "OBSERVATION", 8, 19], ["common", "OBSERVATION_MODIFIER", 31, 37], ["viral URTI", "OBSERVATION", 38, 48], ["prominent", "OBSERVATION_MODIFIER", 60, 69], ["mucosal", "ANATOMY_MODIFIER", 70, 77], ["edema", "OBSERVATION", 78, 83], ["obstruction", "OBSERVATION", 99, 110], ["middle", "ANATOMY_MODIFIER", 118, 124], ["lower", "ANATOMY_MODIFIER", 133, 138], ["parts", "ANATOMY_MODIFIER", 139, 144], ["nasal cavities", "ANATOMY", 152, 166], ["olfactory cleft", "ANATOMY", 201, 216]]], ["There was no relation between the upper respiratory tract involvement and olfactory loss in our patients.", [["upper respiratory tract", "ANATOMY", 34, 57], ["olfactory", "ANATOMY", 74, 83], ["olfactory loss", "DISEASE", 74, 88], ["upper", "ORGANISM_SUBDIVISION", 34, 39], ["respiratory tract", "ORGANISM_SUBDIVISION", 40, 57], ["olfactory", "ORGAN", 74, 83], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["the upper respiratory tract involvement", "PROBLEM", 30, 69], ["olfactory loss", "PROBLEM", 74, 88], ["no relation between", "UNCERTAINTY", 10, 29], ["upper", "ANATOMY_MODIFIER", 34, 39], ["respiratory tract", "ANATOMY", 40, 57], ["olfactory loss", "OBSERVATION", 74, 88]]], ["This may suggest that the olfactory loss is not due to generalized mucosal edema and nasal obstruction, which occurs during a common upper respiratory infection [9] .DiscussionPost-viral olfactory dysfunction is the cause of 18% to 42% of the patients with olfactory loss [30] .", [["olfactory", "ANATOMY", 26, 35], ["mucosal", "ANATOMY", 67, 74], ["nasal", "ANATOMY", 85, 90], ["respiratory", "ANATOMY", 139, 150], ["olfactory", "ANATOMY", 187, 196], ["olfactory", "ANATOMY", 257, 266], ["olfactory loss", "DISEASE", 26, 40], ["edema", "DISEASE", 75, 80], ["nasal obstruction", "DISEASE", 85, 102], ["upper respiratory infection", "DISEASE", 133, 160], ["viral olfactory dysfunction", "DISEASE", 181, 208], ["olfactory loss", "DISEASE", 257, 271], ["olfactory", "ORGAN", 26, 35], ["mucosal edema", "PATHOLOGICAL_FORMATION", 67, 80], ["nasal obstruction", "PATHOLOGICAL_FORMATION", 85, 102], ["olfactory", "ORGAN", 187, 196], ["patients", "ORGANISM", 243, 251], ["olfactory", "ORGAN", 257, 266], ["patients", "SPECIES", 243, 251], ["the olfactory loss", "PROBLEM", 22, 40], ["generalized mucosal edema", "PROBLEM", 55, 80], ["nasal obstruction", "PROBLEM", 85, 102], ["a common upper respiratory infection", "PROBLEM", 124, 160], ["viral olfactory dysfunction", "PROBLEM", 181, 208], ["olfactory loss", "PROBLEM", 257, 271], ["may suggest", "UNCERTAINTY", 5, 16], ["olfactory loss", "OBSERVATION", 26, 40], ["not due to", "UNCERTAINTY", 44, 54], ["generalized", "OBSERVATION_MODIFIER", 55, 66], ["mucosal", "ANATOMY", 67, 74], ["edema", "OBSERVATION", 75, 80], ["nasal", "ANATOMY", 85, 90], ["obstruction", "OBSERVATION", 91, 102], ["upper", "ANATOMY_MODIFIER", 133, 138], ["respiratory", "ANATOMY", 139, 150], ["infection", "OBSERVATION", 151, 160]]], ["Suzuki et al. [31] were able to detect rhinovirus, coronavirus, parainfluenza virus, and Epstein-Barr virus in the nasal discharge of patients with postviral olfactory dysfunction for the first time.", [["nasal", "ANATOMY", 115, 120], ["olfactory", "ANATOMY", 158, 167], ["rhinovirus, coronavirus, parainfluenza virus", "DISEASE", 39, 83], ["postviral olfactory dysfunction", "DISEASE", 148, 179], ["rhinovirus", "ORGANISM", 39, 49], ["coronavirus", "ORGANISM", 51, 62], ["parainfluenza virus", "ORGANISM", 64, 83], ["Epstein-Barr virus", "ORGANISM", 89, 107], ["nasal", "ORGAN", 115, 120], ["patients", "ORGANISM", 134, 142], ["olfactory", "ORGAN", 158, 167], ["coronavirus", "SPECIES", 51, 62], ["parainfluenza virus", "SPECIES", 64, 83], ["patients", "SPECIES", 134, 142], ["parainfluenza virus", "SPECIES", 64, 83], ["Epstein-Barr virus", "SPECIES", 89, 107], ["rhinovirus", "PROBLEM", 39, 49], ["coronavirus", "PROBLEM", 51, 62], ["parainfluenza virus", "PROBLEM", 64, 83], ["Epstein-Barr virus", "PROBLEM", 89, 107], ["postviral olfactory dysfunction", "PROBLEM", 148, 179], ["parainfluenza virus", "OBSERVATION", 64, 83], ["Barr virus", "OBSERVATION", 97, 107], ["nasal", "ANATOMY", 115, 120]]], ["They suggested that other mechanisms, apart from nasal obstruction, can be responsible for olfactory loss in this setting [31] .", [["nasal", "ANATOMY", 49, 54], ["olfactory", "ANATOMY", 91, 100], ["nasal obstruction", "DISEASE", 49, 66], ["olfactory loss", "DISEASE", 91, 105], ["nasal", "ORGANISM_SUBDIVISION", 49, 54], ["olfactory", "ORGAN", 91, 100], ["nasal obstruction", "PROBLEM", 49, 66], ["olfactory loss", "PROBLEM", 91, 105], ["nasal", "ANATOMY", 49, 54], ["obstruction", "OBSERVATION", 55, 66]]], ["The exact ESR, first hour erythrocyte sedimentation rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitrogen; SD, standard deviation; N, number mechanism of post-viral olfactory loss is not completely understood.", [["erythrocyte", "ANATOMY", 26, 37], ["blood", "ANATOMY", 127, 132], ["post-viral olfactory", "ANATOMY", 195, 215], ["aspartate", "CHEMICAL", 63, 72], ["alanine", "CHEMICAL", 96, 103], ["blood urea nitrogen", "CHEMICAL", 127, 146], ["post-viral olfactory loss", "DISEASE", 195, 220], ["aspartate", "CHEMICAL", 63, 72], ["alanine", "CHEMICAL", 96, 103], ["urea", "CHEMICAL", 133, 137], ["nitrogen", "CHEMICAL", 138, 146], ["erythrocyte", "CELL", 26, 37], ["AST", "SIMPLE_CHEMICAL", 58, 61], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 63, 89], ["ALT", "SIMPLE_CHEMICAL", 91, 94], ["alanine", "AMINO_ACID", 96, 103], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 104, 120], ["BUN", "SIMPLE_CHEMICAL", 122, 125], ["blood", "ORGANISM_SUBSTANCE", 127, 132], ["urea", "SIMPLE_CHEMICAL", 133, 137], ["olfactory", "ORGAN", 206, 215], ["AST", "PROTEIN", 58, 61], ["aspartate aminotransferase", "PROTEIN", 63, 89], ["ALT", "PROTEIN", 91, 94], ["The exact ESR", "TEST", 0, 13], ["erythrocyte sedimentation rate", "TEST", 26, 56], ["AST", "TEST", 58, 61], ["aspartate aminotransferase", "TEST", 63, 89], ["ALT", "TEST", 91, 94], ["alanine aminotransferase", "TEST", 96, 120], ["BUN", "TEST", 122, 125], ["blood urea nitrogen", "TEST", 127, 146], ["SD", "PROBLEM", 148, 150], ["standard deviation", "PROBLEM", 152, 170], ["post-viral olfactory loss", "PROBLEM", 195, 220], ["post-viral olfactory loss", "OBSERVATION", 195, 220]]], ["Direct damage of the olfactory pathway by the virus, viral involvement of the olfactory bulb, and indirect damage caused by the subsequent inflammation of olfactory neurons and supporting cells are among the suggested mechanisms (as was noted in influenza infection) [9, 32] .", [["olfactory", "ANATOMY", 21, 30], ["olfactory bulb", "ANATOMY", 78, 92], ["olfactory neurons", "ANATOMY", 155, 172], ["cells", "ANATOMY", 188, 193], ["inflammation", "DISEASE", 139, 151], ["influenza infection", "DISEASE", 246, 265], ["olfactory", "ORGAN", 21, 30], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 78, 92], ["olfactory neurons", "CELL", 155, 172], ["cells", "CELL", 188, 193], ["olfactory neurons", "CELL_TYPE", 155, 172], ["Direct damage of the olfactory pathway", "PROBLEM", 0, 38], ["the virus", "PROBLEM", 42, 51], ["viral involvement of the olfactory bulb", "PROBLEM", 53, 92], ["indirect damage", "PROBLEM", 98, 113], ["the subsequent inflammation of olfactory neurons and supporting cells", "PROBLEM", 124, 193], ["influenza infection", "PROBLEM", 246, 265], ["olfactory bulb", "ANATOMY", 78, 92], ["inflammation", "OBSERVATION", 139, 151], ["olfactory neurons", "ANATOMY", 155, 172]]], ["There was no significant relationship between sinonasal symptoms and olfactory loss in our study, which may support this proposed mechanism.", [["sinonasal", "ANATOMY", 46, 55], ["olfactory", "ANATOMY", 69, 78], ["olfactory loss", "DISEASE", 69, 83], ["sinonasal", "ORGAN", 46, 55], ["olfactory", "ORGAN", 69, 78], ["sinonasal symptoms", "PROBLEM", 46, 64], ["olfactory loss", "PROBLEM", 69, 83], ["our study", "TEST", 87, 96], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24]]], ["However, the post-viral olfactory loss is usually noted a few weeks after the resolution of sinonasal symptoms, while our patients reported the olfactory loss during the first weeks of their disease.", [["post-viral olfactory", "ANATOMY", 13, 33], ["sinonasal", "ANATOMY", 92, 101], ["olfactory", "ANATOMY", 144, 153], ["olfactory loss", "DISEASE", 24, 38], ["sinonasal symptoms", "DISEASE", 92, 110], ["olfactory loss", "DISEASE", 144, 158], ["olfactory", "ORGAN", 24, 33], ["sinonasal", "ORGAN", 92, 101], ["patients", "ORGANISM", 122, 130], ["olfactory", "ORGAN", 144, 153], ["patients", "SPECIES", 122, 130], ["the post-viral olfactory loss", "PROBLEM", 9, 38], ["sinonasal symptoms", "PROBLEM", 92, 110], ["the olfactory loss", "PROBLEM", 140, 158], ["their disease", "PROBLEM", 185, 198], ["olfactory loss", "OBSERVATION", 24, 38], ["olfactory loss", "OBSERVATION", 144, 158], ["disease", "OBSERVATION", 191, 198]]], ["There are few studies regarding the recovery rate of olfactory dysfunction in COVID-19.", [["olfactory", "ANATOMY", 53, 62], ["olfactory dysfunction", "DISEASE", 53, 74], ["olfactory", "ORGAN", 53, 62], ["few studies", "TEST", 10, 21], ["olfactory dysfunction", "PROBLEM", 53, 74], ["COVID", "TEST", 78, 83], ["few", "OBSERVATION_MODIFIER", 10, 13], ["olfactory dysfunction", "OBSERVATION", 53, 74]]], ["Lechien et al. [23] reported a 44.0% short-term (2 weeks) olfaction recovery rate .5% of these patients reported complete improvement of the olfactory impairment which is quite higher than the recovery rate of common post-viral olfactory loss [28, 33] .", [["olfactory", "ANATOMY", 141, 150], ["olfactory", "ANATOMY", 228, 237], ["olfactory impairment", "DISEASE", 141, 161], ["post-viral olfactory loss", "DISEASE", 217, 242], ["patients", "ORGANISM", 95, 103], ["olfactory", "ORGAN", 141, 150], ["olfactory", "ORGAN", 228, 237], ["patients", "SPECIES", 95, 103], ["olfaction recovery rate", "TEST", 58, 81], ["the olfactory impairment", "PROBLEM", 137, 161], ["olfactory impairment", "OBSERVATION", 141, 161], ["higher", "OBSERVATION_MODIFIER", 177, 183]]], ["Trotier et al. [29] showed that in some patients with idiopathic olfactory loss, the inflammatory obstruction can be found only in the olfactory clefts, and not in the rest of the nasal cavities and sinuses.", [["olfactory", "ANATOMY", 65, 74], ["olfactory clefts", "ANATOMY", 135, 151], ["nasal cavities", "ANATOMY", 180, 194], ["sinuses", "ANATOMY", 199, 206], ["idiopathic olfactory loss", "DISEASE", 54, 79], ["inflammatory obstruction", "DISEASE", 85, 109], ["olfactory clefts", "DISEASE", 135, 151], ["patients", "ORGANISM", 40, 48], ["olfactory", "ORGAN", 65, 74], ["olfactory clefts", "PATHOLOGICAL_FORMATION", 135, 151], ["nasal cavities", "MULTI-TISSUE_STRUCTURE", 180, 194], ["sinuses", "MULTI-TISSUE_STRUCTURE", 199, 206], ["patients", "SPECIES", 40, 48], ["idiopathic olfactory loss", "PROBLEM", 54, 79], ["the inflammatory obstruction", "PROBLEM", 81, 109], ["idiopathic", "OBSERVATION_MODIFIER", 54, 64], ["olfactory loss", "OBSERVATION", 65, 79], ["inflammatory", "OBSERVATION_MODIFIER", 85, 97], ["obstruction", "OBSERVATION", 98, 109], ["olfactory clefts", "ANATOMY", 135, 151], ["rest", "ANATOMY_MODIFIER", 168, 172], ["nasal cavities", "ANATOMY", 180, 194], ["sinuses", "ANATOMY", 199, 206]]], ["Hoffmann et al. [34] showed that the SARS-CoV-2 infects cells through interactions between its spike (S) protein and the ACE2 protein on target cells.", [["cells", "ANATOMY", 56, 61], ["cells", "ANATOMY", 144, 149], ["SARS", "DISEASE", 37, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 37, 47], ["cells", "CELL", 56, 61], ["spike (S)", "GENE_OR_GENE_PRODUCT", 95, 104], ["ACE2", "GENE_OR_GENE_PRODUCT", 121, 125], ["cells", "CELL", 144, 149], ["spike (S) protein", "PROTEIN", 95, 112], ["ACE2 protein", "PROTEIN", 121, 133], ["target cells", "CELL_TYPE", 137, 149], ["the SARS", "TEST", 33, 41], ["CoV", "TEST", 42, 45], ["2 infects cells", "PROBLEM", 46, 61], ["protein", "TEST", 105, 112], ["the ACE2 protein", "TEST", 117, 133], ["target cells", "OBSERVATION", 137, 149]]], ["This interaction requires cleavage of the S protein by the cell surface protease TMPRSS.", [["cell surface", "ANATOMY", 59, 71], ["cell", "CELL", 59, 63], ["TMPRSS", "GENE_OR_GENE_PRODUCT", 81, 87], ["S protein", "PROTEIN", 42, 51], ["cell surface protease", "PROTEIN", 59, 80], ["TMPRSS", "PROTEIN", 81, 87], ["the S protein", "TREATMENT", 38, 51], ["the cell surface protease TMPRSS", "TREATMENT", 55, 87]]], ["Base on analyzing the RNAsequencing datasets, Brann et al. [33] found that both ACE2 and TMPRSS are expressed by olfactory epithelial supporting cell and stem cells, and not olfactory sensory neurons, per se.", [["olfactory epithelial", "ANATOMY", 113, 133], ["cell", "ANATOMY", 145, 149], ["stem cells", "ANATOMY", 154, 164], ["olfactory sensory neurons", "ANATOMY", 174, 199], ["ACE2", "GENE_OR_GENE_PRODUCT", 80, 84], ["TMPRSS", "GENE_OR_GENE_PRODUCT", 89, 95], ["olfactory epithelial supporting cell", "CELL", 113, 149], ["stem cells", "CELL", 154, 164], ["olfactory sensory neurons", "CELL", 174, 199], ["ACE2", "PROTEIN", 80, 84], ["TMPRSS", "PROTEIN", 89, 95], ["olfactory epithelial supporting cell and stem cells", "CELL_TYPE", 113, 164], ["olfactory sensory neurons", "CELL_TYPE", 174, 199], ["olfactory epithelial", "OBSERVATION", 113, 133], ["supporting cell", "OBSERVATION", 134, 149], ["stem cells", "OBSERVATION", 154, 164]]], ["Accordingly, they hypothesized that the infection of these cells is the cause of olfactory dysfunction in patients with COVID-19 [34] .", [["cells", "ANATOMY", 59, 64], ["olfactory", "ANATOMY", 81, 90], ["infection", "DISEASE", 40, 49], ["olfactory dysfunction", "DISEASE", 81, 102], ["COVID-19", "CHEMICAL", 120, 128], ["cells", "CELL", 59, 64], ["olfactory", "ORGAN", 81, 90], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["the infection of these cells", "PROBLEM", 36, 64], ["olfactory dysfunction", "PROBLEM", 81, 102], ["COVID", "TEST", 120, 125], ["infection", "OBSERVATION", 40, 49], ["olfactory dysfunction", "OBSERVATION", 81, 102]]], ["We know that the infected cells secret proinflammatory cytokines and chemokines, resulting in an influx of inflammatory cells [9] .", [["cells", "ANATOMY", 26, 31], ["inflammatory cells", "ANATOMY", 107, 125], ["cells", "CELL", 26, 31], ["cells", "CELL", 120, 125], ["infected cells", "CELL_TYPE", 17, 31], ["proinflammatory cytokines", "PROTEIN", 39, 64], ["chemokines", "PROTEIN", 69, 79], ["inflammatory cells", "CELL_TYPE", 107, 125], ["the infected cells", "PROBLEM", 13, 31], ["proinflammatory cytokines", "TEST", 39, 64], ["chemokines", "TEST", 69, 79], ["an influx of inflammatory cells", "PROBLEM", 94, 125], ["infected cells", "OBSERVATION", 17, 31], ["inflammatory cells", "OBSERVATION", 107, 125]]], ["This reaction can also lead to localized mucosal edema in the narrow olfactory cleft, hindering the odors pass to the olfactory mucosa ( Fig. 1) [35] .", [["mucosal", "ANATOMY", 41, 48], ["olfactory cleft", "ANATOMY", 69, 84], ["olfactory mucosa", "ANATOMY", 118, 134], ["edema", "DISEASE", 49, 54], ["mucosal edema", "PATHOLOGICAL_FORMATION", 41, 54], ["olfactory cleft", "ORGAN", 69, 84], ["olfactory mucosa", "MULTI-TISSUE_STRUCTURE", 118, 134], ["This reaction", "PROBLEM", 0, 13], ["localized mucosal edema", "PROBLEM", 31, 54], ["the narrow olfactory cleft", "PROBLEM", 58, 84], ["localized", "OBSERVATION_MODIFIER", 31, 40], ["mucosal", "ANATOMY", 41, 48], ["edema", "OBSERVATION", 49, 54], ["narrow", "OBSERVATION_MODIFIER", 62, 68], ["olfactory cleft", "OBSERVATION", 69, 84], ["olfactory mucosa", "ANATOMY", 118, 134]]], ["This mechanism can also affect the neurons as bystanders.", [["neurons", "ANATOMY", 35, 42], ["neurons", "CELL", 35, 42]]], ["However, the neuroinvasiveness of some coronaviruses, including SARS-CoV, has demonstrated in both mice and humans [36] .", [["coronaviruses", "DISEASE", 39, 52], ["coronaviruses", "ORGANISM", 39, 52], ["SARS-CoV", "ORGANISM", 64, 72], ["mice", "ORGANISM", 99, 103], ["humans", "ORGANISM", 108, 114], ["mice", "SPECIES", 99, 103], ["humans", "SPECIES", 108, 114], ["SARS-CoV", "SPECIES", 64, 72], ["mice", "SPECIES", 99, 103], ["humans", "SPECIES", 108, 114], ["some coronaviruses", "PROBLEM", 34, 52], ["SARS", "PROBLEM", 64, 68], ["coronaviruses", "OBSERVATION", 39, 52]]], ["Accordingly, there are imaging studies of the brain by MRI, showing a transient increase in volume or hyperintensity of the olfactory bulb and the brain regions that are associated with olfaction [37, 38] .", [["brain", "ANATOMY", 46, 51], ["olfactory bulb", "ANATOMY", 124, 138], ["brain", "ANATOMY", 147, 152], ["brain", "ORGAN", 46, 51], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 124, 138], ["brain", "ORGAN", 147, 152], ["imaging studies of the brain", "TEST", 23, 51], ["MRI", "TEST", 55, 58], ["a transient increase in volume or hyperintensity of the olfactory bulb and the brain regions", "PROBLEM", 68, 160], ["brain", "ANATOMY", 46, 51], ["transient", "OBSERVATION_MODIFIER", 70, 79], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["volume", "OBSERVATION_MODIFIER", 92, 98], ["hyperintensity", "OBSERVATION", 102, 116], ["olfactory", "ANATOMY_MODIFIER", 124, 133], ["bulb", "ANATOMY_MODIFIER", 134, 138], ["brain", "ANATOMY", 147, 152], ["regions", "ANATOMY_MODIFIER", 153, 160]]], ["It seems that more pathologic investigations on the involved nasal mucosa or cadaveric brain specimens are needed to find out the exact responsible mechanisms.DiscussionFever has announced as a main symptom of COVID 19, with a prevalence ranging from 38 to 95.8% that may be due to the various factors including severity of the disease [22, 39, 40] .", [["nasal mucosa", "ANATOMY", 61, 73], ["brain specimens", "ANATOMY", 87, 102], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 61, 73], ["brain specimens", "CANCER", 87, 102], ["pathologic investigations", "TEST", 19, 44], ["cadaveric brain specimens", "TEST", 77, 102], ["the disease", "PROBLEM", 324, 335], ["nasal mucosa", "ANATOMY", 61, 73], ["brain", "ANATOMY", 87, 92], ["disease", "OBSERVATION", 328, 335]]], ["The prevalence of fever in Mao et al. [22] study was 61% while Lechien et al. [23] reported in less than 50% of their patients.", [["fever", "DISEASE", 18, 23], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["fever", "PROBLEM", 18, 23], ["study", "TEST", 43, 48], ["fever", "OBSERVATION", 18, 23]]], ["In our patients, fever as a presenting symptom reported by 31.5% of the patients, while it was detected in 54.3% of the patients during the hospitalization period.DiscussionSARS-CoV-2 showed great potential for dissemination became a pandemic during 2.5 months [20] .", [["fever", "DISEASE", 17, 22], ["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 120, 128], ["fever", "PROBLEM", 17, 22], ["a presenting symptom", "PROBLEM", 26, 46], ["DiscussionSARS", "TEST", 163, 177], ["CoV", "TEST", 178, 181], ["dissemination", "PROBLEM", 211, 224], ["a pandemic", "PROBLEM", 232, 242]]], ["Although it may be related to the structure of the virus per se, one explanation could be the shedding and spreading of the virus by the infected people with very mild symptoms, similar to those of an URTI, which could be quite misleading.", [["URTI", "DISEASE", 201, 205], ["people", "ORGANISM", 146, 152], ["people", "SPECIES", 146, 152], ["the virus", "PROBLEM", 47, 56], ["the shedding", "PROBLEM", 90, 102], ["the virus", "PROBLEM", 120, 129], ["very mild symptoms", "PROBLEM", 158, 176], ["an URTI", "PROBLEM", 198, 205], ["may be related to", "UNCERTAINTY", 12, 29], ["virus", "OBSERVATION", 51, 56], ["infected", "OBSERVATION_MODIFIER", 137, 145], ["very", "OBSERVATION_MODIFIER", 158, 162], ["mild", "OBSERVATION_MODIFIER", 163, 167], ["symptoms", "OBSERVATION", 168, 176], ["URTI", "OBSERVATION", 201, 205]]], ["These patients with subtle symptoms may unintentionally breach the quarantine rules.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["subtle symptoms", "PROBLEM", 20, 35]]], ["Hence, those who have olfactory loss without any sinonasal symptoms need to be considered as probable cases of COVID-19 during the pandemic [21, 23] .", [["olfactory", "ANATOMY", 22, 31], ["sinonasal", "ANATOMY", 49, 58], ["olfactory loss", "DISEASE", 22, 36], ["olfactory", "ORGAN", 22, 31], ["sinonasal", "ORGAN", 49, 58], ["olfactory loss", "PROBLEM", 22, 36], ["any sinonasal symptoms", "PROBLEM", 45, 67], ["COVID", "TEST", 111, 116]]], ["This may be of great importance in controlling the spreading of the COVID-19.", [["COVID-19", "DNA", 68, 76], ["the COVID", "TEST", 64, 73], ["may be of", "UNCERTAINTY", 5, 14], ["great", "OBSERVATION_MODIFIER", 15, 20], ["importance", "OBSERVATION", 21, 31]]], ["Although we designed a prospective study, data about the presenting symptoms was collected retrospectively.", [["a prospective study", "TEST", 21, 40], ["the presenting symptoms", "PROBLEM", 53, 76]]], ["In this study, the olfaction and sinonasal symptoms were evaluated only in patients with COVID-19 that were able to answer the questionnaire and were hospitalized.", [["sinonasal", "ANATOMY", 33, 42], ["sinonasal", "ORGAN", 33, 42], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["this study", "TEST", 3, 13], ["the olfaction and sinonasal symptoms", "PROBLEM", 15, 51], ["COVID", "TEST", 89, 94]]], ["Therefore, the reported frequency may not exactly be the same in milder or very severe forms of COVID-19.", [["COVID-19", "CHEMICAL", 96, 104], ["COVID", "TEST", 96, 101]]], ["The other limitation is that the patients were not evaluated with a standard olfactory test; this was due to the condition of patients with dyspnea and the preventive protocols that limited unnecessary contacts of persons and instruments during the pandemic.", [["dyspnea", "DISEASE", 140, 147], ["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 126, 134], ["persons", "ORGANISM", 214, 221], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 126, 134], ["persons", "SPECIES", 214, 221], ["a standard olfactory test", "TEST", 66, 91], ["dyspnea", "PROBLEM", 140, 147], ["the preventive protocols", "TREATMENT", 152, 176], ["the pandemic", "PROBLEM", 245, 257]]], ["The correlation between olfactory loss and sinonasal symptoms may need to be evaluated in larger studies.ConclusionSudden temporary olfactory loss and URTI symptoms have a considerable prevalence in patients with COVID-19 and need to be considered as the symptoms of this infection.", [["olfactory", "ANATOMY", 24, 33], ["sinonasal", "ANATOMY", 43, 52], ["olfactory", "ANATOMY", 132, 141], ["olfactory loss", "DISEASE", 24, 38], ["olfactory loss", "DISEASE", 132, 146], ["URTI", "DISEASE", 151, 155], ["infection", "DISEASE", 272, 281], ["olfactory", "ORGAN", 24, 33], ["sinonasal", "ORGAN", 43, 52], ["olfactory", "ORGAN", 132, 141], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207], ["olfactory loss", "PROBLEM", 24, 38], ["sinonasal symptoms", "PROBLEM", 43, 61], ["larger studies", "TEST", 90, 104], ["ConclusionSudden temporary olfactory loss", "PROBLEM", 105, 146], ["URTI symptoms", "PROBLEM", 151, 164], ["COVID", "TEST", 213, 218], ["the symptoms", "PROBLEM", 251, 263], ["this infection", "PROBLEM", 267, 281], ["olfactory loss", "OBSERVATION", 132, 146], ["infection", "OBSERVATION", 272, 281]]], ["There was, however, no association between URTI symptoms and the prevalence of olfactory loss in these patients, emphasizing that the pathology may not be the generalized mucosal swelling that happens during an URTI with common coronaviruses.", [["olfactory", "ANATOMY", 79, 88], ["mucosal", "ANATOMY", 171, 178], ["URTI", "DISEASE", 43, 47], ["olfactory loss", "DISEASE", 79, 93], ["mucosal swelling", "DISEASE", 171, 187], ["URTI", "DISEASE", 211, 215], ["olfactory", "ORGAN", 79, 88], ["patients", "ORGANISM", 103, 111], ["mucosal", "PATHOLOGICAL_FORMATION", 171, 178], ["patients", "SPECIES", 103, 111], ["URTI symptoms", "PROBLEM", 43, 56], ["olfactory loss", "PROBLEM", 79, 93], ["the pathology", "PROBLEM", 130, 143], ["the generalized mucosal swelling", "PROBLEM", 155, 187], ["common coronaviruses", "PROBLEM", 221, 241], ["olfactory loss", "OBSERVATION", 79, 93], ["may not be", "UNCERTAINTY", 144, 154], ["generalized", "OBSERVATION_MODIFIER", 159, 170], ["mucosal", "ANATOMY", 171, 178], ["swelling", "OBSERVATION", 179, 187]]]]}